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Symposium on Tumour Suppressor Genes
Functional analyses of candidate tumour mippresser genes
E.J. Stanbridge
University of California, Irvine, California, USA.
Evidence has been accumulating for loss of genetic infor-
mation associated with various human malignancies. This
evidence has been based upon cytogenetic analyses and
restriction fragment length polymorphism (RFLP) analyses.
Using these techniques, deletion of discrete regions ofspecific
chromosomes have been detected. Human cancers have been
associated with specific deletions on single chromosomes (for
example, retinoblastomas) or multiple chromosomes (for
example, colorectal carcinomas). These deletions have been
interpreted as inactivation of tumour suppressor genes. With
few exceptions (rb-l and p53) the genes have not been cloned
and linkage analysis data are not available. To provide func-
tional evidence for unknown and putative tumour suppressor
genes, we have developed techniques for single chromosome
transfer. Data were presented indicating tumour suppression
via monochromosome transfer. In most cases, the predicted
chromosome had a tumour-suppressing effect. In others, for
example, neuroblastoma, this was not the case. Furthermore,
we have been able to dissociate the induction of differen-
tiation from tumour suppression in neuroblastoma. Recent
refinements of the microcell transfer technique have allowed
us to transfer portions of single chromosomes, thereby, more
finely mapping the region responsible for tumour suppres-
sion.
p53 as an oncogene and a tumour suppressor gene.
Different point mutations in p53 in human and murine
cancer exert a common effect on the proteins conformation
and function.
D.P. Lane, J. Gannon, J. Bartek, R. Greaves, A. Harris,
K. Gatter & R. Iggo
ICRF Clare Hall Laboratories, South Mimms, Potters Bar,
Herts. EN6 3LD, UK.
The human p53 gene is located on chromosome 17p. Recent
studies have shown that this is a frequent site-of allele loss in
many human tumours including lung, colon, breast, and
brain tumours. Histological staining using a panel of new
anti-p53 antibodies isolated in our laboratory has shown that
overexpression of the p53 protein is present in over 50% of
primary lung and breast tumour biopsies. Similarly at least
30% of colon cancer samples showed high level expression of
p53 protein. Work with cell lines has shown that overexpres-
sion of the p53 protein is synonymous with mutation.
Since using a new PCR based strategy, we found that six
out of six breast cancer cell lines that overexpressed p53 were
only expressing mutant RNA. In agreement with the results
from Vogelstein's laboratory, all of the mutations were point
missense mutations that altered evolutionarily conserved
amino acids. These results were extended to direct sequencing
of mRNA from lung biopsies. All histologically positive
tumours were found to be expressing mutant p53 mRNA,
whereas no mutation was found in a histologically negative
tumour. These results suggest that mutation of p53 is the
most common genetic event so far deted in human cancer.
A new monoclonal antibody to p53 only immunoprecipitates
p53 encoded by mutant genes. Using this antibody we estab-
lished that t-he different mutations in p53 exert a common
effect on the proteins conformation. The mutant proteins
behave as both gain of function mutants, in that they have
acquired a dominant transforming function, and loss offunc-
tion mutations, in that they have lost tumour suppressor
activity. One way to reconcile these findings is to suggest that
the mutant proteins act directly to inactivate wild type p53
function. This leads to an attractive model of p53 mutation
in human cancer. Results on the inhibition of SV40 DNA
synthesis by mutant and wild type p53 provide a powerful
paradigm for the normal function of p53 as a suppressor of
cell growth.
Some aspects of the genetics and biology of colorectal
carcinoms
Sir Walter Bodmer
Imperial Cancer Research Fund, UK.
The gene for the dominantly inherited susceptibility to colon
cancer, adenomatous polyposis coli (APC), has been local-
ized to chromosome 5q21. Allele loss in tumour, compared
to normal tissue, from sporadic cases of colorectal carcin-
omas has clearly implicated the APC gene in 40% or more of
all cases. Two further clear cut examples of genetic changes
involving loss or suppression of normal functions in colorec-
tal carcinomas are for p53 on chromosome 17 and the DCC
gene, described by Vogelstein, on chromosome 18.
The control of differentiation is likely to be one factor
underlying such recessive genetic changes during carcino-
genesis. A small proportion of human colon carcinoma
derived cell lines can be induced to differentiate structurally
when grown in a collagen type I gel. This differentiation is
triggered by a cell surface collagen receptor of the integrin
family. Somatic cell hybrid analysis shows that the ability to
bind to collagen type 1, and so to differentiate, is controlled
by a gene on chromosome 15. Hybrids which differentiate are
essentially non tumorigenic in nude mice. This provides an
explanation for recessive control of tumorigenesis, namely by
lack of a receptor mediating differentiation induction. In
agreement with these ideas, the expression of collagen recep-
tors is often reduced in moderate and poorly differentiated
colorectal adenocarcinomas. There is also evidence that one
or more members of the CEA family of adhesion molecules
may interact with certain integrins to mediate effective bind-
ing to collagen. The common expression of CEA in colorec-
tal carcinomas may, therefore, be related to a disruption of
this function.
Studies of the control of differentiation should eventually
provide an explanation for the functional basis of the selec-
tion for recessive genetic mutations, such as for APC and
other genes, during progression of colorectal carcinoma.
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Genetic alterations underlying colorectal tumorigenesis
B. Vogelstein
The Johns Hopkins Oncology Center, Baltimore,
MD 21231, USA.
Colorectal tumours develop through clinically and histolog-
ically defined stages which make these neoplasms an excellent
system for investigating the genetic alterations responsible for
tumour initiation and progression. Studies from our labor-
atory, and by others, have revealed the following principles
underlying the development of colorectal neoplasia.
All colorectal tumours are monoclonal in composition,
suggesting that neoplasia develops from the transformation
of a cell(s) from within a single crypt. The presence of
specific genetic alterations in early colorectal tumours addi-
tionally supports the idea that tumours of all sizes represent
the clonal expansion of a single transformed cell.
The various stages of tumorigenesis appear to be the result
of accumulated changes in both oncogenes and tumour-
suppressor genes; the latter predominate. Mutations of at
least 4-6 genes appear to be required, in general, for car-
cinoma formation, while smaller numbers of mutations
suffice for benign tumorigenesis.
Although amplification of certain oncogenes occasionally
occurs in colorectal carcinomas, K-ras is the only oncogene
known to be involved in a large percentage of tumours.
Codons 12 and 13 of the K-ras oncogene are frequent targets
ofmutations, and such mutations are found in approximately
50% of intermediate and late stage adenomas as well as in
carcinomas.
DNA is consistently hypomethylated in colorectal tumours
at all stages, and this represents a very early event in neo-
plasia. Hypomethylation has been demonstrated to lead to
aberrant chromosome segregation in vitro and the hypo-
methylation found in tumours in vivo could lead to the loss
of wild-type tumour-suppressor genes through similar segre-
gation abnormalities.
Most of the genetic changes so far identified in colorectal
tumours involve tumour suppressor genes, as inferred from
allelic deletion analysis. Two chromosomal regions (17p and
18q) are lost in over 75% of colorectal carcinomas, and at
least 6 additional loci (including 5q) are each lost in more
than a quarter of the carcinomas.
The gene responsible for familial adenomatous polyposis
has been mapped to chromosome 5q. The chromosomal
region containing this gene is lost in over one-third of
sporadic adenomas but is deleted infrequently in the
adenomas of FAP patients.
The suppressor gene on chromosome 17p has been tenta-
tively identified as the p53 gene through a combination of
allelic deletion analysis and molecular cloning. A relatively
small region of 17p was found to be consistently lost in
colorectal tumours and this region contained the p53 gene.
Detailed analysis of the residual p53 genes remaining in
colorectal tumours showed that the residual p53 gene usually
contained a missense mutation. These and other studies sug-
gest that the wild-type p53 gene might suppress neoplastic
growth, and that mutations in the p53 gene abrogate this
suppression. A mutation of one p53 allele is often followed
by loss of the wild-type allele, and this loss generally coin-
cides with the transition from adenoma to carcinoma.
A small region of chromosome 18q was found to be
consistently deleted in colorectal cancers, and a strategy
employing chromosome walking and cross-species-hybridiza-
tion eventually led to the identification of a candidate supp-
ressor gene in the region. The gene, called DCC (for deleted
in colorectal carcinoma) was found to be expressed in many
normal tissues, but its expression was reduced or absent in
most colorectal carcinomas. Several examples of somatic
mutations within the DCC gene were identified in colorectal
cancers. Interestingly, the DCC gene has several structural
characteristics which suggest it is a cell adhesion molecule.
The cell adhesion mediated by DCC may be important in
negatively controlling epithelial cell growth.
The genetic alterations noted above occur in a preferential
order. Hypomethylation is present very early, ras gene muta-
tions and chromosome 5q allelic losses generally precede 18q
allelic losses, which in turn precede 17q allelic deletions.
However, detailed analysis of individual tumours at different
stages of development suggest that it is the total accumula-
tion of changes, not their order with respect to one another,
that is most important in determining biological behaviour.
This accumulation of changes has important practical im-
plications. Carcinomas with greater than the median number
of changes are much more likely to metastasize to distant
organs than those with fewer mutations, irrespective of size
or histopathological characteristics. Such information forms
the basis for a prognostic test which may have clinical utility.
Molecular basis of tumour suppression by the human
retinoblastoma gene
Wen-Hwa Lee
Department of Pathology, M-012 and Center for Molecular
Genetics, School of Medicine, University of California, San
Diego, La Jolla, CA 92093, USA.
A class of cellular genes in which loss-of-function mutations
are tumorigenic has been proposed. Such genes would nor-
mally act to suppress the cancer phenotype at the cellular or
organism level. The gene determining susceptibility to here-
ditary retinoblastoma (RB) appears to operate in exactly this
fashion, and is the first cancer suppressor gene to be molec-
ularly cloned. The RB gene contains 27 exons dispersed over
more than 200kb and expresses a 4.7kb mRNA ubiqui-
tously. From the sequence analysis of the RB cDNA, the
predicted RB protein has 928 amino acids with mol.wt.
about 106 kDa. Several antibodies, prepared according to the
sequence, recognized the putative RB protein (apparent m.s.
110 kDa) in normal cells, but do not detect this protein in
retinoblastoma cells. The RB protein is a nuclear phospho-
protein capable of binding to DNA and to form a complex
with oncoproteins of several DNA tumour viruses.
Consistent with its ubiquitous expression pattern, RB gene
inactivation is not only limited to retinoblastomas. Many
other cancers such as osteosarcoma, breast carcinoma, small
cell lung carcinoma and prostatic carcinoma contain inacti-
vated RB genes, suggesting that RB may act as a general
cancer suppressor gene. We have introduced, through retro-
viral-mediated gene transfer, a cloned RB gene into ret-
inoblastoma, osteosarcoma, prostate carcinoma and breast
carcinoma cells that have inactivated endogenous RB genes.
Expression of the exogenous RB gene consistently suppressed
their tumorigenicity in nude mice. Each individual clone of
these tumour cells with exogenous RB protein expression was
non-tumorigenic in nude mice. However, after prolonged
culturing some of the clones lost the expression of the RB
protein and regained tumorigenic ability. This tight correla-
tion strongly indicated that the RB gene is essential to
tumorigenesis in these tumour cells.
In an attempt to address the potential cellular function of
this gene, we have observed that Rb protein phosphorylation
oscillates with cell-cycle and the unphosphorylated form is
present predominantly in the GO/GI phase. Furthermore,
when cells were induced to differentiate only the unphos-
phorylated form of Rb could be detected, suggesting that RB
protein was modulated through phosphorylation and may
play an important role in these cellular functions. A working
hypothesis is proposed to interpret how Rb participates in
cell proliferation and differentiation in relation to its role in
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Transformation suppressor genes
M. Noda, H. Kitayama, S. Kanazawa, S. Murata,
S. Kumar, T. Matsuzaki & Y. Ikawa
Tsukuba Life Science Center, The Institute of Physical and
Chemical Research (RIKEN), 3-1-1 Koyadai, Tsukuba,
Ibaraki 305, Japan.
To understand the molecular mechanism of malignant cell
transformation, we have been isolating and characterizing
suppressor mutants (flat revertants) from a v-Ki-ras- trans-
formed NlH3T3 cell line, named DT. Our recent study has
demonstrated that flat revertants could be isolated from DT
cells after transfection of normal human fibroblast cDNA-
expression library, and that this strategy is useful in detecting
such genes that, when overexpressed, interfere with the trans-
forming activity of the oncogene (we collectively call such
genes as "transformation suppressor genes").
Through this method, we have isolated and molecularly
characterized several biologically active cDNA species. One
of the cDNAs, named Krev-1, was found to encode a ras-
related protein and exhibit an activity of inducing flat rever-
tants at frequencies of 2-5% of total transfectants when
introduced into DT cells. Toward understanding the
mechanisms of action of Krev-l protein, we constructed a
series of point mutants of Krev-I cDNA as well as some
chimeric genes consisting of fragments of H-ras and Krev-1
cDNAs, and tested their biological activities in DT cells as
well as in HT1080 human fibrosarcoma cells harbouring the
activated N-ras gene. Substitutions of the amino acid resi-
dues in the putative guanine nucleotide-binding regions
(Asp'7 and Asn"6), in the putative effector-binding domain
(residue 38), at the putative acylation site (Cys'81), and at the
unique Thr6' residue all decreased the transformation sup-
pressor activity. On the other hand, substitutions such as
Gly'2 to Val'2 and Gln63 to Glu63 were found to increase
significantly the transformation suppressor/ tumour suppres-
sor activity of Krev-l. These findings are consistent with the
idea that Krev-l protein is regulated like many other G-
proteins by guanine triphosphate/guanine diphosphate-ex-
change mechanism, probably in response to certain negative
growth-regulatory signals. Furthermore, study with the
chimeric genes revealed that the determinants for the sup-
pressor activity reside in the N-terminal one third of the
Krev-l encoded polypeptide.
The second cDNA we have characterized, named Krev-3
was found to encode the carboxy-terminal one third of
'tenascin', also known as cytotactin, hexabrachion, etc., in-
cluding fibronectin type III repeats. Tenascin has been
reported to exhibit mitogenic activities as well as cell
adhesive activities. Study of the mechanism of action of the
cryptic protein produced from the Krev-3 cDNA may yield
an important clue to the understanding of the physiological
functions of this extracellular matrix protein.
Our in vitro approach has been useful in isolating bio-
logically interesting genes, and further studies on these and
other genes and their products may yield important insights
into the regulatory mechanisms of cell growth and, possibly,
into the aetiology of some naturally occurring tumours as
well.
Wilms tumour; a developmental anomaly
N. Hastie
MRC Human Genetics Unit, Western General Hospital,
Crewe Road, Edinburgh EH4 2XU, UK.
Wilms tumour (WT) is an embryonic kidney tumour which is
thought to result from failure of normal mesenchymal stem
cell differentiation. The tumour arises through loss of func-
tion of at least one so-called tumour suppressor(s) gene
which maps to the short arm of chromosome 11.
The precise location of a WT predisposition gene is known
through the association of WT aniridia (lack of an iris),
genitourinary abnormalities and mental retardation in the
WAGR syndrome. Individuals with this syndrome almost
invariably have constitutional deletions of one chromosome
11 which always involve band I1plI3. A combination of
deletion mapping and analysis by pulsed field gel electro-
phoresis with a large number of DNA markers has led to a
high resolution map of the 11 p13 region so that the locations
of the WT and aniridia genes are known. The gene responsi-
ble for the genital abnormalities in WAGR patients maps
within the same 350 kb region as the WT gene, raising the
possibility that the gonadal anomalies result from mutation
or deletion of the WT gene itself.
We have been working with a candidate WT gene isolated
in the laboratory of David Housman at MIT. This gene
encodes a protein with four zinc fingers which is likely to
play a role in transcriptional control. Consistent with a
development role for the WT gene we show by in situ hybrid-
ization that this candidate is specifically expressed in the
condensing mesenchyme and glomerular epithelium of deve-
loping metanephros and mesonephros. In addition, the gene
is expressed in the genital ridge and fetal gonads, a finding
which supports the notion that genital anomalies in WAGR
patients result from mutation in the WT gene itself. In
tumours, we find the cell types expressing the gene corres-
pond to the cell types which express the gene during normal
nephrogenesis.
Symposium on Management of Cancer
Screening for Cancer
J. Chamberlain
Royal Marsden Hospital, Sutton, Surrey, UK.
The purpose of screening is to detect presymptomatic neo-
plasia at a stage in its natural history at which treatment will
arrest its progression. The success of screening must, there-
fore, be judged by a fall in mortality from the cancer in
question. Although screening tests are available for many
different cancers and have been shown to result in the diag-
nosis of a high proportion of cancers at an early stage, very
few trials have assessed the impact of screening on mortality.
At the present time, screening is of proved value only for
breast cancer and cervix cancer. A number of well-conducted
trials of screening for lung cancer have failed to show any
benefit. Screening for other cancer sites, including large
bowel, melanoma, ovary and stomach, is currently being
investigated in research studies from which some preliminary
results are available.
Even when it has been shown that screening can improve
prognosis, doubt may remain about the cost-effectiveness of
a public health screening programme. The physical, psycho-
logical and financial costs need to be measured and weighed
against the size of benefit, for example, in years of life
gained. Screening is likely to put an increased burden on
diagnostic services in order to sort out people with false
positive, from those with true positive, screening results.BRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS 477
Analgesia for cancer pain
G.W. Hanks
Royal Marsden Hospital, Fulham Road, London, SW3 6JJ,
UK.
Morphine is the strong opioid analgesic of choice for severe
cancer pain and the use of morphine by the oral route is now
being promoted around the world by the WHO. This is a
relatively recent development; there was previously a wide-
spread reluctance to use morphine in this way because of
doubts about its efficacy (Rane et al. (1982) Acta Anaesth.
Scand. Suppl. 74, 97). Opinion gradually changed because of
the extensive empirical experience with oral morphine in the
United Kingdom. We can now attempt to explain why there
were doubts about the activity of oral morphine and why
morphine by this route is in fact very effective in the manage-
ment of chronic cancer pain. Crucial to these explanations is
the role of morphine-6-glucuronide (Hanks et al. (1987)
Lancet, 2, 723), a metabolite of morphine which is up to 45
time more potent than the parent drug in some animal
models.
Alternatives to oral morphine were discussed: pethidine
and methadone are best avoided; buprenorphine may have a
limited role; phenazocine and epidural morphine may be
indicated in patients suffering intolerable side effects from
systemic morphine.
Adjuvant drugs or co-analgesics will invariably be required
in conjunction with morphine. The most commonly used
groups of drugs are the non-steroidal anti-inflammatories for
bone pain, corticosteriods for nerve compression, or infil-
tration, and other pain caused by pressure from a tumour
mass; anticonvulsants for stabbing dysaesthetic pain related
to nerve damage and occasionally other dysaesthesiae; and
muscle relaxants for muscle spasm pain.
Drugs are not, however, sufficient by themselves. Pain and
suffering in the cancer patient are invariably compounded by
anxiety, fear, depression, hopelessness and misunderstanding.
Empathy, explanation and reassurance may have a profound
pain-relieving effect. A variety of physical and other non-
drug measures may also have an important part to play in
the management of cancer pain.
The potential for NMR spectroscopy in oncology
J.R. Griffiths
The CRC Biomedical Magnetic Resonance Research Group,
St George's Hospital Medical School, London SW17 ORE,
UK.
NMR spectroscopy (MRS) permits chemical analysis of liv-
ing tissue without taking biopsies or administering exogenous
substances. Numerous studies are in hand throughout the
world to apply MRS both in the oncology clinic and the
laboratory.
Potential uses of MRS in oncology fall into three main
categories. The 31P or 'H spectra of the tumour itself give us
information about metabolites such as ATP or lactate that
can be used for diagnosis, prognosis, choice of therapy or
monitoring therapy. Animal studies suggest that hypoxic tis-
sue can be detected and that there are marked metabolic
changes after successful therapies of various kinds. Exo-
genous probe substances may be administered and their spec-
tra used to give similar information. For instance, fluorinated
radiosensitizer compounds could be used to label hypoxic
tissues and assist planning of radiotherapy. The spectra of
anticancer drugs can be detected in tumours or in normal
tissues and we may follow their activation and detoxification.
Most work so far has been on 5-fluorouracil and its anal-
ogues; formation of fluoronucleotides in animal tumours has
successfully predicted therapeutic response.
In practice, the application of MRS is limited by its low
sensitivity. In animal studies, subcutaneous tumour of 1 cm3,
or less, can be observed but in patients the tumour is often
much further from the surface and volumes of greater than
50 cm3 usually have to be studied to obtain a spectrum in a
reasonable time. In many cases this will mean that only
primary tumours can be examined. Nevertheless, information
obtained may guide subsequent therapy ofmetastatic disease.
AIDS and malignancies
A. Dalgleish
Medical Research Council, CRC, Watford Road, Harrow,
Middlesex, UK.
AIDS is the definition of terminal HIV infection. Kaposi's
sarcoma (KS) and non-Hodgkin's lymphoma are prominent
manifestations of AIDS. They are probably associated with
profound immunosuppression induced by HIV and are not
necessarily induced by other oncogenic agents. Two main
types of lymphoma are seen and probably have different
mechanisms of pathogenesis due to HIV infection. The
clinical spectrum of KS is broad and the pathogenesis was
reviewed in detail in the light of recent work at the NIH.
Other malignancies such as Hodgkin's disease, and anal and
oral squamous carcinoma have been reported in HIV infect-
ed people and their significance to HIV infection were re-
viewed.
The management of primary bone tumours
R.L. Souhami
Dept ofOncology, University College and Middlesex School of
Medicine, Mortimer Street, London WI, UK.
In large, multicentre trials the 5-year survival of operable
osteosarcoma is now 60-65%. This is an improvement on
the results of the early 1970s, when only 25% of cases were
alive at 3 years. The major impact on survival has come from
intensive combination chemotherapy which has also facil-
itated limb-sparing surgery which is now feasible in 70% of
cases in the UK. It is probable that chemotherapy of short
duration will produce as good results as the longer program-
mes. This, and the best use ofdrug combinations, is currently
the subject of controlled trials. Improvements in chemo-
therapy are necessary for the 40% who relapse and for those
who present with metastases. The management of pulmonary
metastases remains a difficult problem and the criteria for
metastasectomy are not clearly defined.
In Ewing's sarcoma, the main problem is the treatment of
large tumours which are associated with a worse prognosis
both for local relapse and pulmonary metastasis. Combina-
tions of surgery and radiotherapy will probably be needed
for optimum local control. In both Ewing's sarcoma and
osteosarcoma, surgery of the axial skeletal tumours in
specialized units is now more widely performed.
Chemotherapy with new agents, such as ifosfamide, has not
been shown to have an advantage over less int_nsive
regimens. Randomized trials are, regrettably, seldom per-
formed. Such trials are feasible if there is national and inter-
national collaboration.
It is now clear that high-grade spindle-cell sarcomas of
bone are chemosensitive. Histological necrosis, often com-
plete, is frequently found after pre-operative chemotherapy.
The use of chemotherapy may improve survival in these
tumours where surgery alone is associated with a 3-year
survival of only 30%.478 BRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS
1990 Bagshawe Lecture
Matching basic research to the management of cancer: the
view from the other side of the fence
J.A. Wyke
CRC Beatson Laboratories, Beatson Institute for Cancer
Research, Garscube Estate, Switchback Road, Bearsden,
Glasgow G61 IBD, UK.
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Symposium on Supportive Care and the Control ofToxicity in Cancer
Therapy
Dose-response relationships in chemotherapy ofmalignant
disease
W. Hryniuk
Ontario Cancer Foundation, Hamilton Regional Cancer Centre
& McMaster University, Hamilton, Ontario, Canada.
In animal model systems, outcome of chemotherapy depends
upon drug dose, tumour sensitivity, and tumour burden.
Animal models do not provide for reduced dosage or delay
due to toxicity, and optimum treatment can be determined by
treating beyond lethal toxicity. This is not possible in
humans. Instead, attempts to define optimum treatment while
avoiding toxicity have resulted in a plethora of schedules,
combinations, and schemes to reduce doses and delay treat-
ments. However, these schemes and schedules have obscured
dose-response relationships. This becomes very important
when the most toxic effect of treatment may be death from
insufficient treatment.
We suggest dose-response relationships can be rediscovered
and studied by reducing all to how much drug is given per
unit time, as mg m-2 weekly. This we refer to as dose inten-
sity. Dose intensity may be calculated from intended drug
doses ("projected dose intensity"), or from dose received
after reductions and delays for toxicity ("received dose inten-
sity"). To calculate received dose intensity, treatment delays
are assumed equivalent arithmetically to dose reductions. For
regimens containing only one drug, dose intensity may be
calculated simply by disregarding the protocol schedule and
expressing the treatment in the standard form: mg m2
weekly. For regimens containing more than one drug, dose
intensity can still be calculated provided the drugs are of
approximately equivalent activity. This is done by arbitrarily
choosing one regimen as the standard and expressing all
other regimens relative to the arbitrarily chosen standard.
Dose intensity, either for single agents or combination regi-
mens, correlates very well with outcome in various malignant
diseases.
Data from animal model systems suggest that dose inten-
sity and total dose are both determinants of antitumour
effect but to different degrees; dose intensity appears to be
relatively more important in treatment of faster-growing
tumours while total dose may be more important in treat-
ment of slower-growing tumours. There are insufficient data
to determine whether this is also true in humans. There are
no data from either model systems or the clinic which ad-
dress the issue of whether dose intensity or total dose are
more important according to the phase of treatment, that is,
whether "induction" or "maintenance".
In order to integrate these concepts into a paradigm for
cancer chemotherapy it is useful to recognize two parallel
hierarchies of factors which determine outcome. Treatment
outcome is primarily dependent on the sensitivity to cyto-
toxic drugs of individual tumour and normal cells, seconda-
rily dependent upon the growth rate and rythm of both
tumour and normal tissues, and finally dependent upon the
size of tumour burden and size of the normal tissue reserves.
This paradigm suggests three sequential broad treatment
strategies. First, the most active least toxic drug(s) must be
selected. Second, remission must be induced by an optimal
combination of dose intensity and total dose of the chosen
drug(s) given to a limit of toxicity specified at the outset of
the investigation. Third, the residual tumour burden must be
eradicated without incurring an unacceptable long-term defi-
cit in normal tissue functioning. It is possible to specify
formally the sequence ofinvestigations required to implement
these three broad treatment strategies.BRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS 479
The clinical role of the haemopoietic growth factors
D. Crowther
Department of Medical Oncology, Christie Hospital and Holt
Radium Institute, Manchester M20 9BX, UK.
Since the first publication in 1987 showing that G-CSF given
by continuous intravenous infusion ameliorates the neutro-
penia and reduces the incidence of infection following inter-
mittent combined chemotherapy for cancer (Bronchud et al.,
1987), there have been a number of reports indicating bene-
ficial effects in this context using both G- and GM-CSF. In
our first study, the period of neutropenia was significantly
shortened (by a median of 80%) and the neutrophil count
levels were above normal again by 14 days following chemo-
therapy. In view of these results, a further study was under-
taken to examine the possibility of using intensive 2-weekly
chemotherapy under cover of G-CSF. Treatment with doxo-
rubicin at doses of 75, 100, 125 and 150mg m-2 was follow-
ed by infusion of G-CSF for 11 days. Again the neutrophil
counts returned to normal within 12 to 14 days allowing the
delivery of up to 3 cycles of high dose chemotherapy at
intervals of 14 days. These studies demonstrated that inten-
sive chemotherapy with dose limiting myelodepression can be
given with increased frequency under cover of G-CSF. Our
studies using GM-CSF have also shown that administration
by continuous i.v. infusion can reduce the period of life-
threatening neutropenia following high dose melphalan
(120 mg m-2) without resort to autologous bone marrow
transplantation (ABMT). In this study, the period of granu-
locytopenia (< 500 g x 1091 ') following melphalan was less
than 15 days. This compares favourably with other series
using high dose melphalan followed by ABMT without CSF
where the duration of severe neutropenia was prolonged
beyond 3 weeks. Enhanced neutrophil recovery has been
demonstrated following conventional and high dose chemo-
therapy allowing the use of accelerated chemotherapy of
higher dose intensity than would have been possible without
the use of a myelopoietic growth factor.
Improvement in the neutrophil count using G- and GM-
CSF has been observed in patients with marrow graft failure,
bone marrow failure from a variety of causes, myelodysplas-
tic syndrome, AIDS undergoing therapy with AZT, cyclic
neutropenia, Kostman's syndrome and in patients undergo-
ing chemotherapy for acute myelogenous leukaemia. To date,
most of these studies have involved relatively few patients
but major large randomized studies are underway to confirm
these findings. Although enhanced platelet recovery has been
observed following the use of GM-CSF, these effects have
been relatively modest but early trials with IL-3 and the
combined use of growth factors are showing more beneficial
effects on platelet counts in patients with some forms of bone
marrow failure. The administration of haemopoietic growth
factors has increased the yield of peripheral blood stem cells
allowing the use of these cells as rescue following ablative
chemotherapy and it would appear that the combined use of
growth factors including IL-3 is likely to increase the yield
further.
Proteins and small peptides have been identified which are
capable of inhibiting haemopoiesis and their future use in
reducing bone marrow toxicity is an exciting prospect.
Studies of the possible use of GM-CSF and M-CSF in
enhancing host antitumour activity are only just beginning.
Although continuous intravenous infusion has been accom-
panied by more pronounced effects than bolus intravenous or
subcutaneous administration, optimal routes and schedules of
administration have not been established for the various
therapeutic indications. The recognition of periodic behav-
iour in biological systems and the introduction of new
mathematics involving chaos theory is providing an explana-
tion for some of these observations. New ways in which
therapeutic benefits of a biological agent may be enhanced
involve such considerations.
The development of selective 5-HT3 receptor antagonists as
anti-emetic agents
G.J. Sanger
SmithKline Beecham Pharmaceuticals Research Division,
Coldharbour Road, The Pinnacles, Harlow, Essex CMJ9 5AD,
UK.
The original selective antagonists of the 5-hydroxytryptamine
(5-HT) 5-HT3 receptor (formerly the 5-HT M receptor) were
developed for uses other than the control of cytotoxic-
induced emesis (King & Sanger (1989), Drugs of the Future
14, 875). However, the availability of such compounds
enabled the link to be established between 5-HT3 receptors
and cytotoxicity-induced emesis (Sanger (1990) Can. J.
Physiol. Pharmacol., 68, in press).
High doses of metoclopramide reduce cisplatin-evoked
emesis in patients with cancer. We hypothesized that these
high doses might exert an action which was different to that
of the lower doses of metoclopramide, which are used to
increase gastric motility and to prevent milder forms of
emesis. Examination of the pharmacology ofmetoclopramide
showed that high concentrations antagonize 5-HT3 receptors
(and have other actions), whereas lower concentrations
enhance gut cholinergic activity, increasing gastric motility,
and antagonize dopamine D2 receptors, preventing mild
emesis. The possibility that 5-HT3 receptors were involved in
the mechanism of action of high-dose metoclopramide was
then strengthened by the finding that BRL 24924
antagonized cisplatin-induced emesis in ferrets. This com-
pound is a selective stimulant of gastric motility and also an
antagonist of 5-HT3 receptors. Therefore, we repeated the
experiments with MDL 72222, a more selective 5-HT3 recep-
tor antagonist, demonstrating for the first time that cisplatin-
evoked emesis could be selectively and completely prevented
(Miner & Sanger (1986), Br. J. Pharmacol., 88, 497).
Since these observations were made, several selective 5-HT3
receptor antagonists have been described. Granisetron (BRL
43694) was developed as both an anti-emetic agent and as a
5-HT3 receptor antagonist. Earlier compounds, such as ICS
205-930 and ondansetron (GR 38032F) were quickly switch-
ed to anti-emetic usage. By using these new drugs, several
additional features emerged. First, the ferret is a good model
of cytotoxicity-induced emesis in cancer patients (Sanger,
1990). Second, changes in ferret behaviour can be used as an
index of nausea, and granisetron will prevent both of these
events (Bermudez et al. (1988), Br. J. Cancer, 58, 644). Third,
granisetron will prevent emesis when given prophylactically,
or after emesis has begun. The latter activity occurs within
seconds after intravenous dosing (Bermudez et al., 1988) and
has also been demonstrated in cancer patients (Cassidy et al.
(1988), Proc. ASCO., 7, 356). In the ferret experiments, the
abolition of emesis was followed by a normal pattern of
eating behaviour. Fourth, 5-HT3 receptor antagonists are
selective in their action and do not cause sedation or prevent
emesis evoked by apomorphine and morphine in ferrets
(Sanger, 1990) or by abnormal motion in man (Stott et al.
(1989), Br. J. Clin. Pharmacol., 27, 147). Finally, granisetron
does not interfere with the antitumour activity of cisplatin
(Goddard et al. (1990), Cancer Chemother. Pharmacol., 25, in
press), further illustrating the selectivity of anti-emetic
activity for at least this compound.
5-HT3 receptor antagonists may prevent cytotoxicity-
evoked emesis by acting at the level of the abdominal vagus
(Andrews, Rapeport & Sanger (1988), Trends in Pharmacol.
Sci., 9, 334). However, the location of 5-HT3 receptors
within the human dorsal vagal complex (Reynolds et al.
(1989), Eur. J. Pharmacol., 174, 127) now suggests that
either terminal of the vagus could be an important site of
action.
Future evaluation of selective 5-HT3 receptor antagonists
promises to be exciting. An important area of investigation
is the role 5-HT3 receptors might play in the changes in
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by the cancer itself. In support of this possibility, we have
shown that granisetron reduces the conditioned taste aver-
sion evoked by radiation therapy in rats (Boyle & Sanger,
(1988), Proc. 'Nausea & Vomiting: A multidisciplinary per-
spective. Ottawa, Canada, November 12-13. Abstr A6, 25).
In the context of anticancer treatment, 5-HT3 receptor anta-
gonists could, therefore, exert a wider range of activities
than currently envisaged.
Review of clinical results with 5HT3 antagonists in
controlling emesis
D. Cunningham
Institute of Cancer Research, Royal Marsden Hospital,
Downs Road, Sutton, Surrey SM2 SPT, UK.
Nausea and vomiting are considered by patients to be the
worst side-effects of chemotherapy. Conventional antiemetic
agents such as dopamine-receptor antagonists, steroids and
benzodiazipines are usually only partially successful in con-
trolling these symptoms, particularly where there is a
significant emetogenic challenge such as is associated with
cisplatin. In conventional doses metoclopramide antagonizes
the dopamine receptor but in higher, more therapeutically
useful, doses it also antagonizes 5HT3 receptors. The deve-
lopment of specific 5HT3 receptor antagonists has resulted in
significant improvement in emesis control without the
unwanted side effects associated with dopamine-receptor
antagonists such as extrapyramidal reactions, sedation and
drowsiness.
The most widely studied drugs in this class are ondanset-
Frank Rose Memorial Lecture
Cancer chemotherapy in the 1990s: achievements and
prospects
B.A. Chabner
Division of Cancer Treatment, National Cancer Institute,
USA.
Cancer chemotherapy enters the 1990s with a history of a
few dramatic successes and many unfulfilled expectations.
The most striking successes have been realized in uncommon
tumours, such as the childhood leukaemias, choriocarcinoma
and testicular cancer, while the common solid tumours have
proved resistant, except in the adjuvant setting. Nonetheless,
notable advances have recently occurred in the adjuvant
therapy of colon cancer and breast cancer and there is now
good reason to hope that our rapidly expanding knowledge
of mechanisms of drug resistance and drug interactions will
lead to effective, rationally designed regimens, using currently
available drugs. The most important of these concepts, and
the therapeutic strategies likely to result from their applica-
tion, are discussed and critically evaluated. Foremost among
these concepts are the modulation of 5-fluorouracil by
leucovorin, PALA (N-phos-phonoacetyl-L-aspartic acid), and
cisplatin; the reversal of multidrug resistance with calcium
channel blockers and other complex cyclic amines; and dose
intensification strategies.
In addition to considering clinical strategies for enhancing
the effectiveness of chemotherapy, new strategies for dis-
ron, granisetron and ICS 205-930 and since the initiation of
clinical studies in 1987 several thousand patients have
received these compounds. They are extremely safe, well
tolerated and side effects, which are infrequent, include
headache and constipation. The clinical efficacy suggested by
pilot studies have now been confirmed by randomized trials
against conventional antiemetics. With chemotherapy
regimens of low to moderate emetogenicity, complete con-
trol of emesis is possible in 80-85% of patients but with
cisplatin there is still a significant proportion of patients,
probably in the region of 40%, where complete control of
emesis is not possible. The number of treatment failures is
dependent on the dose of cisplatin administered, also the
sex of the patient, such that complete control of emesis is
possible in 70-75% of males but in only 35-45% of
females. Randomized comparative studies have shown
ondansetron and granisetron to be superior, or at least
equivalent, to high dose metoclopramide, with or without
dexamethasone, in the management of cisplatin-induced
emesis, with predictably fewer side-effects. There have been
no studies comparing the 5HT3 antagonists with each other
but on the basis of published phase II and III studies they
appear to be broadly similar. The optimum scheduling for
these compounds has not yet been established; they have
high receptor affinity and therefore simple pharmaco-
dynamic modelling is inappropriate. A single intravenous
dose will probably provide adequate cover for 12-24 hours
and thereafter oral therapy will be given. To prevent delayed
emesis the duration of therapy is likely to be 3-5 days. For
treatment failures the addition of dexamethasone to
ondansetron has already been shown to improve emetic con-
trol and the combination of a 5HT3 receptor antagonist and
steroid will be the subject of randomized studies in the
future.
covering anticancer drugs are described. The National
Cancer Institute (USA) has recently implemented a
significant change in screening strategy based on the use of a
panel of multiple human cell lines, against which will be
tested a variety of synthetic chemicals as well as natural
products derived from plants and marine animals, and
recombinant biologicals. The rationale, strategy and early
results of this effect were described, and alternatives, such as
screening and synthesis directed at key biochemical targets
and design based on molecular modelling, were considered.
Finally, the position that cancer chemotherapy will remain
the primary tool for treatment of disseminated cancers but
will be used in more creative regimens with radiation therapy
and biological therapies was defended. Chemotherapy in the
year 2000 will use many of the current drugs, but will
integrate these agents with radiation therapy at the earliest
stages of disease for such tumours as breast cancer, head and
neck cancer and lung cancer, and will employ biological
agents to kill tumour cells (monoclonal antibodies), ablate
specific toxicities (colony-stimulating factors), promote sen-
sitivity to chemotherapy (growth factors and differentiating
agents), and discourage the development of drug resistance.
It is my rash prediction that a high percentage of patients
with non-metastatic presentations of colon, breast, head and
neck, bladder and oesophageal cancer, and perhaps even
malignant melanoma, will be cured by mixed-modality ther-
apy, each element enhancing the basic chemotherapeutic
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Chemical modulation of toxicity
P.S. Schein
US Bioscience Inc., Union Meeting Corporate Center, 920-B
Harvest Drive, P.O. Box 220, Blue Bell, PA 19422, USA.
Chemoprotection is an emerging discipline in cancer pharma-
cology, with two principal goals, reduction of the toxicity of
conventional doses of chemotherapy and allowance for
higher than usual doses to be administered safely and with
improved efficacy. The protector must not concurrently inter-
fere with the cytotoxic action on neoplastic tissue. Much
effort has been directed toward reducing toxicity for a prin-
cipal organ at risk: mesna-ifosfamide urothelial injury;
ICRF-187-doxorubicin cardiac toxicity; sodium thiosulphate-
intraperitoneal administered cisplatin renal toxicity; gluta-
thione-cisplatin renal toxicity; ACTH (4-9) analogue-cisplatin
neuropathy. Of increasing interest are the attempts to achieve
systemic protection where multiple organs are subject to
damage as with the use of high dose combination chemo-
therapy.
Diethyldithiocarbamate (DDTC) provides protection
against many forms of cisplatin toxicity without inhibiting
tumour response in murine models. However, in clinical trials
DDTC produced treatment-limiting adverse autonomic
effects, including severe diaphoresis, chest discomfort and
agitation, while the life-threatening haematological toxicity of
high dose carboplatin therapy was not apparently amelio-
rated.
Ethiofos (WR-2721) is a thiol that was selected from a
series of 4400 chemicals screened for radioprotective proper-
ties because of its superior efficacy and relative safety. High
tissue concentrations of the protective thiol are found in
normal organs within minutes after intravenous administra-
tion, whereas tumours have a limited uptake and therefore
remain vulnerable to chemotherapeutic attack. The profile
that has emerged in animal studies and Phase II and III
clinical trials is reduced toxicity to bone marrow, kidney,
peripheral nervous system and eighth nerve after treatment
with high doses of cisplatin and/or alkylating agents, with no
loss of antitumour efficacy. Hospitalizations resulting from
complications from intensive drug treatment are also decreas-
ed. In addition, preclinical studies have demonstrated that
ethiofos can reduce the mutagenic and carcinogenic activities
of radiotherapy and chemotherapy. Studies of combinations
of chemoprotectors and bone marrow colony stimulatory
factors are now planned as a new approach for achieving
dose-intensification with chemotherapy.
Clinical results with interferon and tumour necrosis factor
P. Selby
Institute for Cancer Studies, University of Leeds,
St James's Hospital, Leeds LS9 7TF, UK.
Despite the great success of interferon alpha in the manage-
ment of hairy cell leukaemia and its more modest success in
the management of other haemopoietic cancers, the place of
interferon in the management of solid tumours remains limit-
ed. In collected experience in the management of renal cancer
in almost 800 patients the response rate is only 16% (95%
confidence intervals, R 14-18%) and most responses are for
less than one year. A detailed analysis of the relationship
between dose and response does not suggest that further dose
escalation will increase response rates and the route of
administration does not influence outcome. No trials have
been completed which show a prolongation of survival with
interferon alpha although historical comparisons suggest that
there may be a prolongation of survival for a few patients.
Although the drug shows some activity in malignant
melanoma, neuroendocrine tumours, lymphoma, ovarian
cancer and carcinoid the effects are relatively trivial when
interferon is used to treat advanced disease. The advent of
interferon gamma and interferon beta has not resulted in
improved clinical results to date.
Greater promise exists for the use of interferon alpha to
maintain remissions after their induction by chemotherapy.
Significant results are reported in multiple myeloma and
indolent non-Hodgkin's lymphoma and trials are in progress
to evaluate this approach in ovarian cancer and lung cancer.
Adjuvant studies for renal cancer and malignant melanoma
are also in progress and in these areas the drug remains of
considerable interest.
Tumour necrosis factor was introduced enthusiastically as
the result of encouraging results in experimental animal
models and great public exposure. Phase I trials have been
completed using a number of routes and schedules and the
maximum tolerated dose in most studies is between 200-400
,Lgm-2 and limiting toxicities are hypotension, hepatic
enzyme changes and thrombocytopenia. At maximum toler-
ated doses in man the plasma concentrations are consider-
ably less than those required to produce regression of mouse
tumours. Clinical results are disappointing. Although target-
ed phase II studies are not yet reported in detail, cumulative
unpublished experience suggests that tumour regression is
uncommon and that no consistent pattern is emerging. The
value of tumour necrosis factor in combination with cyto-
toxic drugs or other biological treatments remains to be
explored.
Is there still a future for the small molecule in
developmental cancer chemotherapy?
M.F.G. Stevens
CRC Experimental Chemotherapy Group, Pharmaceutical
Sciences Institute, Aston University, Birmingham B4 7ET, UK.
Compounds which evolved from the in vivo screening pro-
grammes of the 1960s (S180-based), the 1970s (L1210, P388)
and 1980s (human xenografts) have, in general, failed in the
clinic and programmes directed towards the development of
analogues of these compounds should not have high priority.
Small molecule chloroethylating agents (nitrosoureas, imid-
azo-tetrazinones, chloroethyl sulphonates) are a case in point
where inherent resistance of human tumours with a capacity
to repair guanine 0(6)-alkylations (the Mer+ phenotype) can-
not be overcome, even at drug doses eliciting life-threatening
thrombocytopenia. The actions of small molecule 'antimeta-
bolites', which interfere with DNA replication and cellular
proliferation by inhibiting key DNA synthesizing and proces-
sing enzymes can be subverted by the tumour cell's ability to
amplify genes coding for these essential proteins. Looking
into the future, new generations of drugs designed to inter-
fere with the potein products of oncogenes (growth factors,
growth factor receptors) could be similarly flawed by the
target cell's simple resort to amplify the appropriate gene(s).
Only in the specific area of hormonal dependent tumours is it
clear that new small molecular weight drugs (i.e. mol.
wt. <500) might still make a major impact in the treatment
of common disease.
There is a school of thought that subscribes to the view:
'To cure a complicated disease requires a complicated
molecule'. However, clinical experience with some of the new
products of biotechnology (interferons, interleukins, tumour
necrosis factor, differentiation enhancers, tumour suppressor
factors, monoclonal antibodies alone, or conjugated to cyto-
toxins) does not engender overwhelming optimism. Undeni-
ably, these products elicit remarkably selective biological
effects in specific cell types. Certain of these properties
can also be promoted by small molecules, the prototype
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hexamethylene bisacetamide (mol. wt. 200) and the immune-
stimulant bropirimine (mol. wt. 260) being cases in point.
New research programmes directed to the discovery of small
synthetic agents which mimic the properties of the natural
'biological response modifiers' could have exciting outcomes.
In the longer term the prevailing pharmacological revolu-
tion, driven by opportunities presented by the products of
biotechnology, will be supplanted by a new era of chemical
synthesis. Close encounters of the molecular kind between
the new pharmacological tools and their targets rely on just a
few hydrogen bond contacts, or ionic or hydrophobic inter-
actions to trigger the biological effects; the bulk of the
molecule is irrelevant except insofar as it is essential to bring
these microstructures into functioning juxtaposition. Oppor-
tunities will soon emerge for the synthetic chemist to design
surrogate small(ish) molecules with appropriately-positioned
groups to mimic the properties of these natural molecules. If
the essence of the cancer problem concerns controlling the
expression of tumour-associated genes, then new generations
of molecules capable of selectively recognizing specific
nucleotide sequences in the major groove of DNA will be
required.
Realistic goals for the pharmaceutical industry in anticancer
drug development
R.C. Jackson
Parke-Davis Pharmaceutical Research Division,
Warner-Lambert Company, Ann Arbor, Michigan, USA.
Continued progress in anticancer drug development will
require both improved agents for the treatment of currently
sensitive malignancies, and the development of new kinds of
agent for those diseases that are at present almost totally
refractory to chemotherapy, such as metastatic colon car-
cinoma, and non-small cell lung cancer. Major advances in
this second category will require approaches to drug develop-
ment that exploit recent advances in the basic biology and
biochemistry of cancer. Areas under intensive study in the
pharmaceutical industry include agents directed at oncogene
products, and their associated growth factor receptors and
signal transduction pathways; novel topoisomerase inhibitors;
and new non-DNA-targeted compounds active against cells
with the multi-drug resistant (MDR) phenotype. While
macromolecular agents may be active against micrometas-
tases, because of drug delivery problems it seems likely that
small molecules will continue to be the most effective ap-
proach against established solid tumours. These ideas will be
illustrated by four approaches to the development of new
drugs for colon carcinoma.
A high proportion of colon tumours are intrinsically
MDR-positive, they have high DNA-repair activity and a
high fraction of non-cycling (Q) cells. These three properties
in combination confer resistance to all existing drugs. Thus,
one approach is to develop new cytotoxic agents active
against targets other than DNA, active against Q-cells and
able to overcome the MDR phenotype. With increasing
knowledge of tumour cell growth factor requirements, the
possibility arises of developing synthetic antagonists of
growth factor receptors. One growth factor for colon cancer
cells is gastrin, and synthetic antagonists (e.g. proglumide)
are known. Newer antagonists with high specificity and
nanomolar potency have been shown to inhibit growth of
colon cancer cells. Another class of agents, exemplified by
dinoline, have marked activity against colon carcinoma xeno-
grafts, with very low toxicity. The possibility exists that the
antitumour activity of this kind of compound is mediated by
effects on ion channels. Finally, kinetic studies predict the
existence of novel kinds of antimetabolite that act on sites of
positive feedback regulation. These compounds may switch
off pathways at substoichiometric concentrations, may dem-
onstrate "all-or-nothing" dose-response relationships, and
their target pathways may "remember" being inhibited, i.e.
stay switched off after inhibitor is removed.
These latter three classes of agents have more in common
with central nervous system drugs than with traditional
cytotoxic agents. Pharmaceutical industry laboratories, with
extensive experience (and large compound collections) in
CNS pharmacology are in a strong position to explore these
novel approaches to selective growth regulation.
Circulatory catabolic factors produced in cancer cachexia
S.A. Beck, T. McDevitt & M.J. Tisdale
Cancer Research Campaign Experimental Chemotherapy
Group, Pharmaceutical Sciences Institute, Aston University,
Birmingham B4 7ET, UK.
We have studied a transplantable colon adenocarcinoma of
the mouse (MAC16) as a model of human cancer cachexia.
This tumour produces extensive mobilizing of body fat at
small tumour burdens and without a reduction in food
intake. As a model of fat mobilization, we have used murine
epididymal adipocytes in vitro. Both FFA and glycerol
release from mouse adipocytes were enhanced by MAC16
adenocarcinoma extracts, suggesting the possibility of
lipolytic factors which may be responsible for the cachexia
seen with this tumour model. Using DEAE cellulose and
exclusion chromatography, the lipolytic factors were separ-
able and resolved into a number of fractions. Following
SG50 exclusion chromatography, the lipolytic factor(s) was
resolved into three fractions ofapparent molecular weights of
3, 1.5 and 0.7 kDa. Lipolytic factors of the same molecular
weight and charge characteristics on DEAE cellulose were
found in the serum and urine of cachectic cancer patients,
but not in normal serum or urine even after acute starvation.
A study of 26 cancer patients with various degrees of cach-
exia showed that the amount oflipolytic activity in the serum
correlated (R = 0.77) with the amount of weight loss they
had experienced. These results suggest that the lipolytic fac-
tors may be responsible for the cachexia seen in experimental
animals and humans.
Alterations in glucose metabolism in tumour-induced
cachexia
H.D. Mulligan & M.J. Tisdale
Cancer Research Campaign Experimental Chemotherapy
Group, Pharmaceutical Sciences Institute, Aston University,
Birmingham B4 7ET, UK.
Alterations in host glucose metabolism with the development
of cachexia were investigated using a murine colon adenocar-
cinoma (MAC16). This tumour produces about 33% loss of
body weight in male mice when the tumour burden repre-
sents only 2% of the total body mass. Weight loss occurs
without a decrease in food and water intake. This tumour
has been compared with another murine adenocarcinoma
(MAC13) of the same series in which cachexia does not
accompany tumour growth. Occasionally, growth of the
MAC16 tumour does not result in cachexia. Non-cachectic
MAC16 tumour bearing mice were therefore investigated as
an internal control.
From in vitro studies, we have shown that the MAC16 cell
line uses less glucose and produces more lactate and less CO2
per cell than the MAC13 cell line. We used a double-labelling
tracer technique to investigate the rate of glucose utilization
in vivo. The rate ofglucose utilization by the MAC16 tumour
was significantly less than that of the MAC13 tumour
(p<0.05). The rate ofglucose utilization by the testes, colon,
spleen and kidneys of cachectic mice was lower than the
corresponding organs of mice bearing the MAC13 tumour.
Animals bearing the MAC16 tumour that were cachectic also
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MAC16 tumour that were not cachectic. We have shown that
the rate of glucose utilization by the brain is significantly less
in all tumour bearing animals when compared to non-tumour
bearing controls. These results suggest that cachexia, which
occurs as a result of MAC16 tumour growth, involves a
decrease in the rate of glucose utilization by the host suggest-
ing that there may be a change to alternative substrates such
as lipids. The effect on host tissues may be due to a defect in
one or more of the enzymes involved in glucose metabolism.
Infective complications during chemotherapy for small cell
lung cancer (SCLC) in a population not subject to dose
reduction after severe or life-threatening sepsis
J.A. Radford', D. Ryder2, D. Dodwell', A.G. Kamthan'
& N. Thatcher'
'CRC Dept of Medical Oncology and 2Dept of Medical
Statistics, Christie and Wythenshawe Hospitals. Manchester,
UK.
Following severe (WHO grade 4) or life-threatening (WHO
grade 5) sepsis it is common practice to reduce doses of
cytotoxic drugs in subsequent cycles of treatment. This is
based on the assumption that fatal sepsis may result if full
doses are continued. However, such reduction in dose inten-
sity may adversely affect the outcome of chemotherapy. We
have studied a cohort of 383 patients with SCLC who
received treatment between May 1984 and June 1988 accord-
ing to five consecutive chemotherapy protocols administered
at the two hospitals comprising the Manchester Lung Group.
None of the patients were subject to any reduction in pro-
tocol dose although in occasional cases treatment was
delayed to allow full recovery from episodes of severe infec-
tion or myelosuppression. A total of 1,966 cycles of
chemotherapy were administered to 383 patients and of these
54 (7%) had at least one episode of severe or life-threatening
sepsis (SLTS). Seventeen (4.4%) patients died of infection; 4
deaths occurred in the group of 54 experiencing previous
SLTS ((7.4%) and 13 in the 329 patients with no previous
SLTS (3.9%)). Although statistically this is a highly
significant difference (P<0.005), only 4 deaths in this series
were potentially avoidable by dose reduction, the majority
(13) having occurred without the prior warning of SLTS in
earlier cycles of therapy. We consider that the concept of
dose reduction in cancer chemotherapy should be re-
examined.
Treatment of tumour-induced hypercalcaemia (TIH) with
pamidronate (APD): effect of infusion rate and scheduling
D. Dodwell', A. Howell2, & A. Morton2
'Dept. of Medical Oncology, Christie Hospital, Wilmslow
Road, Manchester M20 9BX, UK and 2Dept. of Nephrology,
Wellesley Hospital, Ontario, Canada.
Although a variety of mechanisms may contribute to the
pathogenesis of tumour-induced hypercalcaemia (TIH), the
most important pathophysiological process is excessive bone
resorption. The bisphosphonates, structural analogues of
pyrophosphate, are potent osteoclast inhibitors and slow the
rate of osteoclast-mediated bone resorption. They are
reported to be effective in over 80% of cases of TIH. Pami-
dronate is one of the most active ofcurrently available drugs,
but optimum dose rates and scheduling are not yet known.
We have performed three randomized studies in patients with
TIH (corrected serum Ca"+ > 3.0 mM) using a dose of
60 mg: to compare the results of an infusion given over one
day (8 hours), two days (4 hours each) or four days (2 hours
each) (30 patients); to determine the comparative efficacy of a
2 vs 4 hour infusion, (20 patients); and to compare 8 vs 24
hour infusions (25 patients). All patients were rehydrated
before treatment. Seventy-five patients (20% breast cancer,
37% non- smallcell lung cancer, 16% myeloma, 27% others)
are assessable to date. All but 4 patients achieved normocal-
caemia after pamidronate (71/75, 95%). No patient was com-
pletely refractory to pamidronate. The mean time to achieve
normocalcaemia was 5 days and there were no significant
differences between treatment groups in terms of time to
achieve a normal serum calcium, in the rate of fall or the
nadir. The hypocalcaemic effect of pamidronate was notice-
able the day after infusion, but there was a tendency for
those patients having a 24-hour infusion to have a short lag
phase. Urinary calcium excretion was markedly reduced with
no significant differences between treatment groups. Altera-
tions in systemic treatment and early death in some patients,
despite attaining a normal serum calcium, meant that it was
difficult to evaluate 'duration of normocalcaemia'. However,
there appeared to be little difference between treatment
groups. Median time for hypercalcaemia to recur was 23
days. Median survival of patients for whom no antitumour
treatment was available was less than 3 months. Toxicity was
minimal; rarely asymptomatic fever occurred after treatment.
These studies have shown that pamidronate is a safe and
effective drug in the treatment of TIH and that a single
infusion of 60 mg over 2 or 4 hours is as effective as 24 hours
or daily infusion regimens and is therefore to be preferred
because of its simplicity. It is clear however that the prog-
nosis for such patients remains poor, unless specific anti-
tumour therapy is available.
Dose intensity in ovarian cancer
J.R. Hardy", W.M. Hryniuk2 & E. Wiltshaw'
'Dept. of Gynaecologic Oncology, Royal Marsden Hospital,
London SW3, UK and 2Hamilton Regional Cancer Centre,
Hamilton, Ontario, Canada.
The relationship between outcome and projected dose inten-
sity (DI) has previously been analysed for first-line chemo-
therapy of advanced ovarian cancer. The DI of the CHAP
regimen (cyclophosphamide, hexamethylmelamine, adriamy-
cin, cisplatin) was used as the standard, DI = 1.0 (Levin, L.
& Hryniuk, W.M. (1987), J. Clin. Oncol., 5, 756). When
published combination regimens were analysed, the relative
DI of cisplatin correlated significantly with response and
survival. The median DI of 5 courses of standard carboplatin
(GFR based, equivalent to 367 mg m-2) and/or cisplatin
100 mg m-2 in the treatment of 96 patients with stage 3 or 4
ovarian cancer in this unit was 0.4 (range 0.38-0.42). The
response rate of 55% seen with this regimen corresponds to
that predicted by Levin and Hryniuk at this DI. We have
therefore analysed the DI of cisplatin (50 mg m-2) when used
in combination with high dose carboplatin (920mgM-2) in
the treatment of 18 patients with stage 4 ovarian cancer. The
median received DI for this regimen is 1.05 (range
0.83-1.05). This predicts for a response rate of >90%,
whereas the response rate seen was only 67%. This may
reflect the inclusion of only stage IV patients in the study.
Alternatively the relationship between DI and response may
not be linear at high dose.
Need nephrotoxicity limit dose intensity strategies in
ovarian cancer?
J. Hardy, S. Tan, I. Fryatt & E. Wiltshaw
Dept. of Gynaecologic Oncology, Royal Marsden Hospital,
London SW3 6JJ, UK.
The relative lack of cross toxicity between cisplatin and
carboplatin may enable dose intensity escalation not possible
with either agent alone. We have evaluated the renal toxicity
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tion. The glomerular filtration rate (GFR) using 51Cr EDTA
has been measured before and following treatment in patients
with ovarian cancer receiving: standard dose carboplatin
(CB), calculated according to GFR; AUC 6, equivalent to
300-400 mg m 2; cisplatin (CS) 100 mg m 2; high dose car-
boplatin (CB H-D), AUC 11, equivalent to 900-1000 mg
m 2; and high dose carboplatin in combination with cisplatin
(CB-HD + CS) 30-50 mg m-2. The Wilcoxon one-sided test
of difference was used to calculate the median reduction in
EDTA.
Median EDTA
No. of pre- post-
Group patients treatment treatment Median reduction
CB 80 67.5 59.0 -3.0 NS
CS 66 82.5 49.0 -35.5 p<0.001
CB H-D 26 80.5 66.0 - 12.5 p<0.OO1
CB H-D+CS 24 88.5 64.0 -15.5 p<O.001
The greatest reduction in EDTA was seen following single
agent cisplatin. High dose but not conventional dose carbo-
platin resulted in a significant reduction in EDTA but this
has been shown to be reversible when repeated >3 months
following completion of therapy. The addition of cisplatin at
doses up to 50 mg m-2 in order to increase dose intensity did
not add to the nephrotoxicity of high dose carboplatin alone.
Comparative opiate receptor affinities of morphine and its
active metabolite morphine 6-glucuronide
P. Thompson', D. Hucks', L. McLoughlin2,
A. Grossman', L. Rees2 & M. Slevin'
Depts. of 'Medical Oncology and 'Chemical Endocrinology,
St Bartholomew's and Homerton Hospitals,
London ECIA 7BE, UK.
Morphine-6-glucuronide (M6G) is a metabolite of morphine
(M) with greater analgesic activity. It has been suggested that
the 1i 2 receptor may be responsible for much of the toxicity
of M (Pasternak & Wood (1986), Life Sciences, 38, 1889).
Preliminary studies in man suggest M6G causes less respir-
atory depression and less nausea (unpublished data). Specific
opiate (J, gAl, p2 and 0) receptor-binding assays have been
performed to determine if this observed difference is due to
differing opiate receptor subsite affinities.
The methodology of Yoburn et al. ((1988), Life Sci., 43,
1319) using tritiated and cold enkephalin ligands was adapted
to give an ICG value for both compounds at each of the
specific opiate receptors. Opiate receptors were prepared
using brains from Wistar rats. Opiate receptor-binding assays
were performed in Tris-HCl buffer (pH 7.4) at 37°C. Assays
were in triplicate for cold ligand, M and M6G over the
concentration range 10-5 to 10-9. All assay tubes were
incubated for 5 minutes at 37°C before the addition of cold
ligand, M or M6G, and for 15 minutes after. The bound
ligand was separated from the free by filtration under
vacuum through Whatman.GF/B glass fibre filters. The filter
was then subjected to scintillation counting. The IC50 was
defined as the concentration which inhibits 50% of specific
binding of tritiated ligand. Results are shown in the table.
Receptor Morphine IC50 (nM) ±SEM M6G IC50 (nM) ± SEM
11 14± 1 (n=4) 84±16 (n=4) p=0.03
1 291±73 (n = 4) 219±18 (n = 5) NS
gA2 13± 2(n=4) 60± 8 (n = 5) p = 0.02
a 495±78 (n = 4) 240±35 (n = 5) p = 0.03
These results suggest that M has a higher affinity for the
p2 receptor than M6G and that the jA2 receptor may be
principally involved in mediating the toxicity of M thereby
accounting for the toxicity difference between the two com-
pounds. The increased affinity ofM6G for the a receptor may
in part explain its increased analgesic potency.
Comparison of the respiratory depression induced by
morphine and its active metabolite morphine--glucuronide
P.I. Thompson*", L. John2, J.A. Wedzicha2 &
M.L. Slevin'
'Dept. of Medical Oncology, St Bartholomew's and
Homerton Hospitals, London ECIA 7BE; and 'Dept. of
Thoracic Medicine, London Chest Hospital, London
E2 9JX, UK.
Morphine-6-glucuronide (M6G) is a metabolite of morphine
(M) and has been shown to have more potent analgesic
activity than M in animals (Tohuku (1971) J. Exp. Med.,
104, 45). Animal studies suggest an improved therapeutic/
toxic ratio. To determine if this hypothesis holds true for
man, 10 normal volunteers took part in a double-blind ran-
domized study comparing the effect of M 10 mg 70 kg-' i.v.
with M6G 1.0, 3.3 and 5.0 mg 70 kg-' i.v. on respiratory
function. Studies on each volunteer were carried out at least
one week apart. Resting respiratory function was monitored
for 10 minutes at 15 minutes before injection and at 0.25,
0.75, 1, 2, 3, and 4 hours after injection. The following
respiratory parameters were assessed: minute ventilation (VE),
respiratory rate, tidal volume (VT), expired CO2 and 02
concentrations (FeCO2 and FeO2), PaCO2 levels 15 minutes
before and 45 minutes after injection, and continuous trans-
cutaneous pCO2 and PO2 and O2 saturation. An ischaemic
model of pain, using a sphygmomanometer cuff inflated to
250mmHg for 5 minutes, was used to assess comparative
analgesic potency at 30 minutes before and 0.5, 1.5, 2.5 and
3.5 hours after injection. Analgesic potency equivalence to M
10mg 70kg-' was approximately 3.3 70 kg-' M6G. Mean
changes in respiratory parameters at 15 minutes are shown in
the table. P-values compare M6G doses with M
10 mg 70 kg-'.
M M6G M6G M6G
lOmg 1.Omg 3.3mg S.Omg
Change PaCO2 4.6 -0.6 -0.52 0.80
(mmHg) (p <0.005) (p <0.005) (p <0.05)
% Change VE -22.2 -2.7 -7.5 -7.7
(p<0.05) (p<0.05) (p = 0.09)
% Change FeCO2 5.9 -4.6 -4.4 -7.1
(p<0.01) (p<0.01) (p<0.5)
Nausea or vomiting was experienced by all but one subject
receiving M but was not seen with M6G. All subjects exper-
ienced mild to moderate drowsiness with M compared with
none for M6G. M6G is a potent analgesic and this study
suggests it causes less respiratory depression than M as
shown by a lack of rise in PaCO2 and % change FeCO2, and
lesser fall in VE. This difference may be explained by the
lower binding affinity of M6G to the gA2 opiate receptor
(unpublished observations) thought to be implicated in the
respiratory depression but not in the analgesia seen with M
(Life Sci. (1986), 38, 1889).
High dose prochlorperazine infusion for cisplatin (P)
induced emesis: double-blind randomized cross-over
comparison with high dose metoclopramide
S.S. Akhtar, Z. Akhter, M.A. Bhat & G. Mohammed
Dept. of Medical Oncology S.K.I.M.S., Post Bag 27,
Srinagar, Kashmir, India 190011.
This double-blind, randomized, cross-over study was con-
ducted to compare the safety and efficacy of high dose
prochlorperazine and dexamethasone (HDPD) with an effec-
tive and safe combination of high dose metoclopramide and
dexamethasone (HDMD) in controlling P-induced emesis.
All patients entered had received no prior chemotherapy
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patients received high dose P(100 mgmr-2) as a part of their
treatment. Either prochlorperazine (40 mg loading dose as an
infusion, 30 minutes before CT followed by 80 mg infusion
over 8 hours) or metoclopramide (3 mg kg-' loading dose as
an infusion, 30 minutes before CT followed by 4 mg kg-'
infusion over 8 hours) was administered. Dexamethasone
20 mg, common to both the arms, was administered 30
minutes before CT. Of the 20 evaluable patients complete
control of emesis was observed in 4(20%) with HDPD and
1(5%) with HDMD. Significantly fewer vomiting and retch-
ing episodes were observed with HDPD than with HDMD
(P<0.01). The overall severity of nausea was significantly
less with HDPD (P<0.05). There was no significant differ-
ence in the incidence of adverse reactions and the treatment
was well tolerated. We conclude that HDPD combination is
a well tolerated and more potent antiemetic combination for
P-induced emesis.
An increase in subclinical follicular lymphoma (FL) can be
detected by the polymerase chain reaction (PCR) and may
be the best predictor of clinical relapse
C.G.A. Price, S. Grant, E.L. Dorey, F.E. Cotter, B.D.
Young, A.Z.S. Rohatiner & T.A. Lister
ICRF Dept. of Medical Oncology, St. Bartholomew's
Hospital, London EC], UK.
PCR has been used to examine peripheral blood (PB) and/or
bone marrow (BM) for the presence of t(14;18) cells in
patients at low risk of recurrence of FL. The following
results were obtained: 5/8 patients with stage I disease (after
conventional staging investigations, including BM examina-
tion) had subclinical BM infiltration at presentation; and 3
patients had circulating t(14;18) cells despite being in con-
tinuous clinical remission for 10, 11 and 15 years respectively.
These findings raise general questions about the prognostic
value of small numbers of t(14;18) cells detected during
remission of FL. Of greater importance may be quantitative
information about the level of infiltration within the range
exclusively detected by PCR, i.e. approx. 1 cell in 106 to 1 cell
in 100. We have used a quantitative adaptation of PCR,
which incorporates a limiting dilution assay, to compare
levels of infiltration between patients and in sequential sam-
ples from the same patients in follow up. The results in a
group of patients who went on to receive intensive
chemoradiotherapy supported by autologous transplantation
(ABMT) after achieving complete remission from recurrent
FL are illustrative: (i) 10 patients with t(14;18) + ve FL all
had evidence of infiltration in harvested BM although this
was morphologically and phenotypically normal. The level
ranged from I cell in 106 to 5%; (ii) one patient had increas-
ing subclinical infiltration of BM detected in annual 'surveil-
lance' samples before relapse 21 years after ABMT; (iii) 3
patients who remain in remission > 18 months after ABMT
have circulating t(14;18) cells which have increased in
number at least 10-fold in one year. Further follow up is
required, but it seems possible that such quantitative evalua-
tion will be more useful in predicting clinical outcome than
mere demonstration of PCR positivity.
Disease assessment with the polymerase chain reaction
(PCR) in follicular small cleaved cell lymphoma
T. Hickish', M. Soukop2, T.J. McElwain' &
D. Cunningham'
'The Royal Marsden Hospital, Sutton, Surrey; and
2Glasgow Royal Infirmary, Scotland, UK.
A characteristic in 80% of follicular small cleaved cell lym-
phomas (FSCCL) is the 14:18 translocation which juxtaposes
the bc12 gene on chromosome 18 to 5' of one of immuno-
globulin junctional exons (JH) of the heavy chain locus. The
breakpoint in bcl2 may occur through the major breakpoint
region (MBR), the minor cluster region (MCR) or rarely 5'
to the bcl2 gene. The resulting DNA sequence is unique to
the malignant clone and can be used as a template for the
PCR.
Currently we are evaluating the role of PCR in monitoring
disease status in FSCCL. PCR is performed using a bcl2-JH
concensus sequence oligonucleotide primer pair. For one pair
the bc12 primer is directed approximately 200 bp upstream
compared to that of another pair (220 bp for the MBR and
150bp for the MCR). Reaction products are run on an
agarose gel stained with ethidium bromide and visualised
under UV light. A fragment is authentic, that is, is due to
PCR across the 14;18 breakpoint, if between reactions its size
difference corresponds to the difference in the priming posi-
tions of the bcl2 directed primers. Our system enables PCR
across 1.3 Kb of both MBR and MCR and allows for the
detection of the majority of bc12 rearrangements.
Results: (sensitivity 1 in 105 cell - determined using a cell line
(SU-DHL4) carrying the t(14:18))
Tumours: 7/14 MBR + ve
3/14 MCR + ve
4/14 no rearrangement detected
Marrows: 7/14 PCR + ve
PCR + ve/histology -ve = 2
PCR = ve/histology + ve = 0
Blood: 2/19 PCR + ve in patients in relapse
These data show PCR is able to upgrade the marrow staging
in a proportion of patients (14%). Furthermore PCR of
blood may be of value in providing additional staging in-
formation. In this series the instance of bc12 rearrangements
is lower than reported by others. We are exploring other
targets for PCR which may be more generally applicable to B
cell malignancies.
The relationship between C-erbB-2 expression, S-phase
fraction (SPF) and clinical outcome in breast cancer
S.M. O'Reilly, D.M. Barnes, R.S. Camplejohn,
R.R. Millis, J. Bartkova, R.D. Rubens & M.A. Richards
ICRF Clinical Oncology Unit, Guy's & Richard Dimbleby
Dept for Cancer Research, St Thomas' Hospitals, London,
UK.
Overexpression of the c-erbB-2 oncogene has been associated
with a shorter relapse-free survival (RFS) and survival (S) in
breast cancer patients. To test whether the adverse prognosis
associated with gene expression is due to more rapid prolifer-
ation of c-erbB-2 positive tumours, the relationship between
c-erbB-2 expression (assessed immunohistochemically), SPF
(measured by flow cytometry) and prognosis was analysed
for 172 women with primary breast cancer. c-erbB-2 staining
was independent of tumour size, nodal status, tumour grade
and DNA ploidy but was more common in ER negative
tumours (P = 0.02) and PgR-ve tumours (P = 0.03). Only a
weak correlation between c-erbB-2 staining and SPF was
observed (r=0.18). For women with node negative disease,
c-erbB-2 staining did not significantly influence either RFS or
S. In contrast, women with node positive disease whose
tumours were scored as c-erbB-2 positive had a significantly
shorter RFS (P = 0.006) and S (P = 0.02) than their c-erbB-2
negative counterparts. Multivariate analysis showed that c-
erbB-2 staining and SPF gave independent information on
RFS for women with node positive disease. We conclude that
the adverse prognosis associated with c-erbB-2 expression is
not solely attributable to more rapid proliferation of the
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Prognostic significance of C-erbB-2 oncoprotein expression
in breast carcinomas
A.H. McCann, P.A. Dervan, M. Codd, W. Gullick &
D.N. Carney
Mater Hospital, Dublin & Hammersmith Hospital, London,
UK.
Using the 21N polyclonal antibody, we have immunohisto-
chemically stained 314 primary breast carcinomas to identify
tumours overexpressing the C-erbB-2 oncoprotein. Positive
membrane staining was present in 17% (n = 53) of these
carcinomas. Using the X2 test C-erbB-2 positive tumours were
significantly associated with poorer grade (P<0.01) and with
a poorer degree of differentiation (P<0.03) but not with any
other prognostic factors investigated. C-erbB-2 positive
patients had a shorter disease free interval (P<0.001) and
overall survival (P<0.001). Stratifying patients on the
basis of ER status indicated that C-erbB-2 + /ER - patients
had an overall worse prognosis than the other subgroups
(P<0.001). Over-expression of this oncoprotein also pre-
dicted for a worse prognosis in patients with axillary node
metastases (P<0.001) and in patients who had a grade II
tumour (P<0.001). We conclude that the C-erbB-2 oncopro-
tein may be a valuable predictor of disease outcome in
defined subsets of patients.
Chimeric human/mouse bispecific monoclonal antibodies
S. Songsivilai, P.M. Clissold & P.J. Lachmann
Molecular Immunopathology Unit, MRC Centre, Cambridge
CB2 2QH, UK.
The production of murine bispecific antibodies (BsAbs) has
concentrated mainly on two methods: fusion of two hybrid-
omas or hybridomas and immune cells; and chemical linking
of two antibody molecules or their derivatives. For in vivo
immunotherapy, human immunoglobulins would be preferred
since the rodent monoclonal antibodies induce an anti-glo-
bulin response. In a recent development, murine antibodies
have been genetically modified by replacing the constant
regions with their human counterparts. These chimeric
human antibodies have been shown to be less immunogenic
than rodent antibodies.
We describe a new strategy for producing bispecific anti-
bodies by introducing two sets of chimeric human/mouse
immunoglobulin genes with two different specificities into
murine myeloma cells. Variable regions of the heavy and
light chain immunoglobulin genes of a murine hybridoma
secreting an IgGl,k antibody to hepatitis B surface antigen
(HBsAg) were amplified by the polymerase chain reaction
(Orlandi et al. (1989) Proc. Natl Acad. Sci. USA, 86, 3833),
and cloned into expression plasmids containing human con-
stant region genes, gamma 1 and kappa, respectively. These
plasmids were co-transfected with the expression plasmids
containing chimeric human/mouse immunoglobulin genes for
anti-NIP specificity (Bruggemann et al. (1987), J. Exp. Med.,
166, 1351), into a murine myeloma cell line. Bispecific anti-
ABsAg-anti-NIP antibodies were identified in the cell culture
supernatants. This approach can be used to produce bi-
specific antibodies for in vivo immunodiagnosis and therapy,
and will enable BsAbs to be made, that cannot be produced
by conventional techniques.
Ricin toxin a chain cytotoxicity against tumour cells
mediated by a bispecific monoclonal antibody, and its
potentiation by ricin toxin B chain
M.J. Embleton, M.V. Pimm, R.A. Robins, R.W. Baldwin,
A. Charleston & A. Markham
Cancer Research Campaign Laboratories, University of
Nottingham, University Park, Nottingham NG7 2RD, UK.
A bispecific monoclonal antibody recognizing both carcino-
embryonic antigen (CEA) and ricin toxin A chain (RTA) was
investigated for its ability to target RTA to CEA-expressing
tumour cells in vitro. The antibody, 636, induced highly
significant cytotoxicity against gastric carcinoma line
MKN45 in the presence of recombinant or minimally glyco-
sylated RTA used at a concentration below that known to be
intrinsically toxic. Anti-CEA and anti-RTA monospecific
antibodies did not mediate increased RTA cytotoxicity, and
636 was not inhibitory in the absence of RTA. Cytotoxicity
was dependent on 636 antibody concentration and was selec-
tive for CEA-expressing cells; it did not occur with CEA-
negative cells. The addition of ricin toxin B chain (RTB)
markedly potentiated cytotoxicity in the presence of both
RTA and 636. It could also potentiate the effect of RTA
alone, but was much less efficient than when 636 antibody
was included. The bispecific antibody also substantially
restored the cytotoxic activity of whole ricin in the presence
of galactose at a concentration which blocked binding of the
toxin to target cells. It was concluded that the 636 bispecific
antibody was highly effective in targeting the toxic moiety of
the molecule to CEA-expressing cells, and did not interfere
with the ability of the B chain to facilitate cellular incorpora-
tion.
Endocytosis of immunotoxin H65-RTA in relation to its
cytotoxicity for CD5-bearing target cells
V.S. Byers'2, I.Z.A. Pawluczyk', D. Fishwild2, S. Carroll2,
M.R. Price', R.A. Robins', A. Clarke' & R.W. Baldwin'
'Cancer Research Campaign Laboratories, University of
Nottingham, Nottingham NG7 2RD, UK and 2XOMA
Corporation, Berkeley, CA, USA.
Monoclonal antibody H65 reacts with an epitope on the
CD5 molecule expressed upon the majority of human T
lymphocytes. An immunotoxin constructed by conjugating
this antibody to the A-chain subunit of ricin toxin (RTA) is
specifically cytotoxic in vitro for normal and leukaemic T
cells and has proved efficacious for the treatment of T cell
mediated diseases. This includes suppression of graft versus
host disease in bone marrow transplantation and treatment
of rheumatoid arthritis. Analysis of the in vitro cytotoxicity
of H65-RTA for normal and malignant T cells has demon-
strated different pathways of immunotoxin action. In the
initial phase (2 to 3 hours) of target cell exposure to
immunotoxin, cytotoxicity is greatly enhanced by potenti-
ators, whereas, following further incubation cytotoxicity is
effected without the requirement for potentiators. The rela-
tionship between immunotoxin H65-RTA endocytosis and
target cell cytotoxicity has been investigated to provide a
clearer understanding of the influence of potentiators. Under
the conditions selected, the amount of cell bound H65-RTA
endocytosed by MOLT-4 cells over a 60-minute incubation
period was determined to be in the region of 20 to 35%.
This process was sensitive to acidification of the cytosol by
treatment with ammonium chloride and regulation of the
Na+/H+ exchanger with amiloride. Inhibition of endocytosis
of H65-RTA by cytosol acidification is consistent with up-
take being by receptor mediated endocytosis. Internalised
immunotoxin proceeds to be rapidly transferred to the lyso-
somes when degradation processes may render it non-func-
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cytotoxicity for MOLT-4 cells is markedly enhanced by the
presence of ammonium chloride during the initial period of
immunotoxin endocytosis (Byers et al., in preparation) since
this treatment is considered to slow lysosomal trafficking.
Although receptor mediated endocytosis appears to be a
major pathway for entry of H65-RTA into target cells, some
immunotoxin is also endocytosed by other routes not inhib-
ited by cytosol acidification. This is viewed as the component
active following prolonged exposure of target cells to
immunotoxin.
New monoclonal antibodies recognizing colorectal tumour
associated epitopes derived by stimulation of idiotypic
networks
L.G. Durrant, E. Jacobs, M.R. Price, R.A. Robins,
E.B. Austin & R.W. Baldwin
Cancer Research Campaign Laboratories, University of
Nottingham, Nottingham NG7 2RD, UK.
Stimulation of the host idiotypic network to produce anti-
bodies which recognize autologous tumour is a new approach
for the therapy of colorectal cancer. The monoclonal anti-
body C14 is an IgM antibody which recognizes the Y hap-
tenic blood group antigen, which is a very useful colorectal
tumour associated epitope. In a search for an IgG variant of
C14, for new useful tumour associated epitopes and to inves-
tigate the potential network that would be stimulated by an
anti-C14 idiotypic antisera we have used the C14 monoclonal
antibody to stimulate idiotypic networks.
Rats were immunized with this monoclonal antibody and
the serum was purified by removal of anti-mouse antibodies
on an irrelevant mouse IgM column and then the anti-idio-
typic antibodies were bound and eluted from C14 mono-
clonal antibody. The resultant antiserum was highly specific
for C14 monoclonal antibody and inhibited binding of C14
to Y hapten. This antiserum was used to induce mice to
produce anti-anti-idiotypic antibodies to the C14 monoclonal
antibody some of which should recognize the Y hapten (this
is highly expressed on the C14 antigen purified from saliva).
However, after 4 injections, although a weak anti-C14 anti-
gen response could be detected, the predominant response
was the induction of mouse anti-rat antibodies. To boost the
specific response the mice were then given C14 antigen. High
titres of anti-C14 antigen antibodies were induced. Following
cell fusion 5 new monoclonal antibodies recognizing C14
antibody have been derived. One of these antibodies binds to
Y hapten. All of the monoclonal antibodies preferentially
bind to colorectal tumour rather than normal tissue and they
recognize a cell surface and a secreted antigen. They all
recognize related epitopes as determined by competition and
bridging assays and they all share idiotypic determinants as
recognized by the purified rat anti-C14 idiotypic anti-sera.
Stimulation of idiotypic networks not only can lead to the
generation of new monoclonal antibodies recognizing tumour
associated epitopes, but also they allow characterization of
the potential networks that can be stimulated by idiotypic
immunotherapy.
Antibody directed enzyme prodrug therapy (ADEPT) in
human tumour xenograft models
S.K. Sharma', K.D. Bagshawe', G.T. Rogers',
P.J. Burke', C.J. Springer', P. Antoniw', R.W. Boden',
F. Searle', R. Melton2 & R. Sherwood2
'CRC Labs, Med. Oncology, Charing Cross Hospital,
London W6 and 2PHLS, CAMR, Porton, Hants., UK.
The targeting of enzymes to human tumours where they can
convert relatively harmless prodrugs into potent cytotoxic
alkylating agents has been established in a human choriocar-
cinoma (CC3) and a human colon adenocarcinoma xenograft
(LS174T). Our preliminary studies have been carried out with
carboxypeptidase G2 (CPG2) targeted to either CC3 or to
LS174T xenografts after linking to F(ab')2 fragments of anti-
hCG or anti-CEA. Optimal localization occurred by 24
hours. In the CC3 model, clearance of enzyme activity from
plasma occurred within 72 hours allowing administration of
the prodrug and elimination of the tumour. In the LS174T
model, enzyme activity persisted in blood which resulted in
conversion of prodrug with lethal effects. A safe level of
enzyme in blood was reached only after six days when effici-
ency of targeting was impaired. Injection of prodrug under
these conditions did not cause significant growth delay. Re-
producible growth delay was, however, obtained when a
galactosylated monoclonal antibody (SB43), raised against
CPG2, was injected 19 hours after the conjugate. SB43 in-
activated residual enzyme activity in blood and accelerated
clearance without diminishing localized enzyme, enabling the
prodrug to be given within 24 hours without toxicity. Use of
SB43 allows the cycle ofconjugate and prodrug to be repeat-
ed to achieve an enhanced therapeutic effect.
Phase I/II study of chimeric B72.3 antibody in
radioimmunotherapy of colorectal carcinoma
R.H.J. Begent, J.A. Ledermann, K.D. Bagshawe,
A.J. Green, A.M.B. Kelly, D. Lane, D.S. Secher,
M.R. Dewji & T.S. Baker
Cancer Research Campaign Laboratories, Charing Cross
Hospital, London and Celltech Ltd., Slough, UK.
The toxicity, immunogenicity and distribution of a chimeric
antibody with mouse B72.3 variable regions and human IgG4
constant regions (Whittle et al. (1987), Prot. Eng., 1, 499) has
been investigated in patients with colorectal carcinoma. Six
patients have received 10-20mg of the antibody labelled
with 20-50 mCi "'I. Treatment was repeated after 3-4
weeks provided that no human antimouse IgG, nor human
antichimeric antibody, was found in the patients' serum. One
to three (mean two) treatments have been given and two
patients remain eligible for further treatment. One patient
produced human antichimeric antibody and human anti-
mouse antibody after the first treatment. No anti-antibody
response has been found in the other five patients. No tox-
icity attributable to the treatment was seen. Serial
measurements of activity in tumour, blood, liver and lung
were made using single photon emission tomography with
scatter correction (Green et al. (1990) Eur. J. Nucl. Med. in
press). Mean beta half-life of clearance of antibody from
blood was 116 hours (range 37-166), from tumour 226 hours
(range 162-256), from liver 155 hours (range 141-173) and
from lung 166 hours (range 135-182). Antibody localization
was seen in tumours where radioactivity was retained longer
than in other tissues. Repeated therapy with chimeric B72.3
antibody is feasible in some patients.
The role of degradable starch microsphere (DSM) in
antibody targeted therapy for hepatic metastases from
colorectal cancer: a preliminary study
A. Jewkes, S. Darby, M. Winslet, W.H. Allum
& J.W. Fielding
Academic Dept. of Surgery, Queen Elizabeth Hospital,
Birmingham, UK.
Hepatic metastases occur in 30-50% of patients and < 10%
are resectable. Treatment by chemotherapy, or radiolabelled
monoclonal antibody (MAb), is controversial. Even after
regional perfusion, MAb is taken up in minute proportions
requiring lethal body doses for therapy. Temporary cessation
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perfusion may, however, increase tumour MAb uptake and
minimise body irradiation.
Eleven patients (mean age 60 [39-80] years) with hepatic
metastases (replacement = 45% [30-55%] from a gastro-
intestinal primary [colorectal = 8, gastric = 3]) underwent CT
scanning, liver biopsy and hepatic angiography after in-
formed consent. DSM (300 mg) was then administered ± anti
CEA MAb LI1-285-14 via the hepatic artery. Biodistribution
was monitored with a Spherex Monitoring System. Angio-
graphy failed in 4 patients. In 7, after DSM alone, the
hepatic passing fraction was reduced to 66.3 ± 11.5%. After
DSM + whole antibody MAb (200jig) (n = 3), there was no
hepatic antibody retention after 3 minutes. After DMA +
antibody fraction (Fab 300 mg) (n = 4), a median of 8%
(0-27%) of injected dose was retained for a minimum of 3
(3-20) minutes with a subsequent plateau.
Co-administration of DSM with whole antibody is unlikely
to increase intrahepatic MAb targeting. In conjunction with
FAb2 fragments, however, DSM may reduce monoclonal
washout and have a role in the targeting of fractionated
MAb therapy for hepatic metastases.
Properties of c-myc methylphosphonodiester/phosphodiester
chimeric antisense oligonucleotides
D.M. Tidd, D.G. Spiller, C.C. Goodwin &
H.M. Warenius
CRC Dept of Radiation Oncology, University of Liverpool,
Clatterbridge Hospital, Wirral, L63 4JY, UK.
A normal phosphodiester oligodeoxynucleotide 15-mer com-
plementary in sequence to the first 5 codons of the c-myc
gene has been reported to inhibit MYC protein synthesis in
HL60 cells and mitogen stimulated lymphocytes when pre-
sented exogenously in culture media. However, several UK
laboratories, including our own, have been unable to repro-
duce these results and we have ascribed this failure, at least
in part, to the rapid degradation of the oligonucleotide
by serum nucleases, predominantly a 3'-phosphodiesterase,
present in the culture media. Methylphosphonate oligonuc-
leotide analogues are resistant to nucleases but are poorly
soluble, exhibit weak hybridization affinity and are unable to
activate degradation of target RNA by ribonuclease-H. Pro-
gressive replacement of terminal phosphodiester linkages by
methylphosphonates in the myc antisense 15-mer resulted in
stepwise reductions in the melting temperature (Tm) of hy-
brids formed with a synthetic target RNA from 54°C to
38C. However, the chimeric oligonucleotide with three
methylphosphonodiester linkages at each end was freely solu-
ble, exhibited reasonable hybridization efficiency (Tm = 48C)
and being exonuclease-resistant was considerably more stable
in culture media than the all-phosphodiester molecule. In
addition, the chimeric oligonucleotides retained the capacity
to direct degradation of target RNA by ribonuclease-H. We
conclude that by combining the desirable properties of both
structures, chimeric oligonucleotides may offer some advan-
tage over either type of oligonucleotide alone. However,
considerably more work is required to define the parameters
which govern the efficacy of antisense oligonucleotides in
intact cells.
Single step transformation of human epitheial cells by
mutant H-ras oncogene
D. Wynford-Thomas', J. Bond', S. Staddon2
& N.R. Lemoine2
'CRC Thyroid Tumour Biology Group, UWCM, Cardiff
and2ICRF Molecular Oncology Group, Hammersmith
Hospital, London, UK.
Although there is overwhelming correlative evidence for a
role of ras oncogene mutation in human tumorigenesis, ex-
perimental proof has been surprisingly problematic. In
human, in contrast to rodent, cells, there has been striking
failure to demonstrate transforming effects of ras in vitro,
despite its apparent involvement at an early stage in many
tumours such as colon and thyroid. Using the thyroid as a
model, we have now re-examined this question using ampho-
tropic retroviral vectors. Primary epithelial (follicular) cell
cultures obtained from normal'human thyroid were infected
with medium from the following amphotropic retroviral pro-
ducer cells: 1) psi-CRIP-DOEJ, containing the human H-ras
val 12 mutant driven by a MoMuLV LTR; 2) psi-CRIP-
MTF24, containing the same gene driven by a zinc-inducible
metallothionein promoter; and 3) psi-CRIP-RASIIGAL, con-
taining viral H-ras. One to two weeks after infection, rapidly-
growing colonies were visible against the quiescent normal
background epithelium (-50 per dish of 101 infected). Two
distinct morphologies were seen: a) a typical cobblestone
epithelial pattern; b) fusiform/strap-like cells not evident in
the normal culture. Representative clones of both types
showed positive immunostaining for epithelial cytokeratins 8
and 18, and for the thyroid-specific protein thyroglobin. Ex-
pression of ras protein, assessed immunocytochemically and
by Western blotting using Ab Y13-259, was increased relative
to the normal epithelium. Preliminary data suggest a high
degree of anchorage independence (P.E. in methocel -20%).
Clonal growth ceased at around 20p.d.; no immortalized
derivatives have been observed. We conclude that expression
of mutant c- or v-H-ras can induce partial transformation of
a differentiated normal human epithelial cell while preserving
tissue-specific functions.
Multiple events in tumour development and progression in
colorectal carcinogenesis
C. Paraskeva', S. Harper', A. Hague', K. Audcent',
R.A. Mountford2, D.C.C. Bartolo3 & A.C. Williams'
'Dept. Pathology, The Medical School, University Walk,
Bristol BS8 ITD; and Depts. 2Medicine & 3Surgery, Bristol
Royal Infirmary, Bristol BS2 8HW, UK.
To understand the function of tumour suppressor genes it is
important to have suitable model cell culture systems for the
re-introduction of these genes into cells whether by transfec-
tion, infection or microcell fusion and to know at which
stage (precancer or cancer) in the multistage process of car-
cinogenesis these genes act. We have isolated a series of cell
lines from colorectal adenoma, premalignant tumours some-
times called polyps, and carcinomas from familial adeno-
matous polyposis and sporadic patients (Paraskeva et al.
(1984), Int. J. Cancer, 34, 49; Paraskeva et al. (1989), Cancer
Res., 49, 1282). Analysis of these cell lines indicated that
chromosome 1 may be involved in in vitro immortalization.
Monosomy for chromosomes 17 and 18 are important and
central steps in colorectal carcinogenesis but are insufficient
for the tumorigenic phenotype. Potential biological markers
to study tumour progression and the possible role of these
suppressor genes include: aneuploidy, in vitro immortaliza-
tion, abnormal differentiation, clonogenicity, ras gene activa-
tion, production of proteinases and tumorigenicity. We have
used these markers in experiments to transform a diploid
premalignant adenoma cell line through a series of sequential
steps to a tumorigenic phenotype. This is the first experi-
mental evidence for the adenoma carcinoma sequence and
provides an in vitro model to study multistage carcinogenesis.
In collaboration with Eric Stanbridge we are reintroducing
by microcell fusion back into precancer and cancer cell lines
chromosomes implicated in colorectal carcinogenesis and
examining the cells for the suppression of the transformed
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Clonal composition of primary tumours and their
metastases studied by genetic tagging with a neomycin
resistance gene B
F. Moffett, D.F. Badan, J.B. Taggart & D. Tarin
Nuffield Department of Pathology, Oxford University, John
Radcliffe Hospital, Headington, Oxford OX3 3DU, UK.
When eukaryotic cells are transfected, the site of integration
of the donor DNA into the genome is random, unless special
steps are taken to target its insertion. Previous work has
indicated that integration patterns for any transfectant,
visualized as a specific arrangement of bands by probing
Southern blots of its DNA, are characteristic and stable
(Talmadge et al. (1987), Invasion Metastasis, 7, 197). Using
DNA integration patterns to tag cells is a potentially power-
ful technique in tumour biology to study the behaviour of
cell populations. The present work was undertaken to re-
examine questions related to the clonal composition of
tumours during their growth and spontaneous metastasis.
Data suggest that the stability of banding patterns is not
absolute and may prompt caution in the analysis of lineage
and behaviour with this method. A mouse fibrosarcoma line
(KHT) was transfected with a cosmid construct carrying a
neomycin resistance gene. DNA from resistant clones was
screened using pSV2 neo as a probe. Four cell lines, each
with a different banding pattern, were injected (s.c.) both
individually and as a mixture, into immunosuppressed mice.
After four weeks, DNA from primary tumours and their
associated metastases were analysed. It was found that, in
agreement with previous work, most tumours arising from
the mixed population gave a banding pattern consistent with
that of one of the original cell lines, CB16. However, the
results also indicated that the integration pattern of some cell
lines can change in vivo. Compared to their primary tumours,
fewer bands were present in DNA from individual metastases
and in some cases new bands were observed. We conclude
that in most primary tumours arising from the inoculation of
mixed tagged clones the majority of cells are likely to be the
progeny of only one of the original cell lines. However, the
integration patterns of DNA from metastases suggested
secondary deposits can develop from variants not detected in
the injected cell population, but which arise subsequently by
genetic recombination and selection events. In a second series
of experiments using a non-metastatic line it was apparent
that a large number ofclones in the inoculum may contribute
to tumorigenicity. The different results with two lines may
reflect intrinsic properties of the cells.
Inhibition of '"I-EGF binding to quiescent Swiss 3T3
fibroblasts and XB/2 keratinocytes by UVB light
G. Brooks, M.W. Goss & I.R. Hart
Imperial Cancer Research Fund, Lincoln's Inn Fields,
London WC2A 3PX, UK.
Ultraviolet (UV) radiation is a major causative agent in
human skin cancer. Exposure of cells in vitro to high doses of
UV radiation leads to severe cytotoxic effects resulting from
DNA damage, whereas lower doses (I -100 J m-2) produce a
variety of more subtle biological effects, including DNA syn-
thesis and cell proliferation. The biochemical mechanisms
leading to these low dose effects currently are unknown. We
now show that exposure of Swiss 3T3 fibroblasts and XB/2
keratinocytes to UVB (302 nM) irradiation causes a dose-
dependent inhibition of '251I-EGF binding which is maximal
60 minutes after initiation of the assay. Doses required to
evoke a 50% inhibition of binding in the fibroblasts and
keratinocytes are 81 J m-2 and 85 J m-2 respectively. Trypan
blue exclusion assays showed this inhibition was not due to a
cytotoxic effect. Scatchard analyses of normal and UVB-
treated cells demonstrated that UVB exposure resulted in a
decrease in the number of high affinity binding sites with no
change in affinity constant. EGF receptor transmodulation
was mediated via a protein kinase C (PKC)-independent
pathway since UVB failed to stimulate phosphorylation of
the 80 kDa substrate protein of PKC. Furthermore, down-
regulation of PKC levels failed to affect the extent of UVB
induced inhibition of 25I-EGF binding. '25I-PDGF binding to
these cells was unaffected by light doses up to 280 J m2,
indicating that inhibition of '251I-EGF binding is a specific
event. Thus, the transmodulation effect of UVB on the EGF
receptor appears to be mediated through a novel signal trans-
duction pathway.
The role of serum in the inhibition of growth by activators
of protein kinase C (PKC) in human A549 lung carcinoma
cells
T.D. Bradshaw & A. Gescher
CRC Experimental Chemotherapy Group, Pharmaceutical
Sciences Institute, Aston University, Birmingham B4 7ET, UK.
The growth of A549 cells cultured in medium with 10% fetal
calf serum (FCS) is arrested for 6 days by the PKC activator
12-0-tetradecanoyl-phorbol-13-acetate (TPA) (Dale & Ges-
cher (1989), Int. J. Cancer, 43, 158). Cells grown in media
supplemented with 2% Ultraser (US), a defined serum subs-
titute, underwent only a very transient growth inhibition of
<24 h following TPA treatment. The hypothesis was tested
that serum constituents play a role in the maintenance of
growth arrest. Cells were cultured with either FCS or new
born calf serum (NBCS). Growth was assessed by measuring
incorporation of [3H]-thymidine into the cells after incubation
for 48 hours with TPA (10 nM). In the presence of 10, 5, 1
or 0% FCS TPA reduced growth to 10 +2, 28 + 10, 43 + 6
and 87 ± 6% of control respectively (mean ± SD, n = 9). In
cells supplemented with NBCS (10%) TPA decreased cell
proliferation by only 48 ± 2% (n = 6). Total PKC activity
was similar in naive cells maintained in FCS or NBCS, but in
medium the US PKC activity was only 32 ± 3% (n = 9) of
that seen in cells with FCS. Exposure to TPA under all
conditions caused translocation of PKC from the cytosolic to
the particulate fraction and its subsequent downregulation.
The PKC activator and experimental antitumour drug bryo-
statin 1 inhibited cell growth only transiently in the presence
or absence of FCS, but it caused translocation and down-
regulation of PKC similar to TPA. It appears that main-
tenance of TPA-induced growth inhibition involves complex
PKC-independent processes mediated by serum factors.
Effects of oestradiol, TPA and bryostatin on growth, the
transcriptional regulation of oestrogen responsive genes and
the expression of TGF-1 in human breast tumour lines
J. Nutt, A.L. Harris & J. Lunec
Cancer Research Unit, University of Newcastle upon Tyne,
UK.
The phorbol ester, TPA (10 nM), produced a marked reduc-
tion in the growth of MCF7 cells in full growth medium but
had only a small effect on MDA and T47D cells. The effect
of TPA on MCF7 cells was partially reversed by bryostatin,
suggesting bryostatin does not mimic TPA in this system
even though both are believed to act via effects on protein
kinase C. When the oestrogen receptor +ve MCF7 and
T47D cells were maintained in charcoal-stripped serum, the
increase in DNA synthesis on stimulation with oestradiol was
inhibited with 50 nM TPA in MCF7 cells but not in T47D
cells. The effects of these treatments on the expression of the
oestrogen responsive genes pNR2 and pNR100 (Cathepsin-D)
were examined. Rather than preventing transcription of these
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pNRl00 mRNA levels in MCF7 cells and the combined
effect of oestradiol and TPA had a marked synergistic effect
in increasing the mRNA levels of these genes. In T47D cells
pNR2 transcripts were not detected and the increase in
pNR100 expression was not affected by TPA.
We conclude that the inhibitory effect of TPA on the
growth stimulation of MCF7 cells by oestradiol was not due
to a general inhibition of the expression of oestrogen respon-
sive genes.
An alternative possibility examined was that the inhibitory
effects of TPA on MCF7 cells might be due to the stimula-
tion of TGF-P, acting as an autocrine inhibitory growth
factor. Oestradiol treatment of MCF7 cells reduced the levels
of TGF-P mRNA, whereas TPA produced a marked in-
crease. The combined effect of TPA and oestradiol further
increased TGF-P mRNA above the levels seen with TPA
alone. Bryostatin had little effect of TGF-P expression either
alone or in combination with oestradiol. These observations
suggest that the inhibitory effect of TPA on MCF7 cells is
due to an autocrine inhibition by TGF-P.
Synthesis and release of TGFa from the myeloid leukaemia
cells HL60 treated with phorbol ester
D. Davies, S. Farmer & P. Alexander
Department of Medical Oncology, The University of
Southampton, Southampton General Hospital, S09 4XY, UK.
We had previously shown, immunohistologically, that macro-
phages which had infiltrated human carcinomas contained
TGFa. To learn more about the synthesis and release of
TGFx by macrophages we investigated, as a model system,
HL60 cells that had been induced to differentiate and express
a macrophage phenotype. In the absence of the phorbol
ester, PMA, HL60 cells did not stain for TGFa. After cultur-
ing for 24 hours in the presence of PMA, the cells became
adherent and also expressed the monocyte-macrophage sur-
face marker CD11 as well as TGFa. The amount of TGFa
observed, immunohistologically, increased with further cul-
turing and plateaued after 72 hours. Concomitantly, we
detected TGFa-like activity in the supernatant of the cul-
tures. The TGFx was measured after the culture supernatants
had been separated chromatographically and the fractions
assayed for their ability to initiate, in confluent and quiescent
foreskin fibroblasts, DNA synthesis which was capable of
being inhibited by antibodies directed against the EGF recep-
tor, but not by antibodies against EGF. Acid as well as
detergent extracts of PMA treated HL60 cells yielded TGFa-
like activity, the majority of which co-chromatographed with
6 kDa TGFa on a monoQ ion exchange column. The
amount of TGF(x-like activity associated with the cells was,
however, much less than that found in the culture super-
natant. When these experiments were repeated in the
presence of protease inhibitors, the TGFa-like activity in the
culture was reduced by 80%, whereas the cell associated
TGFa-like activity was increased four-fold, or more, and
showed a different pattern on chromatography. Since the
production of diffusible TGFx can be blocked by inhibiting
protease activity in the differentiated HL60 cells, it seems
likely that the tumour growth promoting properties of
macrophages may require not only the production of TGFa,
but also the action of proteases.
Multdple neuropeptides mobilise calcium in small cell lung
cancer
P.J. Woll & E. Rozengurt
Imperial Cancer Research Fund, PO Box 123, Lincoln's
Inn Fields, London WC2A 3PX, UK.
Small cell lung cancer (SCLC) typically secretes a variety of
peptides and hormones. Of these, the bombesin-like peptides
including gastrin releasing peptide (GRP), have attracted
attention as putative autocrine growth factors. Mobilization
of cytosolic calcium is an early event in the action of GRP
and other growth factors. Using the fluorescent calcium
indicator, Fura-2-AME, in five independent SCLC cell lines,
we now show that the neuropeptides bradykinin, cholecysto-
kinin, glanin, neurotensin and vasopressin, in addition to
GRP, stimulate rapid, transient increases in cytosolic calcium
in SCLC, at nanomolar concentrations. Responsiveness to
individual peptides is heterogeneous between the diverse cell
lines, but the ability to respond to regulatory peptides is a
general phenomenon. Peptide responses demonstrate homo-
logous desensitisation and are blocked by ligand-specific
antagonists, indicating that they are mediated by distinct
receptors. We suggest that multiple calcium-mobilizing
neuropeptides may regulate the growth of SCLC.
In vitro and in vivo response of A549 cells to a factor
partially purified from steroid-treated human fetal lung
fibroblasts
V. Speirs & R.I. Freshney
CRC Department of Medical Oncology, University of
Glasgow, Glasgow G12 9LX, UK.
We have purified, partially, a factor from steroid-treated fetal
lung fibroblast conditioned medium. This factor, designated
MOG-FDF, is heat and alkali stable, but acid labile and
partially protease labile. Incubation of A549 alveolar lung
carcinoma cells with MOG-FDF induced pulmonary surfac-
tant synthesis, a marker associated with differentiation in
this cell line. MOG-FDF had no effect on A549 cell growth
in monolayer, but reduced clonogenicity in suspension
(p<0.02) and plasminogen activator activity (p<0.002) by
30%. There was also a 40% increase in total cellular and
secreted glycosaminoglycans. These observations imply that
the cells are becoming more differentiated and potentially less
malignant. Intraperitoneal administration of MOG-FDF to
nude mice bearing A549 xenografts markedly reduced the
growth of the xenograft (p<0.01). This was accompanied by
an alteration in tumour histology, with extensive tissue reor-
ganization and the formation of glandular-like structures,
suggesting movement towards a more differentiated pheno-
type. Preliminary observations with xenografts of three other
tumours suggest that the carcinostatic effect of MOG-FDF
may be specific, at least to lung.
Inherent sensitivity to chemotherapeutic drugs of testis tumour
cell lines
G.R. Coren, E.J. Osborne, M.C. Walker, D.I. Harris,
T.A. Maheady, C.N. Parris & J.R.W. Masters
University College London, St Pauls Hospital, 24 Endell
Street, London WC2H 9AE, UK.
Continuous cell lines derived from non-seminomatous testi-
cular germ cell tumours are hypersensitive to cisplatin and
adriamycin (Walker et al. (1987), J. Natl Cancer Inst., 79,
213) and gamma-radiation (Parris et al. (1988), Int. J. Radiat.
Biol., 53, 599), reflecting the curability of these tumours in
patients. To determine if testis tumour cell lines are hypersen-
sitive to chemotherapeutic drugs with different mechanisms
of action (antimetabolites, topoisomerase II inhibitors, anti-
biotics, alkaloids and alkylating agents), we compared the
sensitivities of five bladder cancer cell lines with those of
six testis tumour cell lines to twelve anticancer agents
(adriamycin, m-amsacrine, bleomycin, cisplatin, colchicine,
5-fluorouracil, methotrexate, methylnitrosourea, mitomycin-
C, mitozolomide, vinblastine, VP-16). Dose-response curves
were obtained using a MTT assay, with a minimum of three
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mean IC,, (concentration of drug causing a 50% inhibition
of cell growth), the testis tumour cell lines were more sen-
sitive to every agent. For the drugs most frequently used to
treat testicular tumours, the mean ICo of the bladder cancer
cell lines was greater than that of the testis tumour cell lines
by a factor of 1.9 for vinblastine, 4.3 for cisplatin, 8.3 for
VP-16 and 16.2 for bleomycin. These data confirm that testis
tumour cell lines are hypersensitive to anticancer agents with
various mechanisms of action, and indicate that these human
cancer cell lines provide a model system with which to inves-
tigate the molecular basis of drug sensitivity.
Can culture of A549 carcinoma cells under conditions
conducive to differentiation alter the chemosensitivity of the
cells to adriamycin?
V. Speirs & R.I. Freshney
CRC Department Medical Oncology, University of Glasgow,
Glasgow G12, UK.
A549 cells were cultured on filter wells with, or without,
foetal lung fibroblasts in the presence and absence of 0.25 tAM
dexamethasone (DX), since these conditions are known to
enhance differentiation in this particular cell line, and the
response of the cells to adriamycin (ADR) was determined.
With ADR alone (no fibroblasts), there was an increase in
plating efficiency of about 10%, and an increase in colony
size, at sub-toxic drug concentrations (,0.1 riM). DX alone
reduced the number of colonies by approximately 20%.
Combining DX with various concentrations of ADR gave a
greater stimulation of clonal growth (50%) at sub-toxic con-
centrations. On the addition of fibroblasts transfilter, control
plating efficiency increased from 50 to 59% and from 41 to
66% in the presence of DX. Low concentrations of ADR
had no growth stimulatory effect in the presence or absence
of DX. While there was no difference in the ID50 in the
absence of fibroblasts, in the presence of fibroblasts DX
reduced the ID50 from 3 JM to 0.2 JM. These results suggest
that conditions conducive to maximum induction of differ-
entiation may increase chemosensitivity at pharmacological
concentrations. As the anomalous increase in plating
efficiency in low concentrations of ADR was abolished by
culture in fibroblasts, this may be a nutritional artefact.
Overexpression of P-glycoprotein in Chinese hamster ovary
cells following fractionated X-irradiation in vitro
R.D.H. Whelan"2, K. Deuchars2, L.K. Hosking', V. Ling2
& B.T. Hill'
can influence Pgp expression and screening programmes
designed to correlate Pgp expression with clinical drug resis-
tance should therefore be extended to include irradiated
tumours.
Sensitivity and resistance to platinum compounds in human
lung cancer cell lines
P.R. Twentyman, K.A. Wright & T. Rhodes
MRC Clinical Oncology and Radiotherapeutics Unit,
Hills Road, Cambridge CB2 2QH, UK.
Cisplatinum (CP) is one of the most effective drugs in the
treatment of small cell and non-small cell lung cancer as well
as other malignancies. A major objective of analogue syn-
thesis is the development of compounds which retain activity
in CP-resistant cells. We have developed a panel of human
lung cancer cell lines with a range of sensitivities to CP and,
from three of them, sublines with acquired CP-resistance.
Dose response curves have been obtained using a 6-8 day
MTT assay with continuous drug exposure. Seven small cell
lines gave ID50 values for CP ranging from 0.034 to 0.50pg
ml'-' whilst the values for large cell line COR-L23 and
adenocarcinoma line MOR were 0.12 and 0.85ptg ml-'
respectively. Resistant sublines of small cell NCI-H69, COR-
L23 and MOR, derived by in vitro exposure to increasing
doses of CP, showed 9-fold, 4-fold and 3-fold resistance to
CP respectively. For CP, carboplatin (CB), iproplatin (CHIP)
and tetraplatin (TET) the range of ID50 values for the small
cell panel was 14.7, 10.0, 6.0 and 3.6 respectively. Resistance
factors ( = ID50 resistant/ID50 parent) for the lines with
acquired resistance were:
DRUG
CP
CB
CHIP
TET
NCI-H69
8.8
3.9
2.3
1.0
COR-L23
4.3
6.5
5.3
5.6
MOR
3.5
1.5
1.0
0.9
It is clear that the CP-resistant subline of COR-L23 has a
much broader resistance profile than the other lines. In NCI-
H69 and MOR, total lack of cross-resistance to TET is seen.
Similarly the range of IDso values in the small cell panel is
the lowest for TET. CP-resistance in this panel of cell lines
cannot be accounted for by variations in glutathione or
glutathione S transferase activity and further mechanistic
studies are in progress. The lines provide an appropriate
model system for screening new platinum analogues for use
in the clinical therapy of lung cancer.
'Imperial Cancer Research Fund Laboratories, London WC2A
3PX, UK; and 2Ontario Cancer Institute, Toronto, Canada.
Clinical drug resistance has been observed in patients treated
not only with chemotherapy, but also with prior radio-
therapy. We have previously shown that in vitro exposure of
a series of mammalian tumour cell lines to fractionated
X-irradiation resulted in the expression of resistance to vinca
alkaloids and epipodophyllotoxins, but not to anthracyclines
or to X-rays (NCI Monograph (1988), 6, 177). The basis of
this resistance has been studied with a series of X-ray-treated
Chinese hamster ovary cell lines. Consistent with the classic
multidrug resistance phenotype these lines: i were resistant to
multiple drugs, but not to X-rays; ii had increased levels of
P-glycoprotein (Pgp), as judged by Western immunoblotting
using the C219 monoclonal antibody; iii showed reduced
tritiated-vincristine accumulation; and iv were sensitive to
reversal of vincristine resistance by verapamil. Pgp over-
expression occurred without Pgp gene amplification or
significant alteration in Pgp mRNA levels, implicating an
alteration at the translational and/or post-translational level.
These data provide evidence that exposure to X-irradiation
A multinuclear NMR investigation of biochemical
differences between sensitive and multidrug resistant cell
lines
M.R. Muller', T.A. Moore2, P.G. Morris2
& P.R. Twentyman'
'MRC Clinical Oncology and Radiotherapeutics Unit,
MRC Centre, Hills Road, Cambridge CB2 2QH; and
2Department of Biochemistry, University of Cambridge,
Tennis Court Road, Cambridge CB2 IQW, UK.
Multinuclear NMR spectroscopy is a powerful technique for
the study of the metabolism of sensitive and drug resistant
cells. As a model, we used the established human lung cancer
cell line H69/P and its multidrug resistant counterpart H69/
LX10. We compared the 'H and natural abundance '3C
spectra of perchloric acid extracts of the parent resistant cell
line. The most striking difference was one new peak in each
of the spectra from resistant cells which has been identified as
formate. The new peaks have identical chemical shifts to
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when the pH was increased from 7.0 to 11.0. A non-acid
extraction method also showed the presence oflarge amounts
of formate in resistant cells indicating that formate was not
an artefact of the perchloric acid extraction procedure. Fur-
thermore, comparison of 'H and '3C spectra from a multi-
drug resistant variant EMT6/AR1.0 of the mouse tumour cell
line EMT6/P also showed the presence of an equivalent
formate peak. Studies are underway to explain the possible
role of formate in multidrug resistance.
Repair of platinum-induced DNA damage in cell lines and
human tumours
P. Harnett, I. Hickson & A.L. Harris
Molecular Oncology Laboratory, Imperial Cancer Research
Fund, John Radcliffe Hospital, Headington, Oxford OX3 9DU,
UK.
Human tumours exhibit a spectrum of response to platinum
compounds, ranging from marked sensitivity (e.g. testicular
carcinoma) to de novo resistance (e.g. pancreatic carcinoma).
We are investigating the potential role of DNA excision
repair mechanisms in the spectrum of tumour response to
platinum. Protein extracts prepared from cell lines or direct
biopsies of human tumours are reacted with plasmid DNA
containing intrastrand platinum-DNA adducts. Platinum
excision repair events are detected by the incorporation of
radioactive nucleotides into repair patches. Protein extracts
from a platinum sensitive testicular carcinoma cell line show
considerably less excision repair capacity than an extract
made from normal human testis. Preliminary results suggest
that extracts from direct biopsies of bladder and ovarian
carcinoma (platinum sensitive tumour types) possess less
platinum repair capacity than extracts from HeLa or lym-
phoblastoid cell lines. Platinum sensitive CHO cell lines
deficient in repair of inter- and intrastrand platinum cross-
links have also been defined using this assay. The results
suggest that DNA repair mechanisms may play a role in
tumour response to platinum chemotherapy. This in vitro
assay may also allow the characterization of DNA repair
mechanisms at the protein or genetic level.
The identification of drug resistance in ovarian malignancy
using the MTT assay
J.M. Sargent, J.K. Wilson, A.W. Elgie, C.G. Taylor
& J.G. Hill
Departments of Haematology and Gynaecology, Pembury
Hospital, Kent TN2 4QJ, UK.
The prognosis of ovarian cancer (FIGO Stage III or IV) is
very poor. A predictive drug sensitivity test before each
course of chemotherapy could improve long-term survival.
We describe a feasibility study using the MTT assay to assess
the sensitivity of individual ovarian tumours to cytotoxic
drugs. Ascitic fluid (38) and/or tumour biopsies (27) were
obtained from 46 patients. There was a linear relationship
between cell numbers and the OD of formazan produced.
Incubating 1 x 105 cells with 100iLg MTT for 4 hours gave
optimum formazan production. Formazan crystals were dis-
solved in DMSO. Cells obtained from ascitic fluid and solid
tumour in the same patient showed the same sensitivity
profile. Good reproducible results were obtained from 41
patients. Drug effect was remarkably varied between patients.
The platinum derivatives produced the greatest cytotoxic
effect. De novo resistance to all drugs tested was found in
15% of cases. On comparison of the effects of the platinum
analogues and anthracycline analogues, similar effects were
found in 62% and 75% of samples respectively. Cross-
resistance patterns were comparable to the clinical response
rates. In view of the variation in drug effect between patients,
the proximity to clinical response rates, the ease of testing
and high percentage of successful assays, we believe this
method is suitable for identifying drug resistance in ovarian
cancer.
Nifedipine plus etoposide in the treatment of metastatic
solid tumours: a phase I study
P.A. Philip', K. Tonkin', S. Monkman2, J.R. Idle2,
J. Carmichael' & A.L. Harris'
'ICRF Clinical Oncology Unit, Churchill Hospital, Oxford
OX3 7LJ; and 2Department of Pharmacological Sciences,
University of Newcastle, Framlington Place, Newcastle upon
Tyne, TE2 4HH, UK.
Heterogeneous expression of P-glycoprotein in breast cancer
using two monoclonal antibodies, C219 and MRK16
G.C. Wishart', J.A. Plumb', J.J. Going2, A.M. McNicol2,
C.S. McArdle3 & S.B. Kaye'
'CRC Department Medical Oncology, 2 Glasgow University,
University Departments Pathology and 3Surgery, Royal
Infirmary, Glasgow, UK.
A previous study showed detectable levels of mdr-I mRNA
in primary breast cancers using a cDNA probe to mdr-1. We
have now investigated P-glycoprotein (P-gp) expression by
immunocytochemistry on frozen sections of 28 primary
breast cancers (all untreated) using two monoclonal
antibodies against different epitopes of P-gp (C219 and
MRK16) and an indirect alkaline phosphatase method.
Staining with C219 revealed heterogeneous expression in
epithelial cells in 21 of 29 tumours with marked stromal
staining in 25. Although levels of staining were lower with
MRK16 the same pattern was observed with expression in
both epithelial (16 of 28) and stromal (12 of 29) cells. The
stromal cells were confirmed as non-epithelial by positive
staining with a monoclonal antibody against vimentin and
the absence of staining when incubated with the anti-
cytokeratin Cam 5.2. These results confirm P-gp expression
in untreated primary breast cancers and suggest that stroma
may play a role in drug resistance in breast cancer.
Nifedipine (NF) is a calcium channel blocker commonly used
in the treatment of hypertension and angina. In vitro studies
have shown that it can reverse multidrug resistance (MDR)
phenotype. Etoposide (E) is active in a variety of solid
tumours. We investigated 14 patients with different solid
tumours who were judged to be resistant to conventional
systemic therapy; renal cell ca (5), breast ca (3), hepatoma
(2), ovarian adenoma (2), soft tissue sarcoma (1), melanoma
(1). Nine patients had received prior chemotherapy with
agents other than E. Patients were treated with NF slow-
release in 6-day courses repeated every 3 weeks. NF dose was
raised from 40 mg to 80 mg twice daily, with only one dose
escalation permitted per patient. E was administered i.v. on
day 2 (100-200 mg m-2) and orally on days 3 and 4
(400-600 mg per day). Plasma NF levels were determined in
10 patients at the third dose of NF;
Dose
mg
40
60
80
mean Cmax
tg 1-'
155.0
208.7
261.3
mean AUC
lAgh-1 ml-'
1.0
2.4
2.7
no.
2
5
3
Median number of courses received was two. Side effects
of NF were significant at the 80 mg dose level and correlated
well with the pharmacokinetic data; 3 out of 6 patients
experienced headaches and dizziness, 2 of whom had to have
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greater than 30 mmHg. Myelosuppression was encountered
with E, with 4 patients developing WHO grade 3/4
leucopenia and 1 patient grade 3 thrombocytopenia. These
toxicities were greater than expected and could refer to
altered E pharmacokinetics which has been investigated in 10
patients. There were no objective responses to this regimen.
The predominant mode of action of E is via topo II
isomerase. However, E has been shown to be involved in
MDR phenotype. Although the clinically achievable levels of
NF (<1ItM) may have an effect on other parameters such
as tumour blood flow, these levels are significantly lower than
those that modify MDR in vitro (> 5IAM). Therefore, NF is
unsuitable for clinical trials assessing modulation of MDR
because of its toxicity.
A clinical pharmacological assessment of the potential
clinical application of a single isomer D-verapamil as a
resistance modifier
J.L. Godden, J.H. Ahmed, P.A. Meredith & H.L. Elliott
Department of Medicine & Therapeutics, Stobhill General
Hospital, Glasgow G12 3UW, UK.
It is widely accepted that the calcium antagonist verapamil,
which is a racemic mixture of D- and L-isomers, is able to
increase chemosensitivity in several multidrug-resistant cell
lines but clinical applicability has been restricted by the
cardiotoxic side effects of the high doses required to produce
concentrations equivalent to in vitro activity (2-6.6;M;
900-2700 ng ml-'). There is experimental evidence that D-
verapamil may be less cardiotoxic than racemic verapamil
but with comparable activity as a drug resistance modifier
(Plumb et al. J. Biochem. Pharmacol. in press). Therefore,
this study investigated the cardiovascular side effects and
plasma concentrations of D-verapamil in man.
In a double-blind, crossover, partially randomized study of
8 healthy male volunteers (age 27 ± 7 years, weight
74.5 ± 6.5 kg) single doses of placebo, 240 mg racemic
verapamil and 3 doses (250, 500 and 1000 mg) of D-
verapamil were assessed during a series of study days, at
weekly intervals, with measurements of cardiac conduction
(PR interval on ECG), plasma drug concentrations, blood
pressure and heart rate at frequent intervals up to 12 hours
after dosing. Significant prolongation of the PR interval by
53 ± 21 ms occurred with 240 mg racemic verapamil and was
not exceeded by any dose of D-verapamil: 17 ± 6 with
250 mg, 29 ± 19 with 500 mg and 41 ± 28 ms with 1000 mg.
However, transient postural hypotension was observed with
1000 mg D-verapamil. Peak plasma drug levels in the target
range were obtained with both 500 mg and 1000 mg D-
verapamil and predictions of steady state concentrations
indicate that 500 mg three times a day would produce the
concentrations desired for drug resistance modulation (i.e.
over 1000 ng ml-') for most of the 24 hours without serious
cardiovascular adverse effects.
The in vitro and in vivo testing of pyrrolidino-iodo-tamoxifen,
a new analogue of the antioestrogen tamoxifen
S.K. Chander', R. McCague2 & R.C. Coombes'
'St George's Hospital Medical School, London SW17, and
2Institute of Cancer Research, Sutton, Surrey SM2 SNG, UK.
Biological activity of a new analogue of the antioestrogen
tamoxifen, pyrrolidino-iodo-tamoxifen (PIT - R. McCague,
Halogenated Tamoxifens, Brit. Pat. Appl. 8621908/1986), was
investigated in vitro using the MCF-7 cell line and in vivo
using the hormone responsive, oestrogen receptor expressing
NMU induced rat mammary tumour. Oestrogen receptor
binding studies using rat uterus cytosol showed that PIT had
at least five times greater relative binding affinity for the
oestrogen receptor compared with tamoxifen. Cell culture
studies were carried out to investigate the effects of PIT on
the growth of MCF-7 cells. These cells were grown in
Dulbecco's Modified Eagles medium without phenol red and
supplemented with 5% steroid depleted fetal calf serum. Cell
counts were made after 7-days treatment with 100 nM drug.
PIT caused a two-fold greater inhibition of cell growth,
which was significantly different compared to tamoxifen
(P<0.001). The in vivo activity ofPIT was investigated using
the rat model. PIT was given at a dose of 0.2 mg per rat in
0.2 ml peanut oil intramuscularly for 5 days a week for 4
weeks. Tumour measurements were made once a week. PIT
caused regression of all tumours and 58% regressed by
> 50%. In comparison, tamoxifen, given at the same dose as
PIT, did not cause regression of all tumours. Of those which
did regress, only 42% regressed by >50%. In conclusion,
our preliminary studies on PIT have shown it to be a more
effective inhibitor of oestrogen than tamoxifen both in vitro
and in vivo, consistent with its greater binding affinity for the
oestrogen receptor.
In vitro and in vivo inhibitory effects of the gastrin
receptor (GR) antagonist L-365,260 on the rat pancreatic
tumour cell line, AR42J
S.A. Watson', P.J. Elston', L.G. Durrant' & D.L. Morris2
'Cancer Research Campaign Laboratories and 2Department
of Surgery, University of Nottingham, Nottingham
NG7 2RD, UK.
The pancreatic tumour cell line AR42J was found to be
positive for GR as assessed by a radio ligand binding assay
using 1251 Gastrin-17 (G17). The affinity of receptors (5 x 104
cell-') for binding human G17 was 1 x 10-9M. L-365,260
(Merck, Sharpe and Dohme) is a benzodiazepine and a selec-
tive GR antagonist binding to both GR and CCKB receptors.
It was found to bind competitively to GR on AR42J cells,
with the concentration inducing 50% inhibition of 5 x 10-1'
M '25I G17 binding being 4.5 x 10-8 M for L-365,260 com-
pared with 6 x 10-9 M for G17 itself. Inhibition of 1251I G17
binding to AR42J cells induced by prior incubation (1 hour)
with unlabelled G17 began to reverse after 3 hours from 80%
to 33% and 23% after 4 hours. Prior incubation with L-
365,260 induced greater inhibition of binding of 125I G17;
60% at 3 hours and 51% at 4 hours which was significant
(P<0.05). G17 was found to be mitogenic for AR42J cells
as assessed by "Se-selenomethionine uptake and cell counting
(growth stimulation 170 to 250% of untreated control at the
optimal concentration of 5 x 10-10 M G17). L-365,260 at
2.5 x 10-6 M and 2.5 x 10-7M (55 x and 5.5 x the dose
required to displace 5 x 10-10 M '25I G17) reduced optimal
G17-stimulated mitogenesis in 3/3 experiments. The growth
of AR42J xenografts in nude mice was increased to 280% of
PBS treated controls by administration of G17 (10 ig per
mouse daily by osmotic mini-pump, P<0.027). This stimula-
tion was blocked by co-administration of L-365,260, dosed
orally (5 mg kg daily, P<0.034). We have shown that 71%
of human colorectal and 100% of human gastric primary
tumour cells possess GR (5 x 102 to 104 per cell), thus
therapy with potent GR antagonists may have therapeutic
potential.
Growth modulation of two lymphoma cell lines by a novel
calcitriol analogue MC903
T. Hickish', M. Soukop2, B.C. Millar', T.J. McElwain'
& D. Cunningham'
'Royal Marsden Hospital, Sutton, Surrey and 2Glasgow
Royal Infirmary, Scotland, UK.
After apparently successful induction chemotherapy almost
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therefore there is a requirement to develop novel treatments
for application to the maintenance phase. We have pre-
viously shown that alfacalcidol, which is metabolized to cal-
citriol, can produce tumour regression in 30% of patients
with low grade non-Hodgkin's lymphoma. The dose-limiting
toxicity of alfacalcidol is hypercalcaemia but the analogue
MC903 has similar antiproliferative effects to calcitriol but
100 times less of an effect on mineral metabolism. We have
studied the growth modulating effect of calcitriol and MC903
(Leo laboratories) on two diffuse histocytic cell lines SU-
DHL8 and SU-DHL4. The latter has a t(14;18) characteristic
of 80% of follicular small cleaved cell lymphoma. Toxicity
was measured using the incorporation of 3H thymidine and
by the growth of colonies in soft agar. Results were:
Survivingfraction
Cpm Controls Calcitriol MC903 molar
Min-' Mean SD Mean SD Mean SD 10-6 10-7 10-8
SU- 22079 4564 706 346 112 46 MC .46 .50 .53
DHL4 903
SU- 3815 1218 229 134 202 103 calci- .48 .52 .54
DHL8 triol
These data show MC903 and calcitriol produce a similar
reduction in the thymidine uptake suggesting an antiprolif-
erative effect on both cell lines. The clonogenic assay shows
an antiproliferative effect that is similar for the two drugs on
the clonogenicity of SU-DHL4 cells. These data suggest
MC903 may be an effective antiproliferative agent in lym-
phoma and indicate a role for a calcitriol analogue in the
maintenance phase of low grade lymphoma.
Mechanism of flavone acetic acid-induced tumour blood
flow inhibition
V. Mahadevan, S.T.A. Malik, A. Meager & I.R. Hart
Imperial Cancer Research Fund, Lincoln's Inn Fields,
London, WC2A 3PX, UK.
Flavone acetic acid (FAA), an investigational antitumour
agent which is active against several subcutaneously (s.c.)
transplanted murine tumours, causes early shutdown of
blood flow in these tumours. Indeed, this effect is believed to
be a prime determinant in FAA's antitumour action. How-
ever, the mechanism whereby FAA induces this vascular
shutdown is unknown. By measuring the clearance of intra-
tumourally injected radiolabelled Xenon ('33Xe) as an index
of tumour blood flow, we have demonstrated an early, pro-
gressive and sustained reduction of blood flow in a s.c. Colon
26 tumour in Balb/c mice treated with intraperitoneal (i.p.)
FAA (200 mg kg-'). This reduction, noticeable as early as
one hour after FAA injection, peaked at 3 hours (T+ (min)
for 133Xe clearance 117.3 ± 36.4 vs 7.8 ± 0.85, for controls
n = 5/ group). Significant inhibition was still apparent 48
hours after a single injection of drug. Intravenous pretreat-
ment of tumour bearing mice with an antiserum against
recombinant murine tumour necrosis factor-a prevented this
observed blood flow inhibition (Ti (min) 10.8 ± 1.2 vs
65.6 ± 8.0 for controls pre-treated with non-immune sheep
serum. n = 7/ group). Furthermore, in vitro, FAA induced
TNF secretion from murine peritoneal cells and splenocytes.
Our results indicate that FAA-induced vascular shutdown in
Colon 26 tumours is mediated by tumour necrosis factor.
Induction of tumour hypoxia by TNF and FAA: interaction
with bioreductive drugs
The role of the vasculature in the anti-tumour action of
flavone acetic acid
L.J. Zwi', B.C. Baguley2, J.B. Gavin' & W.R. Wilson'
'Department of Pathology, University of Auckland
and 2Auckland Cancer Research Laboratory, Auckland,
New Zealand.
Flavone acetic acid (FAA), an experimental anti-cancer agent
with a broad spectrum of activity against solid tumours in
mice, appears to act by an indirect mechanism. Using a
double label fluorescent marker technique, we showed that
FAA caused discrete foci of perfusion loss within 15 minutes
of administration in Colon 38 and EMT6 tumours. In addi-
tion, FAA caused more than 100 times the level of cell kill in
vascularized intramuscular EMT6 tumours compared to
avascular EMT6 intraperitoneal spheroids (Zwi et al. (1989),
J. Natl Cancer Inst., 81, 1005). Site- or size-related factors
other than vascularization were excluded by examining the
effect of FAA on EMT6 spheroids undergoing vasculariza-
tion in the mouse peritoneum. Surprisingly, the outer zones
of the spheroids remained avascular after the necrotic cores
were replaced by vascularized tumour tissue, allowing com-
parison of the responses of vascular and avascular tumour
tissue within the same tumour mass. FAA treatment resulted
in haemorrhagic necrosis of the vascularized core, while the
outer avascular zone remained viable. The results indicate
that a major part of FAA-induced tumour cell killing is
dependent on the presence of blood vessels, and that the
mode of cell death i3 predominantly ischaemic. FAA appears
to belong to a class of agents (including endotoxin, tumour
necrosis factor-a, interferons and interleukin-1) which cause
tumour necrosis in association with vascular effects, although
FAA is the only synthetic or small molecule known to act in
this way.
H.S. Edwards, J.C.M. Bremner & I.J. Stratford
MRC Radiobiology Unit, Chilton, Didcot, Oxon OXI1 ORD,
UK.
Physical clamping occludes the blood supply to subcutaneous
murine tumours thus decreasing the supply of oxygen and
producing 100% radiobiological hypoxia. Tumour necrosis
factor (TNF) modulates the activity of certain immune
system components leading ultimately to a reduction in
tumour blood flow. We studied how TNF treatment influ-
ences the radiobiological hypoxic fraction using an in vivo/in
vitro clonogenic assay. The radioprotective effect of clamping
was compared to that produced by various concentrations of
TNF administered to mice at various times before irradia-
tion. When TNF was given at a dose of 2.5 x I05 U kg-' an
increase in tumour hypoxia was seen after 30 minutes. Close
to 100% radiobiological hypoxia (equivalent to that resulting
from clamping) was reached one hour after treatment and
lasted for up to 16 hours. The minimum dose of TNF that
produced a level of hypoxia comparable to clamping was
1 x 105 U kg-' when administered three hours before irradia-
tion. TNF was combined with the bioreductive drugs RSU
1069 and SR 4233 in the KHT and RIF-l murine sarcomas
and the antitumour effect was assessed by a regrowth delay
assay. When an 80 mg kg-' dose of RSU 1069 was admin-
istered to mice bearing the KHT sarcoma 15 minutes before
TNF (1 x I05 U kg-') a mean specific growth delay of 3.9 +
0.6 was seen. When the second bioreductive drug SR 4233
(50 mg kg-') was combined with the same TNF treatment a
mean specific growth delay of 3.5 ± 0.9 was produced. TNF
alone at this dose and both RSU 1069 and SR4233 alone
have no effect on tumour growth. Qualitatively similar results
were obtained with flavone acetic acid (FAA), although the
lowest dose that induced close to 100% tumour hypoxia,
200mgkg-', also provided a substantial effect when used
alone in the RIF-I tumour.BRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS 495
Enzyme-directed bioreductive drugs: metabolism of
developmental indoloquinone E09 and related agents by
DT-diaphorase
P. Workman, M.I. Walton, M. Binger, S.M. Bailey
& N.R. Suggett
MRC Clinical Oncology Unit, MRC Centre, Hills Road,
Cambridge CB2 2QH, UK.
The indoloquinone series is undergoing preclinical develop-
ment under the auspices of EORTC. The lead compound
E09 [3-hydroxy-5-aziridinyl-I-methyl-2-(H-indole-4,7-indione)
-propenol] is expected to enter clinical trial in 1990. The
chemistry of this agent suggests it would function as a potent
bioreductive alkylating agent. Indeed, it has excellent hypoxic
cell specificity for a quinone, together with preferential
activity for solid tumours versus leukaemias in vitro. In many
cases the cytotoxicity profile is superior to that of the bench-
mark bioreductive quinone alkylating agent mitomycin C
(MMC). The role of one versus two electron (le vs 2e)
reduction in the bioactivation of quinone alkylating agents
remains controversial. The obligate 2e donating enzyme DT-
diaphorase may potentially bioactivate or detoxify quinones,
but recent results suggest that mitomycin C is not meta-
bolized by this enzyme (Workman et al. (1989), Br. J.
Cancer, 60, 800). Therefore, we have examined the ability of
E09 and related agents to act as substrates for reduction by
DT-diaphorase. Human HT29 colon carcinoma and rat UK
Walker 256 tumour cells were used as rich sources of DT-
diaphorase. Activity was measured spectrophotometrically by
reduction of cytochrome c or by loss of drug absorbance at
510 nm. Both preparations were able to metabolize E09
much more efficiently than MMC, the latter being barely
detectable. For equal menadione reduction rates, the rat
DT-diaphorase was about 10-fold more efficient at E09 meta-
bolism compared to the human enzyme. Km values were
20-30gM. For a methoxy analogue the relative rates were
similar to those for E09. With the aziridine ring-opened
derivative E05A the reduction rates were markedly lower. We
conclude that DT-diaphorase does metabolize the indolo-
quinones, and the biological significance of this is now under
scrutiny.
Demonstration of low and biologically insignificant
bioreduction rates for mitomycin C (MMC) by
DT-diaphorase
M.I. Walton, P.J. Smith & P. Workman
MRC Clinical Oncology Unit, MRC Centre, Hills Road,
Cambridge CB2 2QH, UK.
DT-diaphorase [NAD(P)H; (quinone-acceptor) oxidoreduc-
tase, EC. 1.6.99.2] is an obligate two electron (2e) donating
enzyme. It detoxifies simple quinones by direct reduction to
hydroquinones, bypassing the reactive semiquinone free rad-
ical. There has been considerable interest in DT-diaphorase
involvement in the bioactivation/detoxification of the more
complex quinone bioreductive alkylating agent MMC, and
recent results suggest that MMC is not a substrate for the
enzyme (Workman et al. (1989), Br. J. Cancer, 60, 800). We
have now used increased sensitivity assays to assess this
reaction and to determine its biological significance. Prepara-
tions used included extracts of the enzyme-rich UK Walker
256 rat tumours and HT29 human colon carcinoma cells,
and also purified Walker (from R.J. Knox) and human
kidney (from G. Powis) enzymes. No activity could be deter-
mined by MMC loss or metabolite formation on HPLC with
multidiode assay detection. However, very low, dicoumarol-
inhibitable rates could be detected using transfer of electrons
from enzyme-reduced MMC to cytochrome c (cyt c). For
both the rat and human enzyme, rates were about 200-fold
lower than for the standard substrate menadione. With the
rat enzyme the Km was high at 1 mM and the Vma, low at
6 nmol cyt c reduced min-' Unit enzyme-'. Using an agarose
gel mobility assay, we could demonstrate no conversion of
purified, negatively supercoiled, circular, double-stranded
pBR322 plasmid DNA to either relaxed circular, linear or
degraded forms by DT-diaphorase-MMC mixtures. Relaxa-
tion indicative of single-strand nicking was however seen in
the positive controls combining DT-diaphorase with indolo-
quinone E09. We conclude that DT-diaphorase can reduce
MMC, but at extremely low rates, and this is unlikely to be
of biological significance.
In vitro antitumour activity of membrane-active analogues
of platelet activating factor (PAF)
P. Workman, C. Dive, M. Lohmeyer & J. Donaldson
MRC Clinical Oncology Unit, MRC Centre, Hills Road,
Cambridge CB2 2QH, UK.
Various agents structurally related to PAF are in develop-
ment as antitumour agents. The cytotoxicity of these agents
at pharmacological concentrations may involve multiple
effects on membrane structure and signal transduction, in-
cluding changes in membrane fluidity, inositol lipids, calcium
signalling and protein kinase C. We have compared the
cytotoxic effects of PAF, ET-18-OCH3, SRI 62-834 and hex-
adecyl phosphocholine (HPC) on various cell lines. These
were the EMT6 mammary tumour and its multidrug resistant
(MDR) variant AR.0; the UK Walker 256 rat tumour; the
HT29 human colon carcinoma; and the HL60 human leukae-
mia. The MTT tetrazolium dye reduction assay was used.
ID50 values varied between the different agents. SRI 62-834
and ET-18-OCH3 were the most potent and PAF the least,
with HPC intermediate. Variation between cell lines was also
seen. For example with SRI 62-834 the IDm was 0.3tiM in
HL60, 3ltM in HT29, 15yM in Walker and 751M in the
EMT6 parent line. The IDm value of 100gM in the MDR
variant indicated that there was minimal cross-resistance to
adriamycin (ADM). In view of the membrane activity of
ADM and the membrane localization ofthe P170 MDR drug
efflux pump, we determined the effect of SRI 62-834 on
ADM sensitivity in the EMT6 lines. At 10 and 20tm SRI
62-834, there was minimal effect on IDs values for ADM
(0.05fig ml-' in the EMT6 parent and 2fig ml' in AR1.0.
For 1 and 2liM SRI 62-834 the ADM ID50 in HT 29 was
also unchanged at 0.03jig ml-'. We conclude that the
various PAF analogues have varying cytotoxic potencies in
the cell lines used; wide differences in activity occur across
various cell lines; and analogue SRI 62-834 does not
modulate ADM sensitivity in the parent or MDR lines
tested.
A limited sampling strategy for the calculation of etoposide
pharmacokinetics
S.P. Joel, L. Heap, S. Robbins, P.I. Clarke & M.L. Slevin
ICRF Department of Medical Oncology, St. Bartholomew's
and Homerton Hospitals, London ECIA 3BE, UK.
Recent interest has focused on the calculation of pharmaco-
kinetic parameters of cytotoxic drugs from a limited number
of blood samples (Egorin et al. (1989), ASCO, 243). In
response to this a limited sampling model has been developed
for the calculation of etoposide pharmacokinetics in patients
receiving etoposide 100 mg m 2 as a 2-hour infusion. Blood
samples for etoposide estimation were taken at 18 time points
over a 24-hour study period. The model was derived from
stepwise forward regression analysis of etoposide concentra-
tion (C) at 18 time points (independent, variable) against
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model used 3 time points (1.5 hours (h), 1Oh and 24h) to
predict AUC (r2 = 0.97). Further, stepwise forward regression
analysis of elimination rate constant (k,,) against log, concen-
tration produced only 2 significant time points, 10 h and
24 h, accounting for 91% of the variability in kl,,. From the
predicted AUC and kj1 the volume of distribution (Vd) and
clearance (Cl) could also be predicted. The ability of this 3
time point model (AUC = 12.7C,oh + 32.OC24h + 3.26CI.5h
- 3.771) to predict AUC, k,,, Vd and Cl was tested in a
further 28 data sets. The model proved highly predictive for
AUC (vs measured AUC r = 0.95) and was unbiased (mean
percentage error (MPE), (± SEM), - 1.2 + 1.4%) and pre-
cise (mean absolute percentage error (MAPE), (± SEM),
5.4 ± 1.0%). The model also proved highly predictive for kj
(r = 0.91, MPE = 2.7 ± 1.7%, MAPE = 7.5 ± 1.0%) and Cl
(r = 0.98, MPE = 3.3 ± 1.6%, MAPE = 6.4 ± 1.2%), and
slightly less predictive for Vd (r = 0.87, MPE = 1.6 ± 2.7%,
MAPE = 11.6 ± 1.6%). This study demonstrates that the
AUC of etoposide after i.v. infusion can be reliably predicted
from a limited number of samples, and that the model can
reasonably be extended to include other pharmacokinetic
parameters.
Biochemical effects, antitumour activity and
pharmacokinetics of oral and intravenous pamidronate
(APD) in the treatment of skeletal breast cancer
D. Dodwell', A. Howell', A.R. Morton2, P. Daley-Yates3
& J. Ford4
'Department of Medical Oncology, Christie Hospital,
Wilmslow Road, Manchester, M20 9BX, UK; 2Department
of Nephrology, Wellesley Hospital, Ontario, Canada;
'Department ofPharmacy, University ofManchester, UK; and
'Ciba-Geigy, Basle, Switzerland.
We have studied the antitumour and biochemical effects,
toxicity, and pharmacokinetcs of both intravenous and an
enteric-coated oral preparation of pamidronate (Ciba-Geigy)
in two phase I/II trials in patients with bone metastases from
breast cancer. In the intravenous trial, 22 assessable patients
with progressive bone metastases from breast cancer (16 of
whom had elevated calcium excretion with a fasting urine
calcium/creatinine ratio (UCCR) >0.4 mmol/mmol before
treatment) were treated with 30 mg intravenous pamidronate
weekly, for 4 weeks and thereafter fortnightly for six months
or until disease progression. Responses, as defined by
sclerosis of previous lytic metastases, occurred in 4 patients
and an additional 7 patients achieved stable disease. There
was a significant reduction in the level of calcium excretion.
There was also a significant improvement in pain symptoms.
Median response duration (inc. 'no change') was 9 months.
Toxicity was minimal.
In the oral study, 17 women with progressive bone metas-
tases from breast cancer (16 with elevated calcium excretion)
were given oral pamidronate at doses from 150 mg to 600 mg
daily (cohorts of 4 patients) for four weeks. Thereafter all
patients were continued on 300 mg daily. There have been no
responses and only one patient has achieved stable disease.
Pain symptoms were unaffected. There was, however, a
similar fall in mean calcium excretion to that seen in the
intravenous study. There were no significant differences in
efficacy between treatment groups within the oral study, but
gastrointestinal toxicity was dose limiting at 600 mg daily. In
addition we have studied the bioavailability of pamidronate
in 7 patients taking 300 mg daily of the oral preparation.
Three sequential 24-hour urine samples were collected from
each patient and the concentration of drug estimated accord-
ing to the method of Daley-Yates et al. (J. Chromatography,
1989). Mean absorption (assuming a similar renal excretion
to that seen after an intravenous infusion) varied from 0.16%
to 0.41%. Despite similar effects on calcium excretion the
oral enteric-coated preparation of pamidronate was poorly
absorbed and this may explain the lack of any antitumour
effect. More active bisphosphonates may circumvent the
problem of poor bioavailability.
Improving drug delivery to liver metastases: the effects of
angiotensin II
D.M. Hemingway', D. Chang2, J.A. Goldberg', S.A. Jenkins2
& T.G. Cooke'
'University Departments of Surgery, Royal Infirmary,
Glasgow; and 2Royal Liverpool Hospital, Liverpool, UK.
Angiotensin II, a hepatic artery vasoconstrictor, has been
shown to increase the tumour:liver blood flow ratio in
patients with colorectal liver metastases. We have tested the
effects of regional or systemic angiotensin II on the distribu-
tion of a marker resembling chemotherapeutic drugs to relate
these blood flow changes to drug delivery in a hypovascular
model of liver tumour. Metastases were induced by the intra-
portal inoculation of 106 HSN sarcoma cells. 9'9Tc labelled
methylene diphosphonate was injected into the hepatic artery
after either an intravenous infusion, or an intra-arterial bolus
of angiotensin II.
Results, expressed as % injected dose per gram of tissue x
10', were:
Controls IA Angiotensin IV Angiotensin
Liver Tumour Liver Tumour Liver Tumour
** * **
1 3.55±0.15 5.17±0.55 11.1±1.1 23±5.7 16±5.4 9.6±3.0
min
90 0.79±0.07 0.61 ±0.04 6.4± 1.4 3.3+0.07
min
*P<0.01 **P<0.02
These results indicate that Ia angiotensin causes significant
retention of marker in tumour, but that intravenous angio-
tensin causes greater retention in normal liver. Angiotensin
should be given intra-arterially to maximize delivery of
chemotherapeutic drug to liver tumour.
Antioxidant vitamins (A, E and C) and lactulose in the
prevention of the recurrence of adenomatous polyps:
preliminary results of a controlied study
M. Ponz de Leon, L. Roncucci, P. Di Donato & M. Perini
Instituto Patologia Medica and Instituto Semeiotiva
Medica, Univ. Modena 41100, Italy.
It is now generally accepted that adenomatous polyps repre-
sent the natural precursor of many colorectal cancers.
Although polyps can easily be removed at endoscopy, they
tend to reappear in approximately 30% of the patients at one
year. We evaluated the long-term administration ofvitamins,
because of their antioxidant effect, or lactulose, which lowers
the intestinal pH, thus limiting the degradation of primary
bile acids to the more toxic secondary bile acids, in the
reduction of the recurrence rate of colonic polyps. After
endoscopic removal of polyps, 253 patients were randomized
into 3 groups: a vitamins (A 30,000 U, E 70 mg and C I g
daily); b. lactulose (20-40 g daily); and c. no treatment.
Control endoscopies were carried out after 6, 12, 18 and 24
months. Among the 129 patients followed for at least 12-18
months, the cumulative recurrence of polyps was 4 in group
a, 8 in group b and 24 in group c. The difference was
statistically significant by Life-Tables and Log-Rank tests (X2
15.0, P<0.001). These preliminary results, therefore, suggest
that either vitamins or lactulose may reduce the recurrence
rate of adenomatous polyps, though the effect seems more
marked for antioxidant vitamins. Both agents deserve to be
further investigated for the prevention of colorectal cancer.BRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS
Outcome of patients relapsing after treatment of
non-seminomatous testicular germ cell tumours
J.A. Ledermann, L. Holden, E.S. Newlands, G.J.S. Rustin,
R.H.J. Begent & K.D. Bagshawe
Cancer Research Campaign Laboratories, Department of
Medical Oncology, Charing Cross Hospital, London W6 8RF,
UK.
Progression of metastatic non-seminomatous testicular
tumour during treatment generally carries a poor prognosis
but the outcome of patients (pts) who relapse or progress
after a partial or complete remission is less well known.
Between 1977 and 1988 we treated 48 pts who had been off
treatment for a median of 8 months (range 1-85); 28 pts had
been in complete remission (11 after surgery) and 20 had
residual radiological abnormalities. Twenty-three pts (47.9%)
were at 'low risk' of relapse (MRC criteria 1989) as they had
low serum tumour markers (hCG<10,000 iu 1-'; AFP<
1,000kul-'; <20 lung metastases; and no brain, bone or
liver metastases). Radiotherapy had been given to 11 of this
group and in 6 it was the only treatment. Twenty-seven/48
pts (58.2%) had previously been treated with the POMB/
ACE regimen and 18 (66.7%) of these were in a 'high risk'
group; 9 pts had been treated with PVB and 6 with other
chemotherapy regimens. Relapse therapy comprised etopo-
side 150 mg m-2 and cisplatin 75 mg m-2 alternating each
week with vincristine 1.2 mg m2, methotrexate 300 mg m-2,
folinic acid rescue and a 24-hour infusion of bleomycin
15 mg in 28 pts. POMB/ACE was given to 12 and other
platinum regimens to 8 pts. The median survival is 23.5
months with a predicted survival at 10 years of 33%. Ten pts
have been followed for more than 5 years and none has
relapsed. Resection of tumour was performed in 15/20 sur-
vivors; 6 of whom had active tumour at surgery. Nineteen of
the survivors (8 from low risk and 11 from high risk group)
had initially received chemotherapy; provided their tumours
retained chemosensitivity long term survival is possible.
Node negative breast cancer: prognostic subgroups defined
by tumour size and flow cytometry
S.M. O'Reilly, R.S. Camplejohn, D.M. Barnes, R.R. Millis,
R.D. Rubens & M.A. Richards
ICRF Clinical Oncology Unit, Guy's Hospital, London
SE] 9RT; and Richard Dimbleby Department for Cancer
Research, St Thomas' Hospital, London SEJ 7EH, UK.
Adjuvant therapy for patients with node negative breast
cancer is most easily justified for those at highest risk of
relapse. We have examined the impact of tumour size,
tumour grade, oestrogen receptor (ER) status, tumour ploidy
and S-phase fraction on relapse-free survival (RFS) for 169
patients with node negative breast cancer in order to identify
groups of patients at high and low risk of relapse. Patients
with small tumours ( < 1.0 cm) had a significantly longer
RFS than those with larger tumours (P = 0.005), with 96%
remaining relapse free at 5 years. Patients with tumours
< 1.0 cm were thus excluded from analysis when attempting
to define a group with a poor prognosis. Within the group of
patients with tumours > 1.0 cm, neither ploidy (P = 0.63)
nor ER status (P = 0.3) predicted for RFS. Patients with
grade 1 or 2 infiltrating ductal tumours had a significantly
better prognosis than those with grade 3 tumours (P = 0.04).
Patients whose tumours were > 1.0 cm with an SPF < 10%
had a 5 year RFS of 78% compared with a 5 year RFS of
52% for those with an SPF>10% (P=0.006). We have
combined tumour size and SPF to identify 3 prognostic
groups:
Patients No 5 year RFS
Tumour < 1.0 cm 33 96%
Tumour > 1.0 cm 45 78%
+ SPF A 10%
Tumour > 1.0 cm 71 52%
+SPF >10%
These prognostic groupings may help identify patients most
suitable for adjuvant therapy.
High dose epirubicin as primary chemotherapy in advanced
breast carcinoma: a phase II study
D.W. Miles, M.A. Richards', R.D. Rubens',
J. Carmo-Pereira2, F.O. Costa2 & E. Henriques2
'ICRF Clinical Oncology Unit, Guy's Hospital, London,
UK; and 2Instituto Portuges de Oncologia Francisco
Gentil, Lisbon, Portugal.
A linear dose response relationship has been reported for
doxorubicin (D) in the treatment of advanced breast cancer.
However, the dose of D which can be given safely is limited
by both myelosuppression and cardiotoxicity. We have there-
fore conducted a phase II study using epirubicin (E), an
analogue of D which is reported to be less cardiotoxic, at
high dose (120 mg m-2) in patients (pts) with locally
advanced or metastatic breast cancer. Forty pts (median age
52, range 29-65, previous non-anthracycline containing
adjuvant chemotherapy 6/40) were treated every three weeks
for a median of 8 courses (range 2-10, median cumulative
dose 960 mg m-2, range 240-1200 mg m-2). Response rate
was 26/40 (65%) with a complete response rate of 9/40
(23%). Median duration of response was 7 months (range
1-15), median survival was 13 months (range 2-20). Tox-
icity: WHO grade IV leucopenia was observed in 10/10 pts in
whom nadir counts were measured on day 10 but only 1/40
pts developed neutropenic sepsis. Left ventricular ejection
fraction fell by > 15% in 5/40 pts but reverted to normal
after stopping E. As the dose of E was limited by myelosupp-
ression, the use of colony stimulating factors to allow further
dose escalation is now being investigated.
Mitomycin, ifosfamide and cisplatin: an effective,
pre-operative treatment for oesophageal carcinoma
H. Matthews, S. Walker, A. Steel & M.H. Cullen
East Birmingham Hospital & Queen Elizabeth Hospital,
Birmingham, UK.
In 1986 we began evaluating systemic therapy for oesoph-
ageal carcinoma (OC) and reported the difficulty, noted by
others, of assessing response to chemotherapy (CT) in this
tumour. To resolve this we studied the effect of brief, pre-
operative ('neo-adjuvant') CT in patients with apparently
operable squamous or undifferentiated tumours, not requir-
ing urgent surgery, to allow assessment of direct operative
and microscopic response. Mitomycin (M), and cisplatin (C)
are active in OC. Cullen et al. (1988) have shown that MC
with ifosfamide (I) is an active and acceptable combination in
squamous lung cancer, and so MIC was chosen for this
study. Eleven previously untreated cases of obstructing OC (9
squamous, 2 undifferentiated) aged 55-73 (median 63) were
treated with 2 courses of MIC (M 6 mg m-2, C 50 mg m-2).
All had pre- and post-treatment CAT scans and barium
swallows. Toxicity was as reported for MIC in lung cancer
(Cullen et al. (1988), Br. J. Cancer, 58, 359). Complete
resection (left-sided subtotal oesophagectomy) of macro-
scopic tumour was possible in all 11 cases and there were no
operative or post-operative deaths. Evidence of macroscopic
response to chemotherapy was seen in all resected specimens.
497498 BRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS
In six this was complete with normalization of mucosal
appearances with residual scarring. In the remaining five
cases there was epithelialization of ulcerated mucosa and
flattening of ulcer margins. Histological examination revealed
no evidence of malignancy in three cases. Two patients died
of OC (at 4 and 20 months) and 8 cases are still in remission
(median FU 8 months).
Prolonged administration of single-agent oral etoposide in
small cell lung cancer (SCLC)
P.I. Clark', B. Cottier', S.P. Joel2, P. Thompson2
& M.L. Slevin2
'Mersey Lung Cancer Group, Clatterbridge Hospital,
Merseyside L63 IXG; and 2Department of Medical
Oncology, St. Bartholomew's and Homerton Hospitals,
London ECJA 7BE, UK.
Pharmacological studies in man suggest that the schedule-
dependent efficacy of etoposide in SCLC is related to the
prolonged maintenance of low blood concentrations of drug.
Thirty elderly or unfit patients with SCLC received single-
agent oral etoposide 50 mg twice daily for the first 14 days of
a 21-day cycle, for a maximum of 6 cycles. The median age
was 65 and the median Karnofsky performance score was 60;
23 patients had extensive disease and 7 limited disease. All 30
patients are evaluable for initial response and toxicity; 27
have responded, response rate 90%, 25 achieving a partial
and 2 a complete response. Remissions range from 1 + to
9 + months. All patients developed alopecia. Gastrointes-
tinal toxicity was mild. The median white cell and neutrophil
counts in cycle 1 were 4.8 and 3.0 on day 15 and 3.4 and
1.8 x 1091-' on day 22. There was no thrombocytopenia.
The mean peak plasma concentration of etoposide after a 50
mg dose was 2.3 jg ml-' (range 0.9-3.9), compared with a
mean peak value of 15.0jig ml-' after a 2-hour infusion of
100mgm-2. Prolonged durations of administration of low
dose oral etoposide are thus clearly very active in SCLC, yet
bone marrow toxicity is mild. This study supports the hypo-
thesis that the schedule-dependency of etoposide is related to
the maintenance of low blood concentrations of drug.
Epirubicin, cisplatin and 5-fluorouracil is effective treatment
in advanced gastric cancer
D. Cunningham, A. Cahn, N. Menzies-Gow, R.D. Rosin,
J. Mansi & H.A.F. Dudley
Royal Marsden Hospital, Sutton, Surrey; St Mary's
Hospital and The Central Middlesex Hospital, London. UK.
This schedule was devised to reduce the myelosuppression
related to 5-fluorouracil and theoretically to increase the
amount of tumour topoisomerase II, one of the targets for
the anthracyclines. Fourteen patients, mean age 56 (range
41-78), with histologically confirmed locally advanced or
metastatic gastric carcinoma were treated with cisplatin (C)
60 mg m-2 i.v., epirubicin (E) 50 mg m-2 i.v. day 1 and
5-fluorouracil 200 mg m-2 daily as a continuous i.v. infusion
via a central line using an ambulatory pump for a maximum
of 21 weeks (8 courses of CE). All patients had measurable
disease and 2 had received prior chemotherapy. Performance
status was 1 in 11 and 2 in 3. There were 9 PR and 1 CR
(confirmed at laparotomy) with an overall response rate of
71%. A positive response to treatment was associated with
improved PS in all patients. The median survival of respond-
ing patients had not been reached. Median WBC nadir was
3.4 x I09 1-' (range 1-6.8) and median platelet nadir 160 x
I091-' (range 60-413). WHO grading of leucopenia was 4 gd
0, 3 gd 1, 5 gd 2, 2 gd 3 and platelets 10 gd 0, 2 gd 2, 2 gd 1.
One patient had diarrhoea gd 2, 1 patient had rhinorrhoea, 2
patients complained of loss of taste and 3 patients had
plantar-palmar erythema. Alopecia was gd 3 in 7, gd 2 in 3,
gd 1 in 4. Overall, CEF was well tolerated on an out-patient
basis with significant activity in gastric cancer and deserves
further investigation in phase III studies.
A phase II study of anthrapyrazole CI 941, a highly active
new drug against advanced breast cancer
J.L. Mansi, I.E. Smith, D. Talbot, D. Button, I. Judson
& A.H. Calvert
The Royal Marsden Hospital, Fulham Road, London,
SW3 6JJ, UK.
CI 941 is one of a number of anthrapyrazole compounds
synthesized in an attempt to produce a drug at least as active
as adriamycin but less toxic. In particular, it does not possess
the paraquinone grouping associated with free radical genera-
tion and thus has less potential for cardiotoxicity. In experi-
mental murine tumours, it was shown to have activity similar
to adriamycin and better than mitozantrone. In phase I
studies its major toxicity was myelosuppression with a max-
imum tolerated dose of 55mgm-2. Fourteen patients (pts)
with advanced breast cancer have so far received CI 941,
50 mg m-2 by i.v. bolus, 3 weekly, in a phase II study. The
median age was 55 (range 23-66), median ECOG perfor-
mance status I (range 0-2); 6 pts had received previous
chemotherapy, but not an anthracycline. Seven (64%) of 11
pts so far assessable for response (at least 2 courses) achieved
an objective partial response, including 3/5 (60%) previously
treated pts, and 4 (36%) stable disease (SD). Response by
site: soft tissue 6/9; lung 3/3; liver 3/4; and bone 1/5. Toxicity
(WHO) was minor: alopecia grade I in 10 and grade 2 in 4,
nausea and vomiting grade 0 in 3, 1 in 5, and grade 2 in 6
pts, and lethargy in 8. One pt had a dose reduction because
of a suspected neutropenic infection; there were no other
dose reductions, no deaths and no evidence of cardiotoxicity
as assessed by left ventricular ejection fraction. Median res-
ponse duration has not been reached. These early results
suggest that CI 941 is a highly active and well-tolerated new
agent in advanced breast cancer and warrants further study.
A comparison of response, survival and quality of life
(QoL) using 2 doxorubicin (Dox) schedules of equal dose
intensity in metastatic breast cancer
C.J. Twelves', A.J. Ramirez', M.A. Richards', P. Hopwood2,
J. Ferguson2, W. Gregory', R. Swindell2, W. Scrivener',
J. Miller2, A. Howell2 & R.D. Rubens'
'ICRF, Guy's Hospital, London; and 2Christie Hospital,
Manchester, UK.
Doxorubicin is the single most active cytotoxic agent in
patients (pts) with advanced breast cancer. This randomized
study compared 2 Dox schedules of equal planned dose
intensity in 59 pts. Twenty-eight received 75 mg m-2 every 3
weeks (Dox q3w) x 4, and 31 received 25 mgm2 weekly
(Dox qlw) x 12. Median age was 52 years (range 41-74);
none of the pts had received prior chemotherapy for
advanced disease.
The dose intensities administered for Dox q3w and qlw
were similar (84% and 75% of that planned respectively).
Response was assessed by UICC criteria in all pts. The
response rate for Dox q3w was 50% and for Dox qlw 58%
(P>0.05). Median survival with Dox q3w did not differ
from Dox qlw (8 vs. 6.1 months; P>0.05). Treatment tox-
icity assessed by WHO criteria was the same with the 2
schedules. Quality of life was assessed at 0, 6 and 12 weeks
in 54 of the pts using the Rotterdam Symptom Checklist
(RSCL). In the 21 pts randomized to Dox q3w who com-
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psychological adjustment (P = 0.001). No such improvement
was seen in the 21 pts randomized to Dox qIw (P = 0.48).
These differences in psychological adjustment between the
treatment arms were also apparent for pts who completed
treatment as planned. We conclude that although the two
schedules were of equal dose intensity, efficacy and WHO
toxicity, psychological adjustment was better in those receiv-
ing Dox every 3 weeks.
Fludarabine in chronic lymphocytic leukaemia (CLL) and
non-Hodgkin's lymphoma (NHL)
J.S Whelan', C.L. Davis', S.A.N. Johnson3, A.J. Norton2,
A.Z.S. Rohatiner' & T.A. Lister'
'ICRF Department of Medical Oncology, and 2Department
of Pathology, St Bartholomew's Hospital, London; and
3Musgrove Park Hospital, Taunton, Somerset, UK.
Fludarabine (FLU) is a fluorinated analogue of adenine
arabinoside which is resistant to metabolism by deamination
while retaining cytotoxicity. It has been reported to have
particular activity in low grade lymphoid malignancies.
Twenty-seven patients (9 CLL, 18 NHL) were treated with
FLU at 25mgm2 by i.v. push daily for 5 days, repeated
every 21-28 days. All patients had previously received both
single agent and combination therapy. The median number
of previous treatments was 3. Six of 9 patients with CLL are
evaluable for response, 2 patients having concurrent second
malignancies and one still in treatment. A partial response
was achieved in 2/6, static or progressive disease in 3/6 and
I patient with recurrent pulmonary infections died of pneu-
monia after 2 cycles of FLU, the lymphocyte count having
fallen from 248 x I09 1' to 3.4 x 109 1-'.
Ten patients with follicular lymphoma have been treated,
of whom 7 are evaluable for response and 3 are still receiving
FLU; 5/7 had bone marrow infiltration, 2 as the only site of
disease, 2/7 had stage III disease. PR was achieved in 3
patients, 2 had no response and I patient had progressive
disease. One patient died of probable fungal infection after 2
cycles when clinical evidence of response was apparent. Seven
out of 8 patients with diffuse lymphoma (6 lympho-
plasmacytoid and 2 small cell centrocytic lymphomas in the
Kiel classification) are evaluable, I patient currently being
treated. All patients had stage IV disease. Complete remis-
sion was achieved in 1/7, no response was seen in 4/7 and 2
patients died, I of pulmonary embolus and the other of
lymphoma. FLU has been well tolerated, the major toxicity
being infection related to myelosuppression. One patient had
an episode of disorientation soon after receiving treatment
while in complete remission of lymphoplasmacytoid lympho-
ma after 3 cycles of FLU. No evidence of neurological deficit
was found and CT scan and EEG were normal. Despite
selection of patients who had been heavily pretreated, FLU
was active in both CLL and follicular lymphoma. FLU
seems to be only occasionally effective in diffuse lymphoma.
Further studies are needed to define the therapeutic role of
this agent earlier in the natural history of these diseases.
Efficacy and safety of the non-steroidal antiandrogen,
Casodex, in early clinical trials for advanced prostate
cancer
B. Waymont', G.R.P. Blackledge', C.J. Tyrell2,
M.R.G. Robinson3 & J.L. Williams4
'Clinical Trials Unit, Queen Elizabeth Hospital,
Birmingham; 2Plymouth General Hospital; 3Pontefract
General Hospital; and 4Royal Hallamshire Hospital
Sheffield, UK.
Casodex is a non-steroidal antiandrogen which seems to be
peripherally selective and is without the side effects of proges-
tational antiandrogens. On this basis it is at present under-
going clinical trials for the treatment of advanced prostatic
cancer. Initial pharmacokinetic studies indicate a half-life of
about seven days so a once daily oral dose is suitable with
better patient acceptability.
In a dose finding study, 174 patients with advanced pros-
tatic cancer were recruited. The acid phosphatase at entry
had to be more than twice normal and patients received
Casodex for 12 weeks. Response, for this study, was defined
as a 50% reduction in acid phosphatase at 8 weeks. At an
initial dose of 10 mg daily, 11 of 39 patients (28%) re-
sponded. At a dose of 30 mg daily, 23 of 42 patients (55%)
responded and at a dose of 50 mg daily, 61 of 93 patients
(66%) responded. Objective response was also assessed using
modified National Prostatic Cancer Project (NPCP) criteria
after 12 weeks treatment. A partial response was evident in
23% of patients receiving 10 mg Casodex daily, 42% of
patients receiving 30 mg daily and 45% of patients receiving
50 mg daily. Adverse reactions associated with Casodex
therapy included breast swelling and tenderness in approx-
imately 50% patients and hot flushes in approximately 20%
patients receiving the 50mg dose, due to pharmacological
effects. Two patients were also reported to show an elevation
in liver enzymes following 50 mg daily. No other serious side
effects or significant gastrointestinal toxicity was noted. The
efficacy and safety of the 50 mg dose is currently being
evaluated in Phase II clinical studies and will be further
assessed in randomized Phase III clinical studies.
Pattern of intraperitoneal spread in epithelial ovarian
cancer (EOC): a new prognostic factor?
R. Varma, G. Blackledge, D. Luesley, K.K. Chan &
K. Kelly
Cancer Research Campaign Clinical Trials Unit, Queen
Elizabeth Hospital, University of Birmingham, Edgbaston,
Birmingham B17, UK.
The majority of patients with EOC present when the disease
has already spread beyond the ovaries and its management is
based upon surgery to achieve complete macroscopic clear-
ance followed by active platinum-containing chemotherapy.
There are two distinct patterns of intraperitoneal spread, a
predominantly bulky spread of disease or seedling spread
throughout the peritoneal cavity, the prognostic implications
of this are unclear. In an attempt to determine this a retro-
spective analysis was carried out on 107 patients with stage
II-IV disease who were entered into a randomized study of
EOC carried out by the West Midlands Ovarian Cancer
Group from Nov '81 to Nov '86. The overall median survival
of the study group was 20 months. Sixty-four patients were
found to have predominantly bulky disease and 43 had seed-
ling spread. Survival for the patients with bulky disease
was significantly longer than for those with seedling disease,
(O/E 0.76; XI2 = 10.3; P = 0.001). This difference remained
significant after controlling for the effect of pathology, differ-
entiation, age and performance status using Cox multiple
regression analysis. The amount of residual disease following
primary laparotomy was also highly significant (X22 = 40.8,
P<0.0001). This study suggests that disease in the absence
of seedlings has a favourable prognosis owing to the increas-
ed likelihood of optimal surgery in this group of patients. It
is never possible to achieve complete macroscopic clearance
in the patients with seedling spread. Since surgical resection
was always attempted in this study, it is unclear whether this
survival difference is an effect of surgery or due to disease
biology. A randomized trial of surgery is under way to
investigate this and other factors, such as the response to
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Does tumour necrosis factor (TNF) determine the pattern
of metastasis of ovarian cancer?
S.T.A. Malik, M.S. Naylor, A. Oliff & F.R. Balkwill
Imperial Cancer Research Fund, Lincoln's Inn Fields,
London WC2A 3PX, UK; and Merck, Sharpe & Dohme,
West Point, Philadelphia, USA.
We have examined the effect of intraperitoneal TNF therapy
on three intraperitoneal human ovarian cancer xenografts in
nude mice. Parameters studied included: a. survival of mice;
b. analysis of peritoneal cell populations; c. post-mortem
appearances; and d histological analysis of the peritoneum.
The results show that while moderate dose, I fig TNF, in-
creased the survival of mice bearing two out of three xeno-
grafts, it also promoted the adherence and establishment of
peritoneal metastases. This effect was independent of the
antitumour activity of TNF, as peritoneal micrometastases
were also observed in the TNF-resistant xenograft. Attenua-
tion of the marked neutrophil influx into the peritoneum seen
after i.p. TNF, by pretreatment of mice with an anti-murine
CR3 receptor antibody, did not affect tumour implantation.
To examine the possible role of endogenous tumour produc-
tion of TNF in determining metastasis, we have studied the
effects of intraperitoneal injection of Chinese Hamster Ovary
(CHO) cells transfected with the TNF gene, in nude mice.
The pattern of metastasis was studied using standard histo-
logy, immunohistology, in situ hybridization, and localization
of radiolabelled cells in vivo. Our results show that the CHO
transfectants give rise to peritoneal, liver, and lung metas-
tases, and that these can be specifically inhibited by anti-
TNF antibody. Neutralization of TNF activity may therefore
be a realistic therapeutic option in the treatment of some
cancers.
Growth stimulation of human ovarian carcinoma cell lines
by 17 f-oestradiol or epidermal growth factor
S.P. Langdon, A.J. Crew & W.R. Miller
ICRF Medical Oncology Unit, Western General Hospital,
Edinburgh, UK.
The mechanisms of growth control in human ovarian carcin-
oma cells are undefined. The majority of ovarian tumours
contain receptors for oestrogen (ER) (Slotman (1988), Anti-
cancer Res., 8, 147) and 35% contain receptors for epidermal
growth factor (EGFr) (Bauknecht (1988), Gynecol. Oncol.,
29, 147). It is feasible that oestrogen or EGF might modulate
growth of these tumours.
The effects of 17 P-oestradiol (E2) and EGF have therefore
been tested against the ER + ve PEO4 and ER -ve PEO14
human ovarian tumour lines in vitro. Addition of E2 (0.1 or
10 nM) to ER +ve PEO4 cells in phenol red-free RPMI
1640 containing 10% fetal calf serum stripped of oestrogen,
markedly stimulated growth and this effect could be inhibited
by the anti-oestrogen, tamoxifen (1 ,AM). Neither E2, nor
tamoxifen, at these concentrations had any measurable effect
on the growth of the ER -ve PEO14 cell line. EGF at
concentrations of 1 pM - 10 nM stimulated growth of PEO14
cells grown in either 0.5% or 5% serum-containing medium,
or in serum-free medium (RPMI + hydrocortisone, insulin,
transferrin and selenium). The PEO4 cell line was not
stimulated by EGF under any of these conditions. These
studies indicate that, in culture, human ovarian carcinoma
cells may show sensitivity to either E2 or EGF.
Trophic responses of colorectal tumour cultures to TGFx
IGF-I, IGF-II and gastrin
L.G. Durrant', S.A. Watson' & D.L. Morris2
'Cancer Research Campaign Laboratories, University of
Nottingham NG7 2RD; and 2Department of Surgery,
University Hospital, Nottingham NG7 2UH, UK.
The factors controlling the growth of colorectal tumours are
not well understood. We have previously shown that gastrin
plays a central role in the stimulation of gut tumour pro-
liferation. This study shows a synergistic response to gastrin
and the growth factors TGFa, IGF-I and IGF-II in promot-
ing tumour cell proliferation.
Colorectal tumours are disaggregated with collagenase to
produce a highly viable single cell suspension of cells. These
are then placed in culture in the presence of varying doses
of gastrin or growth factors before assessing proliferation
by incorporation of 75Se-selenomethionine. Four out of 9
tumours responded trophically to gastrin and TGFx alone
but 6/9 responded to the combination of both, 4 with a
synergistic increase in growth and 2 with an additive re-
sponse. Four out of 9 tumours responded trophically to
IGF-I and 3/4 tumours responded to IGF-II. There was a
synergistic growth response to TGFa and IGF-I in 2 tumours
and to IGF-I and gastrin in two tumours. The only tumour
tested which failed to respond trophically to IGF-II, showed
a synergistic response to the presence of IGF-II and gastrin.
These results suggest that gastrin antagonists may be even
more effective at inhibiting gastrointestinal tumour cell proli-
feration than would be predicted by the response of tumours
to gastrin alone. Furthermore drugs such as the somatostatin
derivative, Sandostatin, which prevents the secretion of gas-
trin and TGFx should be very effective at inhibiting colorec-
tal tumour growth.
Relationship between growth inhibition by cytokines
(interferons and tumour necrosis factor) and receptor
binding in human lung cancer cell lines
S.A.B. Jabbar & P.R. Twentyman
MRC Clinical Oncology and Radiotherapeutics Unit, Hills
Road, Cambridge CB2 2QH, UK.
Interferons (IFNs) and tumour necrosis factor (TNF) bind to
specific receptors on the cell surface. We have investigated
the relationship between the responsiveness to cytokines in
terms of growth inhibition and the extent of receptor binding
in a panel of human lung cancer cell lines. Growth inhibition
was assessed after 6-8 days of growth of cells in RPM1 1640
medium with the cytokines added at the beginning of this
period. Receptor analysis was carried out using '25I lodo-
tyrosyl human recombinant IFN-y or TNF-a (Amersham).
Small cell lines POC, COR-L47 and COR-L88 showed 60,
50, and 10% growth inhibition respectively by I kU ml-' of
IFN-'y. However, all 3 lines gave similar maximum '25I IFN-y
binding at 15 minutes. At 37°C, however, the rate of decrease
of binding (presumably due to receptor internalization and
degradation) was less in COR-L88 than in the other two
lines. A multidrug resistant variant (COR-L23/R) of the large
cell line COR-L23 showed greater sensitivity to growth
inhibition by IFN-,y than the parent. Receptor binding of 125I
IFN-y was also 50% greater in the resistant than the parent
line. Similarly, increased sensitivity to TNF-x in multidrug
resistant variant MOR/R of adenocarcinoma line MOR was
accompanied by increased binding of 25I TNF-x. Scatchard
analysis showed that the number of receptors/cell was similar
in MOR and MOR/R (6 k) but that the affinity constant is
50% higher in the latter. In six cell lines, the effect of IFN-'y
pretreatment on 125I TNF-x was measured. In none of the cell
lines was there a significant change in the binding pattern as
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growth inhibition by TNF-a was increased following IFN-'y
pre-incubation. It appears unlikely from the data that the
responsiveness of lung cancer cells to cytokines can be
predicted from a simple measure of receptor binding. Cells
showing significant specific binding can be quite refractory to
growth inhibition by the cytokine in question.
TGF-beta is implicated in the failure of tamoxifen
treatment in breast cancer
A.M. Thompson"2, C.M. Steel2, D.J. Kerr3 & U. Chetty'
'Department of Surgery, Royal Infirmary, Edinburgh EH3
9YW; 2MRC Human Genetics Unit, Western General
Hospital, Edinburgh EH4 2XU; and 3Beatson Institute,
Garscube Estate, Switchback Road, Glasgow G61 1BD, UK.
The peptide growth factor transforming growth factor beta
(TGF-beta) inhibits breast epithelial cell growth in vitro. The
anti-oestrogen tamoxifen in these cells increases TGF-beta
levels and is also inhibitory in vitro. Using densitometry of
Northern blots the expression of TGF-beta mRNA has been
quantified in breast tumour tissue from 45 untreated and 11
tamoxifen-treated patients. In the 56 tumours, TGF-beta
mRNA expression was significantly higher in premenopausal
women (P = 0.05) but was independent of oestrogen receptor
status and other clinical and pathological parameters. Within
tamoxifen-treated patients high expression was demonstrated
in all 6 patients with progressive tumour growth whereas low
levels were present in 4 of 5 with static tumour. These data
suggest that failure of tamoxifen treatment in breast tumours
is associated with high, rather than low, levels of TGF-beta,
contrary to expectations from in vitro studies.
Interleukin 6 is a growth factor for myeloid but not
myeloma cells from human bone marrow aspirates in vitro
B.C. Millar, J.B.G. Bell, J.K. Joffe, A. Montes, J.L. Millar,
T.R. Bradley, R. Gooding', P. Riches' & T.J. McElwain
Institute of Cancer Research and Royal Marsden Hospital,
Sutton, Surrey; and 'Westminster Hospital, London, UK.
Several groups have claimed that interleukin 6 (IL-6) is a
growth factor for human myeloma cells in vitro. We examin-
ed bone marrow aspirates from 13 myeloma patients to
determine whether rhuIL-6 affects the clonogenicity of mye-
loma in vitro. Myeloma cells from 11/13 patients produced
colonies (MY-CFUc) in vitro in our assay system, which uses
a heavily irradiated feeder layer of HL60 cells as an underlay
in soft agar. The addition of rhuIL-6 (100 units per plate)
resulted in 6/13 of the same samples producing myeloma
colonies in this culture system. Furthermore, addition of
anti-IL-6 (I 1tg per plate) failed to inhibit MY-CFUc from
6/7 samples.
Conditioned medium from human peripheral blood mono-
nuclear cells (PB-CM) contains approximately 4 ng ml-' IL-6
and is necessary for the growth and maintenance of the
murine B9 hybridoma cell line, which will not replicate in
medium containing rhuIL-6. Mononuclear cells from a
second group of 10 myeloma patients were cultured in soft
agar (0.3% final concentration) in a mixture of 50:50 PB-CM
and fresh growth medium (a modification of Eagles MEM +
20% FCS + 1% BSA + 1.0 mM Gin). Nine of the 10 samples
produced myeloid colonies which consisted of macrophages,
monocytes and granulocytes. In no instance were MY-CFUc
produced. Addition of anti IL-6 to this culture system
reduced the number of myeloid colonies in 7/7 samples.
Conditioned medium from the human bladder carcinoma cell
line 5637, which is used as a source of granulocyte macro-
phage colony stimulating factor (GM-CSF), contains approx-
imately 4 ngml-' IL-6. Addition of anti IL-6 (0.5fg
1.5 ml-') to cultures of GM-CFUc from normal donor bone
marrow reduced the number of colonies by 80%. These data
provide evidence that IL-6 is a growth factor which affects
the proliferation of myeloid but not myeloma cells in vitro.
The effects of prolonged treatment of patients with
advanced cancer with low-dose subcutaneous interleukin 2
(IL2)
R.C. Stein', V. Malkowska2, S. Morgan2, C. Aniszewski',
A. Galazka3, D. Bevan2, E.C. Gordon-Smith2
& R.C. Coombes'
'Clinical Oncology Unit and 2Department of Haematology,
St George's Hospital Medical School, London SW17 ORE,
UK; and 3Glaxo IMB, Geneva, Switzerland.
IL2 has been shown to have useful activity in the treatment
of some advanced cancers in phase II studies. Existing regi-
mens involving i.v. administration are cumbersome and treat-
ment toxicity is substantial, especially at high doses. We have
investigated the effects of prolonged outpatient treatment
with self-administered, low-dose IL2 given once daily by s.c.
injection. Thirty patients with advanced cancer have been
given 0.1, 1, 10 or lOOpg (16-16,000 units) IL2 (Bioleukin,
Glaxo) daily for 8 weeks, 5 days weekly, followed by a
4-week observation period. No systemic side effects were
observed at the 3 lower doses and only 3/13 patients required
dose reduction from lOtg daily for intolerance (fever, rash,
nausea and vomiting, and lethargy). Minor skin reactions
occurred at all doses. Immunological and clinical activity
were observed at 1OOLg daily. Immunological effects in 8
patients consisted of: a modest sustained lymphocytosis from
week 2; eosinophilia in 6 patients; and a rise in natural killer
(NK) and IL2-stimulated lymphocyte activated killer (LAK)
cell activity to a mean of 2.1 and 2.0 times pretreatment
levels (P<0.01). Two of six patients with renal cell carcin-
oma treated with 100gg daily had partial responses of dura-
tions 3 + and 9 months, and 2 had stable disease for >6
months. Low-dose, long-term s.c. IL2 is clinically and
immunologically active and in comparison with other IL2
regimens it has only minor toxicity and is easy to administer.
These characteristics, make it suitable for study in the
adjuvant setting.
Interferon-a2b (IFN-(x2b) as initial therapy in combination
with chlorambucil (CB) and as maintenance therapy in
follicular lymphoma (FL)
C. Price, A. Rohatiner, W. Steward2, J. Wright, A. Norton',
D. Deakin3, N. Bailey4, G. Blackledge4, D. Crowther2
& T.A. Lister
ICRF Department of Medical Oncology & 'Department of
Histopathology, St Bartholomew's Hospital, London ECJ;
Departments of2Medical Oncology & 3Radiotherapy, Christie
Hospital, Manchester; and 4West Midlands CRC Clinical
Trials Unit, Queen Elizabeth Hospital, Birmingham, UK.
Since 1985 the combination of CB (10 mg daily; initially for 6
weeks, then alternating fortnights for 12 weeks) and IFN-a2b
(Schering-Plough; 2 x 106 unitsm2 three times weekly s.c.
continuously for 18 weeks) has been compared in a random-
ized trial with CB alone (as above) in previously untreated
patients with stage III and IV FL. Responding patients have
subsequently been randomized to maintenance IFN-a2b (M-
IFN), or no further treatment (NT). To date, 111 patients
have been treated and 104 are evaluable for response (57 CB,
47 CB + IFN-a2b), with a median follow up of 28 months.
There was no significant difference in response rate. The
major toxicity of the initial therapy was myelosuppression,
which was more frequent with CB + IFN-a2b; 32 patients
(65%) required a delay in treatment, or dose modification,
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intolerant of the systemic toxicity of IFN-a2b. There was no
mortality related to treatment. Actuarial survival at 3 years
is 75% for all patients, regardless of therapy. For the 68
patients who have entered the second phase of the trial, there
was a significant difference in duration of remission in favour
of M-IFN (median not yet reached vs. 9 months for NT,
P=.014). Fewest relapses have been seen in patients who
received IFN-a2b in both phases of the study. Accrual to the
trial continues; this preliminary analysis indicates that M-
IFN may extend remission duration in FL.
A phase II study of ifosfamide and a2 interferon (Intron
A) in advanced non-small cell lung cancer
M.J. Lind', N. Thatcher2, H. Gurney2 & A. Kamthan2
'University Department of Clinical Oncology, Newcastle
General Hospital, Newcastle upon Tyne NE4 6BE; and
2CRC Department of Medical Oncology, Christie Hospital,
Manchester M20 9BX, UK.
Forty-five patients with advanced non-small cell lung cancer
who were symptomatic from their disease, or clinically pro-
gressing, were treated with a combination of X2 interferon
(Intron A) and ifosfamide. Each patient received a2 interferon
(Intron A) 3 megaunits three times a week until disease
progression, or to a maximum of 12 weeks. In addition,
patients received ifosfamide 1.5 g m2 given as a thirty
minute i.v. infusion on days 1-5 with equidose mesna given
as a 12-hour infusion. Courses were repeated three weekly
until disease progression, or to a maximum of 4 courses. A
total of 128 cycles of ifosfamide were administered to 45
patients. Haematological toxicity was generally mild with
median nadir white blood cell counts as follows: 2.95 x I091'
(course 1), 2.40 x 09 1-' (course 2), 2.85 x 09 1-' (course 3),
2.10 x 109 1- l (course 4). Intravenous antibiotics were admin-
istered on five occasions. Non-haematological toxicity
was mild and reversible. There were no instances of haemorr-
hagic cystitis, and only two episodes of ifosfamide ence-
phalopathy. Toxicity attributable to interferon consisted of
mild myalgia and pyrexia in 10% of patients. There were two
complete responders and seven partial responders giving an
objective response rate of 20%. Twenty-three patients had
stable disease, eight progressive disease and there were three
early deaths. The median survival following the start of
therapy was 8 months. In conclusion, this study does not
demonstrate potentiation of the antitumour action of ifos-
famide by a2 interferon (Intron A).
The role of oestrogen receptors and C-erbB2 in the long
term prognosis of breast cancer
J.H.R. Winstanley, S.M. Holt,. R.S. Rudland,
B.R. Baraclough, A.M. Platt-Higgins, W.D. George,
K. Griffiths, R. Nicolson & T.G. Cooke
University Departments of Surgery & Biochemistry, Liverpool
& Glasgow, and the Tenovus Institute, Cardif, UK.
Oestrogen receptor status was one of the earliest cellular
markers of prognosis to be described in breast cancer and
our group was one of the first to observe its short term
prognostic significance. Since then a number of other mark-
ers have been described, one of the most recent being the
proto-oncogene C-erbB2 whose protein product is expressed
at the cell surface and which shares significant sequence
homology with the EGFR. Initial short term studies of both
mRNA and cell surface protein have indicated an expression
of up to 30% and an association with tumours of poor
prognosis.
We have re-evaluated our original group of patients, in
whom oestrogen receptor was studied, to assess the long term
significance of oestrogen receptors and, using an immuno-
histochemical technique, evaluated the expression and signi-
ficance of C-erbB2 in the same group of patients. Oestrogen
receptor status was evaluated in 708 patients with stage I and
II breast cancer treated between the years 1975 and 1981
with either modified radical mastectomy or simple mastec-
tomy with axillary sampling. We used a radiolabelled ligand
binding technique, and paraffin sections from 423 of this
group were stained using an immunoperoxidase technique
with the 21N polyclonal C-erbB2 antibody. Although a
highly significant survival advantage was seen in the oest-
rogen receptor positive patients (X2 = 6.69; P = <0.009) this
was entirely accounted for by a short term improvement in
stage II disease. Presence of C-erbB2 though was associated
with significantly poorer survival which was present through-
out the study and affected both stage I and II disease.
(x2 = 7.674; P = <0.0056). Although ER status can now
only be regarded of short term significance in stage II
disease, C-erbB2 significantly predicts long term prognosis for
both stage I and II disease.
Allele loss from chromosome 17p and p53 gene expression
is important in the pathogenesis of breast cancer
A.M. Thompson"2, J. Prosser2, G. Cranston2, C.M. Steel2,
U. Chetty' & W.R. Miller'
'Department of Surgery, Royal Infirmary, Edinburgh
EH3 9YW; and 2MRC Human Genetics Unit, Western
General Hospital, Edinburgh EH4 2XU, UK.
Allele loss from the short arm of chromosome 17 (17p) and
mutations of the p53 gene on 17p from tumour suppressor
gene to oncogene have been demonstrated in colorectal and
lung cancer. The aim of the present study was to determine
whether similar abnormalities may be detected in breast
cancer. In 80 primary breast tumours we examined allele loss
from 17pl3 with Southern blots of paired blood and tumour
DNA, p53 gene mRNA expression by laser densitometry of
Northern blots and used the polymerase chain reaction and
DNA sequencing to identify p53 gene mutations. 17p allele
loss was demonstrated in 42 of 76 informative tumours
(64%). No p53 mRNA was demonstrated in 33 of the 76
tumours, whereas there was over-expression of p53 mRNA
compared to normal breast tissue in 24 tumours. Allele loss
with probe YNZ 22.1 correlated with low oestrogen receptor
protein (P = 0.029) and over-expression of p53 mRNA
(P = 0.042). Mutations in exons 5 and 6 of the p53 gene were
detected in some tumours with over-expression of p53
mRNA. These data suggest that chromosome 17p is impor-
tant in breast cancer. Absence of p53 tumour suppressor
gene expression or deletion of a regulatory locus (adjacent to
YNZ 22.1) allowing over expression of mutant, oncogenic
p53 are proposed as key events in the pathogenesis of breast
cancer.
An immunocytochemical method for detection of progesterone
receptors in breast tumours
E. Anderson, K. Healy, L. Jones & A. Howell
Departments of Clinical Research and Medical Oncology,
Christie Hospital and Holt Radium Institute, Manchester
M20 9BX, UK.
An immunocytochemical method for detecting progesterone
receptors (PR) has been developed and used to determine the
PR status of 325 breast tumour specimens too small for
ligand binding assay. Briefly, after blocking endogenous per-
oxidase activity, 5tm fixed, frozen sections were incubated
with the primary antibody (Transbio, France) overnight at
4°C. Binding of primary antibody to the receptor was visual-
ized using peroxidase-conjugated secondary and tertiary
antibodies followed by the chromogen (diaminobenzidine).
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and mounted. The oestrogen receptor (ER) status of all the
tissue samples was determined using the ER-ICA kit (Abbott
Labs). Receptor content was expressed as the percentage of
tumour cells that showed specific staining and a level of
5% was used as the cut-off between positive and negative
tumours. Of the 325 samples assayed, 45% were ER + /
PR +, 27% were ER-/PR- with 15% and 13% being
ER + /PR - and ER - /PR + respectively. In a subgroup of
51 tumours, PR was additionally assayed by the iso-electric
focusing (IEF) method previously used in this laboratory for
receptor assessment in small tumour samples. Whilst there
was a statistically significant correlation between the two
methods (P<0.001 by Spearman's Rank Correlation test), it
was clear that the IEF method seriously underestimated the
proportion of PR + tumours (49% vs 69%; P<0.001 by x2
test). To our knowledge this is the largest group of tumours
to date to have their PR content assayed by an immunocyto-
chemical method. We conclude that the PR immunocyto-
chemical assay is a relatively simple and reliable technique
and is the method of choice for the estimation of PR in small
breast tumour samples.
Prognostic factors in breast carcinoma
D.J. Hehir, A. McCann, K. Cronin, D. Carney, P. Dervan,
W.P. Hederman & S.J. Heffernan
Departments of Surgery, Oncology, and Pathology, Mater
Hospital, Dublin 7, Ireland.
Nucleolar organizer regions are loops of DNA which possess
ribosomal RNA genes, and are readily demonstrable by silver
staining. The argyrophilia can be assayed on routinely pro-
cessed histological tissue by direct counting (Ag-NORs), and
is an indicator of mitotic activity (Smith & Crocker (1988),
Histopathology, 12, 113). Recent studies have demonstrated
significantly increased Ag-NORs in malignant vs benign
breast tumours (Giri et al. (1989), J. Pathol., 157, 307). The
aim of this study was to correlate Ag-NOR activity with
survival in a group of women previously treated for breast
carcinoma and currently under review. Fifty patients treated
by partial mastectomy and radiotherapy were serially review-
ed for signs of recurrent disease. [Mean 60 ± 94 months].
Original paraffin-embedded histological specimens were sec-
tioned, stained and coded. Ag-NOR's were counted in 100
cells per slide.
Results a b c
Disease recurrence Diseasefree
@ 36 months @ 60 months Non Survivors
Ag-NORs 24.8 6.7 19.7 7 27 6.7
a vs b P<.05 b vs c P<.01
Our findings suggest that nucleolar organizer regions are of
prognostic significance in breast carcinoma. They may have
clinical application in dictating therapeutic options for breast
carcinoma.
Mutant p53 is a common genetic abnormality in human breast
cancer and associated with EGF receptor and neu expression
A.L. Harris', E. Horak2, K. Smith', L. Hurley2, S. LeJeune',
M. Greenall3 & D. Lane4
'ICRF Molecular Oncology Laboratory, Institute of Molecular
Medicine, John Radcliffe Hospital, Headington, Oxford
OX3 9DU; 2Nuffield Department ofPathology, John Radcliffe
Hospital, Headington, Oxford OX3 9DU; 'Nuffield
Department of Surgery, John Radcliffe Hospital, Headington,
Oxford OX3 9DU; and 4ICRF Clare Hall, Blanche Lane,
Potter's Bar, South Mimms, Herts EN6 3LD, UK.
Deletions of chromosome 17p have been reported in a high
proportion of breast cancers. To investigate the role of p53
activation in primary human breast cancer and follow up the
observation of frequent 17p deletions, we used a monoclonal
antibody that recognized a specific isotope expressed by
mutated forms of p53, to stain primary breast cancers. This
has been correlated with the expression of other gene
markers that are associated with a poor prognosis, EGFr and
neu; 23/29 (80%) of EGFr positive tumours expressed
mutant p53, and only 7/25 EGFr negative tumours (27%,
P<.05). There was no association with lymph node status or
ER status, but there was an association with poorly different-
iated tumours. Neu was expressed in 6/16 p53 positive
tumours with cytoplasmic staining, whereas only 1/18 p53
negative tumours had such staining.
The anti-metastatic gene NM23: its expression in human breast
cancers
C. Hennessy', J.A. Henry2, F.E.B. May2, B.R. Westley2,
B. Angus2 & T.W.J. Lennard'
Departments of 'Surgery and 2Pathology, University of
Newcastle-upon-Tyne, Newcastle-upon-tyne, NE2 4HH, UK.
Recently attention has been focused on the genetic basis of
the metastatic phenotype. The ras oncogene and its protein
p21 are implicated in the complex process of tumour metas-
tasis. If tumour metastasis could be accurately predicted, the
therapeutic options for patients might be optimized, which
may possibly lead to improved long term survival. A recently
described antimetastatic gene may provide part of the ans-
wer. nm23 expression has been investigated in animal experi-
mental systems and found to have an inverse correlation with
tumour metastatic potential. When its expression in 27
human primary breast cancers, 10 by Northern blots and 17
by in situ hybridization, was assessed it showed strong cor-
relation with lymph node involvement (Bevilacqua et al.
(1989), Cancer Research, 49, 5185). We have assessed the
level of nm23 mRNA expression in a series of 59 human
primary breast cancers by Northern transfer. Hybridization
was carried out to RNA using a digested fragment of the
murine pnm23-1 plasmid, with hybridization to the human
cell line HeLa RNA as internal control. Hybridization to a
mRNA band of 0.8 kb was identified, confirming the obser-
vations of other authors. After quantitative analysis, by scan-
ning densitometry, the pnm23 mRNA levels were correlated
with lymph node involvement. Of 35 tumours from lymph
node positive patients, 28 (80%) demonstrated low levels of
expression, whereas only 9 out of 20 tumours (37.5%), from
lymph node negative patients, had similarly low levels. When
the distribution was assessed by the x2 test it showed that
these differences were significant, (X2 = 12.47 with P<0.02).
nm23 is a useful indicator of the metastatic potential of
human cancers and requires further study in relation to the
long term survival of these patients.
Argyrophil nucleolar organizer regions in colorectal cancer
Z. Rayter', P. Surtees', G. Tildsley2 & C. Corbishley2
'Department of Surgery, St Peter's Hospital, Chertsey and
2Department of Pathology, St George's Hospital, London
SW17, UK.
Argyrophil nucleolar organizer regions (AgNORs) are in-
creased in a variety of malignant cells compared with their
normal counterparts. A recent study has claimed that
AgNORs have prognostic value in Dukes C colorectal cancer
(Moran et al. (1989), Br. J. Surg., 76, 645). We have studied
the AgNOR counts in 95 tumours resected from patients in
whom a minimum 5-year follow-up was available. In 71
specimens, adjacent normal mucosa was also examined.
Formalin-fixed paraffin wax-embedded sections were stained
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Pathol., 151, 111]. AgNORs were counted in 100 normal and
100 carcinoma cells, and the results expressed as AgNORs
per cell. There was a significant difference between AgNORs
per cell in tumour cells (median 1.92, range 1.42-2.95) com-
pared with normal cells (median 1.46, range 1.10-1.80,
P<0.001). There was no significant difference in AgNORs
per cell in each Dukes stage, or between tumours which were
well -, moderately -, or poorly - differentiated. Finally, there
was no correlation of AgNORs with prognosis.
Cyclic AMP binding proteins in human colorectal cancer and
mucosa
A.W. Bradbury, D.C. Carter & W.R. Miller
Department of Surgery, Royal Infirmary, Edinburgh
EH3 9YW, UK.
Cyclic AMP analogues inhibit growth and promote different-
iation of human colorectal cancer cell lines in vitro. These
effects are mediated through specific cyclic AMP binding
proteins (cAMP-BP) (Tagliaferri et al. (1988), Cancer Res.,
48, 1642). The aim of the present study was to measure levels
of cAMP-BP in human colorectal cancer and mucosa. Speci-
mens were obtained from 50 patients with colorectal cancer.
In each case tissue was removed from tumour (T), adjacent
(MA) and distant (MD) histologically benign mucosa. Cyto-
sols were prepared by homogenization and high speed centri-
fugation. Levels of cyclic AMP-BP were then determined
using a 'H-cAMP - competitive binding assay (Miller et al.
(1988), Br. J. Cancer, 52, 531) and results expressed as fmol
cAMP bound mg-' cytosol protein. Tumours had significant-
ly higher levels of cAMP binding (3453 ± SD 1772) than
either MA (2286 ± 906) or MD (2666 ± 1086) (P<0.0001 by
paired t-test). Binding was also significantly lower in MA
than in MD (P<0.001 by paired t-test). Furthermore, bind-
ing was significantly influenced by tumour stage and grade.
Levels were higher in Dukes B (n = 30, 3948 ± 1677) than
Dukes C (n = 17, 2232 + 856) tumours and well- and moder-
ately-differentiated cancers (n = 35, 3654 ± 1724) as compar-
ed to those which were poorly differentiated or mucinous
(n = 15, 2595 ± 1185). In conclusion, cAMP-BP are over-
expressed in colorectal cancer compared with normal
mucosa, particularly that adjacent to the tumour, and levels
correlate with stage and grade of disease.
Detection of allele loss in bronchial biopsies of lung tumours by
use of the polymerase chain reaction
P.S. Ganly & P.H. Rabbitts
MRC Clinical Oncology and Radiotherapeutics Unit, MRC
Centre, Hills Road, Cambridge CB2 2QH, UK.
One way of searching for tumour suppressor genes important
in lung carcinoma is to look for frequently occurring
chromosomal deletions. This may be done at the molecular
level by comparing DNA obtained from paired tumour and
normal patient tissue, and observing loss of polymorphic
alleles by Southern blotting. The disadvantage to this ap-
proach is that it relies upon obtaining more tumour tissue
than is provided by small bronchial biopsy samples, which do
not usually yield sufficient DNA for conventional Southern
blotting. The biopsy specimen is frequently the only material
obtained during a patient's treatment course and therefore
many tumours cannot contribute any information to this
deletion mapping approach. We are, therefore, attempting to
use the Polymerase Chain Reaction (PCR) to amplify DNA
at loci from chromosome 3p which are commonly deleted in
lung tumours. After sequencing around the Msp 1 polymor-
phic site at D3S2, primers were constructed which directed
PCR amplification of a 473 bp product from D3S2, which
could be cut at the polymorphic site to give two fragments of
equal length. Heterozygotes thus had two alleles of 473 and
236 bp, which were analysed on agarose gels. Normal and
tumour tissue from 15 patients who were informative (heter-
ozygous) at D3S2, and had been studied for allele loss at this
locus by Southern blotting, were studied using PCR. Results
obtained by the two methods were identical. DNA was then
successfully amplified from bronchial mucosal biopsies of 5
informative patients, and partial allele loss was detected in
one who had large cell anaplastic carcinoma. This method
may be useful in identifying allele loss in small samples, and
thus permit study of many more patients than is now possi-
ble, facilitating location by deletion mapping of the tumour
suppressor gene on 3p.
Deletion mapping of chromosome 3 in small cel lung
carcinoma patients
M.C. Daly', P.H. Rabbitts', N.M. Bleehan', P. Hasleton2,
S. Spiro3, B. Carritt4, R. Souhami' & J. Bergh'
'CORU, MRC Centre, Hills Road, Cambridge; 2Department
of Pathology, Wythenshawe Hospital, Manchester;
'Department of Histopathology, The Brompton Hospital,
London; 4MRC Human Biochemical Genetics Unit, University
College, London, UK.; and 'Department of Oncology,
University of Uppsala, Uppsala, Sweden.
The tumours of patients with small cell lung carcinoma
(SCLC) frequently show deletions on the short arm of
chromosome 3. The region of the chromosome commonly
deleted may harbour a tumour suppressor gene. Despite
reports of the loss of polymorphic alleles on 3p, the number
of probes used in each case have been insufficient to allow
the delineation of the deletion in molecular terms. We pre-
sent the genotype analysis of 9 SCLC patients obtained using
14 probes which spanned the entire length of chromosome 3
and which identified 18 restriction fragment length polymor-
phisms. We established that 7 out of the 8 pairs of normal
and tumour DNA samples, showed reduction to homozyg-
osity in the tumour DNA at each locus that was informative
for a 3p polymorphism. In addition, a single unmatched
tumour sample was shown to be homozygous at every 3p
locus tested. By contrast, 2 out of 3 informative patients plus
the unpaired tumour sample retained heterozygosity at loci
which mapped to the long arm of chromosome 3. The extent
of the deletion varied among patients ranging from loss of
part of the short arm to deletion of an entire homologue.
One of the patients has proved particularly useful in setting a
distal boundary to the deletion. This patient was
heterozygous at both the THR (3p24) and D3S2 (3pl4-p21)
loci, but showed allelic loss at other loci on 3p proximal to
band 3p2l. Using comparative densitometric analysis, we
have demonstrated that this patient contains 2 copies of the
D3F15S2 (3p21) locus, the latter of which is almost con-
sistently subject to allelic loss in SCLC tumours. In order to
compare effectively the extent of the the deletion in this
patient with those of other studies, further physical evidence
is required for the relative localizations of probes within the
band 3p21. By the use of a large repertoire ofchromosome 3
specific probes, we have detected a very informative patient
for defining the boundaries of the 3p deletion.
Production of insulin-like growth factor -I (IGF-I) and IGF-I
binding proteins by human lung tumours
J.G. Reeve, J.A. Payne & N.M. Bleehen
MRC Clinical Oncology and Radiotherapeutics Unit, MRC
Centre, Hills Road, Cambridge CB2 2QH, UK.
The production of insulin-like growth factor I (IGF-1) and
IGF-I binding proteins (BPs) by human lung tumours cell
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substances in the serum of lung cancer patients investigated.
Radioimmunoassay and immunoradiometric assay were used
to measure IGF-I in acid extracted cell-conditioned media
and serum samples. For the detection of IGF-BPs in condi-
tioned media and serum '25I-IGF-I was cross linked to pro-
teins using disuccinimidyl suberate in the presence or absence
of excess cold IGF-I. Samples were electrophoresed on 7-
15% linear gradient gels and IGF-BPs detected by subse-
quent autoradiography. Whilst small cell lung cancer (SCLC)
cell lines secreted both IGF-I and low molecular weight BPs
(25-30 kDa), the non-small cell lung cancer cell (NSCLC)
lines examined secreted BPs only. No evidence of increased
serum IGF-I levels was obtained in a cohort of 52 lung
cancer patients having SCLC and NSCLC histologies. In
contrast, serum levels of IGF-BPs were markedly raised in 25
of 27 of lung cancer patients studied. The frequency with
which elevated BPs are detected in lung cancer patients raises
the possibility that IGF-BPs may be clinically useful tumour
markers for both SCLC and NSCLC.
Increased expression of mutant forms of the p53 oncogene in
primary lung cancer
R. Iggo', K. Gatter9, J. Bartek"3, D. Lane' & A.L. Harris4
'ICRF Molecular Immunochemistry Laboratory, Clare Hall,
Blanche Lane, Potter's Bar, South Mimms, Herts EN6 3LD,
UK; 2University Department of Pathology, John Radcliffe
Hospital, Oxford OX3 9DU, UK; 3Research Institute of
Clinical & Experimental Oncology, Brno, Czechoslovakia;
and 4ICRF Oncology Unit, Molecular Oncology Laboratory,
Institute of Molecular Medicine, John Radcliffe Hospital,
Oxford OX3 9DU, UK.
Lung cancer is the commonest fatal cancer in men in the
western world. p53 is a tumour suppressor gene which maps
to chromosome 17p, a common site of allele loss in lung
cancer. Therefore, we examined primary lung cancer samples
of the major histological types for alteration of p53 expres-
sion using new antibodies to p53. Immunohistochemical
abnormalities in p53 expression were found in 28 out of 40
carcinomas, 82% of squamous tumours showing abnormal
p53 expression, whereas p53 expression was undetectable in 7
carcinoid tumours and in all normal lung examined. We
obtained direct evidence for homozygous expression of
mutant p53 mRNA in representative carcinomas by using an
asymmetric polymerase chain reaction (PCR) based mRNA
sequencing strategy. This method allowed us to sequence the
mRNA without any cloning step. All the mutations were
G>T transversions resulting in missense mutations in evolu-
tionarily conserved amino acids. Mutation of the p53 gene is
the most frequently identified genetic change in human lung
cancer and our results suggest that simple immunohisto-
logical methods can be used to provide strong evidence that
such mutation has occurred.
Triazene N-oxides, synthesis and antitumour activity of some
triazene 1-oxides
P.M. Goddard & D.E.V. Wilman
Drug Development Section, Institute of Cancer Research,
Cancer Research Campaign Laboratory, Cotswold Road,
Sutton, Surrey SM2 5NG, UK.
The imidazoletriazene, DTIC is well established in melanoma
therapy and CB 10-277 [1-(4-carboxyphenyl)-3,3-dimethyl-
triazene] is currently undergoing clinical investigation. These
compounds require activation by oxidative metabolism to
display their antitumour effect. As an extension of our work
in this area, we have investigated the antitumour activity of
some triazene 1-oxides, which may have alternative metabolic
requirements.
We report here on the synthesis and antitumour activity of
3-(4-R-phenyl)-l-methyltriazene 1-oxides (I), 3-(4-carbamoyl-
phenyl)-1,3-dimethyltriazene 1-oxide (II) and 1-(4-R-phenyl)-
3,3-dimethyltriazene 1-oxides (III) towards the AdjPC6/A
murine plasmacytoma; CB 10-277 is included for compari-
son.
Compound LD50 EDsr TI
I, R = CONH2 330 15.5 21.3
I, R = COOH >400 270 >1.5
II, R = CONH2 285 195 1.5
III, R=H 35.5 21 1.7
III, R = CONH2 141 18 7.8
CB 10-277 180 11 16.4
The iodine atom in 4-iodotamoxifen reduces the extent of
metabolism by isolated rat hepatocytes
R. McCague, I.B. Parr & B.P. Haynes
Drug Development Section, Institute of Cancer Research,
Sutton, Surrey SM2 5NG, UK.
The search for an analogue of tamoxifen (TAM) possessing
improved in vitro activity, like 4-hydroxytamoxifen but lack-
ing propensity to deactivating metabolic conjugation, led to
4-iodotamoxifen (4-IT). We have reported that this has im-
proved oestrogen receptor binding and effectiveness as an
inhibitor of MCF-7 breast tumour cell growth in culture
compared to TAM (McCague et al. (1989), J. Med. Chem.,
32, 2527). But what about its metabolism?
We have now found that after an hour's incubation with
hepatocytes isolated from rats pretreated with phenobarbital
4-IT was metabolized (extent of 18%) four times more slowly
than TAM (75%). Metabolites formed from 4-IT and
measured by HPLC were modified by demethylation (5%),
N-oxidation (5%), a-hydroxylation with demethylation (1%),
and 4'-hydroxylation (c. 0.5%). All of the metabolites
identified retained the iodophenyl ring. The iodine atom not
only prevented metabolism in its vicinity, but also reduced
side-chain modification, since tamoxifen gives demethylation
and N-oxidation each at 15% (Parr et al. (1987), Biochem.
Pharmacol., 36, 1513). The reduced rate of metabolism of
4-IT by rat hepatocytes is predictive of an increased duration
of action in vivo, a feature which is likely to be beneficial in
breast cancer treatment where sustained drug levels are
needed.
Molecular similarity as a basis for ATP-competitive kinase
inhibition
C.E. Sansom, C.J. McCall & M.F.G. Stevens
Department of Pharmaceutical Sciences, Aston University,
Aston Triangle, Birmingham B4 7ET, UK.
Tyrosine kinase activity is exhibited by a number of oncogene
products. Uncontrolled expression of these proteins may lead
to and help maintain the transformed state (Cromoglio et al.
(1987), Ann. N.Y. Acad. Sci., 511, 256). Quercetin, genistein
and amiloride are inhibitors of tyrosine kinases which are
competitive with the phosphate donor, ATP (Kenyon & Gar-
cia (1987), Med. Res. Rev., 7, 389). Using the crystal struc-
ture of ATP bound to phosphoglycerate kinase (Watson et
al. (1982), EMBO J., 1, 1635) and semi-empirical molecular
orbital calculations with MOPAC IV (QCPE 455; Stewart,
QCPE Bull., 3, 43) we have constructed a model of a kinase-
bound ATP complexed to two magnesium ions. Comparison
of this structure with those of the known tyrosine kinase
inhibitors has shown a significant similarity between the506 BRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS
molecular surface of the adenine moiety and both the bicyclic
portions of the flavone derivatives and the heteroylguanidine
fragment of amiloride. The electrostatic potentials of ATP
and its competitive inhibitors are similar about the 6-NH2
group and about N3 of the adenine residue. These techniques
may be applied to future crystal structures ofATP-dependent
tyrosine kinases leading to a greater understanding of the
specificity of ATP-competitive kinase inhibitors.
Synthesis and biological properties of 2-phenylbenzothiazole
derivatives
C.J. McCall & M.F.G. Stevens
Pharmaceutical Sciences Institute, Department of
Pharmaceutical Sciences, Aston University, Aston Triangle,
Birmingham B4 7ET, UK.
Molecular modelling studies have shown that 2-phenylbenzo-
thiazoles have the potential to mimic both D-16726, an
anticancer anti-oestrogen with a 2-phenylindole nucleus (von
Angerer et al. (1985), Eur. J. Cancer Clin. Oncol., 21, 531),
and genistein, a naturally occurring oestrogenic isoflavone.
Genistein also inhibits tyrosine kinases (Akiyama et al.
(1987), J. Biol. Chem., 262, 5592). A number of hydroxylated
2-phenylbenzothiazoles have been prepared and tested for
oestrogen receptor binding affinity, epidermal growth factor
receptor tyrosine kinase inhibitory activity and cytotoxicity
against the 3T3 and ANN-1 cell lines. ANN-1 cells are
derived from 3T3 cell transformed by the Ableson virus and
express a greater than normal level of tyrosine kinase
activity. Oestrogen receptor binding studies confirmed that
dihydroxy-substituted 2-phenylbenzothiazoles can bind to the
oestrogen receptor. 2-(4-hydroxyphenyl)-6-hydroxy-benzothi-
azole showed the highest relative binding affinity (RBA =
0.70). This value is low relative to oestradiol (RBA = 100)
but comparable to that of genistein (RBAtl). The com-
pounds tend to become more cytotoxic with each additional
hydroxy group but none show differential cytotoxicity
towards ANN-1 or 3T3 cells.
Chemistry and stereochemistry of non-classical lipophilic
dihydrofolate reductase inhibitors
W.K. Chui
Pharmaceutical Sciences Institute, Department of
Pharmaceutical Sciences, Aston University, Aston Triangle,
Birmingham B4 7ET, UK.
4,6-Diamino-2,2-dialkyl-1,2-dihydro-l-(substituted phenyl)-l,
3,5-triazines exhibit antitumour activity by inhibiting the
enzyme dihydrofolate reductase. It has been found that the
inhibitory activity of these triazines depends on the position
of the substituents on the aryl ring. Ortho-substituted triazine
antifolates show reduced inhibitory activity (Kim et al.
(1980), J. Med. Chem., 23, 1248). Large ortho-substituent
restricts rotation about the C-N bond between the aryl and
the triazine rings. This gives rise to chiral atropisomers which
may exhibit different affinity for the enzyme. Such triazine
antifolates have been synthesized by using the 'Three-compo-
nent Method' (Modest (1956), J. Org. Chem., 21, 1). Energy
barrier to rotation about the C-N bond has been calculated
by molecular modelling technique. Enrichment of the chiral
atropisomers has been attempted by diastereomeric salt for-
mation and diastereomeric derivatisation. Separation of the
diasteromeric atropisomers has been achieved by semi-pre-
parative high performance liquid chromatography. The
separated diastereomeric atropisomers were tested for its
inhibitory action against DHFR.
DNA damaging effects of the benzotriazine-N-oxides
N.S. Virk, J.H. Tocher & D.I. Edwards
Chemotherapy Research Unit, Polytechnic of East London,
Romford Road, London E15 4LZ, UK.
The DNA damaging ability of a number of benzotriazine-di-
N-oxides, a novel class of hypoxic cell cytotoxins/radiosen-
sitizers, has been examined. The drugs were electrolytically
reduced under anoxic conditions in the presence of E. coli
DNA and a trace amount of OX174 DNA. The damage was
assessed using a double transfection assay. Under oxic and
anoxic non-reductive conditions all the drugs tested showed
no or very little damage to DNA. However, under anoxic
reductive conditions damage was observed. The lead com-
pound, SR4233, was found to be the most effective drug with
damage being enhanced at acidic pH. At pH 7 a lag phase of
about 1.5 hours was observed before any significant damage
occurred. Slight shoulders were also seen at pH 6 and 5,
whereas at pH 4 no delay occurred. This shows that the
damaging species is probably protonated. The reduction
potential, E1/2, increases, i.e. become less negative, and the
pH is decreased and this correlates well with the increased
damage observed under these conditions. The results indicate
that these compounds could be useful as hypoxic cell cyto-
toxins or used as a basis to make more potent and more
specific hypoxic cell cytotoxins/radiosensitizers.
Electrolytic properties of the benzotriazine-N-oxides
J.H. Tocher, N.S. Virk & D.I. Edwards
Chemotherapy Research Unit, Polytechnic of East London,
Romford Road, London E15 4LZ, UK.
The electrochemical characteristics of a range of benzotria-
zine di-N-oxides, important as new cytotoxic agents with a
high specificity for hypoxic cells, have been examined by a
number of techniques. Reduction of the N-oxide groups
results in the formation of the parent benzotriazine hetero-
cycle, which is also redox active, involving 4- and 2-electron
additions respectively. At alkaline pH these separate stages
can be identified, but at acidic conditions only a single step is
observed. The reduction potentials are found to shift to less
negative values i.e., the drug shows an increased electron
affinity, as the pH is lowered. This trend can be described by
an equation of the form E = apH + b. The mono-N-oxide
shows only a single reduction step, although the reduction of
the N-oxide group can be identified, giving the zero-N-oxide.
This is also confirmed by coulometric measurements. The
variation of the mono- and zero-N-oxides with pH is iden-
tical. The importance of pH in the biological activity of the
di-N-oxides is illustrated by an increased DNA damaging
capability of the reduced drug at acidic pH.
Studies on the novel Distamycin compound FCE 24517 with
respect to DNA interactions and sensitivity to alkylating agents
H. Coley, M. Broggini & M. D'Incalci
Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea
62, 20157 Milan, Italy.
FCE 24517, the benzoic acid mustard derivative of Dista-
mycin A (Dist A) has previously been shown to possess broad
spectrum antitumour activity, in marked contrast to the lack
of activity seen for the latter. Unlike most alkylating agents
the N7 position of guanine in isolated DNa is not the target
for the alkylating moiety of FCE 24517. Present studies
indicate the possibility of alkylation on the N3 positon of
adenine. To study any concomitant alteration of the DNA
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ers Dist A or FCE 24517, DNA footprinting studies were
carried out. Major groove alkylating agents used were uracil
mustard (UM), quinacrine mustard (QM) and a tertiary
amine analogue of dabis maleate 1,4,bis(2'-chloroethyl)-1,
4-diazabicyclo (DM). Maxam-Gilbert DNA sequencing gels
demonstrated a marked difference between the patterns of
alkylation due to QM in the presence of either FCE 24517 or
Dist A. Similar effects were seen with Um and DM and these
results are in some agreement with those of Hartley et al.
(Biochemistry, in press) using Dist A. With the purpose of
evaluating the relevance of these DNA sequence-specific
studies, we plan to evaluate how the combined use of minor
groove binders with alkylating agents can modify their cyto-
toxicity in cell lines with varying degrees of sensitivity to the
alkylating agents.
Potentiation of the cytotoxicity and DNA damaging effects of
VP16 by pretreatment with non-cytotoxic concentrations of
arabinosyl cytosine
C.M. Chresta, R. Hicks, J.A. Hartley & R.L. Souhami
Department of Oncology, University College & Middlesex
School of Medicine, 91 Riding House Street, London
WIP 8BT, UK.
Pretreatment of the human lymphoblastoid cell line CCRF-
CEM with 0.02#M araC enhances both the cytotoxic and
DNA damaging effects of etoposide (VP16). This concentra-
tion of araC is itself non-cytotoxic and results in no
detectable DNA damage, as measured by alkaline elution.
Maximum potentiation of etoposide cytotoxicity and DNA
damage was observed after 48 hours continuous treatment
with araC. Cytotoxicity of VP16 is increased approximately
2.5-fold (IC90 19 ± 3.6jiM for control cells; IC90 7.75 ± 1.8
pM for araC pretreated cells). DNA damage is increased to a
similar degree. Treatment of control CEM cells with I jM
VP16 for one hour results in a single strand break frequency
of 158 ± 36 rad equivalents this frequency is increased to
330 ± 42 rad equivalents by pretreatment with 0.02pm araC
for 48 hours. The DNA protein cross link frequency is
similarly increased, a one hour incubation with 10 iM VP16
resulting in a cross link frequency of 644 ± 130 rad equiv-
alents in control cells and 1809 ± 89 rad equilavents in araC
pretreated cells. Cell cycle analysis demonstrated that 48
hours araC pretreatment resulted in accumulation of cells in
late S/G2M. Enhancement of VP16 activity was also observed
with 24 hour araC pretreatment, at which time the majority
of cells were in early S phase, however, the potentiation was
not as great. Removal of araC allows cells to return to a
normal cell cycle distribution within 24 hours and potentia-
tion of VP16 activity is then lost. All DNA strand breaks
were protein concealed, suggesting a mechanism involving
topoisomerase II.
DNA interstrand crosslinking and sequence selectivity of
dimethanesulphonates
M. Ponti', R.L. Souhami', B.W. Fox2 & J.A. Hartley'
'Department Oncology, University College & Middlesex
School of Medicine, London; and 2Department Exp.
Chemotherapy, Paterson Institute Cancer Research, Christie
Hospital, Manchester, UK.
Members of the homologous series of dimethane sulphonic
acid esters of general formula H3C.SO2.O.(CH2)n.O.SO2.CH3
have been tested for their ability to produce DNA interstrand
crosslinking (ISC) and DNA sequence selectivity of guanine-
N7 alkylation. In a sensitive crosslinking gel assay the effic-
iency of ISC formation, dependent on the ability of the
alkylating moiety to span critical nucleophilic distances with-
in the DNA, was found to be Hexa-DMA (n = 6)> MDMS
(n = 1)>Octa-DMS (n = 8) >busulphan (n = 4). The cross-
linking produced by MDMS was not due to either of its
hydrolysis products, formaldehyde or methane sulphonic acid
(MSA). In contrast, the extent of monoalkylation at guanine-
N7 as determined by a modified DNA sequencing technique
was found to be busulphan>Hexa-DMS>>Octa-DMS,
with little overall sequence selectivity compared to other
chemotherapeutic alkylating agents such as nitrogen mus-
tards. MDMS at the same concentration showed extensive
depurination as a result of the release of MSA. At lower
doses however, where depurination was negligible, a single
strong site of guanine-N7 alkylation was observed in a
guanine-rich 276 base pair fragment of pBR322 DNA in the
sequence 5'-ATGGTGG-3' which was not produced by either
formaldehyde or MSA. Thus structurally similar alkylating
agents can differ in their type and extent of DNa monoal-
kylation and ISC, and in some cases (e.g. MDMS) produce
monoalkylations with a high degree of selectivity.
Thermal potentiation of CCNU in two clonal RIF-1 lines with
different thermo- and chemosensitivity
N. Mitsuhashi, D.J. Honess & N.M. Bleehen
MRC Clinical Oncology Unit, Hills Road, Cambridge
CB2 2QH, UK.
A continuing problem in hyperthermia, as yet unaddressed
for thermochemotherapy, is the calculation of isoeffect doses.
The aim of this study is to compare in vitro isoeffect data for
heat with CCNU in cell lines of differing thermo- and
chemosensitivity. We have used two morphologically distinct
tetraploid clones of the murine RIF-1 line. The first stage is
characterization of the thermal responses of each cell line,
including mea$uring the breakpoint in the time-temperature
relationship and the slope of the curve above and below the
break. This allows accurate calculation of EQ43, the equiva-
lent time at 43°C for isoeffect. EQ43 = ER(43-t)At, where R
is derived from the slopes of the time-temperature curve, and
t is treatment temperature. Thermosensitivity profiles for
both clones have been measured over the range 41-46°C,
plating cells into 25 cm2 flasks 16 hours before heat and
counting surviving colonies 12 days later. PE values are
48 ± 10% for L16 and 90 ± 5% for L20. Results:
R above breakpoint R below breakpoint
Clone Breakpoint (±2se) (±2se)
L16 44°C 0.52 (0.48-0.57) 0.24 (0.21-0.28)
L20 43°C 0.51 (0.47-0.56) 0.08 (0.07-0.10)
R values above the breakpoint are essentially identical, and
are typical of those found for other mouse cell lines. The
difference in thermosensitivity between the lines is reflected in
the higher breakpoint for L16 and its larger R value below
the breakpoint. CCNU dose response curves for a one-hour
treatment have been measured for both lines at 37°C and
selected higher temperatures. Do values are presented below:
DoforCCNU,Ih(gml-') (±2se)
Temperature (CC) L16 L20
37 6.82 (6.19-7.58) 3.09 (2.80-3.44)
41 2.63 (2.35-2.99) 1.34 (1.22- 1.48)
42 2.39 (1.84-3.40) 1.75 (1.59- 1.96)
43 2.55 (2.42-2.70) na
At 37'C L20 is about twice as sensitive to CCNU as L16.
This relative sensitivity appears to be maintained at higher
temperatures. Surprisingly, the decrease in Do caused by heat
appears not to be temperature dependent. In conclusion, this
study shows that universal breakpoints and R values cannot
be assumed for all cell lines, hence both must be measured
for accurate estimation of isoeffect doses.508 BRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS
Dipyridamole enhances increased intracellular dUTP and DNA
strand breakage in A549 (human lung carcinoma) cells treated
with CB3717
N.J. Curtin', G.W. Aherne2 & A.L. Harris3
'Cancer Research Unit, University of Newcastle upon Tyne;
2Department Biochemistry, University of Surrey; and 'Clinical
Oncology, ICRF, Oxford, UK.
N'°-propargyl-5,8-dideazafolic acid (CB3717) is a potent
thymidylate synthase (TS) inhibitor with antitumour activity
(Jones et al. (1981), Eur. J. Cancer, 17, 11). Dipyridamole
(DP) enhances the growth inhibitory effect of CB3717 (Cur-
tin & Harris (1988), Biochem. Pharmacol., 37, 2113) by
inhibiting thymidine uptake and deoxyuridine efflux. We pro-
posed that it would therefore increase intracellular deox-
yuridine nucleotide pools. In this study, we have used a
sensitive RIA (Piall et al. (1989), Anal. Biochem., 177, 347) to
measure intracellular dUTP and alkaline elution to measure
DNA strand breaks in A549 cells treated with CB3717 ± DP.
In control cells and those treated with DP alone dUTP was
virtually undetectable but increased in response to CB3717 in
a dose and time related way: 3 iLM CB3717 24 h = 46.1 + 9.6;
30gM CB3717 4 h = 9.6 ± 3.7 and 30gM CB3717 24 h =
337.5 ± 37.9 pM dUTP 10-6 cells. DP further increased the
dUTP in a dose responsive way: 3 yM CB3717 + 1 liM DP
24 h = 174.7 ± 57.7 3lM CB3717 + 10^tM DP 24 h = 482 ±
80 pM dUTP 10-6 cells. DNA strand breakage also increased
with CB3717 dose and exposure time and was further in-
creased by DP. Nascent DNA was more sensitive to
CB3717 ± DP than was mature DNA. Substantial strand
breakage was seen in nascent DNA after only 4 h with
30 sM CB3717 + 1 ItM DP. The finding that both intracel-
lular dUTP and DNA strand breakage were coordinately
increased with CB3717 alone and in combination with DP
supports the hypothesis that thymineless death in mammalian
cells can be mediated by uracil misincorporation into DNA.
Comparative enzymology of the bioreductive metabolism of the
aziridinyl dinitrobenzamide CB 1954: microsomal enzymes
versus DT-diaphorase
M.I. Walton & P. Workman
MRC Clinical Oncology Unit, MRC Centre, Hills Road,
Cambridge CB2 2QH, UK.
CB 1954 [5-(aziridin-1-yl)-2,4-dinitrobenzamide] exhibits
unusually high potency against the UK Walker 256 tumour.
Recent results by Knox et al. ((1989) Biochem. Pharmacol.,
37, 4661 & 4671) strongly suggest this results from
metabolism of the drug to the highly toxic 4-hydroxylamine
by the high DT-diaphorase activity present in the tumour
cells. Since DT-diaphorase is an 'oxygen insensitive' obligate
two electron (2e) donating enzyme, the results do not appear
to explain the preferential cytotoxicity of CB 1954 under
hypoxia versus aerobic conditions; also, a broader spectrum
of metabolites is seen in vivo. As part of an 'enzyme-directed'
approach to bioreductive development we have compared the
range of metabolites and oxygen sensitivity for CB 1954
bioreduction as catalysed by DT-diaphorase-rich Walker and
HT29 human colon carcinoma cells and C3H mouse liver
microsomes. A high resolution HPLC assay was developed
which allows separation of all the known metabolites of CB
1954. For the DT-diaphorase preparation we confirmed the
4-hydroxylamine as the sole metabolite. Its formation was
inhibited almost completely by 1OM dicoumarol and the
rates were similar in air or nitrogen, confirming the proposed
oxygen insensitivity. For equal activities of menadione reduc-
tion, the rat DT-diaphorase was 5 times more active than the
human in catalysing CB 1954 reduction. The 4-hydroxyl-
amine was also the predominant metabolite in mouse liver
microsomes. But in addition we also detected appreciable
amounts of the 2-hydroxylamine and the respective 2- and
4-amines. Both cytochrome P-450 and its reductase appear to
be involved and the formation of all the reduced metabolites
was inhibited completely in air. These results suggest that a
range of enzymes may catalyse CB 1954 bioreduction in vivo
and that therapeutic selectivity may be governed by their
relative activities and 'oxygen sensitivities' in normal and
malignant tissues.
Novel, potential bioprotection pathway for the developmental
hypoxic cell cytotoxin SR 4233: catalysis by DT-diaphorase
M.I. Walton & P. Workman
MRC Clinical Oncology Unit, MRC Centre, Hills Road,
Cambridge CB2 2QH, UK.
The cytotoxin SR 4233 (3-amino-1,2,4-benzotriazine-1, 4-di-
oxide) exhibits unusually high selective killing of hypoxic
compared to aerobic cells, and is the lead compound in the
development of this new class of drug for potential use
against solid tumours in man. The most likely mechanism of
action involves single electron (le) reductive bioactivation to
a short-lived oxidizing radical which abstracts hydrogen from
DNA, resulting in single and double strand-breaks. Hypoxic
cell selectivity results from the reversal of le radical produc-
tion by molecular oxygen. It follows that direct 2e reduction
to the single N-oxide will bypass le bioactivation and will be
bioprotective. We and others have shown previously that the
major stable metabolites found in the tumour and tissues of
mice in vivo are the 1-oxide SR 4317 (2e product) and the
parent benzotriazine SR 4330 (4e product). We have also
shown that the enzyme preparations from mouse tissues form
predominantly SR 4317, e.g. 96% in liver microsomes and
cytosol under nitrogen. We have now investigated the role of
the obligate 2e donating flavoprotein DT-diaphorase as a
potential bioprotecting enzyme. Rat UK Walker tumour cells
were used as a rich source of DT-diaphorase. We found that
SR 4233 was readily reduced by Walker cell extracts under
air with NADH as cofactor. Interestingly, and in contrast to
other preparations, the major product was not the 2e product
(10%) but the 4e product SR 4330 (90%). Its formation was
inhibited 82-95% by 100 1M dicoumarol. We believe this to
be the first report of N-oxide reduction by DT-diaphorase.
The predominant formation of SR 4330 suggests that the
drug molecule remains bound to the enzyme active site to
undergo 2 rounds of 2e reduction. We propose further that
metabolism of SR 4233 by DT-diaphorase may potentially
represent an important and novel bioprotection pathway in
vivo.
Lack of correlation between cisplatin sensitivty, drug uptake,
DNA binding, induction and removal of adducts and
glutathione metabolism in a panel of human tumour cell lines
S.A. Shellard, P. Bedford, L.K. Hosking,
A.M.J. Fichtinger-Schepman & B.T. Hill
Cellular Chemotherapy Lab., I.C.R.F., London WC2A 3PX,
UK.
The mechanisms associated with the expression of differential
cisplatin sensitivities in a panel of human tumour cell lines
have been studied. We have investigated drug uptake and
DNA binding, induction and removal of Pt-DNA adducts,
and total glutathione levels and related enzyme activities in
two testicular (SuSa & 833K), one bladder (RT112) and 4
ovarian cell lines (TRI75, TRI70, JAT & SK-OV-3). The
IC%, values for a one-hour in vitro exposure to cisplatin
ranged from 0.11-4.4fg ml-' with the two testicular cell lines
and one of the ovarian lines (TR175) proving most sensitive
and the RTI 12 bladder and SK-OV-3 ovarian tumour cell
lines proving most resistant. These differences in cytotoxicityBRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS 509
were not correlated with either differential drug uptake or
drug-DNA binding. However, increased total glutathione
levels were associated with the most resistant cell lines.
Platinum-DNA adducts were measured using polyclonal anti-
sera in a competitive ELISA either immediately following a
one-hour cisplatin exposure, or 18 hours later. Differential
induction and removal of Pt-DNA adducts does not appear
to correlate with cisplatin sensitivity in these seven lines. For
example, both SuSa cells and TR175 cells were highly sensi-
tive to cisplatin yet the SuSa cells appeared deficient in the
repair of Pt-AG and Pt-GG adducts, whilst the TR175 cells
appeared proficient in the removal of all 4 adducts. In sum-
mary, therefore, no clear pattern has emerged when trying to
correlate these parameters in this range of 'wild type' cell
lines, suggesting not only that multifactorial mechanisms are
operating, but also that different mechanisms appear to pre-
dominate in the different cell lines.
Aphidicolin does not inhibit repair of cisplatin-induced DNA
damage in a human ovarian cancer cell line
W.C.M. Dempke', S.A. Shellard',
A.-M.J. Fichtinger-Schepman2 & B.T. Hill'
ance. To determine possible mechanisms of VP-16 resistance,
we have derived a panel of resistant sublines designated
VPC2, VPC3 and VPC4 from a human testicular teratoma
cell line, SuSa, by continuous in vitro exposure to increasing
VP-16 concentrations. These sublines exhibited 9-, 21- and
-40-fold levels of VP-16 resistance respectively, and also
proved cross-resistant to adriamycin, vincristine and cis-
platin, as determined by colony formation in soft agar. Resis-
tance indices were defined by comparing ICm values (concen-
trations reducing survival by 50% following a 24-hour drug
exposure) of parental cells and VP-16 resistant sublines.
Overexpression of P-glycoprotein was identified in the two
most highly resistant sublines (VPC3 and VPC4), as judged
by Western blot analysis using the C219 monoclonal anti-
body. No differences in tritiated-VP-16 accumulation or
modifications of total glutathione content, glutathione S-
transferase, glutathione reductase or glutathione peroxidase
activities were observed in any of the sublines compared to
parental cells. However, the GST pi isozyme is constitutively
expressed in all these SuSa lines. To investigate further this
resistance we are currently assessing VP-16-induced DNA
single-strand breakage, using the technique of alkaline elu-
tion, and possible alterations in topoisomerase II, in terms of
P4 DNA unknotting activity.
'Imperial Cancer Research Fund, Cellular Chemotherapy,
PO Box 123, London WC2A 3PX, UK; and 2Medical
Biological Laboratory TNO, PO Box 45, 2800 AA Rijswijk,
The Netherlands.
The recently established human ovarian cancer cell line JA-T,
derived from a previously untreated patient (Int. J. Cancer,
1987, 39, 219) expresses intermediate sensitivity to cisplatin.
This cell line has been used to study the effects of aphidicolin
(AG), a specific competitive inhibitor of DNA polymerase
alpha, on the formation and removal of four platinum-DNA
adducts. For the measurement of platinum-DNA adducts,
logarithmically-growing cells were exposed to cisplatin
(10 yg ml-') alone or in combination with AG (5 ligm-'),
which was added one hour before and during cisplatin treat-
ment. After drug exposure for one hour cells were washed
and harvested immediately, or medium (with or without AG)
was added for another 18 hours. DNA adducts were then
measured immunochemically. No differences between the
initial levels of DNA platination and of specific DNA
adducts in the presence or absence of AG were observed.
Following 18 hours post-treatment incubation, the JA-T cells
were shown to be proficient in the repair of all these
platinum-DNA adducts. However, total platination and the
levels of specific DNA adducts decreased by similar rates
with or without AG treatment, indicating that AG does not
alter the formation and removal of cisplatin-induced DNA
adducts. In addition, growth-inhibition data for JA-T cells
have provided some evidence that AG does not modify
cisplatin-induced cytotoxicity. These data indicate that this
non-cytotoxic concentration of AG (5 gpg ml-') does not
modulate repair of cisplatin-induced intrastrand crosslinks in
this repair proficient ovarian carcinoma cell line.
Characterization of VP-16 resistance in a human testicular
teratoma cell line
L.K. Hosking, R.D.H. Whelan & B.T. Hill
Cellular Chemotherapy Laboratory, Imperial Cancer Research
Fund, London WC2A 3PX, UK.
Etoposide (VP-16) is one of the most effective antitumour
agents in the treatment of testicular cancer. However, its
clinical efficacy is limited by the development of drug resist-
The effect of verapamil on the antitumour action of
mitozantrone and doxorubicin against renal carcinoma cells
in vitro
M.O. Symes', T. Lai', A.P. Morgan' & P.J.B. Smith2
'University Department of Surgery and 2Department of
Urology, Bristol Royal Infirmary, Bristol BS2 8HW, UK.
Surgical nephrectomy specimens were obtained from 12
patients with renal carcinoma, 7 at stage II (confined to the
kidney) and 5 at stage III (extension beyond the kidney
without metastases). Following digestion of the solid tumour
with collagenase type II and DNase, the mixed cell suspen-
sion obtained was centrifuged on a NycodenzR column to
separate the carcinoma cells. Carcinoma cells were cultured
with increasing concentrations of mitozantrone (MIT) (Lede-
rle) or doxorubicin (DOX) (Farmitalia) ± verapamil (Verap.)
(Cordilox, Abbot) at a concentration of 1.0 or 3.3 JAM. The
ability of Verap., which limits the action of the cell
permeability glycoprotein P170, to potentiate the action of
MIT or DOX in inhibiting the uptake of 75selenomethionine
by the tumour cells, was measured.
MIT+ 1.0IAM MIT+ 3.3ItM
Drug conc Verap. Verap.
yg/ml Stage II III II III
0.1 0/3Y 1/5 0/6 2/5 YNo sig
1.0 2/3 3/5 3/6 2/5 No of tumours
5.0 0/3 2/5 0/6 3/5 examined
DOX+ Verap. DOX+ Verap.
0.1 0/3 2/3 2/3 3/3
0.5 2/3 2/3 3/3 3/3
1.0 2/3 2/2 3/3 2/3
For MIT, Verap. had a greater effect with tumours at stage
III. DOX showed greater potentiation by Verap. and the
level of significance increased at the 3.3 .LM concentration.
Prolonged culture of the tumour cells before testing led to a
spontaneous decline in their sensitivity to DOX + Verap.510 BRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS
Differences between monoclonal antibodies in
inmunohistochemical detection of P-glycoprotein in human
and mouse multidrug resistant cell lines
M.A. Barrand, T. Tsuruo & P.R. Twentyman
MRC Clinical Oncology and Radiotherapeutics Unit, Hills
Road, Cambridge CB2 2QH, UK.
A variety of monoclonal antibodies are now available for
detecting P-glycoprotein in both normal and tumour tissues
and in multidrug resistant (MDR) cell lines. Although P-
glycoprotein structure appears to be conserved across species,
structural differences between proteins of this multigene
family exist (Endicott & Ling (1989), Ann. Rev. Biochem., 58,
137). We report here differences in the ability of the mono-
clonal antibodies, MRK16, JSB-1 and C219, to detect P-
glycoprotein in certain human and mouse MDR cell lines.
An APAAP (alkaline phosphatase-antialkaline phosphatase)
method was used both for histochemical localization and for
ELISA assay. Both MRK16 at 30 ig ml' and JSB-1 (San-
bio) at 1:20 dilution of ascites stained the outer cell mem-
brane of over 70% of cells in the resistant human cell lines,
H69-LX4, -LX20 and -VR2. Clear quantitative differences by
ELISA were evident between these MDR human cells and
their sensitive parent cell lines. Cells of another human cell
line, L23R, which shows drug resistance unrelated to P-
glycoprotein, were not stained. However these antibodies
were unable to detect differences between the MDR mouse
cell lines, RIF-L.OA, -L.OB, EMT6-AR1.0, -VRl.O and their
sensitive parent lines. There was very weak cytoplasmic stain-
ing in both resistant and sensitive mouse cell lines. By con-
trast C219 (Centocor) at 1Ofig ml-' produced staining
around the outer edge of the human MDR cells and both
strong cytoplasmic and edge staining in the mouse MDR
cells, together with clear quantitative differences by ELISA
between resistant and sensitive cell lines. C219 recognises a
cytoplasmic region highly conserved in all P-glycoproteins
analysed, so representing a more universal probe for the
protein. However C219 reacts also with proteins other than
P-glycoprotein that may share structural homology with P-
glycoprotein but that are not involved in drug efflux
(Thiebaut et al. (1989), J. Histochem. Cytochem., 37, 159).
Gene amplification in methotrexate resistant human
chonocarcinoma cells
G.R. Coren"2, A.D.B. Malcolm', F. Searle2
& K.D. Bagshawe2
'Department ofBiochemistry, Charing Cross and Westminster
Medical School, London W6 8RP; and 2Department of
Medical Oncology, Charing Cross Hospital, London W6 8RF,
UK.
An established cell line, JAR, derived from a human placen-
tal choriocarcinoma, was exposed continuously to methotrex-
ate (MTX). Resistance to a predetermined ICso concentration
was achieved after 45 passages. The cells were then exposed
to stepwise increases in drug concentrations, producing four
resistant sublines: BO (45 passages), Bi ( + 37 passages), B2
(+ 42) and B3 ( + 28), exposed respectively to 0.0075gM,
0.05 JAM, 0.1 AM, and 0.5gM MTX. Resistance was confirmed
by calculating the IC"0 values for all 4 sublines using
the MTT assay, showing relative resistances of 1.0 for the
sensitive parental cell lines and 2.5, 3.6, 6.8 and 23.7 for the
increasingly resistant sublines. 3H-MTX uptake was identical
in all sublines, eliminating the possibility of transport defects.
Using a probe derived from the plasmid pSVDHFR, con-
taining the mouse dihydrofolate reductase mini-gene, slot,
Southern and Northern blot analyses were used to measure
gene and RNA copy numbers in the resistant sublines.
Relative gene copy numbers of 1.0, 1.12, 1.68, 1.82 and 2.68
were obtained for JAR, BO, Bl, B2 and B3 cell lines respec-
tively, with corresponding RNA copy numbers of 1.0, 1.10,
1.41, 1.77 and 2.18. These RNA values possibly represent
normal transcription of amplified genes. The two major im-
plications from this study are firstly that choriocarcinoma
cells are resistant to methotrexate by gene amplification with
no further control evident at the level of transcription.
Secondly, these seemingly low levels of gene amplification are
sufficient to induce resistance in vitro, and thus low level,
'undetectable', amplification may be responsible for clinical
resistance in vivo.
Gene amplification and expression in a series of verapamil
hypersensitive CHO MDR cell lines
M.W. Stow & J.R. Warr
Department of Biology, University of York, Heslington,
York YOJ SDD, UK.
We have previously shown that two vincristine resistant
CHO cell lines are hypersensitive to the calcium channel
blocking agent, verapamil (Warr et al. (1988), Cancer Res.,
48, 4477). In this study, we investigated the properties of two
independently derived series of MDR CHO cell lines which
have been selected in increasing concentrations of vincristine.
The levels of cross resistance, and of verapamil hypersen-
sitivity were determined, and amplification and expression of
six gene classes (isolated from the cell line CHRC5, which
include the genes for P-glycoprotein (mdr gene family) and
sorcin) were examined using Southern and slot-blotting tech-
niques. In general, progressively increasing levels of multi-
drug resistance are associated with increasing verapamil
hypersensitivity but with one exception, VRA33, the most
MDR member. This cell line shows less verapamil hypersen-
sitivity than an earlier member of the series with less multi-
drug resistance (VRA15). Both the MDR series of cell lines
exhibit only small amounts of amplification (<2.5-fold) of
the flanking sequences adjacent to the mdr gene family. There
is no simple correlation between the level of P-glycoprotein
gene amplification and changes in resistance observed in
many cases. Transcriptional activation of the mdr gene is
shown to be important and expression of the gene correlates
with resistance. For example, there is an apparent decrease in
amplification of the P-glycoprotein gene sequences between
VRA15 and VRA33, although the expression of the gene
increases. Transport studies using 3H vincristine show that
the MDR cells have a decreased accumulation but similar
rates of efflux of the drug out of the cells. The level of
intracellular binding of vincristine differs quite considerably
between the MDR cell lines.
The role of hypoxic and nutrient stress in acquired drug
resistance in V79 cells
A.M. Jones, I.J. Stratford & G.E. Adams
MRC Radiobiology Unit, Chilton, Didcot, Oxon. OXJJ ORD,
UK.
The response of cells to treatment with chemotherapeutic
drugs can be radically altered if cells are stressed before drug
exposure. Hypoxia and nutrient deprivation are two such
stresses. These stresses are of particular importance in cancer
chemotherapy as tumour cells in situ are poorly vascularized
and contain certain regions of hypoxia and nutrient depriva-
tion. Such stresses are known to induce sets of cellular
proteins including the oxygen regulated proteins (ORPs) and
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these stress proteins has also been seen to coincide with
increased resistance to certain drugs such as adriamycin
(ADR). We have carried out studies to examine the effect of
stress on cellular survival and acquired resistance to ADR.
Clonogenic survival studies with V79 cells grown in suspen-
sion have shown that previously hypoxic (16 hours exposure
to 95% N2/5% C02) or glucose deprived (4-day maintenance
in glucose-free media containing serum) cells are considerably
more resistant to subsequent exposure to ADR than the
control cells. The presence of the calcium channel blocker,
verapamil, during drug exposure does not reverse this
acquired resistance. An alternative mechanism may involve
the ORP/GRP system enabling cells to become resistant to
ADR through membrane alterations. We examined this pos-
sibility by using an MTT assay to expose previously stressed
cells to ADR either as attached cells or as cells in suspension.
Exposure in suspension gave the same result as clonogenic
survival studies. However, when previously hypoxic cells
were attached before drug exposure the resistance was dra-
matically reduced. This was not seen with glucose deprived
cells suggesting differences in the mode of action of hypoxic
and glucose deprivation in causing drug resistance.
Establishment of six ovarian carcinoma cell lines and
estimation of drug sensitivity in vitro
I.F.D. Stephens, J.A. Plumb, A.B. MacLean' & S.B. Kaye
10EM) by 10-fold. When incubated with either ADR or
DNR (1 LM) intracellular drug accumulation in 2780AD,
estimated by scintillation counting, is markedly reduced when
compared with the parent cell line, A2780. After 5 hours
A2780 accumulates about 4 times as much drug as 2780AD
for ADR and 16 times for DNR. Total drug per cell for
DNR is twice that for ADR in A2780 and halfthat for ADR
in 2780AD. For both drugs the amount per cell is doubled in
the presence of V (6.6SAM). Intracellular drug distribution
studies were carried out by autoradiography with 3H-DNR.
Total drug per cell was estimated as the number ofgrains per cell. These studies revealed two distinct cell types within each
cell line. Large cells with distinct cytoplasm contained about
3 times as much drug as the small cells with little cytoplasm.
For A2780 the results showed a similar pattern to that
obtained by scintillation counting. However, for 2780AD
there was a sharp peak in grain count per cell during the first
hour. The count then decreased to levels comparable to those
seen by scintillation counting. V had no effect on the grain
count for A2780. For 2780AD during the first hour the grain
count increased by 5-fold in the presence of 3.3 t4M V and by 10-fold with 6.6pM V. For longer incubation times the grain
count was doubled in the presence of V. For both cell lines
the majority (about 75%) of the grains were in the nucleus
and there was no evidence that V altered the cellular drug distribution. These results suggest that drug uptake during the first hour may be important in the mechanism of action
of V.
CRC Department Medical Oncology, University of Glasgow
and 'Department of Gynaecology, Western Infirmary,
Glasgow, UK.
Cis-platinum (CDDP) is one of the most active agents in
ovarian cancer. Although relapse with resistant tumour is
common, little is known about the mechanisms of resistance
to CDDP. To study possible mechanisms of drug resistance
in ovarian cancer, six cell lines have been established from
either biopsies or ascites fluid from patients with ovarian
cancer. Five were derived from previously untreated patients
and one from a patient who had received chemotherapy.
They were established by disaggregation with collagenase
followed by a combination of differential filtration and cen-
trifugation through a diswontinuous 'Ficoll-Paque' gradient.
All grow as adherent monolayers with epithelial morphology
and doubling times of about 24 hours. Four have produced
tumours in nude mice and pathological examination of the
tumours has confirmed their similarity to the original
tumour. Sensitivity at early passage to CDDP and adria-
mycin (ADR) has been determined by a tetrazolium based
chemosensitivity assay. For CDDP there is a 6-fold range in
drug sensitivity (ID50, 0.95-6.25 SM). The sensitivities to
ADR are similar (ID50, 2.5-5.6SM) and are significantly
higher than those obtained in this laboratory for many other
tumour cell lines. Thus, these cell lines show a marked degree
of resistance to ADR which reflects the poor clinical response
to this drug. The range of sensitivities to CDDP is small and
this may be related to the fact that most were established
from pretreatment patients. Characterization of further post-
treatment cell lines will clarify this point.
Effect of verapamil on drug sensitivity and intracellular drug distribution in a drug resistant ovarian cancer cell line
W.H. Luo, J.A. Plumb & S.B Kaye
CRC Department of Medical Oncology, University of
Glasgow, Glasgow, UK.
Verapamil (V, 6.6EM) increases the sensitivity to both adria-
mycin (ADR) and daunorubicin (DNR) of an ADR-resistant
ovarian cancer cell line 2780AD (ID50; ADR 7tM, DNR
Ethacrynic acid does not alter glutathione-S-transferase (GST) activity or drug sensitivity of small-cell lung cancer cell lines
with high levels of GST activity
J.A. Plumb, R. Milroy & S.B. Kaye
CRC Department of Medical Oncology, University of Glasgow, Glasgow, UK.
Elevated levels of GST have been implicated in resistance to
a number of chemotherapeutic agents including adriamycin (ADR). We have established 8 small-cell lung cancer cell lines
from biopsies taken from both untreated and treated
patients. These lines show a 50-fold range in sensitivity to
ADR (IDm 18-1050 nM). Drug sensitivity is not related to
P-glycoprotein since none of the cell lines express detectable
amounts of P-glycoprotein as determined by immunocyto-
chemistry or Western blot analysis. There is, however, a
50-fold range in the total activity of GST (8-409 nM CDNB
min-' mg-') and a 4-fold range in the activity of glutathione
peroxidase (GP, 10-40 nM cumene H202min-'mg-'). The
diuretic ethacrynic acid (EA) is a potent inhibitor of GST
activity and it has been suggested that inhibition of GST
could sensitize cells to cytotoxic drugs. When cell
homogenates were incubated with EA (0.2 mM) there was a
marked reduction in the measurable activity of GST. How-
ever, when whole cells were incubated with a non-toxic con-
centration of EA (1 tg ml-i) for up to 24 hours the GST
activity per cell was not altered. Furthermore, when the cell
lines with the highest GST activity (LS263) were exposed to
ADR, cis-platinum or chlorambucil in the presence of EA
(I lagml-') for 24 hours the drug sensitivity was unaffected.
Although the cell lines show a range of drug sensitivities and
a range of both GST and GP activities there is no correlation
between any of these. Thus, drug sensitivity cannot be related
simply to GST activity and EA does not appear to be a
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Confocal microscopy of anthracycline subcellular localization
in classic and atypical multidrug resistance (MDR)
H.M. Coley, P. Workman, P.R. Twentyman & W.B. Amos
MRC Clinical Oncology Unit and Laboratory of Molecular
Biology, MRC Centre, Hills Road, Cambridge CB2 2QH, UK.
The elimination of out-of-focus epifluorescence by optical
sectioning using confocal microscopy allows the subcellular
localization of anthracycline fluorescence to be determined
with markedly improved resolution. We have compared the
subcellular disposition of doxorubicin (DOX) and selected
analogues in classic and atypical MDR lines with that in the
respective parent lines (designated P). The classical MDR line
was the EMT6/AR 1.0 mouse mammary tumour which was
made approximately 40-fold resistant by exposure to DOX
and exhibits hyperexpression ofthe P-glycoprotein membrane
efflux pump. The atypical line was COR-L23/R which has a
lower level of resistance induced by DOX and does not
express P-glycoproteins. We have previously shown that
resistance to DOX in both lines could be partially or com-
pletely circumvented by simultaneous exposure to verapamil
(VRP) or the use of selected DOX analogues, e.g. 9-alkyl
modified such as aclacinomycin A (ACL) or morpholinyl
substituted such as morpholinyl doxorubicin (MRA). Cells
were grown on glass coverslips, exposed to drugs for 2 hours
and then rinsed before analysis on the MRC 500 confocal
microscope (Biorad Lasersharp) with argon laser excitation
at 488 nm and detection in the red. In EMT6/P, DOX
(10fgml-') staining was predominantly nuclear, including
the nuclear membrane and distinct spots of intense sub-
nuclear fluorescence; the cell membrane was unstained but
there was some particulate staining within the cytoplasm.
Staining was very weak in AR 1.0 but was restored almost to
the parental level by VRP (3.3 1tgml-'). The subcellular pat-
tern after DOX plus VRP in AR 1.0 was similar to DOX
alone in EMT6/P but the intercellular heterogeneity was
much greater. MRA (1 pg ml-') staining of both EMT6 P
and AR 1.0 was also similar to DOX in EMT6/P, with no
effect of VRP. ACL (1 ltg ml 1) gave no nuclear fluorescence
in either line, but similar diffuse cytoplasmic staining was
seen along with an intense vesicle-like pattern
in both cases. Comparing DOX in L23/P and L23/R, the
pattern of subcellular fluorescence was similar, being pre-
dominantly nuclear together with some diffuse cytoplasmic
staining. However, the overall level was lower in L23/R and
a characteristic perinuclear granular 'clustering' pattern
which was not seen in the parent. This apparent localization
of DOX within cytoplasmic organelles appears consistent
with a role for a 'membrane-traffic' mechanism in atypical
MDR.
Relationship between intercellular communication and
adriamycin resistance in non-small cell lung cancer
C. Bradley', R.I. Freshney' & J.D. Pitts2
'CRC Department of Medical Oncology, University of
Glasgow; and 'Beatson Institute, Glasgow, UK.
There is evidence that the ability of cells to communicate
with each other through gap junctions is associated with
resistance to radiation and to the cytotoxic lymphokines,
tumour necrosis factor and lymphotoxin. The explanation for
this phenomenon is not clear, although it is possible that
sharing of metabolic pools between coupled cells may allow
them to withstand damage more effectively than isolated
cells. To investig to whether this relationship between gap
junctional communication and cellular resistance is general-
ized, applicable to more conventional cytotoxic drugs, the
strength of coupling of a panel of 7 human non-small cell
lung cancer cell lines was measured and compared to the
chemosensitivity of these lines to adriamycin. Junctional
communication was assessed by autoradiographic detection
of transfer of 'H uridine nucleotides between cells. The
strength of coupling varied widely between the cell lines and
they could be separated into 3 groups: those which exhibit
strong coupling, L-DAN and A549; those which exhibit weak
coupling, SK-MES-1, Calu-3 and NC1-H125; and an inter-
mediate group WIL and NCI-H23. Adriamycin chemosensi-
tivity of each cell line was assessed by both clonogenic and
MTT assays. The range of ID,o values as measured by either
assay was extremely narrow with no significant differences
between the cell lines. Thus, despite the wide spectrum of
junctional communication observed in these lines, this did
not correlate with their adriamycin resistance.
The application of the MTT assay to study drug resistance and
drug combinations in acute myeloid leukaemia
J.M. Sargent, C.G. Taylor, A.W. Elgie & K.K. Wilson
Department of Haematology, Pembury Hospital, Pembury,
Kent TN2 4QJ, UK.
The identification of drug resistance in individual patients
before treatment would be a therapeutic advance in the
management of acute myeloid leukaemia. Our adaptation of
the MTT assay is rapid and simple and we have validated its
use in chemosensitivity testing of blast cells from AML (Sar-
gent & Taylor (1989), Br. J. Cancer, 60, 206). The assay
results correlated with the clinical response in 21 of 23 cases.
In 16 patients with de novo disease tested against up to 6
drugs, one showed resistance to all agents tested, 4 were
resistant to doxorubicin, one to mitoxantrone, 2 to etoposide
and 8 to cytosine arabinoside. Eight patients were tested
against doxorubicin, mitoxantrone and daunorubicin. One
patient showed resistance to doxorubicin and mitoxantrone
but sensitivity to daunorubicin. Two patients, in relapse, had
acquired resistance to doxorubicin whilst remaining sensitive
to mitoxantrone. Sequential analyses in 2 patients over
several months demonstrated increasing resistance to doxo-
rubicin. The MTT assay is a suitable method to study the in
vitro effect of potential resistance modifiers, for example
pre-incubation with the calcium antagonist verapamil pro-
duced a 2 to 3-fold increase in patient's sensitivity to doxo-
rubicin. As few cells are required to test 4 concentrations of
each drug in the MTT assay, it was possible to construct a
model to test for the effects of various combinations in 11
patients. No evidence of synergism was found. To conclude,
the reliability, speed and simplicity of the MTT assay facili-
tates the study of drug resistance, resistance modifiers and
drug combinations in AML.
Penetration of targeting agents into multicellular spheroids
derived from human neuroblastoma
W.J. Angerson', R.J. Mairs2, J.W. Babich' & T. Murray4
'Royal Infirmary, Glasgow; 2Belvidere Hospital, Glasgow;
'The Royal Marsden Hospital, Sutton; and 'Western
Infirmary, Glasgow, UK.
An autoradiographic technique was used to compare the
ability of alternative radiotherapeutic targeting agents to
penetrate multicellular tumour spheroids grown from the
human neuroblastoma cell line NBI-G. Spheroids of approx-
imately 300gm diameter were incubated for 10-120 minutes
at 37C in culture medium containing 0.14 MBq ml-' of
"'I-labelled meta-iodobenzylguanidine (MIBG, specific activ-
ity 41.7 MBq mg-'), P-nerve growth factor (NGF, 18.7 MBq
100fig-'), or the neuroectodermal-specific monoclonal anti-
body UJ13A (21.7 MBq 100jg'1). After removal of un-
bound "'I by washing, calibrated autoradiograms showing
the distribution and relative uptake of the tracer were
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with an image analyser. MIBG was uniformly distributed
throughout the spheroids, unless there was a necrotic core in
which reduced uptake was observed. The mean (± SD) con-
centration of '25I-MIBG was 0.09 ± 0.01, 0.63 ± 0.07 and
1.12 ± 0.20 MBq g' after 10, 60 and 120 minutes incuba-
tion, respectively. NGF was also uniformly distributed, but
at a much lower concentration (3-4% of that of MIBG).
UJ13A was bound predominantly in a thin layer around the
periphery of spheroids, with little penetration to the interior
(3-7% relative to MIBG). These results suggest that whole
immunoglobulin molecules may have poor penetration into
neuroblastoma micrometastases, and may therefore be an
unsatisfactory targeting vehicle, particularly with short-range
alpha or beta emitters.
Comparison of two cytotoxicity assays in an in vitro screening
system for anti-tumour agents
S.P. Fricker
Johnson Matthey Technology Centre, Reading RG4 9NH, UK.
A panel of human tumour derived cell lines has been set up
as an in vitro screening system for new anti-tumour agents.
The seven cell lines chosen for the screen are representative
of different tissue origin (colon, rectum, breast, bladder,
ovary) and clinical responsiveness. The cytotoxicity of test
compounds was assessed against this panel. Two assay systems
for cytotoxicity were compared. These were MTT assay
based on the reduction of the tetrazolium salt by viable cells
and sulforhodamine B (SRB) protein dye which measures
total cell protein. Both are colorimetric assays capable
of semi-automation using standard micro-titre equipment.
Assay conditions were optimized for both methods. Both
assays gave a linear response over the cell number range of
5 x 103-105 cells, but the SRB assay gave a higher absorb-
ance value for a given cell number and a lower background
absorbance. The SRB assay was also found to be more
robust with better endpoint stability. The cytotoxicity of five
test compounds, cisplatin, methotrexate, 5-fluorouracil, vin-
cristine and mitomycin C, was compared using both assay
systems. Dose-response curves were constructed over a con-
centration range of 0-200 tgml' and IC50 values calcul-
ated. Both assay systems gave similar dose-response curves.
ICso values obtained for the five compounds against the seven
cell lines were comparable for both assays. Practical con-
siderations indicate that the SRB assay may be better suited
for a screening system.
Camptothecin, a topoisomerase 1 inhibitor, can induce
differentiation of K562 cells
P. McSheehy, Y. Lampasona, E. Erba & M. D'Incalci
Istituto di Ricerche Famacologiche 'Mario Negri', Via Eritrea
62, 20157 Milan, Italy.
Camptothecin (CPT) is an alkaloid isolated from the Chinese
plant Camptotheca accuminata and was used in clinical trials
in the 1970s. There has been renewed interest in the chemo-
therapeutic role of CPT following the demonstration that it
is a specific and reversible inhibitor of topoisomerase I (Topo
1), which causes potent inhibition of RNA and DNA synthe-
sis and impairment of cell division when the dose exceeds
100 nM. Recent work suggests Topo 1 may have a role in the
control of the differentiation of cells (Gorsky et al. (1989),
Cancer Communications, 1, 83) and the differentiation of
leukaemic cells is a potential new strategy in chemotherapy.
The human erythroleukaemic cell line K562 is an established
model for studies of differentiation in vitro and we have
shown it is sensitive to NaCPT at doses above 100 nM.
Incubation of exponentially growing K562 cells with I tLM NaCPT for 60 minutes followed by recovery resulted in
profound effects on the cell cycle. An initial increase in
S-phase after 2-6 hours followed by a large block in SLG2M
from 12-24 hours was always accompanied by an increase in
the average cell size. Every 24 hours after recovery different-
iation was assessed by the benzidine staining method which
demonstrated a gradual increase in differentiation of the
CPT-treated cells, reaching 40% at 120 hours while untreated
cells were always around 2%. This change was accompanied
by a total or sometimes near-total cessation of cell division
indicating that terminal differentiation had taken place. We
are currently determining if the oncogene-c myc is involved in
this process.
Protection of acute leukaemia cell lines from the cytotoxic
action of mitozantrone by the drug-specific monoclonal
antibody, NO-1
D.J. Flavell & S.U. Flavell
Monoclonal Antibody Unit, University Department of
Pathology, Southampton General Hospital, Southampton
509 4XY, UK.
The potent anti-cancer drug mitozantrone belongs to a class
of agents which includes the anthracyclines which mediate
their cytotoxic effects through DNA intercalation. We recent-
ly described the production of a highly specific monoclonal
antibody (NO-1) against mitozantrone which we subsequent-
ly employed in an immunoassay for quantifying mitrozan-
trone levels in serum (Flavell & Flavell (1988), J. Immunol.
Methods, 115, 179). We demonstrate here that the anti-
mitozantrone antibody NO-I neutralizes the cytotoxicity of
mitozantrone for two different acute leukaemia cell lines
(ALL-1 & MOLT4) in a dose-dependent and highly specific
manner. Complete protection of cell lines is achieved when
antibody is present in ten times excess over drug. No protec-
tion is afforded against the related anthracycline drug
daunorubicin, demonstrating the highly specific nature of
such protection. The mechanism by which antibody protects
cells is probably through the inability of drug-antibody com-
plexes to gain entry to the cell, though this yet remains to be
demonstrated. Such an antibody may have clinical uses in
quickly reducing serum levels of mitozantrone, following
high dose administration as part of the conditioning regime
before bone marrow transplantation and for use in the con-
struction of bispecific antibodies for targeting mitozantrone
to tumour cell populations.
The effect of chemotherapy on circulating multipotent
progenitor cells
D.J. Kerr', A. Kilbey2, M. Freshney2, A. Sproul2,
G. Konwalinka2 & I.B. Pragnell2
'CRC Department Medical Oncology, Glasgow University; and
2Beatson Institute for Cancer Research, Glasgow, UK.
An in vitro, soft agar colony forming assay (CFU-A assay)
for multipotent haematopoietic progenitor cells has been
developed in our laboratory. In this study we report the use
of the CFU-A assay to monitor these cells in the peripheral
blood of normal volunteers (n = 6) and patients (n = 6)
receiving adjuvant chemotherapy for breast cancer (cyclo-
phosphamide 600 mg m-2, 5-fluorouracil 600 mg m-2, metho-
trexate 50 mg m 2 every 3 weeks). Blood samples (10 ml)
were collected into heparinised tubes on ice at weekly inter-
vals. The mononuclear cells were separated by gradient cen-
trifugation and plated in the CFU-A assay. The number of
circulating CFU-A cells were consistent for the control group
(week 0:140 ± 100 x I09 1-'; week 1: 162 ± 98 x 109 11; week
2: 202 ± 101 x 1091-'; week 3:158 ± 69 x 1091-1) but for the
chemotherapy patients CFU-A cells fell from 170 ± 83 x 109
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by week 1 (0) control values (204 ± 98 x I091') by week 2,
and returned to control values (243 ± 105 x I091') by week
3. Preliminary evidence from a parallel study indicates that
subcutaneous administration of GM-CSF to patients receiv-
ing chemotherapy increases the number of circulating CFU-A
cells further. The CFU-A assay may be of use in determining
effective cell yield for autologous bone marrow transplants
from peripheral blood.
Effect of verapamil on daunorubicin accumulation in normal
lymphocytes isolated from patients undergoing chemotherapy
for epithelial ovarian cancer
A.T. McGown', D.J. Murphy2, D. Crowther2 & B.W. Fox'
'Paterson Institute for Cancer Research, and 'Department of
Medical Oncology, Christie Hospital, Manchester, UK.
Multidrug resistance has been implicated as a cause of the
failure of contemporary chemotherapy in many drug regi-
mens. Attempts to overcome this problem by use of agents
which compete with the mdr-associated drug efflux process
(e.g., verapamil) are currently being undertaken. This work
describes the effect of verapamil on daunorubicin accumula-
tion in normal lymphocytes isolated from patients with
epithelial ovarian cancer. Intracellular daunorubicin accumu-
lation was measured by flow cytometry in the presence and
absence of verapamil (6pJM). Results were compared with
data obtained from healthy volunteers. Statistical analysis of
these data show that for healthy volunteers and for patients
who had not received chemotherapy with adriamycin there
was no increase in intracellular daunorubicin on simultan-
eous incubation with verapamil. However lymphocytes from
patients who had undergone previous chemotherapy with
adriamycin showed a highly significant (P<0.001, Mann-
Whitney) increase in anthracycline content following simul-
taneous incubation with verapamil. It is tempting to ascribe
these results in terms of the development of a verapamil-
sensitive drug efflux process in normal lymphocytes of
patients undergoing cytotoxic chemotherapy. It is not known
whether this has any relevance to the drug sensitivity of the
tumour.
Correlation between chemosensitivity to CB10-277 and
0'-alkyl-guanine-DNA alkyltransferase levels in human
melanoma xenografts
J.M. Lunn', B.J. Foster', M. Jones', J. Siraky2 & D.R.
Newell2
'Cancer Research Unit, University of Newcastle upon Tyne,
Newcastle upon Tyne NE2 4HH; and 'Clinical Pharmacology,
Institute of Cancer Research, Sutton, Surrey SM2 SNG, UK.
The resistance of tumours to methylating agents may be
related to the ability of the tumour to repair lesions at the
06-position of guanine in DNA. We have examined human
melanomas to see if resistance to the triazene CB10-277 is
related to their content of the enzyme 06-alkylguanine-DNA
alkyltransferase (06AT). Melanomas were grown as xeno-
grafts in nude mice. CB1O-277 was administered as multiple
intraperitoneal injections and sensitivity to treatment was
assessed by measurement of tumour volume. Xenografts
from two melanomas were resistant to CB1O-277 given at
80 mg kg-' body weight, a dose close to the maximum
tolerated dose, whereas those from a third melanoma dis-
played a dose-dependent sensitivity to the drug. Soluble ex-
tracts, prepared from untreated xenografts, were assayed for
the presence of O6AT activity using a 3H-methyl labelled
substrate. The enzyme was barely detectable in xenografts
which responded to CB10-277 treatment, whereas resistant
tumours had levels of O6AT in the range 150-500 fmolmg-'
protein. Pharmacokinetics were assessed after single intra-
peritoneal injections of 80 mg CB1O-277 kg-' body weight in
non-tumour bearing and tumour-bearing mice. Initial levels
of 1,000 AM CB1O-277 decayed logarithmically over 500
minutes to 10JM, maintaining peak concentrations of the
monomethyl metabolite of 5-10JAM over a period of at least
250 minutes. No significant differences in the pharmaco-
kinetics of the drug could be found between sensitive and
resistant tumours. We conclude that resistance to CBIO-277
is related to O6AT activity in human melanomas.
Combined hydralazine and heat effects on cell survival, growth
delay and relative blood flow in KHT tumours in vivo
D.J. Honess, D. Hu & N.M. Bleehen
MRC Clinical Oncology & Radiotherape4tics Unit, Hills
Road, Cambridge CB2 2QH, UK.
The purpose of this study was to investigate the mechanism
of the enhancement of thermal damage by the vasoactive
agent, hydralazine (HDZ). C3H mice with KHT tumours in
the leg (400mm3) were given HDZ (5mgkg-' i.v) 15 min
before heating the tumour by a combined RF and waterbath
technique which ensures a uniform tumour temperature.
Temperatures studied were 43, 43.5 and 44C. Tumour
damage was assayed by regrowth delay or clonogenic cell
survival, immediately or 24 hours after treatment. Relative
tissue perfusion (RTP) was measured by 86Rb extraction:
5-10JACi 86RbCl were given i.v. 60 sec before killing the
mouse and taking tissue samples. RTP was calculated as %
injected dose per gram of tissue. Tumour response to HDZ
and/or 30 minutes at 43.5C is shown below, together with
the value expected if the effects of HDZ and heat (Hx) are
additive. RTP was measured immediately, 24 h, 48 h and
72 h after treatment. Tumour data for 24 and 72 h are given
below.
RTP as % control
Growth delay Surviving fraction (+2se) (±2se)
(day) +2se Immediate 24 h 24 h 72 h
Hx alone 2.0 1.2 3.5 67 121
(1.82-2.2) (0.9-1.5).10-2 (2.1-5.0).10-' (51-83) (94-148)
HDZ alone 1.1 1.3 9.5 91 100
(1.0- 1.2) (0.6- 1.9).10- '(4.4- 14.6).10-2 (71 -111) (60- 140)
HDZ + Hx 5.1 1.5 5.0 16 24
(4.8-5.4) (0.7-2.4).10- (1.8 -8.2).10-4 (2-30) (16-32)
Exp'd 3.1 1.5 x 10-3 3.3 x10-4 na na
HDZ + Hx (2.8-3.4)
The growth delay for HDZ + Hx was significantly greater
than the sum of the individual treatments (P<0.05). This
shows that hydralazine has enhanced the thermal toxicity and
this finding is similar to that of Horsman et al. (1989, Int. J.
Hypertherm., 5, 123). In apparent contrast, the cell survival
data for both times of assay show that the cell killing for
HDZ + Hx was the same as was predicted for an additive
effect for the individual treatments. This suggests that the
growth delay in these circumstances represents something
other than the initial cell killing measurable by cell survival.
the 86Rb extraction data showed that immediately after treat-
ment RTP was reduced by Hx and HDZ individually and
further reduced by HDZ + Hx. By 24 h the effect of HDZ
was negligible, that of Hx was still evident, and that of
HDZ + Hx was marked. At 72 h RTP following HDZ or Hx
was normal but for HDZ + Hx was still severely depressed.
This finding suggests that the greater than additive growth
delay found for HDZ + Hx is due to the prolonged impair-
ment of tumour perfusion, rather than greater than additive
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Evaluation of bioreductive anti-cancer agents in vivo
S. Cole, H. Edwards, J.C.M. Bremner & I.J. Stratford
MRC Radiobiology Unit, Chilton, Didcot, Oxon OX]] ORD,
UK.
In single modality therapy with bioreductively activated
cytotoxic agents response of the small proportion of hypoxic
tumour cells will be masked by surviving, resistant oxic cells.
Therefore, in order to compare the efficacies of various
potential bioreductive compounds, we have increased the
proportion of susceptible, hypoxic cells in subcutaneous
KHT murine sarcomas in syngeneic C3H/He mice. This was
achieved after administration of the drugs by mechanical
occlusion of the blood supply with a clamp for 90 minutes,
or, alternatively, by irradiation of the tumours before drug
administration. Responses were assessed by growth delay or
in vitro clonogenic assay. The potencies of various 2-nitro-
imidazoles were ranked in the same order, both in clamped
or irradiated tumour assays. Misonidazole and etanidazole
had negligible bioreductive cytotoxic activity, RSU 1164 and
RSU 1131 had moderate effects, while RSU 1069 and RB
6145 were the most effective. Some other types of agent, such
as the benzotriazine-di-N-oxide, SR 4233, and the indolo-
quinone, E09, were more effective against irradiated than
against clamped tumours. This may be a consequence of
rapid metabolism and limited access of such drugs to clamp-
ed tumours. The effectiveness of RSU 1069 and SR 4233 was
also compared in clamped RIF-1, SCCVII and 16/C murine
tumours and in a human melanoma (HX118) and colonic
carcinoma (MAWI, HT29) xenografts in nude mice. From
these experiments we conclude that a variety of factors,
including the enzymology of the tumour model, as well as the
depth and duration of reduced oxygenation, contribute to the
activity of any particular bio-reductive cytotoxin.
Antitumour activity of thymidylate synthase (TS) inhibitory
2-desanmino-2-methyl-NlO-substituted-5, 8-dideazafolate
analogues in a murine model
T.C. Stephens, J.A. Calvete, D. Janes, A.J. Barker,
P.R. Marsham, J.M. Wardleworth, L.R. Hughes,
A. Jackman' & A.H. Calvert'
ICI Pharmaceuticals, Macclesfield, Cheshire; and 'Institute of
Cancer Research, Sutton, Surrey, UK.
An in vitro clonogenic assay using a mutant of the murine
L5178Y lymphoma and a 4-hour compound exposure period
was developed as a prescreen to select TS inhibitors that were
likely to have good in vivo antitumour activity. The mutant
cells were chosen because they are deficient in thymidine
kinase (TK-) and are therefore unable to protect themselves
from TS inhibition by 'salvage' of thymidine (TdR). Anti-
tumour activity is then achievable in rodents where plasma
TdR levels are high. The short exposure period was chosen
to select compounds that were rapidly transported into cells
and retained, giving the prolonged inhibition of TS that is
required for cytotoxicity. Polyglutamation has been shown to
be a major mechanism of intracellular retention (Jackman et
al. (1990), In: Pteridines and Folic Acid Derivatives, in press).
The most active compounds reduced surviving fraction (SF)
to about 0.001 at a dose of 1 tLM and these were progressed
to in vivo antitumour studies, again employing L5178Y TK-
cells. Tumour cells were implanted i.m. into the hind limbs of
DBA/2 mice and compounds were administered 3 days later.
Leg diameters were monitored daily to assess tumour growth.
The most active compounds produced 'cures' at doses of
10-100 mg kg-' and these were progressed to similar studies
employing the 'salvage competent' parent L5178Y TK + cell
line. In this case it was necessary to administer compounds
daily for 5 days in order to observe cures. The most active
analogues included those with methyl or ethyl N1O substi-
tutents where the benzoyl ring was substituted at 2' and 3'
with fluorine, and those where benzoyl was replaced by
pyridine or thiazole.
Initial plasma disposition studies of molecular combinations of
5-fluorouracil and nitrosoureas in mice
P.M. Loadman', M.C. Bibbyl, J.A. Doublel &
R.S. McElhinney2
'Clinical Oncology Unit, University Bradford, BD7 JDP, UK;
and 'MRC Laboratories of Ireland, Trinity College, Dublin 2,
Ireland.
The B-compounds are a series of molecular combinations of
chloro-ethylnitrosoureas (CNUs) and 5-FU synthesized by
McElhinney et al. B3839, B3958, B3996 are highly active
against certain MAC tumours at maximum tolerated dose
(MTD) but this is dependent on the route of administration.
B3839 is effective against the ascitic MAC 15A when given
by the i.p. route and MAC 13 (solid) when given orally.
B3958 is more active against both MAC 13 and MAC 15A
when given by the i.p. route. Neither is active against the
solid MAC 26 which is generally resistant to CNUs. All three
tumours respond to B3996 by both routes. The aim of this
study was to determine whether bioavailability could explain
this spectrum of antitumour activity. Novel HPLC methods
were used to measure plasma levels. B-compounds were
administered to non-tumour bearing NMRI mice in a
suspension of 10% DMSO/arachis oil. The results are
tabulated below:
Maximum
tolerated
C,
PC
B'
B.
B.
'om- dose C.."(fgml- 1)
ound (mg kg- ) oral i.p. oral
13839 50 8.0 29.8 94
13958 50 2.8 28.6 39
13996 100 12.1 35.4 107
Bioavailability (F) = AUC (p.o.)/AUC (i.p.)
terminal
t4(min)
i.p.
16
31
33
AUCtgh ml-'
oral i.p. F oral
15.2 15.3 0.99
5.6 14.5 0.39
10.0 27.1 0.37
These results show bioavailability is not the only criterion.
Other factors including the need to attain threshold concen-
trations for a certain time are reflected in all the profiles
measured. Further tissue distribution studies will be needed
to confirm this.
In vivo response of mouse adenocarcinoma of the colon (MAC)
tumours to indoloquinone E09: correlation with bioreductive
enzyme content
P. Workman', M.I. Walton', M.C. Bibby' & J.A. Double2
'MRC Clinical Oncology Unit, Hills Road, Cambridge
CB2 2QH; 'Clinical Oncology Unit, University of Bradford,
Yorkshire BD7 JDP, UK; and EORTC 'Pharmacokinetics and
Metabolism (PAM) and 2Screening and Pharmacology (SPG)
Groups.
The selection of tumours for screening novel bioreductive
drugs requires careful consideration. A parameter which is
frequently unknown is the bioreductive enzyme content of
the tumour and its relevance to the biochemistry of equiva-
lent human malignancies. The MAC tumours are histologic-
ally comparable to human colon adenocarcinomas. Both
MAC 16 and MAC 26 tumours are relatively slow growing.
But while MAC 16 is highly necrotic and induces host
cachexia, MAC 26 is well vascularized and well-different-
iated. In addition, whereas both tumours are generally resis-
tant to chemotherapy, MAC 16 is more sensitive than MAC
26 to the clinically effective bioreductive alkylating agent
mitomycin C. Since these MAC tumours are in use as screens
for developmental bioreductive drugs including the indolo-
quinone series, we determined the activities of two key reduc-
ing enzymes and sought a correlation between these levels
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and the response to the lead indoloquinone E09 (3-hydroxy-5-
aziridinyl-l-methyl-2 (1H-indole4,7-indione)-propenol. Solid
tumours were grown s.c. in the flanks of NMRI mice. The
activities ( ± 2SE, n = 4) of cytochrome P450 reductase were
similar at 10.7 ± 1.5 and 13.5 ± 2.9 nM cytochrome c reduced
min-' mg protein-' for MAC 16 and MAC 26 respectively.
In contrast, the levels of DT-diaphorase were 15-fold higher
in MAC 16 at 98.3 ± 9.8 than in MAC 26 at 6.2 ± 1.9 (same
units). Both tumours exhibited a dose-dependent response to
E09: single i.p. doses of 2 and 3 mg kg-' gave respective T/C
values in standard protocols of 51% (1 + ) and 45% (2 + ) in
MAC 16 and 89% (0) and 66% (1 +) in MAC 26. A dose of
4.5 mg kg-' was toxic. The results suggest that the greater
sensitivity to E09 of MAC 16 compared to MAC 26 may be
due at least in part to the higher level of DT-diaphorase in
MAC 16. This is consistent with our finding that E09 func-
tions as a bioreductive substrate for both rat and human
DT-diaphorase (Workman et al., this meeting). The results
may be especially relevant to the imminent clinical develop-
ment of E09, as DT-diaphorase has been reported to be
elevated in human cancer, including gastrointestinal malig-
nancies.
Immunocompetence: a necessary component for the
anti-tumour activity of flavone acetic acid (FAA)
M.C. Bibby & J.A. Double
colon tumours imply that the antitumour activity of FAA is
dependent upon the host. In NMRI mice, MAC 15A, 16 and
26 tumours grown subcutaneously (s.c.) respond to FAA
(>90% inhibition) whereas in nude mice, they do not re-
spond. Immunological deficiencies may account for the lack
of activity in nude mice although poor drug distribution may
also play a major role. The aim of this study was to assess
whether differences in FAA bioavailability can explain these
observations.
Sequential excision of tumours and assessment of clono-
genic cell kill in vitro at various time intervals following drug
administration (200 mg kg-' i.p.) indicate that major cell kills
occur between 4 and 6 hours after treatment in MAC 15A
(s.c.) in NMRI mice, whereas limited cell kills are observed
in tumours from nude mice. Peak plasma and plasma AUC
(at 4 hours) values were higher in NRMI than in nude mice
although no significant differences in tumour levels of FAA
exist (375 and 335 g h-' g-' respectively). Two metabolites
of FAA were detected in plasma and liver samples, none of
which was present in significant amounts in tumour samples.
In conclusion, it seems unlikely that differences in FAA or
metabolite bioavailability can account for the differential
activity of FAA in NMRI and nude mice. These studies
suggest that the antitumour activity of FAA requires an
immunocompetent host. Studies to determine the essential
component are currently in progress.
Clinical Oncology Unit, University Bradford, BD7 JDP, UK.
FAA is a synthetic flavonoid with interesting preclinical
activity against a broad spectrum of transplantable solid
murine tumours. There is a clear vascular component to its
mechanism and tumour site is important. Despite preclinical
activity and the fact that clinical studies have indicated that
plasma concentrations associated with murine activity have
been achieved in man, no objective responses have been seen.
FAA has immunomodulatory activity in mice but most pub-
lished studies conclude that this is not a key factor in res-
ponse.
To study the influence of immune status on FAA activity
we have compared responses of two transplantable colon
tumours (MAC 16, 26) in normal NMRI mice with those
growing in thymectomised NMRI mice and nude mice.
Tumours were implanted as trocar fragments in the flank.
There was consistent growth and similar histological appear-
ance in each host. Chemotherapy commenced when tumours
could be reliably measured (day 0, tumour volume approx.
40 mm3) Formulated FAA (a gift from Lipha, Lyon, France)
was dissolved in physiological saline at an appropriate con-
centration for a desired dose to be administered in 0.1 ml
lOg-' body weight (i.p. day 0, 7). Chemosensitivity was
assessed by serial caliper measurements of tumours and
tumour volumes calculated by the formula a2 x b/2 where a is
the smaller and b the larger diameter of the tumour. At a
dose of 200 mg kg-' x 2 both tumour types were highly res-
ponsive to FAA in their normal NMRI host (>50% cures)
but neither tumours exhibited significant growth delay in
thymectomised NMRI or nude hosts. Histological examina-
tion of treated tumours revealed significant areas ofhaemorr-
hagic necrosis in all three hosts. These data suggest a clear
immunological component in the mechanism of FAA and
also that human tumour xenograft studies to date need
careful interpretation.
Comparative studies of flavone acetic acid (FAA)
pharmacokinetics in NMRI and nude mice
R.M. Phillips, M.C. Bibby & J.A. Double
Clinical Oncology Unit, University of Bradford, Bradford
BD7 JDP, UK.
FAA is an unusual compound whose mechanism of action
remains unknown. Recent studies using a panel of murine
Flavone acetic acid: is tumour endotheliumn a primary target?
J.C. Murray', G. Thurston', K.A. Smith', J. Denekemp'
& D. Stern2
'CRC Gray Laboratory, Mount Vernon Hospital, Northwood,
UK; and 2Department of Physiology and Cellular Biophysics,
Columbia University, NY, USA.
Flavone acetic acid (FAA), a novel antitumour agent,
induces haemorrhagic necrosis and regression in many
murine solid tumours, but has no activity towards leukae-
mias and ascitic tumours. In addition, FAA produces a rapid
decrease in tumour blood flow. These findings have led to the
suggestion that the tumour vasculature may be an important
target for this drug with vascular occlusion and consequent
nutrient deprivation contributing to the antitumour effect. To
test this hypothesis we have studied the effects of FAA on
the coagulation system and vascular permeability of tumour-
bearing mice. FAA injected i.p. at doses of 300 mg kg-'
activated the clotting cascade in control and tumour-bearing
mice within 15 minutes. The effect was more pronounced in
tumour-bearing animals and only in tumour-bearing animals
did we detect the disappearance of circulating platelets and
an increase in clotting times by 4-6 hours, suggesting a
consumption coagulopathy. Studies with '25-albumin showed
a concomitant increase in vascular permeability in tumours
and in the livers of tumour-bearing mice only. These results
suggested that the endothelial cell might be the vascular
target of FAA. Therefore further experiments with cultured
human umbilical vein endothelial cells were carried out.
These studies demonstrated that FAA treatment enhances
endothelial procoagulant activity through the induction of
tissue factor and that this activity is enhanced in the presence
of TNF or a partially characterized cytokine isolated from
cultured tumour cell supernatants. FAA treatment also in-
creased the permeability ofendothelial monolayers in a dose-
dependent manner. The data indicate that the vascular effects
of FAA may be mediated through a direct action on endo-
thelial cells, and that the focal nature of FAA's action may
be conferred by the particular susceptibility of endothelial
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The antitumour effects of 5-hydroxytryptamine (5-HT)
D.C. Jenkins, J. Wilkinson, J. Tite, J.N. Stables, P. Topley,
L.S. Holmes, D.J. Linstead & E.B. Rapson
Wellcome Research Laboratories, Beckenham, Kent BR3 3BS,
UK.
5-HT given intraperitoneally at the rate of 10mg kg-' per
day to C57BL/6 mice harbouring newly implanted subcut-
aneous MCA38 colon tumours inhibited the outgrowth of
such tumours by more than 50% and was tumoristatic when
given at similar levels to mice with established tumours.
The compound was similarly active in NK-cell deficient C57
beige mutants but totally inactive in T-cell deficient CDI
nu/nu mice. 5-HT was also inactive against the human colon
tumour xenografts HT-29 and DLD-1 in nu/nu mice and
only weakly active against less immunogenic transplanted
spontaneous mouse tumours such as Lewis Lung (LL/2) and
melanoma B16 in C57BL/6 mice. These results suggest that
5-HT's antitumour activity cannot simply be associated with
its known effects on the restriction of blood flow to tumours.
Its antitumour activity would appear to share some common
features with that seen after interleukin 2 (IL-2) or tumour
necrosis factor alpha (TNF-a) treatment. Activity of 5-HT
is T-cell dependent and seen only against immunogenic
tumours. Experiments to determine which aspects of cellular
antitumour immunity are enhanced by 5-HT treatment are in
progress.
Stage I epithelial ovarian cancer: why bother?
C. Finn, E.J. Buxton, K. Kelly, F.G. Lawton, R. Varma,
G. Blackledge & D.M. Luesley
University Department of Obstetrics & Gynaecology, Dudley
Road Hospital, Birmingham B18 7QH, UK.
A retrospective analysis of all Stage I EOC patients register-
ed at the West Midlands Cancer Registry from 1st January
1980 to 31st December 1984 was undertaken. Completeness
of ascertainment for all malignant tumours in the region is
98%. Two thousand three hundred and ninety-five patients
with ovarian carcinoma were registered during the study
period. All of the above records were examined and 457
records of Stage I ovarian carcinoma were identified. Details
of all possible prognostic factors and demographic data were
recorded. The median age was 58 years. The median duration
of symptoms before presentation was 4 months. Adequate
staging, according to FIGO recommendations, was carried
out in 133 (29%) patients; 293 patients (64%) had Stage Ia
disease, 37 (8%) Stage lb and 124 (28%) Stage Ic disease.
One hundred and forty-three (31%) received adjuvant
chemotherapy and 59 (13%) received adjuvant radiotherapy.
One hundred and sixteen patients (25%) developed recurrent
disease. The overall 5-year survival was 74%. Initial logrank
univariate analysis showed that age, stage, adjuvant chemo-
therapy, histological grade, histological type, distension at
presentation and intact capsule at the time of surgery, were
associated with 5-year survival. The adequacy of surgical
staging was not significantly associated with survival. To
determine the independent prognostic effect of these factors a
stepwise logistic regression analysis was performed using 5-
year survival as the determinant. Poor tumour differentiation,
adjuvant chemotherapy, age and distension at presentation
had independent negative effects upon 5-year survival.
Although a retrospective review of this nature has limita-
tions, and other factors not considered in this analysis may
be important, it would appear that adequate surgical staging
and adjuvant chemotherapy confer no benefit in terms of
5-year survival in Stage I disease.
Analysis of prognostic variables at presentation surgery and
chemotherapy on survival in 165 patients with ovarian
epithelial carcinoma
J.J. Fennelly'2 M. Jones', R. Conroy', M. Pomeroy'
& M. Foley2
'St. Vincent's Hospital; and 2National Maternity Hospital,
Dublin, Ireland.
Multivariate analysis (Log Rank Method) of 165 patients
with epithelial ovarian carcinoma diagnosed between 1973
and 1986 was performed to define prognostic groups for
future treatment strategies. Variables analysed included age,
parity, stage, histology, grade, extent of surgery and type of
chemotherapy. Ten per cent of patients were <39 years,
26% were 40-49 years, 39% 50-59 years, 17% 60-69 years
and 4% were 70 years or over.
Distribution by stage was 24% stage I, 18% stage II, 48%
stage III and 10% stage IV. Hysterectomy and bilateral
salpingoophorectomy plus omentectomy was carried out in
91 patients. Between 1973 and 1979, 64 patients received
treosulfan. From 1980 to 1986, 101 patients received cisplatin
(± treosulfan). Treatment response rates were 57% clinical
complete response (CR), 13% partial response and 30%
nonresponders. However 25% of clinical CR had residual
tumour at second look laparotomy; 27% of patients who
were clear have relapsed. Overall survival at 5 years was
42% + .042SE, Stage I 63%, stage II 58%, Stage III 26%,
and stage IV 0% (P = .001). There was a significant differ-
ence in prognosis, it being better after 1980. There was no
significant difference between various surgical procedures.
However, when corrected for other factors including extent
of surgery there was a significant difference (P = .041) in
favour of platinum-containing chemotherapy.
Randomized trial of oral megestrol acetate (Megace) with
carboplatin in ovarian carcinoma
B.M.J. Cantwell', M.J. Millward', A. Robinson',
K.A. Godfrey2, J. Carmichael3 & A.L. Harris3
'University Department of Clinical Oncology, Newcastle
General Hospital, Newcastle upon Tyne NE4 6BE;
2Department ofObstetrics & Gynaecology, Sunderland General
Hospital, Sunderland SR4 7TP; and 3ICRF Clinical Oncology
Unit, Churchill Hospital, Oxford OX3 7LJ, UK.
Progestogens have reported activity against ovarian carcin-
oma, stimulate the bone marrow, so potentially reducing
chemotherapy-induced myelosuppression, and stimulate
weight gain. In a randomized study, 49 patients received
carboplatin every 28 days for a maximum of 6 cycles either
alone (24 pts) or with continuous oral Megace 160 mg day-'
(25 pts). Starting dose of carboplatin was 400 mg m2, with
graded reductions or escalation to 440 mg m-2 dependent on
nadir (day 21) and pretreatment counts. With > 160 cycles
analysed there is no difference in nadir, or day 28, total white
cells, neutrophils, platelets or haemoglobin between the
two arms. One patient in each arm had to stop carboplatin
because of prolonged myelosuppression. The mean received
dose of carboplatin was 99 mg m-2 per week in the Megace
arm and 97 mg m-2 per week in the no Megace arm
(P = 0.6). Mean weight gain during chemotherapy was 6.1 kg
in the Megace arm- and 2.7 kg in the no Megace arm
(P = 0.02). No patient who received Megace lost weight. No
significant differences in response rate, relapse free survival or
overall survival have become evident. Side-effects due to
Megace have required dose reduction or cessation in 5/25
patients, including unacceptable weight gain in 3 pts.
Megace, in combination with carboplatin, in the schedule
used does not allow higher doses of chemotherapy to be
given or provide additional antitumour activity, but resulting
weight gain may be of benefit in selected patients.518 BRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS
Carboplatin versus sequential ifosfamide carboplatin for
patients with FIGO stage III epithelial ovarian carcinoma
T.J. Perren, S. Tan, I. Fryatt, P. Harper, M. Slevin
& E. Wiltshaw
Gynaecological Unit, Royal Marsden Hospital, Fulham Road,
London SW3, UK (on behalf of the London Gynae Oncology
Group).
One hundred and thirty-five patients (pts) with FIGO stage
III epithelial ovarian carcinoma were randomized to receive
either carboplatin 400 mg m2 every 28 days for 6 courses (C
- 68 pts) or ifosfamide and mesna 5 g m2 every 21 days for
3 courses followed by carboplatin 400 mg m-2 every 28 days
for 3 further courses (I/C - 67 pts). Median age was 58 yrs
(28-77). Fifty-eight per cent were asymptomatic; 32% and
10% respectively had WHO I & II performance status. Eight
per cent of pts had their disease completely resected, whereas
35%, 23% and 34% had <2, 2-5 and >5cm residuum
respectively. Eight per cent, 31% and 61% of pts had
tumours of grade I, II or III respectively. After 3 cycles of
treatment the response rate (CR+ PR) in 54 and 48
evaluable C and I/C pts was 61% (1OCR, 23 PR) and 29%
(2 CR, 12 PR) respectively (P<0.005) and at the end of
treatment it was 66% (23 CR, 19 PR) and 66% (15 CR,
25 PR) in 64 and 61 evaluable pts respectively (ns). Median
follow up was 18 months. Median actuarial time to relapse
for C and I/C was 14 and 12 months respectively; median
survival was 21 and 19 months respectively with 2-year sur-
vival of 43% and 40% respectively. Toxicity was equivalent
in the two arms with the exception of grade III alopecia
which occurred in 5% of C pts compared to 85% of I/C pts.
Ifosfamide appears inferior to carboplatin in terms of res-
ponse and toxicity. A significant proportion of pts resistant
to ifosfamide can be salvaged by carboplatin.
A phase II study of cyproterone acetate in advanced ovarian
cancer
P. Thompson', R. Osborne', M. Slevin', P. Wrigley',
E. Wiltshire2, P. Blake2, P. Harper3, R. Coleman',
D. Morris3, C. Williams4, J. Sweetenham4, A. Young'
& R. Leonard5
'St Bartholomew's & Homerton Hospitals; 2Royal Marsden
Hospital; 3Guy's Hospital; 4Southampton General Hospital;
and 'Western General Infirmary, UK.
The outlook for patients with advanced ovarian cancer
relapsing after platinum-based chemotherapy is poor. In res-
ponse to the finding that ovarian cancer cells exhibit andro-
gen receptors (Hamilton et al. (1981) J. Endocrinol., 90, 421)
and can synthesize androstenedione (Mahlck et al. (1986),
Gynecol. Oncol., 25, 217), 61 patients with advanced ovarian
cancer were treated with the androgen antagonist cypro-
terone acetate at a dose of 100mg t.i.d. Fifty-five patients
had had previous platinum-based chemotherapy and 6
patients considered too frail for first-line carboplatin were
also included. Median age at entry was 63 and median
number of previous chemotherapy regimens was 2. Of 55
evaluable patients, 4 achieved partial remission (PR), 7 static
disease (SD) and 44 had progressive disease (PD). The dura-
tions of PR were 2.5, 3, 10 + and 10 + months. Two of the
4 patients achieving PR had not received platinum-based
chemotherapy owing to frailty, one was in relapse 2.5 years
after complete remission with cisplatin and the fourth patient
had progressed on carboplatin 5 years after first responding
to cisplatin. The median duration of SD was 3 + months.
Overall median survival was 4 months with survival signi-
ficantly dependent on response. Toxicity was minimal. Three
patients experienced malaise, one rash and one dizziness. One
patient developed a venous thrombosis which did not recur
on cessation of treatment. Abdominal disease may have con-
tributed to a further 3 patients experiencing diarrhoea, 2
nausea and 2 epigastric discomfort. Cyproterone acetate is
active, and response to this agent is more likely in patients
who are untreated or have previously responded to chemo-
therapy with long remission.
A phase II trial of goserelin (Zoladex) in relapsed epithelial
ovanan cancer
M.J. Lind', M.J. Millward', B.M.J. Cantwell', J. Carmichael2
& A.L. Harris2
'University Department of Clinical Oncology, Newcastle
General Hospital, Newcastle upon Tyne NE4 6BE; and 2ICRF
Clinical Oncology Unit, Churchill Hospital, Oxford OX3 7LJ,
UK.
Twenty-six patients, median age 57.5 years (range 38-90
years), with relapsed epithelial ovarian cancer (EOC) were
treated with the LHRH analogue, goserelin (Zoladex), given
as a long-acting depot preparation. All patients had
previously undergone debulking surgery and treated with
platinum-containing chemotherapy. The sites of relapse were:
pelvis (13), abdomen (18), ascites (8), lung (3), liver (5) and
supraclavicular nodes (2). Histological grading of the original
tumours was as follows: 3 well differentiated, 4 moderately
differentiated, 13 poorly differentiated, 2 anaplastic, 1 mixed
and 3 unknown. Each patient was treated with 3.6mg of
goserelin monthly until disease progression. A median of 2
cycles of treatment were given to each patient, range 1-11.
There were two partial responses, each of six months dura-
tion and 3 patients had stable disease (of 3, 6 and 11 months
duration). The median survival following commencement of
LHRH agonist therapy was 26 weeks. No toxicity was seen.
It would, therefore, appear goserelin (Zoladex) has limited
activity in the treatment of relapsed, platinum-resistant,
epithelial ovarian cancer.
Glutathione S-transferase (GST) isoenzyme expression in
normal and malignant human ovarian biopsies
J.A. Green, J. Harris, R. Britten, D. Meyer, P. Hendy-Ibbs
& B. Ketterer
CRC Department of Radiation Oncology, Clatterbridge
L63 4JY, UK.
Experiments in animal and human cancer cell lines have sug-
gested that both glutathione and GST may be elevated in cells
resistant to alkylating agents. Minimal data are available
on levels in human malignancy. In this study, fresh biopsies
of 6 normal ovaries and 13 malignant ovarian tumours were
removed at laparotomy and frozen. The levels of GST iso-
enzymes were measured by affinity column HPLC, and total
GST by CDNB substrate. GST Pi was detected in all samples
and GSTa in all except 3 malignant tissues, whereas GST yI
was detected in only 2 malignant samples. There was no
difference in mean levels of individual subunits of alpha and
Pi or of total GST activity between normal and malignant
tissue, although considerable variation was observed. The
mean level ofacGST in the malignant tissue was 0.24 ± 0.1 fig
mg ' protein and of icGST was 3.85 ± 0.821tgmg-' protein.
Corresponding values in normal ovary were 0.46 ± 0.12fg
mg ' protein for aGST and 3.6 ± 0.7jg mg-' protein for
rGST. These studies are being extended to greater numbers
of biopsies, and will be compared to tissue localization of a,
11 and Pi by immunocytochemistry in the same samples.BRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS 519
Cerebral involvement in gestational and non-gestational
trophoblastic malignancy
M.S. Dorreen', A.E. Champion2, D.R. Millar3,
G.W. Pennington3 & F.E. Neal2
'Departments ofClinical Oncology and2Radiotherapy, Weston
Park Hospital, and the 3Jessop Hospitalfor Women, Sheffield,
UK.
Although cerebral involvement by trophoblastic malignancy
is rare, choriocarcinoma has a particular predilection for
pulmonary metastasis and affected patients (pts) are at risk
for cerebral metastasis. In Sheffield, these 'high risk' pts have
not received routine cranial prophylactic therapy. Between
1980 and 1989, 163 pts received treatment for persistent
gestational trophoblastic disease (GTD). Of these, 2 pts aged
22 and 43, developed cerebral disease. Both had presented
with multiple pulmonary metastases and high gonadotrophin
(hCG) levels of 7 x 104 and 1 x 105 U 1-, respectively. Both
had also failed to achieve a sustained complete remission
(CR) despite prolonged, intensive chemotherapy. One, aged 22,
entered CR after a craniotomy and further intensive chemo-
therapy at the Charing Cross Hospital. The other pt died of
widespread choriocarcinoma. Between 1984 and 1989, 250 pts
with testicular germ cell tumours were referred to Weston Park
Hospital and 3 pts aged 25, 32 and 33, developed cerebral
disease. All had presented with pulmonary involvement by
testicular choriocarcinomas (MTT) and hCG levels of 7 x 104
to 1 x 105 U 1-'. One Pt, 25, presented de novo with a cerebral
metastasis and entered CR after a craniotomy and intensive
chemotherapy. The 2nd pt, 32, represented 6 months after a
prompt CR with chemotherapy, with a cerebral lesion. He also
entered CR after craniotomy and further intensive chemo-
therapy. The 3rd pt never attained CR and later developed
multiple cerebral 2°'s, despite negative CSF hCG levels; he
died from extensive MTT. No cerebral metastasis occurred
either in pts with pulmonary involvement by non-trophoblastic
germ cell tumours, or in cases of MTT without pulmonary
involvement. It is recommended that all high-risk pts with
MTT should receive CNS prophylaxis with intrathecal metho-
trexate, in addition to systemic chemotherapy. The recommen-
dations for pts with GTD are less clear, since 14 other pts with
similar high-risk features attained durable CRs without
evidence of CNS disease, during this time of the study. It is,
however, concluded that cure of cerebral disease is possible,
provided this is surgically resectable and is followed up with
multi-agent chemotherapy.
Comparison of cisplatin (P) and carboplatin (C) combination
chemotherapy for metastatic NSGCT
P.M. Wilkinson, G. Read, R.J. Johnson & R. Swindell
Christie Hospital & Holt Radium Institute, Manchester
M20 9BX, UK.
Cisplatin-based combination chemotherapy remains the treat-
ment of choice for both good and poor prognosis patients
with NSGCT. Variants of PVB or other combinations to
reduce toxicity are now being evaluated for patients with
favourable prognostic features (Lancet (1985), i, 8). We have
evaluated a 24-hour combination of cisplatin (100 mgm2
24-hour infusion); etoposide (E), (150mgm2 days 1 and 2)
and vinblastine (V), (6 mg m2 days I and 2) (PEV) in 66
patients with proved metastatic disease. Patients with a
residual abdominal mass after completion of CT received
radical irradiation; 64/66 (97%) achieved a PR and 62 (95%)
are currently NED, (median FU3 years). In an attempt to
reduce toxicity of (P) this combination has been compared to
a combination of CEV in a prospective randomized trial. To
date, 27 patients have been entered and results are:
XRT to Teratoma
CT N CR residual mass death
CEV 14 13 6 1
PEV 13 12 4 1
On this evidence CEV has equal efficacy to PEV. In con-
clusion, carboplatin can therefore replace cisplatin as a less
toxic treatment option.
Clinical pharmacokinetic and metabolism studies with the
anti-cancer drug LL-D491944l
M.A. Graham', A. Setanoians', T. Hamilton', S. Bell',
W. Ten Bokkel Huinink2, C. McDaniel2, L. Adams',
S.B. Kaye' & J. Cassidy'
'CRC Department Medical Oncology, University of Glasgow,
Alexander Stone Building, Garscube Estate, Glasgow G61
IBD, UK.; and 'Netherland Cancer Institute, Amsterdam,
The Netherlands.
LL-D49194ocl (NSC 381856) is a new antibiotic isolated from
the fermentation broth of Streptomyces vinaceus drappus.
Significant antitumour activity has been demonstrated in a
number of experimental tumours in vivo including the P388,
B16, M5076 and the MX-1 tumour xenograft. As a prelude
to phase I clinical studies, a highly sensitive assay has been
developed for the determination of the drug in plasma using
solid phase extraction and HPLC. the drug was extracted
from plasma using 3cc C2-Bond Elut cartridges. Aliquots of
plasma (0.5-4ml) were extracted and plasma contaminants
were eluted to waste with 1 ml methanol/water (1/19 v/v).
The analyte was eluted in 0.6 ml methanol and aliquots of
the methanolic extract (200fl) were diluted with 200,dl
KH2PO4 (5 mM) pH 7, to make the samples compatible with
the HPLC mobile phase. Recovery over the concentration
range 0.1 to 250 ngml-' was 88 ± 8% (r = 0.999) and the
limit of detection was 0.1 ngml-'. Patient samples were
assayed by HPLC (injection volume 25-250 1l) using a
15 cm x 0.46 cm C6 (5 tM) analytical column. The drug was
eluted isocratically in 50% methanol/acetonitrile (1:1 v/v),
50% KH2PO4 (5 mM, pH 7) at a flow rate of I ml min'
(retention time = 8 min) and detected using UV (270 and
405 nm) and fluorescence (excitation at 405 nm, emission at
480 nm) detection. Phase I studies were initiated at 0.25 mg
m-2 (equivalent to 1/10th LD1O in mice) administered as a
single i.v. bolus injection and 2-5 ml blood samples were
taken periodically over 24 hours. Pharmacokinetic studies
showed that the drug was rapidly cleared from the plasma
and the data could be fitted to a biexponential open model
(tl/2a=3.2+±1miin, tl/2P1=18±2 min at lmgm-2). The
dose has been escalated from 0.25 to 4mgm-2 at which
significant ECG changes were encountered with one patient
developing fatal myocardial necrosis. No haematological
changes were observed and a minor response was noted in
one patient with colorectal carcinoma at 0.25 mg m2. A
metabolite (retention time 3.5 min) has been purified from
plasma for identification by mass spectrometry. Preliminary
pharmacokinetic data indicates non-linear pharmacokinetics
with AUC values of 54, 247 and 172 ng ml-' x min at 1, 2
and 4 mg m-2 respectively. The causes of the non-linear
pharmacokinetics and cardiotoxicity are the subject of cur-
rent investigations.
Phase I trial of temozolamide (CCRG 81045; M&B 39831;
NSC 362856)
D.B. Smith', E.S. Newlands', G. Blackledge2, N.S.A. Stuart2,
J. Slack3 & M.F.G. Stevens3
'Charing Cross Hospital, London W6 8RF; 'Queen Elizabeth
Hospital, Birmingham BJ5 2TH; and 'Aston University,
Birmingham B4 7ET, UK.
Temozolamide, the methyl analogue of mitozolamide, dem-
onstrated broad spectrum pre-clinical activity in murine520 BRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS
models and was of particular interest because it readily
undergoes spontaneous ring opening to the active alkylating
metabolite MTIC. This phase I study was initiated with an
i.v. preparation formulated in DMSO. At 200mgm-2 com-
parison of the kinetics following oral and i.v. administration
demonstrated good bioavailability in 4/5 patients and the
study continued with the oral preparation. Dosage incre-
ments were 20% up to 520 mg m-2 and 33% thereafter.
Forty-nine patients were entered at 15 dose levels from
50-1200 mg m-2. Grade 2-3 nausea and vomiting were seen
at all dose levels. Consistent myelosuppression was first seen
at 900 mg m2 and thrombocytopenia, although unpredic-
table, was considered the limiting toxicity at this dose.
Total Wbc Platelets
Dose/mn 2 median range median range
900 2.6 (1.3-21.2) 71 (39-487)
920 5.9 (0.5-16.9) 241 ( 7-530)
1000 3.4 (0.6-11.5) 81 (15- 194)
The wbc nadir occurred at week 3 (median) and the platelet
nadir at week 2 (median). In this part of the trial hints of
activity were seen in melanoma and in a squamous head and
neck tumour. Preclinical studies suggested that the activity of
temozolamide was schedule dependent and the trial is thus
continuing with a 5-day schedule at a dose of 150 mgm2
daily. No myelosuppression has been seen at this dose and
there has been further activity in melanoma. The current
dose level is 180 mg m-2 x 5. Pharmacology was performed
at all dose levels showing that temozolamide exhibits linear
kinetics. The T1 was 1.86 h, apparent volume of distribution
28.241 and clearance 170 + / - 52 ml min-'. This work was
carried out as part of the Cancer Research Campaign Phase
I/II new drug development programme.
Phase I and pharmacology studies of GR63178A, a water
soluble analogue of mitoquidone
D.M. Eccles, J. Cummings, M.E. Stewart, M. Nicolson,
A.J. MacLelland, M.A. Cornbleet, R.C.F. Leonard
& J.R Smyth
Imperial Cancer Research Fund Medical Oncology Unit,
Western General Hospital, Edinburgh, UK.
The pentacyclic pyrroloquinolone GR63178A is a water-
soluble analogue of mitoquidone (NSC382057). The drug is
active against a panel of rodent solid tumours and xeno-
grafts. Scheduling studies in animals favoured daily chronic
dosing. Therapeutic doses in animal studies remarkably
showed no significant toxicity. A phase I trial has been
completed. Twenty-four patients (P) with refractory cancer
(10 previously untreated) received GR63178A in doses rang-
ing from 40-160 mg m2 daily for 5 consecutive days in each
21 day cycle; 37 courses were available for analysis. Dose
limiting toxicity was pain, usually at the sites of known
tumour. At 160 mg m-2 daily 2/3 P experienced WHO grade
3 pain. Nausea and vomiting were seen in 3/4 P at 80 mg
m-2, 12/12 P at 120mgm 2, 1/1 P at 140mgm 2 day and
3/3 P at 160 mg m2 daily. Negligible haematological toxicity
was seen; although WHO grade 1 anaemia was noted in a few
patients, it was not related to dose. A reverse phase HPLC
assay and solid phase sample preparation technique resolves
up to 30 photo-degradation products and is sensitive for the
parent drug down to 1 ng on column. Pharmacokinetic
studies showed Cmax values at 80 mg m 2 daily ranging from
4-13fgml-' and AUCS from 9-29 ggml-'. The MTD in
humans gives pharmacological levels in excess of those
observed at therapeutic doses in the rodent where the AUC
was 7jgml-I and Cmax was 30jgml-'. EORTC and CRC
phase II studies are in progress at 120 mg m2 daily for 5
days every 21 days in a broad spectrum of tumours.
Phase I clinical and pharmacokinetics study of phyilanthoside
(NSC 328426; CRC85/13) using a single dose 30 minute
infusion schedule
A. Lamont, P. Workman, I. Dennis & N.M. Bleehen
MRC Clinical Oncology and Radiotherapeutics Unit, Hills
Road, Cambridge CB2 2QH, UK.
Phyllanthoside is a plant glycoside which acts as a DNA
synthesis inhibitor, with some selectivity against the human
tumour panel. A total of 16 patients (pts) were included:
primary sites were lung (6), breast (4) and other solid
tumours (6). All had prior radiotherapy, 8 prior chemo-
therapy. Phyllanthoside was given as an i.v. infusion lasting
30 minutes. The starting dose was 0.5 mg m-2 (2 pts), rising
through 1 mg m-2 (2 pts), 2, 3, 4 and 5 mgm-2 (3 pts). Dose
limiting toxicity was partially reversible painful peripheral
neuropathy (motor and sensory) appearing at 3 mg m-2
(grade 1 in 1/3 pts) progressively increasing in severity to at
least grade 3 in all patients at 5 mg m2, one of whom had
grade 4 neuropathy and significant cerebellar impairment.
This patient also had the highest peak plasma level of the
drug. Nausea and vomiting occurred at doses above 1 mg
m 2 and was controlled by standard antiemetic therapy.
There was no significant haematological, renal, hepatic, car-
diac or pulmonary toxicity and no cumulative toxicity in 4
patients treated with up to 3 doses at 3 or 4-week intervals
(without escalation) at dose levels 2, 4 and 5 mg m-2. All 16
patients were assessable for tumour response: 15 progressed,
1 static. Plasma levels, measured by HPLC, rose rapidly to
steady state during the infusion, declining rapidly with a ti of
2-3 min. Peak levels were proportional to dose (30-80ng
ml ' at 2 mg m 2; 150-290 ng ml-' at 5mgm-2), with
3-5% of the dose appearing unchanged in urine. None of
the metabolites seen after incubation with mouse or human
plasma could be detected in our patients plasma. The results
indicate that pharmacologically active concentrations of
phyllanthoside can be achieved in man. Alternative infusion
schedules are being investigated further.
Modified BEP chemotherapy for metastatic testicular
teratoma
R.E. Coleman, D. Whillis, G.C.W. Howard, R.E. Taylor
& M.A. Cornbleet
Department of Clinical Oncology, Western General Hospital,
Edinburgh EH4 2XU, UK.
During the past six years 39 men with metastatic testicular
teratoma were treated in this Unit with a combination of
bleomycin, etoposide and cisplatin (BEP). To minimize
inpatient time, hospital visits and the risk of bleomycin lung
toxicity, patients received four to six courses of bleomycin
30 mg and cisplatin 100 mg m-2 on day 1 only plus etoposide
120 mg m-2 (i.v.) on days 1-3. Only eight patients had poor
prognostic features; six with bulky (> 5 cm) disease and four
with PHCG > 1000 iu 1'. Thirteen patients had lung
involvement but in the other 26 disease was confined to
lymph nodes. Twenty-nine patients (74%) are alive and
disease-free. Five patients have died of disease, three pro-
gressed on relapse chemotherapy and are expected to die and
two salvaged by surgery or chemotherapy; 24/31 (77%)
good-prognosis patients and 5/8 (63%) with poor prognostic
features are free of disease after a median follow-up of 31
months (range 11-76 months). However, only 6/13 (46%)
patients with lung involvement (0/3 LI, 5/7 L2 and 1/3 L3)
are alive and disease-free (X2 = 8.1). Chemotherapy was well
tolerated and there were no treatment-related deaths or
episodes of septicaemia. Three patients developed significant
high-tone deafness and tinnitus requiring substitution of
carboplatin for cisplatin. Modified BEP chemotherapy is aBRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS 521
well tolerated alternative to standard BEP chemotherapy for
small volume nodal disease. However, patients with more
advanced disease require more intensive therapy and are best
treated either within clinical trials, or with standard well-
tested regimens.
A less toxic regimen of 5-fluorouracil and high-dose folinic
acid which retains activity in advanced gastrointestinal
adenocarcinomas
P.W.M. Johnson, P.I. Thompson, L. Squires, M.L. Slevin
& P.F.M. Wrigley
ICRF Department of Medical Oncology, St Bartholomew's
and Homerton Hospitals, London, UK.
The combination of high-dose folinic acid with 5-fluorouracil
has improved response rates in several trials in advanced
colorectal carcinoma. This is at the expense of increased
toxicity: regimes using weekly bolus injections produce diarr-
hoea in an average of 50% of patients and occasional toxic
deaths from this, whilst those using daily injections for one
week in four report both diarrhoea and oral mucositis, the
latter in an average of 60% of patients. Both types of regime
have significant rates of myelosuppression, on average in
35%. A regime was recently reported using a different
schedule of 5-fluorouracil and folinic acid, which appeared
better tolerated but equally active (De Gramont et al. (1988),
Eur. J. Cancer Clin. Oncol., 24, 1499). We report results
using the same programme, but with allopurinol mouth-
washes to reduce oral toxicity, in 47 patients with advanced
adenocarcinomas (33 colorectal, 6 gastric, 3 pancreatic, I
hepatocellular and 4 of unknown primary). Patients received
200 mg m2 folinic acid by infusion over 2 hours followed by
an i.v. bolus of 5-fluorouracil 400 mg m-2 then an infusion of
5-fluorouracil 400 mg m-2 over 22 hours. This was repeated
over the next 24 hours. The schedule was given every 2 weeks
for a total of 6 to 12 courses depending upon the response.
The overall response rate was 38% in 37 evaluable patients.
Performance status improved with treatment in 34%. No
toxicity greater than WHO Grade II occurred. Of 219
courses (median 5 per patient) 14% were complicated by
transient diarrhoea and 5% by oral mucositis; 19% of
patients experienced some diarrhoea and 21% stomatitis at
some time, although this was always mild. Only 3% of
courses were delayed by marrow toxicity, and no febrile
neutropenic episodes were seen. We conclude that this regime
demonstrates low toxicity but retains good activity in the
palliative treatment of advanced gastrointestinal adenocar-
cinomas.
Comparison of 1-hour vs 2-hour infusions of disodium
pamidronate (APD) in breast cancer with bone metastases
M.J. Millward, D. Simmons, M. Procter & B.M.J. Cantwell
University Department of Clinical Oncology, Newcastle
General Hospital, Newcastle upon Tyne NE4 6BE, UK.
APD is an effective therapy for malignant hypercalcaemia
and has activity against bone metastases. Doses used have
been 15-90 mg given over 2-24 hours. As part of an ongo-
ing study of APD in breast cancer with bone metastases, 21
normocalcaemic patients (pts) received infusions of 30 mg
APD in 250 ml saline over either one hour (11 pts) or two
hours (10 pts) repeated every 3 weeks to a maximum of 12
doses, with continuous aminoglutethimide and hydrocorti-
sone. Either radiological response or stable disease (SD) for
>3 months in bone was seen in 5/11 pts who received one
hour infusions and 4/10 pts with two-hour infusions. Bio-
chemical analysis in 16 pts who received >4 APD infusions
shows no difference in total lymphocyte count, serum crea-
tinine, alkaline phosphatase, AST, calcium, phosphate,
osteocalcin and calcium excretion between the infusion rates.
Patients with response, or SD, had a progressive fall in
alkaline phosphatase, calcium excretion and osteocalcin over
the duration ofAPD therapy with both infusion rates. When
given over two-hours, side effects related to APD were tran-
sient nausea in one pt and transient bone pain immediately
following infusions in one pt. No toxicity attributable to
APD occurred when given over one hour. These results
suggest that 30 mg APD when given over one hour has an
equivalent effect as the slower infusion rate and this could
allow convenient out-patient use of this drug.
A phase II study of4-hydroxyandrostenedione (40HA) in post
menopausal breast cancer
A. Bowman', M.E. Stewart', M. Dowsett2, D. Gaskell3,
M.E. O'Brien', D.M. Eccles', U. Chetty3, A. Rodger',
R.C.F. Leonard' & J.F. Smyth'
'Departments of Clinical Oncology and 3Clinical Surgery,
University of Edinburgh; and 2Department of Biochemical
Endocrinology, Royal Marsden Hospital, London, UK.
40HA is a potent aromatase inhibitor which suppresses
plasma oestrogen levels without inhibition of adrenal steroid
production. Fifty women (median age 63, range 33-80) with
advanced, measurable breast cancer entered a phase II study
of 40HA. All were postmenopausal or postoophorectomy;
ER was positive in 22 and unknown in 28; 11 patients had
locoregional recurrence only and 39 had distant metastases
(sites: contralateral breast/nodes 21, other soft tissue 20, bone
27, visceral 10). Forty-nine patients had prior tamoxifen (10
adjuvant, 39 therapeutic with a 39% response rate) and 18
also received megestrol. 40HA was administered as a 500 mg
i.m. injection every 14 days and a median of 7 injections
(range 2-30) was given. Partial responses lasting 24 +, 75 +
and 90 + weeks were observed in 3/45 evaluable patients
(7%). Disease was stable for 24 + to 60 weeks in a further
15. Clinical toxicity was mild and there was no significant
haematological or biochemical toxicity. Oestradiol levels in
29 patients were suppressed to a mean (± SEM) of 7.2 ± 0.6
pM 1- (31.2 ± 2.6% of baseline) 7 days after the first injec-
tion of 40HA; although there was some recovery of oestra-
diol before the injections on days 14 and 28, this was not of
sufficient magnitude to account for the low response rate
observed.
A randomized trial of adjuvant aminoglutethimide versus
placebo in postmenopausal patients with node positive breast
cancer
A.L. Jones', T.J. Powles', R.C. Coombes', I.E. Smith'
& D. Easton2
'Royal Marsden Hospital, London & Surrey; and 2Institute of
Cancer Research, Sutton, UK.
Postmenopausal women with histologically confirmed node
positive breast cancer were randomized to receive amino-
glutethimide 250 mg q.d.s. with hydrocortisone 20 mg b.d.
or placebo. Aminoglutethimide has a significant effect on
disease-free survival with 55/153 AG patients and 70/150
placebo patients having developed metastases (X2 6.47,
P = 0.011). There were 55/153 deaths in AG patients and
70/150 in placebo patients (X2 = 3.61, P= 0.57). After allow-
ing for T and N stage the effect on survival is more
significant (X2 = 4.61, P = 0.032). The estimated effect on
relapse rate is a 34% reduction (95% CI 9-53%) and on
survival a 29% (95% CI 1% increase - 50% decrease) reduc-522 BRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS
tion in the death rate. There is no interaction between treat-
ment effect on T on N stage. For 48 ER negative patients
AG did not affect disease-free or overall survival. For 128
ER positive patients the ratio of observed/expected deaths
was 0.74 (NS). There was increased toxicity (lethargy, skin
rash, ataxia) for AG compared with placebo and the trial
was discontinued because of haematological toxicity, with
agranulocytosis and thrombocytopenia in 3 AG patients.
New aromatase inhibitors with lower toxicity could be ex-
plored as adjuvant therapy.
Guy's/Manchester CMF trial in node positive breast cancer: an
update at 8 years
S.M. O'Reilly, M.A. Richards, A. Howell & R.D. Rubens
ICRF Clinical Oncology Unit, Guy's Hospital, London; and
Christie Hospital & Holt Radium Institute, Manchester, UK.
Between 1976 and 1985, 391 women (202 premenopausal, 189
postmenopausal) with node positive breast cancer were ran-
domized after mastectomy and axillary clearance to receive
CMF (n = 193) or no adjuvant therapy (n = 198). Details
and early results have previously been reported (Lancet
(1984), ii, 307). Median follow-up is now 8 years. For pre-
menopausal patients, both relapse free survival (RFS) and
survival (S) were significantly prolonged in patients receiving
CMF (RFS, P<0.001; S, P=0.003). Significant improve-
ments in RFS was seen in premenopausal patients with 1-3
nodes (P = 0.002) and >4 nodes (P<0.001), with ER - ve
(P= 0.002) and ER + ve (P = 0.004) tumours, and with PgR
-ve (P = 0.01) and PgR + ve (P= 0.001) tumours. The
benefit of CMF for patients <40 years was not influenced by
the development of amenorrhoea. Premenopausal patients
aged 41-54 benefited significantly from CMF (P<0.001)
whereas postmenopausal CMF treated patients in the same
age group did not. Indeed, no significant benefit from treat-
ment was observed for any subgroup of postmenopausal
patients. In summary, the previously reported significant
improvement in RFS for premenopausal patients receiving
CMF has been maintained with longer follow-up and an
overall survival benefit has now emerged.
Chemotherapy of advanced breast cancer using mitomycin X,
mitoxantrone and methotrexate (3M) or vincristine,
anthracycine and cyclophosphamide (VAC)
A.L. Jones, T.J. Powles, I.R. Judson, J.R. Hardy
& S.E. Ashley
Medical Breast Unit, Royal Marsden Hospital, Sutton, Surrey,
UK.
Patients with advanced breast cancer were randomized to
receive mitomycin C 7 mg m2q 6 wk, mitoxantrone 7 mg
m-2 q 3 wk and methotrexate 35 mgm-2 q 6 wk (3M) or
vincristine 1.4 mg m-2, doxorubicin, or epidodoxorubicin,
40 mg m-2 and cyclophosphamide 600 mg m-2 q 3 wk
(VAC); 85 patients received 3M and 77 VAC. The average
number of courses per patient for 3M was 5.2 and for VAC
5.4. The overall response rate was 52% for both treatments
with an assessable response of 60% for 3M and 54% for
VAC. There were no differences in response by site. The
median duration of response was 10.2 months for VAC and
8 months for 3M (NS). The median overall survival for both
3M and VAC was 9 months. There was a reduction in
alopecia (P<0.005), neuropathy (P<0.005) and vomiting
(P<0.01) for patients receiving VAC. Haematological tox-
icity was low and similar for each regimen. The response to
cross-over chemotherapy to either 3M or VAC, after failure
of primary chemotherapy, was 30%. 3M is an effective low
toxicity regimen for the management of advanced breast
cancer.
The pharmacokinetics of oral lonidamine in breast and lung
cancer patients
D.R. Newell', J. Mansi2, J. Hardy2, D. Button2, K. Jenns',
I.E. Smith2, R. Picollo3 & B. Catanese3
'University of Newcastle upon Tyne, Newcastle, UK; 2Royal
Marsden Hospital, London, UK; and 3Istituto di Ricerca F
Angelini, Rome, Italy.
Lonidamine is a novel agent which induces mitochondrial
damage in tumour cells. The pharmacokinetics of lonidamine
have been studied as part of the phase II evaluation of the
drug for the treatment of breast and lung cancer. Twenty-
four patients (26 courses) were studied who had been on oral
treatment (450-600 mg day-') for 27-47 days. Plasma lonid-
amine levels were measured by reverse phase HPLC (15 x
0.46 cm Polygosil 60-5 C18 column eluted at 1 ml min '
with 75/24/1 methanol/water/acetic acid) with fluorescence
detection (excitation 295nm - emission 365nm); assay
linearity (1-20 Igml-') r = 0.998, lonidamine recovery
101% intra assay CV 3%, inter assay CV 4%. Plasma sam-
ples were prepared for HPLC by treating with 9 vol. of
methanol followed by centrifugation. Lonidamine was detect-
ed in the plasma of all patients after a 150 mg tablet; peak
conc. 14 ± 7jig ml-' (mean ± SD), time of peak 1.8 ± 1.2 h.
During the study period of 24 hours the trough lonidamine
concentration was 5 ± 3jig ml1' and for 20 courses the
lonidamine half-life was 4.2 ± 2.3 hours. There was no
marked relationship between lonidamine pharmacokinetics
and patient set, age, performance status, tumour type or
metastasis, renal function, hepatic function or plasma protein
level. Neither was there any relationship between pharma-
cokinetics and tolerance to lonidamine. In addition to
lonidamine, fluorescent peaks were detected in plasma which
suggest that lonidamine undergoes metabolism in vivo. One
component was degraded by glucuronidase and hence may be
a glucuronide conjugate. These studies indicate that
lonidamine undergoes reproducible absorption in breast and
lung cancer patients.
Trends in the outcome of lung cancer management: a study of
9090 cases in the Mersey Region
S.W. Watkin, J.A. Green & G.H. Hayhurst
CRC Department of Radiation Oncology, Clatterbridge
Hospital, Merseyside L63 4JY, UK.
A detailed Registry analysis of 9,090 cases of histologically
confirmed lung tumours in Mersey Region was carried out
from 1974-1986. The total number of cases per year remain-
ed constant, but the M:F ratio fell from 3.6:1 to 2.0:1. Age at
diagnosis and histological type were the most important pro-
gnostic factors, with the five-year survival of adenocarcin-
oma, squamous carcinoma, undifferentitaed carcinoma and
small cell carcinoma after treatment being 22.5%, 18.5%,
10% and 3.5% respectively. The survival of patients who
underwent surgical resection in the 3 periods 1974-77,
1978-81 and 1982-86 showed a continuous improvement in
median survival from 13 to 30 months (P<0.001). An
analysis of 741 cases of small cell carcinoma given chemo-
therapy over the same periods showed a highly significant
improvement in survival (P<0.001) with an increase in two-
year survival from 2.5% to 7.5%; this was shown to be
closely associated with the increasing use of intravenous com-
bination chemotherapy. Overall survival curves of all treated
cases showed a significant improvement in median survival
from 8 to 10 months and five year survival from 12.5% to
17.5% (P<0.001). While selection contributes to the dist-
ribution of patients within the different categories, the data
support the argument that there is a survival benefit
associated with appropriate treatment for lung cancer.BRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS 523
Phase II study of VP16 (V), ifosphamide (I) and cisplatin (P)
IVIPI in small cell and non-small cell lung cancer
D.N. Carney & L. Grogan
Mater Hospital, Dublin 7, Ireland.
We have carried out a phase II study of VIP in 20 previously
untreated patients (pts) with lung cancer. Treatment con-
sisted of V: 100mg m-2, 1: 1.0 gm-2 and P: 20 mg m-2 days
1-5 every 3 weeks for a total of 4 cycles. MESNA was used
as a uroepithelial protector. No pts received radiation
therapy. Pts were evaluated for responses after 2 and 4 cycles
of treatment and all CRs were pathologically confirmed.
Among 14 pts with small cell lung cancer (SCLC): (males 10;
females 4; median age 62 years [52-70]) 9 pts had ED and 5
LD. The median ECOG performance status was 2 (1-3).
The overall response rate was 91% (CR 9 pts; PR 4). The
median survival of these pts was 12 months. Among 6 pts (all
male) with locally advanced (4 pts) and metastatic (2)
NSCLC, 4 pts (2 CR; 2 PR) responded to therapy with a
median survival of 8 months. Toxicity of VIP was significant:
leucopenia (WHO 3-4) occurred in 50% and thrombocyto-
penia (WHO 3-4) in 30% of pts; 8 pts had one, or more,
episodes of septicaemia. Neurotoxicity (paraesthesiae) was
observed in 30% but no significant nephrotoxicity or ototox-
icity was observed. Although VIP is a highly effective
regimen in the treatment of SCLC, its significant toxicity and
need for in-patient hospital administration, coupled with
treatment results similar to other regimens, suggests it has a
limited role in the treatment of this disease. Its role in
NSCLC needs further evaluation.
Correction of coagulation abnormalities in small cell lung
cancer using the fibrinolytic agent stanozolol
S. Bicknell', A. Rumley2, J. Douglas2, R. Milroy3, G. Lowe2
& S. Banham3
'CRC Department of Medical Oncology, Glasgow University;
2University Department of Medicine and 3Department of
Respiratory Medicine, Royal Infirmary, Glasgow, UK.
Disordered coagulation parameters have been documented in
several tumours including small cell lung cancer (SCLC).
There is increasing interest in the manipulation of coagula-
tion as a possible therapeutic manoeuvre in SCLC. We have
previously demonstrated an association between increased
coagulation tendency and lack of response to chemotherapy
in SCLC (Milroy et al. (1988), Thorax, 43, 978). We have
now studied the haemostatic effects of the fibrinolytic agent
stanozolol in 18 patients with untreated SCLC. Pretreatment
fibrinogen levels were elevated with a mean of 5.5 g 1-', range
2.32-9.82g1-' (normal range 2-4gl-'). After 7 days treat-
ment with stanozolol 5 mg b.d. orally, fibrinogen levels fell to
a mean of 3.93 g 1-', P<0.001 as measured by paired t test.
The mean levels of plasminogen activator inhibitor also fell
from 25.4UI-' to 19.1 Ul-' (normal range <20U1-'),
P<0.005. Although the clinical significance of these changes
are uncertain we feel stanozolol merits further study as a
potential biological modulator.
The effect of tamoxifen on serum lipids and lipoproteins in
women
A.L. Jones', T.J. Powles', C.R. Tillyer2, J. Treleaven3
& S.E. Ashley4
Departments of 'Medicine, 2Biochemistry, 3Haematology
and4Computing, Royal Marsden Hospital, Sutton and London,
UK.
Tamoxifen has been given to well women at high risk of
developing breast cancer in a randomized double-blind, pla-
cebo controlled trial. Serum lipids and lipoproteins have been
studied in 78 women before and at 2-12 months after,
treatment. In postmenopausal women on tamoxifen there
was a significant fall in total cholesterol (0.85 mM 1'
P<0.005), fasting low density lipoprotein cholesterol (0.91
mMl-', P<0.01) and apolipoprotein B (15.9mgdl-',
P<0.005). The fall in cholesterol in women with elevated
pretreatment levels (>6.5 mM 1-') was even greater (1.91
mM 1', P<0.005). There was no significant change in fast-
ing high density lipoprotein cholesterol, apolipoprotein A or
fasting triglycerides. Premenopausal women on tamoxifen
had significant falls in total cholesterol (0.44 mM 1-',
P<0.05) and fasting low density lipoprotein cholesterol
(0.71 mM 1', P<0.01) but no significant change in other
parameters. There was no adverse effect on fibrinogen/anti-
thrombin 3 ratio. These results indicate oestrogenic activity
of tamoxifen in post menopausal women which may confer
significant benefit on coronary heart and cerebrovascular
disease.
New anti-emetic BRL43694 for the treatment of cytotoxic
induced emesis
O.C. Cockerill, C.J. Gallagher & R.T.D. Oliver
Department of Medical Oncology, The London Hospital,
London El, UK.
BRL 43694 (BRL) is a new anti-emetic with specific anta-
gonism of SHT3 receptors in the brain and gut wall. Nausea
and vomiting (n & v) are serious chemotherapy side effects
against which BRL has been active. Twenty-six patients (pts)
were treated for a total of 45 cycles of chemotherapy as part
of a multicentre trial; 19 pts received cisplatin (P), 10 alone
and 9 with other agents (adriamycin, methotrexate, vincris-
tine, vinblastine). The dose of P was 20-80 mg m 2 depend-
ing on renal function; 12/19 pts received BRL during subse-
quent cycles. Five pts received carboplatin alone, and 2 had
other combinations. The BRL was given as an i.v. infusion
half an hour before the start of chemotherapy, as a single
dose of 40jig m-2. Tumour types were: ovary (11), testis (5),
bladder (14), others (3). Efficacy was assessed by pts and
ward staff as relief from n & v on a scale of 0-3 and side
effects were noted. Overall the BRL was completely effective
in 18/26 (69%) pts and 30/45 (66.6%) cycles with no nausea
or vomiting. Five/26 pts vomited (2 pts 2-4 v, 3 pts >.4 v)
and 3/26 had mild nausea only. Rescue anti-emetics were
required in 4/26 (15%) of pts. Complete control of n & v was
achieved in 12/19 (63%) of pts on P and 5/5 pts on carbo-
platin. Headache occurred in 6 pts (23%) and constipation in
5 pts (19%), but did not interfere with treatment. We con-
clude that BRL is safe and effective against a wide range of
cytotoxic-induced emesis and should be formally tested
against standard antiemetic regimens.
Comparison of the antiemetic ondansetron with dexamethasone
plus domperidone in the prophylaxis of chemotherapy induced
emesis refractory to dexamethasone
R.C. Stein', C. Evans', J. Davenport', L. Carruthers2
& R.C. Coombes'
'Clinical Oncology Unit, St George's Hospital Medical School,
London SW17 ORE; and 2Glaxo Group Research Ltd, Ware,
Herts., UK.
Selective SHT3 antagonists have been shown to be effective in
the prophylaxis of chemotherapy induced emesis in phase II
trials. We report a double-blind study of 26 patients receiving
a variety of non-cisplatin chemotherapy regimens with
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who were randomized to receive either ondansetron or dexa-
methasone and domperidone (Dex + Dom). Thirteen patients
received ondansetron 8 mg (4 mg i.v. + 4 mg p.o.) with
chemotherapy followed by 4 mg p.o. q.i.d. and placebo cap--
sules 1 q.i.d. for 5 days. Thirteen patients received dex-
amethasone 8 mg (4 mg i.v. + 4 mg p.o.) and domperidone
20 mg p.o. with chemotherapy followed by dexamethasone
p.o. 4 mg q.i.d. 2 days, 2 mg q.i.d. 2 days, 1 mg q.i.d. 1 day
together with domperidone 20 mg p.o. q.i.d. for each of the 5
days. The number of vomits and retches and nausea (on a
4-point scale) were recorded daily by patients on diary cards.
Treatment was considered successful if there were no vomits
or retches and nausea was absent or mild. Success rates for
day 1 (acute phase) and days 1-5 (overall study period) were
compared using Mantel-Haenzsel X2 test.
Number (%) successful P
Ondansetron Dex + Dom
Day 1 10 (77) 2 (15) 0.002
Days 1-5 8 (62) 1 ( 8) 0.005
Our results show that ondansetron is considerably more
effective than the combination of dexamethasone and dom-
peridone in the prophylaxis of chemotherapy induced emesis
refractory to dexamethasone. The addition of domperidone
to dexamethasone confers only marginal additional benefit to
dexamethasone alone.
Ondansetron (GR38032F): effective anti-emetic prophylaxis for
patients receiving carboplatin chemotherapy
D.B. Smith', G.J.S. Rustin'2, N. Howell2 & B.A. McQuade3
'Charing Cross Hospital, London; 2Mount Vernon Hospital,
Middlesex; and 'Glaxo Group Research Ltd. (for the North
West Thames Ovary Group), UK.
Carboplatin is significantly less emetogenic than the parent
drug cisplatin. However, there remain patients receiving
carboplatin whose symptoms are inadequately controlled
using standard anti-emetics. This study investigated the activ-
ity of the 5HT3 antagonist ondansetron in patients with
ovarian carcinoma who were treated with a one-hour infus-
ion of carboplatin at a dose of 400 mg m-2. An oral loading
dose of ondansetron (8 mg) was given 15 minutes before the
carboplatin and continued at 8 mg orally t.d.s. for 5 days.
Fifteen patients who had failed a combination of dexa-
methasone (8 mg b.d. x 4) + metoclopramide (20 mg q.d.s.)
and 16 naive patients were studied. Emesis was graded as C:
no episodes; M: 1-2 episodes; m: 3-5 episodes; F: >5
episodes and nausea as none (N), mild (m), moderate (M),
severe (S). Symptoms were recorded in the 24 hours follow-
ing therapy and for days 2-5.
Results:
Refractory Naive
Ist 24 hours days 2-5 Ist 24 hours days 2-5
C 11 N 7 C 9 N 3 C 14 N 10 C 10 N 6
M 2m 5 M3 m 4 M I m 5 M 3m 4
m 2M 2 m 2 M 5 m OM 0 m 2M 5
F 0 S 1 F I S 2 F I S I F I S I
Thus, 11/15 (73%) refractory patients and 14/16 (87%) naive
patients had no emetic episodes in the 24 hours following
JM8 and overall 19/31 (61%) no emesis during days 2-5.
During days 2-5, 17 experienced no, or mild, nausea while
10 (one not recorded) had moderate, and 3 severe, nausea.
Single agent ondansetron is effective anti-emetic prophylaxis
for both refractory and naive patients receiving carboplatin
and will allow a higher proportion to be treated as out-
patients.
Hypothalamic pituitary responses in induced emesis:
relationship to chemically - induced emesis
D.J. Dunlop', K. Harvey2, C.E. Gray2, M. Soukop',
& G.H. Beastall2
'Department of Medical Oncology and 2Institute of
Biochemistry, Glasgow Royal Infirmary, Glasgow G4 OSF,
UK.
Cytotoxic induced emesis is a major dose limiting factor in
the administration of cytotoxic chemotherapy. It has been
reported that endogenous opioid peptides may be markers of
cytotoxic related emesis but the relationship of these peptides
to other neurotransmitters and hormonal systems remains
unclear (Harris (1982), Lancet, 2, 714; Forrest et al. (1987),
Abstract BACR meeting, Newcastle). The aim of this study
was to measure beta-endorphin, ACTH, and cortisol in
voluntary subjects given syrup of ipecacuanha to assess
whether previously documented peaks ofbeta-endorphin seen
in patients experiencing cytotoxic related nausea and vomit-
ing is merely representative of a stress response. A clear
pattern of responses was seen in subjects given ipecacuanha.
Most vomited within 30 minutes; beta-endorphin begins to
rise with the onset of nausea and peaks during actual vomit-
ing (mean rise 367% above baseline), accompanied by a
serum ACTH peak (mean rise 444% above baseline), and a
more delayed and prolonged elevation of serum cortisol
(mean rise 245% above baseline). These responses could be
completely ablated by 2 mg dexamethasone given the night
before. However, all subjects tested so far have still vomited.
These experiments would suggest that nausea and vomiting
are potent triggers of the processing of propiomelanocortin
in the anterior pituitary and rapid release of beta-endorphin
and ACTH into the bloodstream as part of a stress response.
We would also suggest that suppression of the hypothalamic/
pituitary axis has little to do with dexamethasone's function
as an antiemetic.
Treatment for Hodgkin's disease relapsing after chemotherapy;
a report of the first 18 pts receiving VAPEC-B, a weekly
schedule compnrsing 5 cytotoxic drugs and prednisolone with
prophylactic co-trimoxazole and ketoconazole
J.A. Radford & D. Crowther
CRC Department of Medical Oncology, Christie Hospital,
Manchester, UK.
A total of 18 pts (12 male, 6 female; median age 29 yrs) have
received VAPEC-B chemotherapy for relapsed HD. Six pts
were treated in first relapse, seven pts in second relapse and
five pts in third or subsequent relapse. All patients had
received at least one previous adriamycin-containing regimen
and 17 of 18 pts had also received radiotherapy. Initial stage
was I, I pt; II, 5 pts; III, 3 pts; IV, 9 pts and histology was
nodular sclerosing 10 pts; mixed cellularity 2 pts, lymphocyte
predominant 3 pts and HD unclassified 3 pts. A median of 8
cycles of VAPEC-B were administered (range 6-1 1) and 8/18
pts (44%) achieved CR or equivocal CR (minimal residual
abnormality on CXR or CT scan but no palpable disease
and BM/biochemistry normal). A further 5 pts achieved PR,
3 pts had stable disease, 1 pt progressed and 1 pt with
extensive lung disease died of sepsis after week 3. The CR/
equivocal CR rate was the same for pts treated in 2nd or
subsequent relapse as for those in 1st relapse (both 4 of 9,
44%) but overall response (CR & PR) was greater in this
latter group (8 of 9, 88% against 5 of 9, 55%). After
VAPEC-B, 12 pts proceeded to high dose cyclo and BCNU
followed by ABMR. For reasons of massive disease, advanc-
ed age, psychological unsuitability or no auto/allo source of
BM, 5 pts did not and of these 2 continue in CR at 12 and
15 mths (I had nodal disease in 2nd relapse, 1 had nodal
disease and heavy BM involvement in 3rd relapse). Apart
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manageable and subjectively the regimen is well tolerated.
We conclude that weekly cytotoxic therapy is effective in
relapsed HD and should be considered as a possible alterna-
tive to standard three or four weekly treatment in this
disease.
VAPEC-B is Adr. 35 mg m-2 weeks 1, 3, 5, 7, 9, 11; Cyclo.
350mg m2 i.v. weeks 1, 5, 9; Etop. 100mg m2 p.o. daily
for 5 days weeks 3, 7, 11; Vinc. 1.4mg m-2weeks 2, 4, 6, 8,
10; Bleo. 10mg m2 i.v. weeks 2, 6, 10 plus prednisolone
50 mg p.o. daily weeks 1-5, 25 mg daily 6-11 then tailed to
zero, and prophylactic co-trimoxazole 2 tabs 12 h and keto-
conazole 200mg 12 h-1, both for 12 weeks.
A randomized study of adjuvant MVPP chemotherapy after
mantle radiotherapy in P.S. IA-IIB Hodgkin's disease.
10-year follow up
H. Anderson, D. Crowther, D. Deakin & W.D.J. Ryder
Christie Hospital, Manchester, UK.
From Oct. 1974-Aug. 1981, 115 patients with untreated
supradiaphragmatic pathologically staged IA-IIB Hodgkin's
disea4e (HD) were entered into a randomized study of
adjuvant MVPP (mustine, vinblastine, prednisolone, procar-
bazine) or follow up alone after mantle radiotherapy. The
median duration of follow up was 131 months; 56 patients
were treated with radiotherapy (RT) alone and 59 received
RT plus 6 cycles of adjuvant MVPP. Patient characteristics
between the two groups (age, sex, stage, Karnofsky perfor-
mance, bulk disease, histology and number of sites involved)
were not significantly different. One hundred and thirteen
patients achieved a complete remission (CR) with RT alone.
The 10-year survival corrected for intercurrent death was
92%. There were 9 (8%) deaths from HD (5 received RT
alone). Eight patients (7%) developed a second malignancy
of whom 6 have died. There have been 4 other intercurrent
deaths. The 10-year relapse-free survival (RFS) was 80%
overall, 90% in the adjuvant MVPP group and 66% in the
RT group (P = 0.0004). There were 25 relapses, 19 received
RT alone and 6 received adjuvant MVPP. Of the relapsed
patients one progressed and died on adjuvant MVPP, one
relapsed and died of infection before therapy could be given.
The other 23 received chemotherapy ± radiotherapy, 19
(83%) obtained a CR and 4 progressed and died of disease.
Of the CR patients, 3 died in second relapse, 3 had inter-
current deaths and 13 (68%) continue in CR. Univariate
analysis showed the following factors influenced survival -
pruritus P = 0.0014, night sweats P = 0.0016, B symptoms
P =-0.0023, bulk P = 0.0041, monocyte count >0.5 x 109 1'
P = 0.0059, stage IIB P = 0.0157, histology mixed cellularity
P = 0.0227, lymphocyte count < 1.7 x 10 1-' P = 0.0385.
Univariate analysis showed that treatment - RT only
P=0.0004, lymphocyte count <1.7 x 1091-' P=0.0011
and B symptoms P = 0.0269 predicted relapse. Multivariate
analysis was only possible for relapse as there were too
few events to anlayse for HD deaths. Analysis of 24 vari-
ables showed only 3 variables predicted relapse, treatment-
RT alone P =0.0001, lymphocyte count < 1.7 x 1091-
P=0.0005, and haemoglobin <14gl-' P=0.0191. Adju-
vant MVPP has shown a significant improvement in RFS but
not overall survival.
Residual abdominal masses following intensive weekly
chemotherapy for intermediate and high grade non-Hodgkin's
lymphoma (NHL)
J.W. Sweetenham, G.M. Mead & J.M.A. Whitehouse
CRC Wessex Medical Oncology Unit, Southampton General
Hospital, Tremona Road, Southampton S09 4XY, UK.
In patients (pts) with intermediate and high grade NHL
presenting with intra-abdominal disease, a residual abdom-
inal mass is frequently detected radiographically at the end of
chemotherapy in the absence of peripheral lymphadenopathy.
A previous study from the NCI has shown that following
ProMACE-MOPP chemotherapy, resected residual masses
rarely contain viable lymphoma (J. Clin. Onc. (1988), 6,
1832). We have treated 60 pts with advanced intermediate
and high grade NHL with an intensive weekly chemotherapy
regimen as follows: etoposide 150 mgm2 i.v. day 1, doxo-
rubicin 35 mg m-2 i.v. day 1, cyclophosphamide 300 mgm-2
i.v. day 1, methotrexate 100mgm2 i.v. day 8 with leuco-
vorin rescue, vincristine 1.4 mg m-2 i.v. day 8, bleomycin
10 mg m-2 i.v. day 8. Treatment interval 14 days for 6 cycles
with continuous oral prednisolone and cotrimoxazole. Forty
pts had intra-abdominal disease at presentation; 18 pts had
residual abdominal masses detected by CT 4 weeks after
completing chemotherapy. Median follow up for this
group = 19 months (range 6 to 41). Histology (WF): DLC-
13, DM - 4, DSC - 1. Follow up CT scans were performed
at 6-month intervals until complete resolution or disease
progression, and no further therapy was given.
Results: The presence of bulky (>1O cm) abdominal
disease at presentation did not correlate with the presence of
a residual mass. The outcome for residual masses was com-
plete resolution in 6, taking > 1 yr in 2 cases; stable abnor-
mality - 2 (both alive with no disease progression at 24 and
26 months); disease progression i) at site of mass only - 2, ii)
at site ofmass and distant site - 5, iii) at distant site only - 3.
Current status for the 18 pts; alive without disease - 11
(including 2 pts treated with salvage chemotherapy), alive
with disease - 3, dead with disease - 4. For this small group,
no trend was observed for a higher relapse/progression rate
in pts with > 5 cm compared with < 5 cm residual masses.
In conclusion, the presence of residual abdominal masses on
CT does not always imply viable lymphoma; the incidence of
active disease in such pts after this intensive weekly chemo-
therapy regimen is higher than that reported for ProMACE-
MOPP.
Preliminary data from the West of Scotland Lymphoma Group
randomized trial of MOPP versus MOP/EVAP in advanced
or bulky Hodgkin's disease
M. Harding, N. Lucie, N. Reed, R. McNeil, E. Fitzsimmons,
D. Ellis, L. Cram, S. Kaye & M. Soukop
Departments of Medical Oncology and Haematology, West of
Scotland, UK.
In an attempt to improve the treatment of Hodgkin's disease,
we have initiated a randomized trial comparing a hybrid
regime to standard MOPP chemotherapy. Since 1986, 93
patients have been entered, 83 of whom are evaluable. Their
median age at the time of treatment was 34 years (range
14-77); 7 had received prior radical irradiation 1-8 years
previously, the remainder were not pretreated. Tumour stages
were 8 I, 33 II, 22 III and 19 IV; 57 (69%) had B symptoms,
44 (53%) bulk disease and 27 (33%) extranodal lymphoma.
All parameters apart from Stage IV disease were equally
distributed between the treatment groups. Chemotherapy
comprised mustine 6 mg m-2, vincristine 1.4 mg m-2 (max-
imum 2 mg) i.v. on days 1 and 8, with procarbazine
100mgm-2 and prednisolone 25 mgm-2 orally, days 1-14
(MOPP), or identical agents days 1-7, with adriamycin
25 mg m-2, vinblastine 6 mg m-2, etoposide 75 mgm-2 i.v.
on day 8, oral etoposide 150 mgm2 on days 9 and 10, and
prednisolone days 8-14 (MOP/EVAP). The median number
of courses delivered at 28-day intervals was 6 in each arm
(range 1-8). Eighteen patients subsequently received irradia-
tion for CT scan PR or to sites of prior bulk disease. With a
median follow up of 16 months, data are as shown:526 BRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS
MOPP MOP/EVAP
Number treated 40 43
Stage IV disease 14 5
Infected episodes 7 22
Toxic deaths 2 2
CR/No. evaluable 16/26 28/36
PR/No. evaluable 9/26 8/36
Relapses 6 2
Differences are not significant and accrual continues.
Demonstration of DNA interstrand crosslinks in peripheral
blood mononuclear cells in patients undergoing chemotherapy
G.N. Rudd, J.A. Hartley, C.M. Chresta & R.L. Souhami
Department of Oncology, University College & Middlesex
School oJ Medicine, 91 Riding House Street, London
WIP 8BT, UK.
For many cytotoxic agents, such as alkylating agents, DNA
interstrand cross-links (ISCs) are thought to be the lethal
cellular lesion. The formation and repair of these lesions can
be studied in vitro using the technique of alkaline elution
after radioactively labelling DNA. A recent technical advance
has been the use of the fluorescent DNA binding dye, Hoe-
chst 33258, which allows measurement of ISCs without prior
labelling of cells. We have adapted this technique to deter-
mine if ISCs can be demonstrated in peripheral blood mono-
nuclear cells (PBMs) in patients treated with alkylating
agents and platinum analogues. In vitro experiments showed
that ISCs could be detected in clinically relevant dose ranges
and with a sensitivity comparable to in vitro labelling with
radioactivity. After cytotoxic chemotherapy with single
agents ISCs were demonstrated in PBMs of patients with
solid tumours. ISCs were detectable following treatment with
cisplatin and carboplatin. An unexpected finding was the
demonstration of alkali labile sites (but no ISCs) following
ifosfamide administration. This technique promises to yield
valuable information on the onset and repair of DNA
damage in PBM (and leukaemic cells) in patients undergoing
chemotherapy.
Pharmacokinetics of high dose melphalan in patients with a
range of renal function
T.R. McCappin, D.R. Newell, C. Viner, I. Judson, M. Gore,
P. Bedford' & T.J. McElwain
Institute of Cancer Research, Royal Marsden Hospital,
Sutton, Surrey and 'Wellcome Foundation Ltd., Beckenham,
Kent, UK.
It is known that impaired renal function is associated with
increased toxicity of high dose melphalan and an arbitary
dose reduction of 50% is used routinely for patients with a
GFR>40 ml min-'. A study was therefore initiated to inves-
tigate the effects of renal function on high-dose melphalan
pharmacokinetics. To date, 23 patients have been treated
with high-dose melphalan given as a single i.v. bolus injection
over the range 70-200 mg m 2 using two different formula-
tions. Renal function was determined by measuring 5'Cr-
EDTA clearance and a wide range of values was observed
from 39-135 ml min '. Following drug administration blood
samples were collected at 5, 15, 30, 45, 60, 120, 180, 240, 360,
480 and 1440 minutes after injection. Melphalan was ex-
tracted from plasma to methanol by a two-step process and
measured by HPLC with u.v. detection at 254 nm. Plasma
melphalan pharmacokinetics were analysed according to a
two compartment model. A series of 10 parameters was
produced and compared to EDTA clearance to determine
any relationship with renal function. A weak correlation was
observed between renal function and both melphalan clear-
ance and AUC. Further data from patients with poor renal
function are required before more precise recommendations
can be made regarding appropriate dose reductions. No
difference was observed between the two formulations for
any pharmacokinetic parameter.
Correlation coeff. v
Parameter Median EDTA clearance
C1 (I min-'rM-2) 0.3 0.6
AUC (jig ml-' min- rnm2) 654.0 - 0.5
(corr. to 200 mgmr-2)
t1p(min) 53.0 - 0.3
Influence of a 24-hour infusion of hydroxyurea on the uptake
of 5-iodo-2-deoxyundine (IUDR) by bone marrow and tumour
cells
P.A. Phillip', K. Gatter2, H. Turley2, J. Carmichael2
& A.L. Harris'
'ICRF Clinical Oncology Unit, Churchill Hospital, Oxford
OX3 7LJ; and 2Department ofHistopathology, John Radcliffe
Hospital, Oxford OX3 9DU, UK.
Hydroxyurea (HU) is a ribonucleotide reductase inhibitor
which suppresses DNA synthesis in proliferating cells. Solid
tumours readily acquire resistance to HU. IUdR is a
thymidine analogue taken up by cells in the S-phase of the
cycle via the thymidine salvage pathway. Myelosuppression is
the dose limiting toxicity of IUdR. It has been shown using
xenograft model that HU can reduce the uptake of IUdR by
the normal cells allowing the selective introduction of IUdR
into the nuclei of tumour cells that are resistant to HU
(Bagshawe et al. (1987), Br. J. Cancer, 55, 299).
We studied 10 pts with metastatic solid tumours judged to
be resistant to conventional systemic therapy; melanoma (3),
soft tissue sarcoma (2), lung adenoma (1), ovarian adenoma
(1), adenoma unknown origin (1), breast ca (1), relapsed oat
cell lung ca (1). Eight pts had received previous chemo-
therapy other than HU. HU was infused intravenously I g
h-' for a total of 24 hours and 23 hours from the start of
HU infusion, IUdR (100mgm-2) was given intravenously
over 20-30 min. One hour from start of IUdR infusion bone
marrow aspiration was performed (10 pts) using a 22 G/
1.5 in paediatric lumbar puncture needle, followed immedi-
ately by aspiration from superficial tumour deposits (3 pts)
or a malignant effusion (2 pts). IUdR labelling index (IlI)
was determined using BU20 monoclonal antibody and coun-
ting the percentage of stained cells. Three pts on other
chemotherapy received the same dose of IUdR followed by
bone marrow aspiration before receiving any treatment to act
as controls. ILI of bone marrow following HU was signi-
ficantly lower compared to controls. Uptake by tumour cells
was also very low (I melanoma, I angiosarcoma, I ovarian
adenoma, I adenoma unknown origin, and I breast ca). One
pt (melanoma) had a significantly higher ILI pre-HU suggest-
ing inhibition of the IUdR uptake by HU in that pt. It is
possible that there is a differential sensitivity to HU for
tumour and bone marrow cells operating at lower levels of
exposure to HU.
The effect of arterially administered adriamycin-loaded
albumin microspheres on hepatic tumour implants in the rat
J.A. Goldberg, D.J. Kerr, N. Willmott', A. McNicol
& C.S. McArdle
University Departments of Surgery & Pathology, Royal
Infirmary, Glasgow; and 'Department ofPharmacy, University
of Strathclyde, Glasgow, Scotland, UK.
The poor results of systemic chemotherapy for colorectal
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therapy. By loading anticancer agents into biodegradable
particles which become trapped in small vessels following
intrahepatic arterial (IHA) injection, it may be possible to
increase further tumour drug exposure, and hence anti-
tumour effect, without increasing systemic toxicity (Kerr et
al. (1988), Cancer, 62, 878). The aim of this study was to
compare the antitumour effect of adriamycin-loaded albumin
microspheres (ALAM) with that of the drug in solution.
Sprague-Dawley rats bearing three-day-old hepatic implants
of Walker tumour were divided into 4 groups: (A) sham
operated; (B) operated and IHA 'empty' microspheres
(2 mg); (C) operated and IHA adriamycin in solution, (30pg)
and (D) operated and IHA ALAM (2 mg containing 30 lag
adriamycin). The animals were culled 4 days later, the
tumours excised, weighed and submitted for histology.
Tumour weight
Group (n=6) [g] (mean± SD)
A (sham) 0.73±0.21
B (IHA empty microspheres) 1.01±0.27
C (IHA drug in solution) 0.74±0.12
D (IHA ALAM) 0.45±0.08
Tumours were smallest in the group receiving IHA ALAM
(P= <0.05, Mann-Whitney test). The data show that the
cytotoxic effect of adriamycin is enhanced by incorporation
into a slow-release mechanism.
Intrahepatic arterial administration of mitomycin C
microcapsules
D.J. Kerr, J. Goldberg, C.S. McArdle & T. Whatelely
CRC Department of Medical Oncology and Department of
Surgery, University of Glasgow & Department Pharmacy,
University of Strathclyde, Scotland, UK.
We have performed a series of clinical studies which indicate
that angiotensin II can selectively increase the delivery of
isotopically labelled microspheres to hepatic tumour metas-
tases relative to normal liver by a factor of up to 10. As part
of a continuing intrahepatic arterial chemotherapy program-
me ethylcellulose mitomycin C (MMC) microcapsules (80%
drug w/w), 100-200 tm in diameter were synthesized by
coacervation. In vitro, 80% of MMC was released in 1 hour
at 37°C in stirred normal saline. Twenty mg of MMC in
solution or microcapsular form was administered in random
order via indwelling intrahepatic arterial portacaths to 10
patients with hepatic metastatic colorectal cancer. MMC con-
centrations were measured in peripheral venous blood using
an HPLC method, with these results. (Mean ± SD).
Peak conc AUC Clearance T1/2B
(ng ml- ) (ng ml- I h'- ) (I h-') (h)
Free MMC 812±423 438±126 46±8 0.68±0.01
P<O.05 P<O.05 P<0.05 P<O.05
MMC micro- 80±70 143±43 140±31 1.56±0.04
capsules
There was no toxicity with either treatment. There is a clear
potential for dose escalation with MMC-microcapsules and
enhanced tumour targeting with intra-arterial angiotensin II.
The effects of a somatostatin analogue (SMS 201-995) on the
perfusion of liver metastases
D.M. Hemingway, D. Chang', S.A. Jenkins' & T.G. Cooke
University Departments of Surgery, Glasgow Royal Infirmary
and 'Royal Liverpool Hospital, Liverpool, UK.
We have previously reported that inhibition of the growth of
experimental liver metastases by a somatostatin analogue,
SMS 201-995, is partly due to a stimulation of hepatic reti-
culoendothelial activity. Since SMS 201-995 is vasoactive we
have investigated its effects on hepatic haemodynamics in
rats with liver tumours. Hepatic tumours were induced in
rats by the intraportal inoculation of 106 HSN sarcoma cells.
Hepatic and tumour haemodynamics were measured using
the dual microsphere method before and after the adminis-
tration of SMS 201-995 (bolus dose 4pg kg-' followed by
continuous infusion of 4 jigkg-'h-'). SMS 201-995 signi-
ficantly decreased mean hepatic arterial flow 5.69 ± .87 to
2.357 ± .32 ml min-' (P<0.02 Students 't' test),- and normal
liver blood flow .43 ± .08 to .17 ± .02 ml min-' g ' (P<.02
Students 't' test) and decreased mean portal venous inflow
(6.15 ± .64 to 5.43 ± .3 ml min-') and tumour blood flow
(.23 ± .04 to .15 ± .04 ml min-' g9'). These results indicate
that SMS 201-995 markedly reduces hepatic and tumour
blood flow, which may act synergistically with the effect of
the analogue on RES activity to inhibit the growth of liver
tumour.
Intra-arterial phenylephrine increases drug delivery to liver
tumour
D.M. Hemingway', D. Chang2, D. Nott2, S.A. Jenkins2
& T.G. Cooke'
'University Departments of Surgery, Royal Infirmary,
Glasgow; and 2Royal Liverpool Hospital, Liverpool, UK.
The ineffectiveness of regional chemotherapy may be due in
part to the relative avascular nature of most liver metastases.
Manipulation of liver blood flow may alter tumour perfusion
and delivery of drug to tumour. We have investigated the
effects of intra-arterial phenylephrine on the distribution of a
labelled marker to liver and liver tumour. Overt liver metas-
tases were induced in rats by the intraportal inoculation of
HSN sarcoma cells. Tc"m labelled methylene diphosphonate
was injected into the hepatic artery either alone or 30 seconds
after an intra-arterial bolus injection of 10lg phenylephrine
and the distribution of marker to tumour and normal liver
examined. Phenylephrine caused a significant immediate
retention of marker in tumour (mean % injected doseg-'
5.17 ± .55 before, 21.7 ± 5.69 after injection, P<0.01
Students 't' test). Distribution to normal liver also increased
(mean % injected dose g-' 3.55 ± .15 before to 9.62 ± 2.45
after injection). This relative increase was maintained at 90
minutes after injection. Hepatic arterial vasoconstriction by
phenylephrine causes significant retention of marker in both
normal liver and hepatic tumour and may thus be of value in
the regional delivery of drug to liver tumour.
Hair loss due to cytotoxic chemotherapy: a prospective
descriptive study
A. Tierney', J. Taylor', S.J. Closs', U. Chetty2, A. Rodger3
& R.C.F. Leonard3
'Nursing Research Unit, University ofEdinburgh; 2Department
of Surgery, Royal Infirmary; and 3Department of Clinical
Oncology, Western General Hospital, Edinburgh, UK.
The main aim of a descriptive study of chemotherapy side-
effects was to quantify and put in context the issue of
alopecia due to various combination chemotherapy regimens.
Hair loss and vomiting were anticipated as being the most
difficult side-effects by three quarters of the patient sample
(46, 76.7%). The visibility of alopecia placed this above
vomiting in rank order of importance in 35/46 patients. All
patients (pts) were offered scalp cooling (SC) at the first
chemotherapy session but almost half discontinued after the
first application and by the 6th only 16 were still receiving
SC. Decline in use was almost entirely due to the CHOP
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ness of SC. Conversely patients on CMF tended to continue
with SC throughout. The problems of SC were treatment
time, coldness and cap weight. At the end of chemotherapy
30/32 CHOP pts required a wig as against only 1/21 CMF
pts. This last pt suffered severe hair loss after the second
chemotherapy cycle. Pattern and rate and type of hair loss
was variable for CHOP being mild in some patients at the
start becoming severe later, whereas with other patients total
hair loss occurred after the first treatment. For CMF
uniformly gradual thinning of the hair occurred. Patchy hair
loss occurred only in the patient who eventually lost all her
hair. Body hair loss (eye lashes, eye brows, legs, axillary and
pubic) was not significantly different from scalp loss so that
this further measurement did not provide supportive evidence
for the effectiveness of SC. We conclude pts require realistic
information about the pattern and rate of hair loss, the
BACUP booklet being recommended. Counselling may be of
further benefit for individuals especially disturbed by hair
loss. SC for CHOP regimens is ineffective but should be
available for CMF regimens as a standard procedure on the
basis of informed consent.
Side-effects and chemotherapy: anticipation, information and
experience
A. Tierney', J. Taylor', S.J. Closs', U. Chetty2, A. Rodger3
& R.C.F. Leonard3
'Nursing Research Unit, University ofEdinburgh; 'Department
of Surgery, Royal Infirmary; and 'Department of Clinical
Oncology, Western General Hospital, Edinburgh, UK.
In a prospective descriptive study of patients (pts) receiving
combination chemotherapy for breast cancer (adjuvant and
locally advanced), 60 consecutive pts were interviewed before,
during each treatment cycle (max 6) and at the completion of
chemotherapy using CHOP (32 pts), CMF 21, VAP 6 and
CAF 1 pt. Although pts were informed prospectively, their
experience of side-effects was much more diverse than fore-
warned. Thirty-five (58.5%) expected hair loss to be the most
difficult symptom whereas in reality only 13 (21.7%) even-
tually rated this as the worst side-effect even though 65%
experienced it. Of all side-effects, tiredness was reported most
frequently and at any time point never less than 87.5% of
patients had this symptom. Following this, in order, nausea,
anorexia, mouth soreness, pain, vomiting and sore eyes were
reported. Overall about one third of patients found chemo-
therapy side-effects less than anticipated but the general
experience was that the diversity of side-effects had been
underestimated by the doctors and nurses giving advice
before treatment. Approximately 75% of patients felt that a
booklet giving full information would have been valuable.
Generally doctors and nurses warning about side-effects
underestimate the importance of fatigue; patients had been
warned about it in only 50% of cases. Research in other
treatment groups with different regimens is required to test
the generality of these results.
Limitations in the clinical utility of serum markers CA153 and
HMFG2 for monitoring breast cancer
P. Bliss', R.C.F. Leonard', J. Fisken , S.S. Akhtar',
M. Palmer2, U. Chetty3, A. Rodger' & J.E. Roulston3
'Department of Clinical Oncology; 2Clinical Surgery; and
'Clinical Chemistry, University of Edinburgh, Scotland, UK.
The serum from 57 patients with local and advanced breast
cancer was studied using two antibodies against glycoproteins
associated with human breast cancer. Cal53 is a commercial
immunoradiometric assay which claims high sensitivity for
monitoring disease. HMFG2 is a cell surface mucin assoc-
iated with breast cancer and possibly of prognostic signi-
ficance in studies of primary tumour immunopathology.
Immunoassay for HMFG2 was developed locally with the
assistance of Unipath plc. Serology data were correlated
against clinical and radiological assessments of patients
classified as having local regional disease or metastatic
disease (including SCF lymph nodes as Ml). Most patients
with LR were preoperative, Tl-T3.
CaI53 (nr 0-30) HMFG2 (nr 0-40)
No Median Range Elevated No Median Range Elevated
LR (22) 13 (6-48) 1/22 (18) 10 (0- >200) 2/18
Met (30) 70 (11.5-3530) 22/30 (30) 15 (0- >200) 6/30
In this series only Cal53 was adequately sensitive in the
patients with metastatic disease. The sensitivity was 72%.
HMFG2 alone is not an adequate marker for disease activity
in either locoregional or metastatic breast cancer. However, it
may be of value used in conjunction with Cal53. Ca153
clearly deserves further study in a larger series of patients.
A phase I/II study of recombinant human granulocyte-
macrophage colony-stimulating factor in patients receiving
intensive chemotherapy for small cell lung cancer
H. Anderson, H. Gurney, J. Radford, W.P. Steward,
A. Kamthan, J. Chang & N. Thatcher
Christie Hospital, Manchester, UK.
Seventeen patients with small cell lung cancer have been
entered into a dose ranging Phase I/Il study using rhGM-
CSF (Glaxo). In the Phase I study patients received 50, 150,
300 or 500 ig m-2 GM-CSF for 10 days as a daily subcut-
aneous injection. After 4 days off therapy patients received
chemotherapy with adriamycin 50 Lg m-2 i.v., ifosfamide
5 g m-2 with MESNA 3 g m-2 i.v. on Day 1 and VP16
120 mg m-2 i.v. daily for three days. In the Phase I study
there was a significant rise in the neutrophils and eosinophils
and to a lesser extent monocytes at all dose levels and there
was some evidence of a dose-response relationship. In the
Phase II study patients received the same dose of GM-CSF
as in Phase I. GM-CSF commenced 24 hours after the last
dose of chemotherapy and was given for 14 days. Patients
were randomized to receive GM-CSF with either odd or even
courses of chemotherapy. Despite partial abrogation of the
neutropenia associated with chemotherapy (P = 0.04), GM-
CSF failed to reduce the incidence of severe infection - 6
episodes on GM-CSF and 7 not on GM-CSF (P = 0.9).
Timed blood counts over 24 hours showed that peak stimula-
tion of leucocytes occurred 8-12 hr following GM-CSF.
Toxicity, lethargy, myalgia and bone pain, occurred at all
dose levels but was manageable. GM-CSF given as a once
daily subcutaneous bolus is not effective in preventing infec-
tion following intensive chemotherapy for small cell lung
cancer despite reduction of chemotherapy-associated neutro-
penia.
Pharmacokinetics of epirubicin (EPI) in patients with
abnormal liver biochemistry
C. Twelves, N. Dobbs, L. Summers, P. Harper, M. Richard
& R. Rubens
ICRF Clinical Oncology Unit, Guy's Hospital, London
SEI 9RT, UK.
Anthracyclines are metabolized in the liver and empirical
dose reductions are often made in patients with impaired
liver function. We investigated the effects of abnormal liver
biochemistry on the pharmacokinetics of EPI in 12 patients
with breast cancer (3 with normal bilirubin, and aspartate
transaminase (AST) <2 x normal (N); 9 who had liver
metastases and AST>2 x N ± raised bilirubin). TreatmentBRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS 529
was with EPI 25 mgm2 i.v. weekly in all patients. Timed
blood samples were taken for 48 hours after EPI. Plasma
levels of EPI were measured by high performance liquid
chromatography and fitted to a 3-compartment model. The
area under the concentration-time curve to 48 hours (AUC)
was calculated by the trapezoidal method, and terminal half-
life (T1) was estimated.
Bilirubin = N Bilirubin = N Bilirubin> N
AST<2 x N AST>2 x N AST>2 x I
(n = 3) (n = 4) (n = 5)
AUC 606 1011 1301
(ng ml-' h-')
Tt (h) 23 33 43
AST correlated strongly with AUC (r = 0.83; P<0.001) and
T1 (r = 0.87; P<0.001). We conclude epirubicin pharmaco-
kinetics are abnormal in patients with disturbed liver bio-
chemistry. Total exposure to EPI is increased in patients with
either raised serum bilirubin or AST>2 x N.
Metabolism of ethanol and of fusel alcohols by rat oesophagus
V.M. Craddock & M. Abbs
MRC Toxicology Unit, Woodmansterne Road, Carshalton,
Surrey, UK.
Consumption of alcoholic beverages is the main cause of
oesophageal cancer for men in Europe and North America,
but surprisingly the ability of the oesophagus to metabolize
ethanol has not been studied. Many surveys in USA and
France have shown that, for the same amount of ethanol,
certain spirits, especially apple brandy, present a very much
greater risk than does wine or beer. The high fusel alcohol
content of many spirits, especially apple-based spirits, com-
pared with wine and beer, could be the cause. The
metabolism by oesophageal cytosol of ethanol, and of 3-
methyl-butanol (3-Mb) and P-phenethylalcohol, two major
fusel alcohols, was studied. Specific activity (SA) is expressed
as nm NADH formed from NAD+ per mg cytosol protein
per minute, measured over the first 30 sec incubation. The
rate of metabolism of ethanol increased with an increase in
substrate concentration, until at 2 M the SA was about forty
times greater than that of unfractionated liver enzyme
measured at its optimum substrate concentration (7.5 mM).
This high activity at high substrate concentrations has been
reported also for the minor x-ADH of liver, and for stomach
and corneal ADH. The oesophageal enzyme, however, differs
from other forms in its sensitivity to inhibition by pyrazole,
4-methylpyrazole, and by 1,10-phenanthroline. The fusel
alcohols were also actively metabolized at high substrate
concentrations by oesophageal alcohol dehydrogenase, the
SA being about eight times that of liver measured at its
optimum substrate concentration. The oxidation of 3-Mb,
with the formation of 3-methyl-butaldehyde, could be
responsible for the dramatic increase in basal cell replication
which occurs in oesophagus after intubation of 3-Mb, and in
this way spirits containing fusel alcohols could promote car-
cinogenesis.
The assay of the binding of aflatoxin B, to rat albumin
I.O. Olubuyide, G.E. Neal & D.J. Judah
Toxicology Unit, MRC Laboratories, Carshalton, Surrey
SM5 4EF, UK.
The potent hepatotoxin and hepatocarcinogen, aflatoxin B,
(AFB,) is activated by mixed function oxidases to meta-
bolites which undergo macromolecular binding. The binding
of an AFB, metabolite, AFBI-dihydrodiol, to serum albumin
appears to have potential for assaying exposure to the car-
cinogen in human populations, using ELISA techniques. The
feasibility of this has been examined using male Fischer rats
exposed to AFB,. The AFBI dose/albumin binding relation-
ship has been examined using [3H]-labelled AFB, with essen-
tially similar results to those obtained by Wild et al. (1986,
Carcinogenesis, 7, 853). A procedure for the purification and
concentration of the albumin adducts has been examined
using pronase digestion of [3H] AFBI adducted albumin fol-
lowed by Sep Pak and affinity column chromatography.
Radiochemical recoveries were assayed at each step in the
protocol. The pronase digestion has been optimized and the
distribution of label in the hydrolysate examined by HPLC.
The results using in vivo adducted rat albumin have been
compared with those obtained using albumin modified in
vitro by microsomally activated AFB,. Assays of the level of
AFB, adducts based on radiolabel have been compared with
results obtained from ELISA assays. A fraction of the
adducted AFB,, detected by radiolabel, was not recognized
by either the affinity column or the ELISA. This was partly
compensated by the highly immunoreactive nature of the
fraction retained by the affinity column presumably reflecting
the chemical structure of the AFB,-adduct used as the
immunogen in raising the polyclonal antibody. The overall
efficiency of the albumin/ELISA technique developed will be
assessed.
New measurements of thymidine kinase using HPLC
P. Mullan, B. Armstrong, B.M. Hannigan & P.G. McKenna
Biomedical Sciences Research Centre, University of Ulster,
Coleraine, N. Ireland BT52 ISA, UK.
Thymidine kinase (TK) (EC 2.7.1.21) is a key enzyme in
the generation of substrates for DNA synthesis. The TK
enzyme converts thymidine (Thd) to thymidinemonophos-
phate (TMP). This phosphorylation is the only pathway to
introduce Thd into the DNA metabolism, and for this reason
this enzyme is called a salvage enzyme. TK activity is low in
non-dividing cells but increases before the onset of DNA
synthesis. The growth rate of different tumours correlates in
many cases with cellular TK activity. It is therefore clear
that measurement of serum and cellular TK levels may be a
useful adjunct to other forms of markers for cellular pro-
liferation and cancer diagnosis. An alternate method for TK
quantification is reported, using the ability of the enzyme to
convert halogenated analogues of thymidine (e.g. bromo-
deoxyuridine (BrdU), iododeoxyuridine (IdU) etc.) to their
respective monophosphates. These monophosphate products
are measured using high performance liquid chromatography
(HPLC). Preliminary results have shown iododeoxyuridine to
be the preferred substrate of choice as IodUMP determina-
tion is performed at 290 nm, largely excluding absorbance
from other cellular components. This work provides a highly
reproducible method for TK assessment and compares
favourably with previous methods of enzyme measurement.
A technique for measuring DNA single strand breaks and
alkali labile sites in individual cells
V.J. McKelvey', R.R. Tice2 & N.P. Singh3
'Department ofBiological and Biomedical Sciences, University
of Ulster, Coleraine, N. Ireland, UK; 2Integrated Laboratory
Systems, PO Box 13501, Research Triangle Park, N.C.
27709; and 3Biology Department, Eastern Washington
University, Cheney, W.A. 99004, USA.
An electrophoretic assay capable of detecting DNA single
strand breaks and/or alkali labile sites in single cells was
recently introduced by Singh et al. (1988), Exp. Cell Res.,
178, 184). The importance of this assay lies in both its
requirement for only extremely small cell samples (e.g. 10lI530 BRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS
blood) and in its ability to evaluate intercellular differences in
DNA damage or repair in any cell type. This paper presents
a detailed working protocol of the Single Cell Gel (SCG).
Assay technique and its value in assessing DNA damage in,
for example, human peripheral blood lymphocytes following
in vitro treatment with u.v. light. Two doses of u.v. light were
used, namely 6 J m-2 and 20 J m-2, and the lymphocytes
were harvested at 1, 2 and 6 hours following treatment. The
irradiated lymphocytes were embedded in low melting point
agarose on microscope slides, lysed by detergents and elect-
rophoresed under alkaline conditions. Untreated lymphocytes
were processed in parallel. Changes in DNA migration pat-
terns were observed by ethidium bromide fluorescence and
measured using a micrometer. A clear dose response was
observed at each of the three harvesting times examined, and
the extent of the u.v.-induced damage was observed to
decrease over time, until at 6 hours following 6J m-2 u.v.
treatment the lymphocytes examined virtually all displayed
the control level of DNA migration. The potential of the
assay for DNA damage and repair studies is indicated.
Assessment of unscheduled DNA synthesis (UDS) in munne
lymphoma cells exposed to enzymaticaliy generated oxidants
S-A. Richardson, B.M. Hannigan & P.G. McKenna
Biomedical Sciences Research Centre, University of Ulster,
Coleraine, N. Ireland BT52 ISA, UK.
Oxidants (oxygen radicals) are known to induce DNA
damage and, as such, appear to have an important role in
various biological processes e.g., ageing, mutagenesis and
carcinogenesis. Assessment of the precise nature of the
various forms of oxidative DNA damage may allow correla-
tions to be drawn between oxidant activity and pathological
sequelae. Thus, cellular mechanism for the repair of oxidant
damage must also be determined. In this study, oxidants were
generated using the enzymatic system xanthine/xanthine
oxidase (X/XOD) in the presence of L5178Y(S) cells, a radio-
sensitive murine lymphoma cell-line. Xanthine oxidase acts
aerobically upon xanthine to generate oxidants as follows:
X + 02-- + 02-- + uric acid. 02 can give rise to H202 and
the hydroxyl radical OH. The exact mechanism by which
cells are damaged while exposed to X/XOD is still uncertain.
The cells' capacity for excision repair was determined by two
methods: an incorporation assay (Larcom & Smith (1988), J.
Natl Can. Inst., 80, 110) and autoradiography (Cleaver &
Thomas (1981), In: DNA Repair. A Laboratory Manual of
Research Procedures, 277), the latter method being regarded
as a more accurate assessment of UDS. Results indicate that
excision repair occurs in X/XOD treated cells, the extent
varying according to the duration of oxidant treatment,
period of cell recovery and duration of exposure to 3H-
thymidine. The continuing identification of repairable oxid-
ative DNA damage is a necessary strategy in pursuing a
better understanding of the mechanisms of oxidant induced
mutagenicity and carcinogenicity.
Study of the miscoding properties of 0'-methylguanine using
synthetic DNA primer templates
H.B. Tan & P.F. Swann
CRC Nitrosamine-induced Cancer Research Group,
Department of Biochemistry, University College London,
Gower Street, London WCIE 6BT, UK.
06-alkylguanine in the template DNA misdirects the incor-
poration of T during DNA synthesis and the pre-eminent
role of this alkylated base in nitrosamine carcinogenesis is
thought to be a consequence of the resulting mutation. The
accepted belief that the miscoding occurs because 06-alkylG
forms a mispair with T which is more stable than the pair
with C has recently been disproved by melting point studies
which have shown that 06-alkylG:T pairs are less stable than
06-alkylG:C base pairs. This has reopened the question of
why 06-alkylation of G produces G.C to A.T transition
mutations. To clarify this, we are carrying out detailed
analysis of DNA synthesis on synthetic alkylated templates
using the methods of Boosalis et al. ((1987), J. Biol. Chem.,
262, 14689) and Kuchta et al. ((1988), Biochemistry, 27,
6716). These are not yet complete but the preliminary results
show that with the Klenow fragment, the discrimination in
favour of the incorporation of T opposite 06-methylG occurs
during the addition of the base after the mispaired base as
well as during the addition of the mispaired base itself. The
incorporation of the base after a T is much more rapid than
when a C is opposite the 06-methylG. Since the extent of the
3'-5' proofreading is inversely related to the rate of addition
of the following base, this would contribute to the formation
of 06-alkylG:T pairs by allowing less removal of T than of
C from the alkylated base pair by exonucleolytic proof-
reading. The reduced rate of addition of both the C and of
the base following it may be explained by NMR studies
(Kalnik et al. (1989), Biochemistry, 28, 6170) which have
shown that 06-ethylG:C pairs have a 'wobble' configuration
which is accompanied by significant changes to the geometry
of the phosphodiester links in the 'C' strand on both the 3'
and 5' sides of the C, while the 06-alkylG:T pair retains the
Watson-Crick configuration with relatively normal geometry
of the phosphodiester links. These kinetic and NMR studies
suggest that the fidelity of DNA synthesis depends more on
the conformation of the base pairs than on their stability.
Inhibition of DNA methylation
P.A. Hepburn & M.J. Tisdale
Cancer Research Campaign Experimental Chemotherapy
Group, Pharmaceutical Sciences Institute, Aston University,
Birmingham B4 7ET, UK.
Unmodified calf thymus DNA does not act as a substrate
nor does it inhibit the transfer of methyl groups from S-
adenosyl-L-methionine to M. lysodeikticus DNA, by partially
purified eukaryotic DNA methylase. It has been observed,
however, that if the calf thymus DNA is modified by various
agents, it becomes an inhibitor of DNA methylation: 1.
Modification by monofunctional alkylating agents such as
temozolomide or ethazolastone causes a dose-dependent
inhibition of methylation. However, modification by bifunc-
tional alkylating agents capable of cross-linking DNA such
as chlorambucil produces poor inhibitors. 2. Treatment with
'Co radiation causes an inhibition which is dose related and
correlates with the appearance of single strand breaks. 3.
DNA treated with DNAase I which produces single and
double strand breaks also causes an inhibition of methylase
activity, whilst sonicated DNA and DNA treated with the
restriction enzyme MspI does not.
Damage to DNA by these treatments may be related to an
increased exposure of particular bases, as certain poly
nucleotides have been shown to have an inhibitory action. In
particular, a potent inhibition of DNA methylase activity has
been observed with poly [G], poly [I], poly [X], poly [dG],
poly [dC] but not poly [A], poly [U] or poly [C]. These results
point out the importance of the o6 position of guanine in
the binding of DNA methylase to dCpdG, the recognition
sequence for cytosine methylation. The inhibition produced
by the various modifications and the poly-nucleotides
appears to be due to an increased binding of the enzyme to
the inhibitor polynucleotide. These results may have impor-
tant implications in the mechanism of the alteration in pat-
tern of gene expression in neoplastic cells.BRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS 531
Accumulation of MCF-7 human mammary carcinoma cells in
the GO/GI phase of the cell cycle following administration of a
luteinizing hormone releasing hormone agonist
P. Mullen & W.R. Miller
ICRF, Medical Oncology Unit, Western General Hospital,
Edinburgh EH4 2XU, UK.
The Luteinizing Hormone-Releasing Hormone agonist
(LHRHa), buserelin, has been shown to inhibit the growth of
MCF-7 cells in culture (Miller et al. (1985), Nature, 313,
231). The aim of the present study was to determine if such
growth inhibition was accompanied by alterations in the cell
cycle distribution. Effects of buserelin were tested out on
MCF-7 cells previously shown to be sensitive to LHRHa
(MCF-7 1s). A second clone of MCF-7s which were insen-
sitive (MCF-7 1i) were also studied as a negative control.
Growth experiments were carried out by plating cells
(0.5 x 106) in 60 mm petri dishes containing DMEM culture
medium (4 ml) in the absence and presence of buserelin
(10-6M, 10-7M and 10-8M). After 1, 2, 3 and 4 days cells
were harvested by trypsinisation, counted with a haemo-
cytometer and then subjected to DNA analysis using a
Coulter EPICS C flow cytometer. The MCF-7 ls cells were
inhibited by busereline in a dose-related manner. Further-
more, this was accompanied by major alterations in the cell
cycle distribution. Treatment with buserelin produced an
accumulation of cells in the GO/G1 phase of the cell cycle
and a concomitant decrease in both the S and G2/M phases.
No such changes were seen in the LHRH insensitive cell line
in which buserelin produced no significant change in cell
numbers. These results show that the growth inhibitory
effects of buserelin in the MCF-7 cell line are associated with
major changes in the cell cycle parameters.
Direct effects of GnRH analogues in prostatic cancer
A. Qayum', W. Gullick', P. Abel3, G. Williams', K. Melon4,
D. Neal4, K. Sikora2 & J. Waxman2
'ICRF Unit Jor Molecular Oncology, 2Clinical Oncology and
3Urology, Hammersmith Hospital; and 4Freeman Hospital,
UK.
We report high affinity binding (kd = 50 M) of a gonadotro-
phin releasing hormone (GnRH) analogue resulting in
biphasic growth modulation of the human androgen-sensitive
prostatic cancer cell line. LNCaP. This was in contrast to
low affinity, non specific binding (kd = 10 M), without bio-
logical effect in the human androgen insensitive line DU145.
GnRH-like immunoreactivity was demonstrated in the con-
centrated culture media from both cell lines by a GnRH
radioimmunoassay, and this peptides elution profile on
HPLC was identical in nature to GnRH. Nineteen of 22
malignant tumours and 49 of 54 benign prostatic tumours
exhibited high affinity binding. Fourteen of 19 malignant
tumours and 17 of 49 benign tumours exhibiting high affinity
binding contained GnRH-like immunoreactivity suggesting
that this system may be involved in prostatic epithelial
growth in vivo.
The effects of progestins/anti-progestins on proliferation and
progesterone receptor expression in human breast cancer cells
H.W. van den Berg, J. Martin & M. Lynch
Department of Therapeutics and Pharmacology, The Queen's
University of Belfast, UK.
We studied the effects of the progestins, medroxyproges-
terone acetate (MPA) and ORG 2058, and the anti-pro-
gestins, RU 38.486 and ZK 98.299, on progesterone receptor
(PGR) expression and proliferation of ZR-75-1 human breast
cancer cells and variants differing in their steroid hormone
receptor profiles. The relative affinities of progestins/anti-
progestins for PGR in an oestrogen (E2) independent variant
of the ZR-75-1 line (ZR-PR-LT) expressing high basal levels
of the receptor were ORG 2058 = 100, MPA = 200, RU
38.486 = 44, ZK 98.299 = 30. A 5-day exposure of ZR-75-1
cells to 10-9 M E2 in the presence of 10-9 M MPA resulted
in an almost complete blockade of E2 induction of PGR.
10-9 M MPA alone reduced PGR expression in ZR-PR-LT
cells to 20% of basal levels whilst 10-9 M RU 38.486
reduced PGR expression by 50%. In contrast, neither ORG
2058, nor ZK 98.299, treatment (10-9 M) resulted in loss of
PGR. MPA was the most potent anti-proliferative agent in
all cell lines tested, but the ZR-PR-LT line was only mar-
ginally more sensitive than the parent line despite expressing
a 20-fold higher basal PGR concentration. Surprisingly, the
growth inhibitory response to MPA, RU 38.486 and ZK
98.299 was greatest in a tamoxifen-resistant variant (ZR-75-
9al) lacking detectable PGR. These results indicate a poor
relationship between cellular PGR content and proliferative
response to progestins/anti-progestins. The reason for the
marked differences in the ability of these agents to down-
regulate PGR is not known but may be related to differences
in intrinsic glucocorticoid/anti-glucocorticoid activity.
Interferon alpha receptor expression by human breast cancer
cells
J. Martin, B. McKibben & H.W. van den Berg
Departments of Therapeutics, Pharmacology and Medicine,
The Queen's University of Belfast, UK.
Recombinant interferon alpha 2b (IFN) increases oestrogen
receptor (ER) expression in ZR-75-1 human breast cancer
cells (van den Berg et al. (1987), Br. J. Cancer, 55, 255) but
we have been unable to demonstrate induction of ER in a
tamoxifen-resistant, ER negative, variant line (ZR-75-9al). In
this study we have investigated the relationship between IFN
receptor expression and steroid hormone receptor content in
ZR-75-1 cells, the tamoxifen-resistant variant and an oestro-
gen independent subline (ZR-PR-LT). The latter line lacks
binding sites characteristic of the Type 1 ER but expresses
elevated levels of progesterone receptor (PGR). IFN was
labelled with 125I using the lodogen reaction and purified by
HPLC to a specific activity of 298 Ci mM-'. Binding of 1251
IFN to whole cells at 4°C was determined in the presence and
absence of excess cold IFN. ZR-75-1 cells contained 1498 +
541 IFN receptors/cell which fell to 802 ± 447 receptors/cell
during a 5 day exposure to 10-9 M oestradiol (E2). IFN and
E2 therefore appear to have opposite effects on expression of
each other's receptor in this cell line. This E2 induced reduc-
tion in IFN receptor expression is accompanied by a 6-fold
increase in PGR concentration in ZR-75-1 cells. However,
there was no significant reduction in IFN receptor expression
in ZR-PR-LT cells associated with their elevated basal PGR
content. An inverse relationship between IFN and PGR
receptor expression is apparent in the ZR-75-9al line which
lacks PGR and expresses the highest concentration of IFN
receptors (3443 ± 389 sites per cell). This observation sug-
gests that the apparent inability of IFN to induce ER in this
cell line is not a consequence of failure to express IFN
receptors.
Characterization of ligand-binding and processing by gastrin
releasing peptide receptors in small cell and non-small cell lung
cancer cell lines
C. Cardona, J.G. Reeve & N.M. Bleehen
MRC Clinical Oncology and Radiotherapeutics Unit, MRC
Centre, Hills Road, Cambridge CB2 2QH, UK.
Bombesin (BN) and its mammalian homologue gastrin
releasing peptide (GRP) have been shown to stimulate the
growth of small cell lung cancer (SCLC) cell lines in vitro.532 BRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS
However, no obvious correlation was observed between the
in vitro response to BN/GRP and the presence of specific
BN/GRP receptors. Furthermore, the processing events that
occur after BN/GRP binding have not been investigated in
lung tumour cell lines. To gain further insight into the
mechanisms involved in the mitogenic action of BN/GRP,
the expression of GRP receptors and the kinetics of GRP
binding and internalization have been studied in a panel of
10 SCLC and 3 non-SCLC (NSCLC) cell lines. For the
detection of GRP receptors 106 cells were incubated with
0.5 nM '25IGRP for 30 minutes at 37°C in the presence or
absence of 1 pM cold GRP. Cells were pelleted, washed and
specific binding determined. In contrast to previous studies,
specific GRP binding sites were detected consistently on all
SCLC and NSCLC cell lines examined although GRP bind-
ing varied between lines (0.06-2.01 fmol 10-6 cells). For all
cell lines, binding of '25IGRP increased rapidly with time,
peaked after 15-60 minutes depending on cell line, and
subsequently decreased. Extraction of surface-bound ligand
at low pH indicated that the iodinated peptide was inter-
nalized within minutes in both SCLC and NSCLC cells.
Pre-incubation of cells with GRP markedly reduced the
subsequent binding of '25IGRP to SCLC cells but not to
NSCLC cells. These results indicate that GRP receptors are
present on both SCLC and NSCLC cells, that in both cell
types GRP is internalized and degraded, but that in contrast
to NSCLC cells, surface receptors for GRP on SCLC cells
are down-regulated. Hence regulation of the proliferative
response to GRP stimulation may differ in these cells.
Cell membrane receptors for granulocyte and granulocyte/
monocyte colony stimulating factors on bone marrow cells
from leukaemia patients: an autoradiographic study
W.S. Gilmore, M. McCabe, G.B. Nevin & C.P. McGuckin
Biomedical Sciences Research Centre, University of Ulster,
Cromore Road, Coleraine BT52 ISA, UK.
Granulocyte colony stimulating factor (G-CSF) and granu-
locyte/monocyte colony stimulating factor (GM-CSF) are
haemopoietic growth factors involved in the proliferation and
function of cells of the granulocytic and monocytic cell
lineages. These growth factors act on their target cells via cell
membrane receptors. On binding to the cell surface receptor,
the growth factor is thought to activate an, as yet, undefined
signal transduction mechanism resulting in cell proliferation.
In the present study, binding of radiolabelled G-CSF and
GM-CSF to bone marrow cells from patients with haemato-
logical malignancies was observed. Recombinant human G-
CSF (Amersham International PLC) was radioiodinated and
radioiodinated GM-CSF and unlabelled GM-CSF were
obtained from Amersham International PLC. Bone marrow
films were prepared from haematopoietic cells obtained from
trephine biopsy during routine haematological investigation
of patients with various haematological disorders. The
labelled CSFs were then reacted with the bone marrow
smears, which were then dipped in photographic emulsion
and incubated for 7 days in the dark and developed.
Radiolabelled G-CSF bound to cells of granulocytic origin
and patients with chronic granulocytic leukaemia showed
increased binding. Radiolabelled GM-CSF bound to a wide
range of cells including megakaryocytes.
Biodistribution studies in mice with synthetic polypeptide-drug
conjugates
J.A. Clegg', F. Hudecz2, M.V. Pimm' & R.W. Baldwin'
'Cancer Research Campaign Laboratories, University of
Nottingham, UK; and 2Institute of Organic Chemistry, Eotvos
University, Budapest, Hungary.
Synthetic macromolecules are of interest as carriers for
anticancer agents for both non-specific and site-specific
modulation of their biodistribution. In the present study, the
biodistribution in mice has been examined of a range of
synthetic branched polypeptides. These have a poly-L-lysine
backbone and are substituted at epsilon amino groups with
side chains of three alanine amino acids with or without
another terminal amino acid. Polypeptides with terminal Leu,
D-Leu or Pro are basic and polycationic, while those with
terminal Glu are both acidic and basic and thus amphoteric
under physiological conditions. Two groups of polypeptides
of almost identical composition but different molecular sizes
(46 kDa and 200 kDa) were examined. To assess their biodis-
tribution, the polypeptides were labelled with 1251 by reaction
with iodinated Bolton-Hunter reagent. Polycationic polypep-
tides were cleared rapidly from the circulation, the liver being
the major site of clearance. Amphoteric polypeptides showed
the best blood survival, and this was seen with polypeptides
of both molecular sizes. Conjugation of methotrexate or
daunomycin to these amphoteric polypeptides at a molar
ratio of up to 60:1 did not compromise their biodistribution.
These findings suggest that these amphoteric branched poly-
lysine-drug conjugates are candidates for further conjugation
to site specific targeting agents such as monoclonal anti-
bodies.
Anti-methotrexate monoclonal antibodies: their production,
characterization and potential uses
A.D. Curran, E. Jacobs, M.V. Pimms, R.A. Robins
& R.W. Baldwin
Cancer Research Campaign Laboratories, University of
Nottingham, Nottingham NG7 2RD, UK.
A panel of monoclonal antibodies has been raised against the
antifolate drug methotrexate, to assess their potential for use
in drug assays and cancer therapy. Balb/c mice were
immunized with methotrexate (MTX) covalently linked to
human serum albumin (Garnett et al. (1985), Anti-Cancer
Drug Design, 1, 3), with standard techniques being used to
produce the hybridomas. Hybridomas 420 (IgG,) and 533
(IgG2b) were selected in media containing HMT; 634.4 (IgG,)
and 634.42 (IgG,) were selected initially in HAT media but
were quickly transferred to media containing H and T only.
Antibodies were purified by binding to protein A-sepharose
in PBS at pH 8.0, and eluting with 3M NaSCN followed by
dialysis against PBS at pH 7.2. ELISA blocking assays
showed 420 and 533 to be more specific for MTX conjugated
to HSA than MTX alone, whereas 634.4 and 634.42 reacted
equally well with free drug. Blocking assays with MTX
analogues and structural components of the MTX molecule
have shown that 634.4 recognises the pteridine ring end of
the drug, whereas 634.42 recognises the central region of the
molecule. In vitro the antibody has potential for use in drug
assay development: 634.42 has been tested in a quantitative
competitive ELISA for the detection of methotrexate, and
could detect free drug in the range of 1 to 100pg. For in vivo
utilization, the 634.4 hybridoma is being fused with the anti-
CEA hybridoma 365 to generate an antitumour associated
antigen/anti-methotrexate bispecific antibody for the site
specific delivery of free or carrier-conjugated MTX.
Cytotoxicity of monoclonal antibody-targeted methotrexate
against methotrexate-resistant tumour cell lines
K. Affleck & M.J. Embleton
Cancer Research Campaign Laboratories, University of
Nottingham, Nottingham NG7 2RD, UK.
Several methotrexate (MTX)-resistant sublines of osteogenic
sarcoma cell line 791T and colon carcinoma cell line C170
have been derived by continuous selection in the presence of
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cluding assays of the uptake and binding of 3H-MTX and
fluoresceinated MTX have determined that resistance in these
sublines was predominantly due to diminished MTX trans-
port, and that none of them appeared to overproduce the
MTX target enzyme dihydrofolate reductase. A conjugate
of the anti-791T monoclonal antibody 791T/36 linked to
MTX via human serum albumin was provided by Dr M.C.
Garnett. This was cytotoxic selectively for cells bearing
the 791T/36-defined antigen, and was found to be as cyto-
toxic to most of the MTX-resistant 791T sublines as it was to
parental 791T cells. Another conjugate, constructed by link-
ing the anti-colorectal carcinoma monoclonal antibody 505/
4/6 directly to MTX, was also found to be more cytotoxic
than free drug to some of the MTX-resistant C170 sublines,
although these were not as susceptible to conjugates as were
parental C170 cells. It is suggested that targeting to a cell
surface antigen can partially or wholly overcome acquired
drug resistance caused by deficient transport mechanisms.
A syngeneic anti-idiotypic antibody to an antitumour antibody
which induces cellular and humoral antitumour responses
M. Doran, L.G. Durrant, R.A. Robins, E.B. Austin
& R.W. Baldwin
Cancer Research Campaign Laboratories, University of
Nottingham, Nottingham NG7 2RD, UK.
Anti-idiotypic antibodies reactive with the binding site of
antibodies to tumour-associated antigens can generate anti-
tumour responses in tumour patients. 791T/36 is a mouse
monoclonal antibody which recognizes the gp72 human
tumour-associated antigen (791Tgp72). Patients receiving
791T/36-RTA produce strong anti-idiotypic antibody res-
ponses and some develop antitumour responses. 730/71 is an
IgG, syngeneic anti-791T/36 anti-idiotypic antibody. It
specifically blocks the binding of 791T/36 (IgG2b) and ID12
(an IgG2a class switch variant of 791T/36) to 791Tgp72. The
730/71 defined idiotype on 791T/36 is recognized by anti-
idiotypic antibodies in the serum of most of the patients
receiving 791T/36-RTA. 730/71 can evoke cellular and
humoral immune responses against 791T and C170 cells
(human tumour cell lines expressing 79ITgp72). Mice primed
with 730/71, either alone, or with adjuvants, show a signi-
ficantly enhanced delayed type hypersensitivity response to
both 791T and C170 cells, compared with mice primed with
an irrelevant IgG1. Mice, rats and rabbits immunized with
730/71 produce anti-idiotypic antibodies which block the
binding of 730/71 to 791T/36. In each species, a proportion
of the anti-idiotypic antibodies bind 791T cells. These results
show that 730/71 has a potential role in the immunotherapy
of human cancer.
A human monoclonal anti-idiotypic antibody with potential for
induction of antitumour immunity
E.B. Austin, R.A. Robins, L.G. Durrant & R.W. Baldwin
Cancer Research Campaign Laboratories, University of
Nottingham, Nottingham NG7 2RD, UK.
A human monoclonal anti-idiotypic antibody 105AD7 was
produced by fusing a mouse-human heteromyeloma with
lymphocytes from a colorectal cancer patient injected with
mouse monoclonal antibody 791T/36 for tumour immuno-
scintigraphy (Austin et al. (1989), Immunology, 67, 525). In
quantitative flow cytometric assays, the human antibody
completely blocked 791T/36 binding to tumour cells. Tests
with antibody purified by affinity chromatography indicated
a 1:1 stoichiometric interaction between 791T/36 and
105AD7. The complexes formed were stable in the presence
of excess antigen positive tumour cells indicating a high
affinity interaction between 105AD7 and the binding site of
791T/36. Anti-idiotypic antibodies reactive with the binding
site region of anti-tumour antibodies have been shown to
induce anti-tumour responses in animals. Therefore, the
induction of anti-tumour responses in mice and rats follow-
ing immunization with 105AD7 was investigated. Mice inject-
ed with 105AD7 in Freund's adjuvant developed antibodies
reactive with human tumour cell line 791T. Induction of
cellular responses was shown by delayed type hypersens-
tivity reactions in mice and rats, evaluated in coded double
blind experiments. Animals were primed by a subcutaneous
injection of antibody and a DTH response measured by an
increase in ear thickness following tumour challenge. A
significant DTH reaction was observed in animals primed
with 105AD7 and challenged with 791T tumour compared
with those primed with irrelevant human IgG (P<0.01).
Challenge with tumour cells unreactive with 791T/36 did not
induce DTH responses. These data indicate that 105AD7
may be useful as an agent for the stimulation of anti-tumour
responses in humans.
Mapping of monoclonal antibody-defined epitopes on the
repeat peptide of polymorphic epithelial mucins
M.R. Price', S. Briggs' & S.J. Tendler2
'Cancer Research Campaign Laboratories; and 2Department of
Pharmaceutical Sciences, University of Nottingham,
Nottingham NG7 2RD, UK.
Many monoclonal antibodies against human breast carcin-
omas or milk fat globule membranes react with the protein
core of highly glycosylated, polymorphic epithelial mucins
(PEM) and the present investigation was designed to identify
those structures in the mucin core which are recognized by
these antibodies. The protein core of epithelial mucins con-
sists of a repeated sequence of 20 amino acids (Gendler et al.
(1988), J. Biol. Chem., 263, 12820). Initially, a series of
synthetic heptapeptides were prepared, each of which over-
lapped by six amino acids, and several anti-PEM antibodies
were tested for their reactivity with these peptides. In this
way, the minimum linear sequence of amino acids required
for antibody binding was identified for each antibody. All
epitopes were found to reside in a discrete hydrophilic
domain comprising seven amino acids (P D T RPA P) and
each antibody required an epitope with as few as three, and
up to five, amino acids in order to bind. Further synthetic
studies were conducted in which individual amino acid
residues within an epitope sequence were replaced by other
amino acids and the resulting peptides were examined for
antibody binding. Using these synthetic approaches, it is
feasible to define at the molecular level the requirements
for epitope recognition by antibodies and to acquire an
understanding of the specificity of a series of monoclonal
antibodies which are highly reactive against human breast
carcinomas.
Monoclonal antibodies MG7 and MC3 recognize tumour-
associated antigens in cholangiocarcinomas
N. Rothnie', H. Su', B. Fermor', N. Rooney2, E. Dankwa2,
P. Newcomb, C. Wood' & N. Habib'
'Department of Surgery, Royal Postgraduate Medical School,
London; and 2Department of Histopathology, Bristol Royal
Infirmary, Bristol, UK.
Radiolabelled monoclonal antibodies (MoAb) may offer a
new approach to the treatment of cholangiocarcinoma after
biliary decompression. Cross reactivity with normal bile duct
epithelium remains a problem. MG7 and MC3 are murine
MoAbs (IgG2) which have been raised after immunization
with human adenocarcinoma cells. They recognize pancarcin-
oma antigens. The aim of this study was to assess the534 BRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS
immunohistochemical pattern of staining of MG7 and MC3
in cholangiocarcinomas and benign and malignant liver tis-
sue. Formalin-fixed paraffin-embedded, sections of tissue
from normal liver (n = 10), cholangiocarcinomas (n = 8),
colonic liver metastases (n = 5), hepatocellular carcinomas
(n = 5), and benign liver disease (n = 12) were stained with
MG7 using the avidin-biotin peroxidase method. Staining
was assessed by the number of cells staining and by the
cytological distribution. No staining was seen with the nega-
tive controls. All of the cholangiocarcinomas were positive
with MG7, 75% having over 10% cells staining; 7/8 were
positive with MC3, half having over 10% cells staining.
Staining of tumour cells was situated in the apical mem-
branes and the superficial mucin. No staining was seen in
normal liver tissue with either antibody. One case of viral
hepatitis showed slight staining of bile duct epithelium with
MC3, all the other cases of benign liver disease were
negative. All of the colonic metastases were strongly positive
with both antibodies. MG7 and MC3 recognize tumour-
associated antigens expressed on cholangiocarcinomas and
secondary carcinomas in the liver but have minimal reactivity
with bile duct epithelium and normal and benign liver tissue.
Is C219 specific for P-glycoprotein?
G.C. Wishart', J.A. Plumb', J.J. Going2, A.M McNicol2, C.S.
McArdle' & S.B. Kaye'
'CRC Department of Medical Oncology, Glasgow University;
and University Departments of 2Pathology & 3Surgery, Royal
Infirmary, Glasgow, UK.
The monoclonal antibody (MAb) C219 reacts with an epi-
tope on the cytoplasmic face of the transmembrane protein,
P-glycoprotein (P-gp). Recent work has suggested that C219
may cross-react with the heavy chain of myosin in skeletal
and cardiac muscle. By immunocytochemistry with C219 on
frozen sections of primary breast cancers, we have shown
positive staining in stromal cells, thought to be myofibro-
blasts, in 26 of 29 tumours. When the same tumours were
incubated with MRK16, a MAb which reacts with an exter-
nal epitope of P-gp, positive staining was seen in the stromal
cells of only 12 of the 29 cancers.
We have now tested both C219 and MRK16 with two
other tissues known to contain myosin, skeletal muscle and
granulation tissue, by immunocytochemistry. C219 showed
marked reactivity with frozen sections of skeletal muscle
whereas MRK16 did not. When incubated with frozen sec-
tions ofgranulation tissue both C219 and MRK16, as well as
a MAb against myosin, reacted strongly with myofibroblasts.
The higher level of staining with C219 in breast cancer
stroma may represent a possible cross-reaction with myosin
and this is supported by positive staining of skeletal muscle,
unlike MRK16. Alternatively C219 may be recognizing a
form of P-gp which MRK16 does not recognize. The positive
staining with both antibodies in granulation tissue is as yet
unexplained. The amount of P-gp detected by immunocyto-
chemistry is extremely dependent on the antibody used and
results should be interpreted with caution.
Photosensitization by diaminoanthraq0ne
J.A. Hartley', N. Khan', R.L. Souhami', K. Reszka2,
P. Bilski2, C. Chignell2, A. Mendonca3 & J.W. Lown'
'Department of Oncology, University College & Middlesex
School of Medicine, London, UK; 2Laboratory of Mol.
Biophys. NIEHS, Research Triangle Park, NC, USA; and
'Department of Chemistry, University Alberta, Edmonton,
Alta, Canada.
1,4-diamino substituted anthraquinone antitumour agents
such as mitoxantrone and ametantrone do not show visible
light photosensitization whereas the structurally related 1,5-
and 1,8-diaminosubstituted compounds (AMI and AM2)
photosensitize human leukaemic cells in culture and show
significant light-activated damage in an animal model system.
In an attempt to produce simpler and more efficient photo-
sensitizing structures as potential agents for photodynamic
therapy, 1-amino, 1, 5- and 1,8-diamino compounds were
synthesized (containing 4,5-, 4,8- and 4,5- methoxy groups,
respectively). Single oxygen production was found to be very
efficient for the 1,5- and 1,8- compounds and superoxide
radical generation strong for the 1,8 compound and weak for
the others as measured in toluene by luminescence and EPR-
spin trapping techniques, respectively. These compounds
were found to be advantageous in that they were much less
toxic in the dark than AM1 and AM2 with little or no killing
of human leukaemic cells at 250JAM. Only the 1,5-compound
however showed significant light-activated killing below
20JM. In the case of this agent the light-induced dose
modification following a short time of illumination (<2 min,
5 W m2-'>475 nm) was 15-fold, which could be increased
significantly using longer times of illumination. This dose
modification was almost 4 times higher than foT the 1,5-
diamino substituted compound AMI. Attempts to modify
the structures further to shift the absorbance maxima to a
higher wavelength are currently underway.
The effect of phthalocyanine mediated photodynamic therapy
on tumour blood flow, metabolic activity and cell viability
W-S. Chan', N. van Bruggen2, J.F. Marshall', J. Syha2,
E. Proctor2, A.L. Busza2, D. Gadian2 & I.R. Hart'
'ICRF Laboratories, 2Department of Physics in Relation to
Surgery, Hunterian Institute, Royal College of Surgeons,
Lincoln's Inn Fields, London WC2, UK.
Chloroaluminium sulphonated phthalocyanine (ClAISPc) is
an effective agent in the photodynamic therapy (PDT) of
experimental cancer (Chan et al. (1988), Cancer Res., 48,
3048). The present studies were undertaken to determine the
mechanisms behind this efficacy. In vitro colony forming
efficiency (CFE) of neoplastic cells was determined, on single-
cell suspensions from solid tumours, at varying times after
CIAISPc-PDT. No substantial reduction in CFE was
observed until at least 5 hours after treatment and by 24
hours after PDT the CFE was reduced to 0.1% of control
values. In contrast to this relatively slow response to treat-
ment, metabolic activity of the tumour, as assessed by loss of
high energy phosphate in 3'P-NMR spectra, was almost com-
pletely abolished as early as one hour after PDT. Measure-
ment of regional tumour blood flow, by the technique of H2
washout, revealed a gradual decline to zero 4-6 hours after
PDT. These results suggest that while early damage to neop-
lastic cells may develop as a consequence of ClAISPc-PDT
the observed cell death is a relatively late event probably
related to disruption of tumour vasculature.
The expression of Class I and Class II major
histocompatibility complex antigens by renal carcinoma
cells in culture
R. Angus', C.M.P. Collins2 & M.O. Symes'
'University Departments of Surgery and 2Pathology, Bristol
Royal Infirmary, Bristol BS2 8HW, UK.
Surgical nephrectomy specimens were obtained from 6
patients with renal carcinoma. The solid tumour was enzy-
matically disaggregated and the carcinoma cells separated
from the resulting mixed cell suspension by centrifugation on
a NycodenzR column. The carcinoma cells were cultured in
RPM11640 with 1% w/v glutamine 10% v/v newborn calf
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ture drops of medium (0.3 ml) containing 104-cells were
placed in each well of a 3-well slide. After 24 hours culture,
to allow the carcinoma cells to adhere, the medium was
replaced by fresh medium alone, or medium containing 100,
500 or 1000 i.u. of a or y interferon (Wellcome Brolech).
Culture was continued for a further 1, 3 or 5 days. The cells
in one well on each slide were then stained for expression of
Class I MHC by the immunoperoxidase technique using a
monoclonal antibody M736 and cells in a second well for
expression of Class II MHC (M 704 Dako). The cells in the
third well were stained without prior exposure to a MoAb.
Of the 6 tumours, 4 expressed Class I MHC Ag when
cultured in medium alone for one day. The other 2 tumours
expressed class I Ag after culture for 3 days. Class II MAC
Ag was expressed by 3 of the 6 tumours on culture in
medium alone, and this expression was increased in one
tumour and induced in a second by culture in the presence of
interferon. In one tumour the appearance of Class I Ag was
retarded (from I to 3 days) by culture in spent medium.
Expression of MHC molecules on bladder tumour cell line
A.M.E. Nouri, A. Biro, C.V.A. Bunting & R.T.D. Oliver
Departments of Medical Oncology and Immunology, The
London Hospital, London, UK.
A bladder cell line designate CAT has been developed from a
patient with transitional cell carcinoma and has been kept in
culture for at least one year. Phenotypic analysis of cell
surface antigens using monoclonal antibodies (MoAb) have
revealed the loss of MHC class I antigens B7, B44 and Bw6
compared with autologous lymphocytes. These cells were also
found to be negative for class II antigens (DR, DP and DQ).
Treatment of the cells with 2.5% (v/v) active supernatant
(obtained from 48-hour cultured human peripheral blood
mononuclear cells activated with PHA) resulted in the
upregulation of monomorphic (B2-microglobulin-associated)
class I antigen detected by W6/32 MoAb with concomitant
decrease in the expression of free heavy chain (none B2
m-associated) of class I detected by HCIO Mab. It was also
found that this treatment did not result in the expression of
missing polymorphic antigens i.e., B7, B44 and Bw6. Active
supernatant at as low as 0.1% (v/v) induced class II antigens
after 36 hours of culture with order of antigenic strength of
DR> DP> DQ. Preliminary results using dot blotting, locus
and allele specific oligo probes indicated that there may be
less B7 and B44 mRNA in CAT cells compared with autolo-
gous lymphocytes. The results of inducibility of MHC class I
and II antigens to different cytokines including IL-1, IL-4,
TNF and IFNs individually and in combinations will be
presented.
High metastatic ability of a bladder carcinoma cell line in nude
mice
J. Stables', P. Topley', J. Chowaniec2, C. Parry2, L. Holmes',
D. Linstead', D. Jenkins', E. Rapson' & J. Wilkinson'
'Department of Molecular Sciences, Wellcome Research
Laboratories, Beckenham, Kent BR3 3BS; and 2Department of
Histopathology, University College & Middlesex School of
Medicine, London WIP 7LD, UK.
The chemically induced rat bladder carcinoma cell line is
metastatic in immune suppressed mice (Joy et al. (1989), Br.
J. Cancer, 60, 493). Studies on the growth of this cell line in
nude mice following an inoculation of I x 106 cells subcut-
aneously indicated that relatively slow-growing tumours were
produced which reached 0.6 g in weight after 36 days. These
tumours however ulcerated in some animals as early as day
28, necessitating culling, and the experiment was terminated
at day 36, at which time macrometastatic foci were detected
on 40% of the lungs. Experiments have since been performed
in which lung metastases from nude mice inoculated subcut-
aneously with fragments of the RUCL2 tumour have been
selected and passaged subcutaneously in nude mice. By this
method it was hoped that variants of RUCL2 would be
produced which had either a reduced level of ulceration, or
an increased level of metastatic behaviour. Two variants have
been produced, RUCL2T and RUCL2T, which by 45-50
days produce macrometastatic lesions in the lungs of 100%
of the inoculated mice and with a level of ulceration at least
50% lower than that produced by RUCL2. The metastases
recovered displayed the histological features of RUCL2 line,
that is moderate-poorly differentiated transitional cell car-
cinoma. Further work is now in progress to develop the
RUCL2/nude mouse system into a model suitable for the
evaluation of potential antimetastic compounds. If successful,
this model will be invaluable as, unlike the majority of other
models ofmetastasis using carcinoma cell lines, it is represen-
tative of the whole metastatic process.
Evaluation of cell attachment matrix (CAM) coated plates for
primary culture of human tumour biopsies for predictive testing
of radiosensitivity
P. Price, C.S. Parkins, C. Bush, M. Robinson
& T.J. McMillan
Radiotherapy Research Unit, Institute of Cancer Research,
Sutton, Surrey SM2 5NG, UK.
Baker et al. (1986, Cancer Research, 46, 1263) developed an
adhesive tumour cell culture system (ATCCS) using the cell
attachment matrix (CAM) (LifeTrac Inc.) to promote attach-
ment and growth of tumour cells from biopsies so that
response to irradiation could be measured using a mass
culture technique. In the present study, 22 human tumour
biopsies were used to test this system: bladder (11 cases),
cervix (4 cases), sarcoma (3 cases), head and neck (3 cases),
and prostate (1 case). Tumour biopsy weight was mean 3.3 g
(range 1-10 g), with a mean cell yield after 30 min digestion
of 2.5 x 106 (range 0.05-20 x 106). Successful growth was
obtained in 9/20 samples (45%). In all 9 cases, growth at 1
and 7 days showed mainly fibroblasts and a few tumour cells.
By day 14, in 5 cases the morphological appearance of the
cells was that of fibroblasts, while in 2 cervical carcinomas
and 2 sarcomas, the cells were of indeterminate type. Re-
sponse to irradiation was measured using either clonogenic
assay or a mass culture technique (MTT assay) in 4 cases.
SF2 values obtained were 0.25, 0.28, 0.28 and 0.64. The
survival curves from the cells with the low SF2 values were
almost straight, thus confirming the morphological suspicion
that the cells were most likely fibroblasts. In our hands, the
ATCCS would not appear successful in preferentially grow-
ing tumour cells and preventing the overgrowth of fibro-
blasts. Comparison with other surfaces showed that CAM
was no better for establishing tumour cell growth than the
presence of feeder cells or an alternative attachment factor
vitronectin, and was less good than conventional soft agar.
The use of a mass culture technique would also seem inap-
propriate in assessing response to survival when good
exponential growth of tumour cells was never obtained.
Neuroblastoma: a study of radiosensitive human twnour cells
T.J. McMillan, J. Eady, A. Holmes, J. Peacock & G.G. Steel
Radiotherapy Research Unit, Institute of Cancer Research,
Sutton, Surrey SM2 5NG, UK.
Neuroblastomas are radioresponsive tumours and this is re-
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lines derived from these tumours. Each of the two cell lines
examined in this study, HX142 and HX138, demonstrates a
sensitivity to ionizing radiation which is comparable to that
of transformed Ataxia telangiectasia (A.T.) fibroblasts. These
cells do not exhibit a reduced level of cellular recovery in
split-dose or low dose-rate experiments unlike A.T. cells. In
addition they show an inhibition of DNA synthesis following
irradiation which is comparable to resistant normal cells
rather than A.T. fibroblasts. Repair capacity has been assess-
ed using the viral reactivation assay. The level of reactivation
for the two neuroblastoma cell lines was found to be in the
middle of the range seen for resistant tumour cell lines. This
suggests that they do not have a significant repair defect.
Both lines show a higher than average level of DNA double-
strand breaks immediately after irradiation, however the
extent of this is not sufficient to explain fully the sensitivity
of these cells. Therefore, it seems that the sensitivity may be
related to a high level of damage induced in the DNA by the
radiation but that some as yet undetermined processes in-
crease the conversion of this damage into lethal events.
XHI - a new cervical carcinoma cell line: a xenograft model of
invasion and metastasis
X. Han, P.J. Warren, R. Lyle & E. Heyderman
Department of Histopathology, UMDS, St Thomas Hospital,
London SE] 7EH, UK.
A new cervical carcinoma cell line, XHI, has been derived
from a moderately differentiated adenosquamous invasive
carcinoma of the cervix in a woman of 32. It has been
maintained in long term monolayer culture for one year and
for 56 passages. In culture, it has the morphology of adher-
ent polygonal epithelial cells. It is aneuploid, with mean
chromosome number of 78 (range 60-84). Probing with the
MSI and MS31 hypervariable minisatellite probes has shown
its DNA fingerprint to be different from that of other epithe-
lial tumour cell lines maintained in this laboratory - Caski,
A431 and Bowes melanoma. A series of subcutaneous and
intraperitoneal xenografts in nude mice show a moderately
differentiated adenosquamous carcinoma very similar to the
original tumour. At EM level, desmosomes and tonofila-
ments were demonstrated. The subcutaneous xenografts
showed local invasion into host muscle and blood vessels, as
well as perineural invasion. In an initial group of nude mice,
1-5 x 104 XH1 cells were injected intravenously into the tail
vein of 8-week-old nude mice. Two animals which died soon
after injection were shown to have tumour cells in the right
ventricle and in small blood vessels in the lungs. No tumours
were seen in the rest up to 76 days after intravenous injec-
tion. In a more recent experiment, 5 x 104 cells were injected,
and in one of the 6-week-old mice small nodules of tumour
were seen in the lung parenchyma 23 days after injection.
Elsewhere, small organized and endothelialized nodules or
tiny calcified bodies were seen within pulmonary vessels.
These are interpreted as the sites of lodgement of tumour
cells which did not survive, or failed to become established.
We have also raised monoclonal antibodies to whole XH1
cells in BALB/c mice using the P3X63Ag8.653 mouse mye-
loma cell line. Two of them, TDM35 and TDM39, have been
cloned. These antibodies stain formalin-fixed paraffin-embed-
ded tissue sections using an ABC immunoperoxidase method.
They show a marked quantitative difference in staining inten-
sity between normal and dysplastic or frankly malignant
cervical epithelium. The antibodies are being evaluated on a
wide variety of normal and neoplastic tissues.
The derivation and characterization of a gastrin-producing
adenocarcinoma cell line and its response to the anti-secretory
agent, SMS-201-995
S.A. Watson', A.R. Hall', L.G. Durrant' & D.L. Morris2
'Cancer Research Campaign Laboratories, University of
Nottingham NG7 2RD; and 2Department of Surgery,
University Hospital, Nottingham NG7 2UH, UK.
MKN45, a human gastric adenocarcinoma cell line is gastrin-
17 (G17) responsive both in vitro and in vivo. MKN45 xeno-
grafts which were trophically stimulated by G17 were
selected to develop a highly G17-sensitive xenograft line.
Upon successive passages, the selected line became unrespon-
sive to G17, yet its basal growth rate had doubled. This line
was denoted MKN45G. Examination by immunohistology
and flow cytometry revealed that MKN45G had intracellular
gastrin-like immunoreactivity (as detected with a rabbit anti-
G17 polyclonal) in 70 to 80% of cells which could be elimin-
ated by pre-absorbing the polyclonal with G17. This was not
detected in the parental line. Further analysis showed that
the 2 cell lines were 98% epithelial in origin (detection with
an anti-cytokeratin) and both were positive for PGP 9.5, a
polyclonal which detects neuroendocrine function. MKN45G
was highly positive for CEA (80-90% of cells positive)
unlike MKN45 (<5% cells positive). With respect to recep-
tor expression (as measured by binding of radioligands), both
cell lines were positive for gastrin receptors (MKN45:3 x 103,
MKN45G:2 x 103/cell). However MKN45G expressed more
insulin-like growth factor I receptors than MKN45 (MKN45:
3 x 102, MKN45G:2.6 x 103/cell). Both cell lines expressed
SMS-201-995 binding sites. However, in vivo therapy of
MKN45G and MKN45 xenografts with pumped SMS-201-
995 (25pgkg-' daily) resulted in reduced tumour growth
with the former xenografts (P<0.001 after 13 days therapy)
and no effect on the latter xenografts. We have now
identified gastric and colorectal tumour cells from primary
tumours with intracellular gastrin-like immunoreactivity
therefore somatostatin-like analogues may have therapeutic
potential.
Characteristics of newly developed tumour cell line
A.M.E. Nouri', A. Bergbaum3, E. Lederer2 & R.T.D. Oliver'
Departments of 'Medical Oncology & 2Immunology, London
Hospital; and 3Department of Cytogenics, Guy's Hospital,
London, UK.
A tumour cell line designated CAT derived from a patient
with invasive (PT2aG3) transitional cell carcinoma (TCC) of
bladder has been in culture for more than 18 months and
been sub-cultured more than 100 times. The pattern of pro-
liferation (doubling time about 36 hours) of these cells
indicates their metabolically active nature. Epithelial origin
of the cell line was established using whole range of mono-
clonal antibodies (Mab) and electromicroscopic examination.
In parallel, 'Tumour Infiltrating Lymphocytes' (TIL) were
isolated from the original tumour tissue and were expanded
in conditioned medium plus interleukin-2, expressing all the
phenotypic characteristics of normal activated T cells. Bio-
chemical analysis of cell surface molecules of the TIL and
CAT cells revealed the loss of HLA-B44, B7 and Bw6 from
the CAT cells whilst maintaining other class I antigens in-
cluding HLA-Bw4, A2 and A3. No such losses were observed
on TIL. Karyotypic analysis of TIL and CAT cell revealed
the presence of three rearranged chromosomes (4, 11 and 13)
only in the case of CAT cells. Oncogene activation studies
showed no H-ras, Ki-ras or N-ras activation in TIL or CAT
cells. These results are indicative of the presence of activated
T cells at tumour site and are consistent with the suggestion
that they might have become activated in response to puta-
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of these activated T cells to inhibit tumour progression how-
ever, may be due to the loss of class I antigens from the
tumour cells rendering them resistant to killing by cytolytic T
cells.
Inhibition of chemically-induced neoplastic transformation in
vitro by saturated fatty acids
M.J. Embleton
Cancer Research Campaign Laboratories, University of
Nottingham, University Park, Nottingham NG7 2RD, UK.
Exogenous fatty acids can modify tumour cell growth in vitro
and in vivo, and it has been reported that stearic acid and
its analogues can suppress chemical carcinogenesis in vivo
(Habib et al. (1987), Br. J. Cancer, 56, 455). In an attempt to
determine whether this suppressive effect operates preferen-
tially at particular stages of a multistep process, the effect
of stearic acid (SA) analogues was tested at multiple points
in an in vitro transformation system using Syrian hamster
embryo cells. Primary cultures of 12-day embryo fibroblasts
were treated for 2-4 days with 0.5j.g ml-' 3-methylchol-
anthrene (MCA), and 28 days after application of the carcin-
ogen they were exposed continuously to 0.1 Lg ml-' 12-0-
tetradecanoylphorbol 13-acetate (TPA). Untreated cells, or
cells treated with MCA or TPA alone, generally became
sensecent around 6-8 weeks after plating and died, but
cultures treated with both MCA and TPA developed foci of
immortalized cells which progressed to yield classically trans-
formed cells capable of growth in soft agar. Methoxy- and
keto- derivatives of SA inhibited immortalization and trans-
formation at concentrations of 50 and 100tLM, and iodo-SA
was inhibitory at 100 and 200gM. The compounds were
equally active when applied before, during or after MCA,
and before or during TPA treatment. They were thus not
selective for phases involving cellular interaction with MCA
(initiation) or TPA (promotion). Their action appears to be
associated with control of growth or differentiation in a
relatively non-specific manner.
Inhibition of growth of carcinoma cells by inhibitors of
5-lipoxygenase
A. Richter', C. Robinson2, D. Davies' & P. Alexander'
Departments of 'Medical Oncology and 2Clinical
Pharmacology, The University of Southampton, Southampton
General Hospital, S09 4XY, UK.
Concomitant with the stimulation of DNA synthesis by poly-
peptide growth factors, release of arachidonic acid and its
metabolites to prostaglandins and leukotrienes, has been
observed. Products of 5-lipoxygenase (5LPO), such as LTB4
as well as other leukotrienes were found by Palmberg et al.
(1987, J. Cell Sci., 88, 151), to stimulate the initiation of
DNA synthesis in cultured smooth muscle cells at pM con-
centration. We examined the antiproliferative activities of
inhibitors of 5LPO in two systems. Contact inhibited human
foreskin fibroblasts (HFF1), which had undergone only
limited passage, increased incorporation of thymidine (or
125 IUdR used for experimental convenience) by more than
20-fold on exposure to EGF. The 5LPO inhibitors, U-66,858
and AA861 inhibited initiation of DNA synthesis in a dose
dependent manner (50% inhibition at approximately 10-s
M). An antagonist (Ly 171,883) of LTD4 and LTE4 was
inactive, as was the powerful and selective cyclooxygenase
inhibitor, flurbiprofen. The same pattern of activity was also
seen in a proliferation assay in which cells are grown in
medium with 10% serum. The inhibition of proliferation of
HFF1 cells was compared with three carcinoma cell lines,
HT29, A431 and HN5, which express EGF receptors and
produce TGFa. Growth of the carcinoma cells was arrested
by both of the 5LPO inhibitors with a LDio of about
3 x 10- M, whereas HFF1 was significantly more resistant.
Flurbiprofen and the LTD4 and LTE4 antagonist were much
less active. None of the compounds studied affected EGF
receptors. We suggest that certain of the leukotrienes formed
in response to stimulation of EGF receptors contribute to the
mitogenic action of EGF and TGFa. A role for LTB4 in
tumour growth was suggested by El-Hakin et al. (1989, Br. J.
Cancer, 59, 833) who found the concentration of LTB4 in
human squamous cell carcinomas to be 10 times higher than
in unaffected surrounding tissues.
Utility ofprimary cells transformed by collaborating oncogenes
for in vitro antitumour drug assay
E. Rapson, D. Linstead, R. Skinner, L. Holmes, J. Stables,
P. Topley, D. Jenkins & J. Wilkinson
Department of Molecular Sciences, Wellcome Research
Laboratories, Beckenham, Kent BR3 3BS, UK.
There is considerable interest in developing new anticancer
agents which would be more specific for transformed cells in
their action, and thus sparing of normal tissue. Problems
arise in the choice of in vitro assays for the search for such
agents. Ideally such assays should employ cell lines trans-
formed by well defined processes against which new more
specific drugs can be directed, as a preliminary to validating
these processes as targets in naturally occuring tumours. An
approach to the creation of suitable cell lines is the transfor-
mation of non-malignant cells by transfection of known
oncogenes. We have generated a number of transformed cell
lines by transfection of the ras oncogene, and the E7 gene
from human papilloma virus type 16 together into baby rat
kidney primary cells using both constitutive and inducible
expression vectors. We report on the characterization and
dependence upon oncogene expression of these cells and their
possible use for drug assay.
Interactions of adriamycin with human erythrocyte
inositol-lipid metabolism
M.G. Thompson & J.A. Hickman
Cancer Research Campaign Experimental Chemotherapy
Group, Pharmaceutical Sciences Institute, Aston University,
Birmingham B4 7ET, UK.
The aminoglycoside antibiotic adriamycin is a potent anti-
tumour drug in humans and there is evidence to suggest that
it may exert its effects via the plasma membrane. We have
previously shown that, at relatively high concentrations,
adriamycin (10-- 10-3 M) inhibits inositol-lipid metabolism
in human erythrocytes and this may contribute to its antipro-
liferative effects (1987, Cancer Res., 47, 2797). However, at
low concentrations, adriamycin (10-9 M) has been shown to
stimulate cell growth (1989, Cancer Res., 49, 2679), suggest-
ing that it may stimulate inositol-lipid metabolism. We have
recently found that similar concentrations of adriamycin
elevate inositol 1,4,5-trisphosphate levels in human erythro-
cyte vesicles. However, there was no significant decrease in
phosphatidylinositol 4,5-bis-phosphate levels in response to
adriamycin suggesting that stimulated breakdown of this
lipid may not be the reason for elevated levels of inositol
1,4,5-trisphosphate. In addition, the human erythrocyte con-
tains a 5'-phosphomonoesterase which degrades inositol
1,4,5-trisphosphate to inositol 1,4-bisphosphate. A time-
course of inositol 1,4,5-trisphosphate dephosphorylation
showed that the effect of the 5'-phosphomonoesterase was
decreased in the presence of adriamycin. This suggests that
adriamycin may produce elevated levels of inositol 1,4,5-
trisphosphate in human erythrocyte vesicles by inhibiting
inositol 1,4,5-trisphosphate breakdown rather than by stimu-
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An investigation of the mechanism by which the ether lipid SRI
62-834 raises intracellular calcium concentration in HL-60
leukaemia cells
C.M Lazenby, C. Dive, M.G. Thompson & J.A. Hickman
Cancer Research Campaign Experimental Chemotherapy
Group, Pharmaceutical Sciences Institute, Aston University,
Birmingham B4 7ET, UK.
We have previously shown that the membrane active antineo-
plastic ether lipid SRI 62-834 produces a concentration-
dependent rise in cytosolic free Ca2" [Ca2+]i in Quin-2 loaded
HL-60 human promyelocytic leukaemic cells (Thompson &
Hickman (1988), Biochem. Soc. Trans., 16, 278). The aim of
this study was to define the nature of this rise in [Ca^2]i. SRI
62-834 induced a [Ca2"]i rise in Indo-l loaded HL-60 cells
which was biphasic as opposed to that produced by triton
(0.01%) which was monophasic and immediate. A purely
detergent effect is therefore unlikely to be involved. Inclusion
of Mn2+ (known to quench the fluorescence of Indo-1) in the
incubation buffer resulted in the quenching of the second
phase of the SRI 62-834 induced [Ca2+]i response. This
indicated that this component of the response was due to the
influx of extracellular Ca2 . We have also compared the
effects of SRI 62-834 on HL-60 [Ca2+]i with that produced
by the naturally occurring and chemically similar ether lipid
platelet activating factor (PAF). PAF like SRI 62-834 pro-
duced a rise in [Ca2+]i. Although the HL-60 response to SRI
62-834 involves Ca2+ movement across the plasma memb-
rane, it does not appear, however, to be mediated via a high
affinity PAF receptor as PAF antagonists [500fAM] failed to
inhibit the response.
Expression of the c-erbB-2 (neu) oncogene in bladder cancer
K. Mellon', D.E. Neal', C. Wright2, P. Johnston2,
I.P. Corbett2 & C.H.W. Horne2
'Urology Department, Freeman Hospital, Newcastle upon
Tyne NE7 7DN and 2University Department of Pathology,
University of Newcastle upon Tyne, UK.
The proto-oncogene c-erbB-2(neu) encodes a transmembrane
glycoprotein which is similar to the epidermal growth factor
receptor (EGFr). Amplification of the c-erbB-2 gene and
overexpression of its protein product have been reported
mainly in adenocarcinomas arising in various sites and in
breast cancer are associated with a poor prognosis. We have
studied expression of the c-erbB-2 oncoprotein in bladder
cancer. Frozen sections from 45 primary transitional cell
carcinomas of the bladder (29M, 16F; age = 70 + / - 10 yrs;
pTa + Tl = 24, pT2 + pT3 + pT4 = 21; 25 = Grade 2 and
20 = Grade 3) were stained immunohistochemically using a
monoclonal antibody (CB-I 1) against a synthetic peptide
representing residues close to the C-terminus of the predicted
oncoprotein sequence. Tumours were scored for both stain-
ing intensity [0, weak ( + ) or strong ( + + )] and proportion
of tumour cells staining. Seventeen (38%) tumours showed
evidence of positive staining; 5 tumours showed areas of
strong positive staining (4 muscle invasive tumours and 1
pTaG2 which rapidly progressed). Weak positive staining
was noted in a further 4 muscle invasive tumours and in 8
superficial tumours. The c-erbB-2 oncoprotein has been dem-
onstrated in a significant proportion of bladder cancers. The
relationship between its expression, EGFr status and other
risk factors may provide important prognostic information.
Analysis of phorbol ester (PE) binding to protein kinase C
(PKC) using the novel fluorophore bodipy-3-PE and
multi-parameter flow cytometry (FCM)
T.D. Bradshaw, C. Dive & A. Gescher
Cancer Research Campaign Experimental Chemotherapy
Laboratory, Pharmaceutical Sciences Institute, Aston
University, Birmingham B4 7ET, UK.
PKC plays a critical role in cell signalling pathways. We
describe a new method to measure PKC levels in individual
viable cells using a fluorescently tagged PE and FCM. A549
human lung carcinoma cells (106 ml-') were incubated for 10
minutes with 10 nM Bodipy-3-PE ± 5gM unlabelled PE to
determine non-specific binding. Propidium iodide (32gM)
was added immediately before analysis allowing exclusion of
non-viable cells. Ten thousand cells were analysed per sample
with respect to 900 light scatter (a measure of cell size), red
fluorescence (propidium>630 nM) and green fluorescence
(Bodipy-3-PE, 515-560 nM) using a FACS 440 instrument
with argon laser excitation at 488 nM. In competitive binding
studies, cells were co-incubated with increasing concentra-
tions of 12-O-tetradecanoylphorbol-13-acetate (TPA). Dose-
dependent reduction in green fluorescence of 44%-13% was
observed compared to control values with 0.1 nM-I00 nM
TPA respectively. In cells incubated overnight with 10 nM
TPA, an 83% decrease in Bodipy-3-PE binding was seen
suggestive of PKC downregulation. Moreover, in cells culti-
vated in the continuous presence of TPA (10 nM), negligible
specific Bodipy-3-PE binding was detected. These results
agree with those of radiochemical methods of PKC assay.
This new assay is rapid, sensitive and will reveal hetero-
geneity in PKC levels within mixed cell populations. In addi-
tion, it can be combined simultaneously with the assay of
other pertinent cellular parameters such as Ca2+ flux. We are
currently using this assay to explore the competitive nature
of bryostatin binding to the PE receptors.
An automated system for the determination of nucleolar
organizer regions in breast carcinoma
D.J. Hehir, A.M. Seifalian & S.P. Parbhoo
Academic Department ofSurgery, Royal Free Hospital School
of Medicine, London NW3 2QG.
Nucleolar organizer regions (Ag-NOR's) are loops of DNA
with ribosomal genes (Fakan & Hernandez-Verdun (1986),
Bio. Cell, 56, 189). They are useful markers of cellular proli-
ferative activity, and have been used to indicate prognosis
(Ploton et al., (1986), Histochem. J., 18, 5). Ag-NORs are
difficult to quantify, however, owing to subjective bias, pro-
longed counting time, and inter-observer variation. To over-
come this problem, we have used a computerized system to
measure Ag-NORs in archival tissues of patients with breast
carcinomas. Eleven silver-stained histology slides were digit-
ized using a video camera interfaced to a microcomputer,
and for each digitized image 3 different area sizes were
selected. Images were transferred to a Sun workstation, pro-
cessed automatically, and also counted manually. The algo-
rithm for quantifying Ag-NORs is based on histograms of
grey values of preselected regions of interest. Quantitative
information of Ag-NOR counts was determined from the
histograms by fitting with a Gaussian function. A correlation
coefficient of 0.904 was determined for the two methods, and
the standard error of the differences in the two methods was
1.65. This computerized system is useful in determining Ag-
NORs, and therefore may assist in prognosis and therapy of
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Gene expression in oestrogen-dependent human breast cancer
xenograft tumours
A.M. Thompson"2, C.M. Steel2, M.E. Foster2, D.J. Kerr3,
R.A. Hawkins' & W.R. Miller'
'Department of Surgery, Royal Infirmary, Edinburgh
EH3 9YW; 2MRC Human Genetics Unit, Western General
Hospital, Edinburgh CH4 2XU; and 3Beatson Institute,
Garscube Estate, Switchback Road, Glasgow G61 IBD, UK.
Xenograft tumours have been established from the oestrogen-
dependent MCF-7 breast cancer cell line in thymectomized,
irradiated female CBA mice. With serial transplantation
there was evidence of increased tumorigenicity of trans-
planted material (P<0.04, Fisher's exact test), and an
altered pattern of gene expression compared to the original
cells. However, oestrogen-dependence was retained. Follow-
ing injection of the mice with oestrogen, there was an in-
crease in DNA synthesis and mitosis was stimulated with
consequent increase in tumour growth. Laser densitometry
was used to quantify mRNA on Northern blots and showed
that with oestrogen stimulation, c-myc, p53 and pS2 gene
expression was increased whereas TGF-beta expression was
suppressed. This xenograft system demonstrates changes in
gene transcription in response to oestrogen. It thus provides
an in vivo model for molecular and biochemical studies of
hormone-sensitive human breast cancer.
Growth factor and epidermal growth factor receptor expression
in gastric carcinoma
I.M. Paterson', Y, Luqmani2, C. Bennett2
& C.M. Corbishley3
Departments of 'Surgery, 2Oncology and 3Histopathology,
St George's Hospital, London SW17 ORE, UK.
Polypeptide growth factors (GF) may be important in the
development of some tumours but it has not been established
whether they might have a role in the pathogenesis of gastric
carcinoma. The expression of genes encoding Transforming
Growth Factors (TGF) alpha and beta, Platelet Derived
Growth Factors A and B, Insulin-like Growth Factor II and
Epidermal Growth Factor Receptor (EGFR) was examined
by RNA hybridization in benign and malignant gastric tissue
from 22 patients. All the GFs and EGFR were produced in
increased amounts by the gastric carcinoma compared to
benign gastric epithelium (P<0.05). The transcripts were
widely expressed and at least 2 were present in every sample
analyzed. Co-expression of TGF alpha and EGFR was
found in 15 malignant but only 6 benign specimens raising
the possibility of autocrine stimulation in the neoplasms. No
correlation was found between GF expression and tumour
stage or patient survival. GFs may mediate various inflam-
matory processes but no evidence of increased production
was found in 8 specimens demonstrating superficial gastritis
and characterized by a marked inflammatory infiltrate. The
finding of increased GF production by gastric carcinomas
may have therapeutic implications.
The influence of calcium supplementation on experimental
ileo-colonic hyperplasia and carcinogen-induced neoplasia in
the rat
assessed the influence of dietary calcium supplementation
(25 g Ca lactate 1' 24 h-') compared to normal chow on
cellular proliferation and tumour formation in Wistar rats
after 75% small bowel resection and dimethylhydrazine
(DMH 40 mg kg-' for 5 weeks) administration compared
with controls. Cellular proliferation was assessed by an in
vivo stathmokinetic method. SBR (P<0.01 ANOVA: repeat-
ed measures), DMH (P<0.01) and SBR + DMH (P<0.01)
produced a significant increase in cellular proliferation.
Calcium supplementation had no influence on normal cellu-
lar proliferation but produced a significant reduction in
ileal (P<0.02), caecal (P<0.01) and colonic proliferation
(P<0.01) after SBR, DMH and SBR + DMH. Calcium sup-
plements also produced a significant reduction in tumour
(P<0.05) yield in the DMH group but not in the DMH
+ SBR group. This study supports the concept that calcium
supplementation reduces colonic cellular proliferation, but
may not reduce the incidence of neoplasia. As the effect is
similar after both SBR and DMH administration, the
mechanism is likely to be due to both binding of cancer
promoting agents and inhibition of tumour initiation by a
direct action on the cell membrane.
Control 30 DMH 30 SBR 30 SBR + DMH
"Ca + Ca °Ca +Ca "Ca + Ca °Ca + Ca
Ileum 13 12 35 17 27 21 35 21
Caecum 5 7 13 4 11 7 15 7
Colon 6 3 17 5 19 8 16 7
Colon tumours 0 0 13 5 0 0 9 14
The influence of small bowel resection on hydrazine-induced
carcinogenesis in an animal model of colorectal cancer
G. Barsoum, M. Winslet, A. Kappas & M.R.B. Keighley
Academic Department of Surgery, Queen Elizabeth Hospital,
Birmingham, UK.
Subcutaneous dimethylhydrazine (DMH) administration in
the rat is an established method of producing experimental
colonic carcinoma. Colonic hyperplasia after small bowel
resection may promote such carcinogenesis. This study
assessed the influence of 75% mid small bowel resection and
DMH administration (40 mg kg-' for 5 weeks) for 10 and 30
weeks on ileal, caecal and colonic cellular proliferation and
macroscopic tumour formation in the Wistar rat, compared
with controls. The crypt cell production rate (CCPR) (cells/
crypt/h) was assessed by an in vivo stathmokinetic method.
The CCPR at the 3 different sites was significantly different
at 10 and 30 weeks (P<0.01 ANOVA: repeated measures).
The influence of DMH on CCPR was significant in all 3
areas only at 30 weeks (P<0.01). SBR produced a signi-
ficant increase in the ileum and colon at 10 weeks (P<0.01)
and all 3 areas at 30 weeks (P<0.01). Simultaneous SBR
failed to increase cellular proliferation or macroscopic
tumour yield in the DMH model. DMH probably produces
neoplasia by a direct and systemic action. SBR produces
hyperplasia by luminal and hormonal mechanism. As SBR
+ DMH failed to increase tumour yeild it suggests that
hyperplasia does not increase susceptibility to malignant
change by solely increasing the population of at risk malig-
nant cells or rapidly perpetuating any mutational change.
G. Barsoum, M. Winslet, J.P. Neotolemos
& M.R.B. Keighley
Academic Department of Surgery, Queen Elizabeth Hospital,
Birmingham, UK.
Oral calcium supplementation may reduce the colonic prolif-
erative index in patients with colorectal cancer. This study
Control
10
CCPR Result (n = 8)
Ileum 35
Caecum 19
Colon 9
Colon tumours
DMH Control DMH SBR
10 SBRI 30 30 30
(n = 8) (n = 8) (n = 6) (n = 6) (n = 6)
45 66 13 35 27
21 21 5 13 1 1
9 15 6 17 19
0 12
DMH+
SBR 30
(n = 6)
35
15
16
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The relationship between ileo-colonic cellular proliferation and
tumour formation in an animal model of colorectal cancer
G. Barsoum, M. Winslet, D. Youngs & M.R.B. Keighley
Academic Department of Surgery, The Queen Elizabeth,
Birmingham, UK.
Dimethylhydrazine (DMH) administration in the rat results
in an increase in colorectal cellular proliferation and macro-
scopic tumour formation. The influence of such a stimulus on
simultaneous small bowel and caecal cell turnover is poorly
documented. This study assessed the effect of DMH adminis-
tration (40 mg kg' body weight per week) for 5 weeks on
simultaneous ileal, caecal and rectal cellular proliferation and
macroscopic tumour formation at 15 (DMH15 = 22) and 30
weeks (DMH30 = 22) in the Wistar rat, compared with con-
trols (C). CCPR (cells/crypt/h ± SEM) was assessed by an in
vivo stathmokinetic method with vincristine-induced meta-
phase arrest.
ILEUM CAECUM (Left) COLON
Weeks CCPR Tumour CCPR Tumour CCPR Tumour
C15 20.9±1.5a 0 11.2±6.4b 0 5.2±0.4c 0
DMH15 25.9±2.9 0 12.4±0.7 0 6.7±0.7 0
C30 9.10.6ad 0 4.7±0.5be 0 3.9+0c.f 0
DMH30 16.6+ 1.8ad 0 9.6± 1.6b.e 0 9.3+ ±1. f 139
a,b,c,d,e,f: P = 0.05 ANOVA with linear regression in groups.
g: P<0.05 x2, compared to ileum and caecum.
This study confirms that CCPR decreased with age. DMH
administration produced an increase in CCPR at 30 weeks
only, in both ileal and colonic mucosa. Despite the fact that
the caecum contains large bowel mucosa, with carcinogenesis
it acts like small bowel. As in the human condition, tumour
formation predominantly occurs in the left colon. This sug-
gests that tumour formation in the rat model is dependent on
luminal factors as well as DMH-induced cellular hyper-pro-
liferation.
EGF and TGF-B act as markers of tumour progression in
experimental oral carcinogenesis
S.M. Game, A. Stone, C. Scully & S.S. Prime
University Department of Oral Medicine, Surgery and
Pathology, Bristol Dental Hospital, Bristol BS] 2IY, UK.
This study examined the expression of EGF and TGF-P cell
surface receptors, and the growth response to these factors,
in oral keratinocyte cell lines that reflected tumour progres-
sion in the rat-4NQO model of oral carcinogenesis. Tumour
progression was expressed in terms of cellular immortality,
anchorage independence and tumorigenicity. The expression
of cell surface receptors was measured in radio-ligand bind-
ing assays and the response to growth factors by tritiated
thymidine incorporation studies. Keratinocytes from 4NQO-
treated tissues had predominantly fewer EGF and TGF-P
receptors than normal controls. Whilst the expression of
TGF-P receptors was unrelated to anchorage independence
and tumorigenicity, the expression of high affinity EGF
receptors paralleled the emergence of both the anchorage
independent and tumorigenic phenotype. Normal
keratinocytes were stimulated and inhibited, in a dose-
dependent manner, by EGF and TGF-P respectively. By
contrast, studies with immortal/anchorage dependent/non-
tumorigenic and immortal/anchorage independent/
tumorigenic cells demonstrated a progressive independence of
growth factor control. The results suggest that the responses
to EGF and TGF-4, and the expression of cell surface recep-
tors, may be useful markers of the premalignant epithelial
phenotype in the rat-4NQO model of oral carcinogenesis.
An in vitro model of tumour progression in human colorectal
carcinogenesis
A.C. Williams, S. Harper & C. Paraskeva
Department of Pathology, The Medical School, University of
Bristol, University Walk, Bristol BS8 ITD, UK.
To study tumour progression in human colorectal carcino-
genesis, the premalignant human colonic PC/AA adenoma
cell line (Paraskeva et al. (1984), Int. J. Cancer) was trans-
formed in multiple steps towards the malignant phenotype. A
rare clonogenic variant of PC/AA was isolated (AA/Cl)
which, when treated for 14 days with 1 mM of the different-
iating agent sodium butyrate, gave rise to a cell line with
a greater than four-fold increase in colony forming efficiency
(CFE). This anchorage dependent cell line was designated
AA/Cl/SB. On exposure to the carcinogen N-Methyl-N-
Nitro-Nitrosoguanidine (MNG) these cells became anchorage
independent. The resulting cell line was designated AA/Cl/
SB1O. AA/Cl cells treated with the carcinogen alone did not
become anchorage independent. On continuous in vitro pas-
sage, the CFE in agarose of AA/Cl/SB10 has so far in-
creased from 0.16% to 17.3% and the cells have become
tumorigenic, producing moderate to well differentiated
adenocarcinomas in nude mice. AA/Cl, AA/C1/SB and AA/
Cl/SBIO cell lines have common chromosomal abnormalities
which include a deleted chromosome lp, and possible abnor-
malities in chromosomes 17 and/or 18. This in vitro progres-
sion provides the first reported experimental evidence for the
adenoma to carcinoma sequence in human colorectal epithe-
lial cells. Experiments are in progress to investigate allele loss
using polymorphic probes to chromosomes implicated in col-
onic carcinogenesis. The molecular characterization of cells
with different malignant potentials may enable the isolation
of tumour suppressor gene(s).
Expression of PS2 in human stomach
Y.A. Luqmani', C. Bennett', I. Paterson', C. Corbishley',
M.C. Rio2, P. Chambon2 & G. Ryall'
'Medical Oncology, St George's Hospital Medical School,
London SW17 ORE, UK; and 2LGME/CNRS and
U.184/INSERM, Faculte de Medicine, 67085 Strasbourg,
France.
The oestrogen-induced breast cancer related pS2 has been
found to be synthesized and secreted from human stomach
(Rio et al. (1988), Science, 241, 705). We examined its expres-
sion in 75 samples of normal, hyperplastic and malignant
resections, and noted marked differences. Varying transcript
levels were seen in the non-neoplastic groups, with very high
levels in 79% of tissues with gastritis. Only 43% of tumours
were + ve, and high levels seen in only 18%; there was no
correlation to age grading, stage or site, or to expression of
several growth factors. pS2 protein was localized immuno-
cytochemically, to epithelia in the neck region of antral and
body glands, in luminal secretions and in sub-nuclear regions
of foveolar cells. Both dysplastic epithelium and tumour cells
were heterogeneously stained. Immunocytochemically, oes-
trogen receptor was undetectable in 30 tissues examined or in
5 cell lines, two of which expressed pS2. A BamH1 polymor-
phism was observed in KATO III and MKN-28 cells. Thus
pS2 expression, which may be associated with normal gastric
secretory activity, is reduced in malignancy but is high during
non-neoplastic hyperplasia, in complete contrast with its
mode of expression in the breast. The pS2 protein sequence
bears similarities to the pancreatic spasmolytic polypeptide
and both contain a PRO-Tryp-Cys-Phe sequence found only
in the Kringle domain of fibrinolytic proteases, leading to
suggestions ofcommon ancestral origins. So far no biological
activity has been assigned to either the Kringles or to pS2.BRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS 541
Detection by 32P-postlabelling of DNA adducts in the upper
gastrointestinal tract of patients with familial adenomatous
polyposis
A.D. Spigelman', R.K.S. Phillips', D. Scates2 & S. Venitt2
'St Mark's Hospital & Professorial Surgical Unit,
St Bartholomew's Hospital, London, UK; and 2Institute of
Cancer Research, Royal Marsden Hospital, Sutton, Surrey,
UK.
Duodenal adenomas occur almost inevitably in patients with
familial adenomatous polyposis (FAP) whereas gastric aden-
omas are rare. FAP patients are also at high risk of duodenal
cancer. Adenomas and most duodenal cancers cluster around
the ampulla of Vater, suggesting that bile plays a role in
tumour development (Spigelman et al. (1989), Lancet, ii,
783). To test the hypothesis that duodenal tissue in FAP is
exposed to DNA-reactive substances we used 32P-postlabel-
ling to determine adduct levels in DNA from duodenal biop-
sies from 25 controls and 39 FAP patients. The table shows
relative adduct labelling (RAL) of duodenal DNA from con-
trols and FAP patients, grouped by smoking habit.
Controls FAPpatients
Smokers No[A] Yes[B] No[C] Yes[D]
Number 15 10 24 15
RAL values (adducts/109 nucleotides)
Mean 10.1 9.9 30.8 41.5
Median 6.0 10.0 13.0 26.0
Range 0-35 0-29 0-162 3-109
Mann-Whitney 1-tailed P-values: BtA, 0.412; D>C, 0.033; C>A,
0.027; D>B, 0.0014.
Duodenal DNA from FAP patients had significantly higher
adduct levels than DNA from controls. FAP patients who
smoked had significantly higher DNA-adduct levels than
those who did not smoke. These results indicate that duo-
denal DNA from patients at high risk of duodenal neoplasia
carries a higher burden of DNA adducts than DNA from
normal subjects, and that smoking appears to increase this
load. The identity of duodenal DNA-adducts is at present
unknown, as is the nature and origin of the substances
involved in their formation. However, we suggest that bile is
the most likely source, although pancreatic juice must also be
considered, bearing in mind its route of secretion. DNA
damage caused by high adduct levels in DNA may contribute
to the genesis of duodenal neoplasia in FAP by causing loss,
inactivation or mutation of the tumour-suppressor gene
thought to be associated with this precancerous condition.
Production of extracellular matrix degrading enzymes by
human and rat bladder cancer cell lines in vitro
C.A. Parry & J. Chowaniec
Department of Histopathology, U.C.M.S.M., London
WIP 7LD, UK.
Synthesis of extracellular matrix-degrading enzymes, partic-
ularly the metalloproteinases, has been shown to play a
major role in tumour invasion (Liotta et al. (1988), Breast
Ca. Res. Treat., 11, 113). We are currently investigating the
secretion of metalloproteinases by a range of human and rat
bladder cancer cell lines, EJ, T24, RTI 12, RT4 and RU-CL2,
the in vivo growth potential, i.e., tumorigenicity, invasive and
metastatic behaviour of which have been characterized pre-
viously in nude and/or immune-suppressed mice (Masters et
al. (1986), Cancer Res., 46, 3630; Joy et al. (1989), Br. J.
Cancer, 60, 493) as well as their growth in vitro (Marshall et
al. (1977), J. Nati. Cancer Inst., 58, 1743; Parry et al. (1990),
J. Pathol., in press). Serum-free media conditioned by cul-
tures ofcells in the exponential growth phase were concentra-
ted using Amicon concentrators. Samples were then assayed
for the presence of proteins using SDS polyacrylamide gel
electrophoresis under non-reducing conditions. Irrespective of
their species of origin or invasive/non-invasive behaviour in
vivo, all cell lines secreted proteins with approximate mole-
cular weights (MWs) of 74 kDa and 56 kDa. These values
are close to those published for the MWs of type IV colla-
genase, vertebrate collagenase and stromelysin, as well as for
plasminogen activating factors (Alexander & Werb (1989),
Curr. Opin. Cell Biol., 1, 974) and the putative autocrine
motility factor (AMF) proposed as a marker for invasive
bladder cancer (Guirguis et al. (1988), J. Natl Cancer Inst.,
80, 1203). Specific characterization of these two protein
bands is now in progress, using electrophoresis of appropri-
ate polyacrylamide substrate gels.
The influence of the extraceliular matrix on the growth,
differentiation and chemosensitivity of HT29 human colon
adenocarcinoma cells
J.A. Gummer, K.M.S. Townsend, S.P. Langdon
& J.A. Hickman
Cancer Research Campaign Experimental Chemotherapy
Group, Pharmaceutical Sciences Institute, Aston University,
Birmingham B4 7ET, UK.
Epithelial cells grow with a unique morphological polariza-
tion which is essential for their functional properties. HT29
cells grown on plastic substrata are characteristically anaplas-
tic: the conditions of growth dictate against the development
of functional polarity. When HT29 cells were implanted to
the flank of immunodeficient mice they formed relatively well
differentiated tumours exhibiting typical epithelial charac-
teristics. We have subcultured HT29 cells for at least 10
passages on collagen rafts - either on plastic or floating in
media. These cells exhibited tight junctions and microvilli,
with a degree of polarization that was comparable with the
xenografted tumour. The expression of the brush-border
associated enzyme alkaline phosphatase was greater in these
cells (Day 12 values were 125, 182 and 82pM productmg-'
protein for non-released collagen gels, released collagen gels
and plastic respectively). There was an increase in the lag
phase of growth when cells grown on collagen were com-
pared to cells grown on plastic, but the exponential growth
rate was unchanged. Although cells grown on collagen gels
would appear to be morphologically and possibly function-
ally more differentiated than those growing on plastic sub-
strata, we have shown that their chemosensitivity and
clonogenicity to a range of standard cytotoxic agents was
essentially unaltered. However, this system may represent an
interesting model for in vitro studies of carcinoma cell
biology and pharmacology.
Neural cell adhesion molecular expression in human embryonic
and brain tumours
K. Patel, S. Bourne, H.B. Coakham & J.T. Kemshead
ICRF Paediatric & Neuro-Oncology Group, Frenchay
Hospital, Frenchay, Bristol BS16 ILE, UK.
Neural cell adhesion molecules (NCAMs) are a family of
glycoproteins believed to play an important role during
development of the nervous system. A number of isoforms
are generated through alternative splicing of mRNA tran-
scribed from a single gene and through post-translational
modification of the primary protein product. The expression
of these isoforms is temporally and developmentally regu-
lated. In addition, recent evidence suggests that tissue-specific
NCAMs arise through insertion/deletion of short nucleotide
sequences coded for by mini-exons. Recently, we have shown
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different epitopes on NCAM. This has led to a detailed
investigation of NCAM expression in human embryonic and
brain tumours since information in this important area of
research is lacking. Northern blot analysis shows that neuro-
blastoma cell lines express predominantly 6.7 and 5.5 kb
mRNA transcripts, whereas fetal brain expressed 7.4, 6.7,
5.5, 4.3 and 2.9 kb transcripts. The significance of this obser-
vation is unclear at present. Western blot analysis of the
protein isoforms corroborates these findings. Changes in
NCAM were also noted during human brain development
and different areas of brain express different NCAM iso-
forms. Primary brain tumours also showed variability in
NCAM expression. We are currently investigating the pre-
sence/absence of mini-exons, which give rise to tissue-specific
NCAMs, in a variety of embryonic tumours, using the poly-
merase chain reaction.
Vitronectin receptor expression on melanocytes and malignant
melanoma cells
J.F. Marshall, M.H. Horton & I.R. Hart
Imperial Cancer Research Fund, Lincoln's Inn Fields, London
WC2A 3PX, UK.
The level of expression of the vitronectin receptor (VnR), a
member of the integrin family, has been investigated using a
panel of 9 human melanoma cell lines and 4 normal melan-
ocyte strains. The monoclonal antibodies, 13C2 and 23C6
were used in these studies (Davies et al. (1989), J. Cell. Biol.,
109, 1817). Both antibodies immunoprecipitated a hetero-
dimeric molecule of approximately 160kDa (a chain) and
95kDa (p chain) size whose varying levels of expression
correlated well with the ability of melanoma cells to adhere
to vitronectin and fibrinogen substrates. Flow cytometry and
immunoprecipitation analysis showed that considerably less
VnR was expressed by melanocytes than by most of their
transformed counterparts. Initial results suggest a correlation
between subcutaneous growth as xenografts in athymic nude
mice and the expression of higher levels of VnR suggesting
that interactions between this integrin and substrate mole-
cules may play a role in tumorigenesis. Staining of paraffin-
embedded sections of human melanoma with 13C2 antibody
showed that clinical material expressed high VnR levels.
These results suggest that up-regulation of VnR levels may
be associated with transformation of cells of the melanocyte
lineage.
Altered levels of expression of the gp9eHrh (lymphocyte
homing receptor) cell surface molecule in transformed
melanocytes
M. Birch, S. Mitchell & I.R. Hart
Imperial Cancer Research Fund, Lincoln's Inn Fields, London
WC2A 3PX, UK.
The CD44 antigen is a 90kDa cell surface glycoprotein
which appears to be identical to the lymphocyte homing
receptor recognized by the Hermes I and 3 antibodies. In-
creased expression of the CD44 antigen has been reported to
occur in carcinoma, but not normal epithelial, cells (Stamen-
kovic et al. (1989), Cell, 56, 1057). We have monitored the
expression of the gpgoHe"'es antigen on a panel of 9 human
melanoma cell lines and 6 strains of normal human melano-
cytes using CD44, Hermes 1 and Hermes 3 monoclonal
antibodies. Immunoprecipitation of surface iodinated cells
with all three antibodies revealed a 90 kDa band, indicating
that cells of the mclanocyte lineage express this receptor at
their cell surface. Normal melanocytes appeared to express
much lower levels of gp90HeO than melanoma cells and this
was confirmed by FACS and ELISA assays on viable and
fixed cells. Northern blot analysis of mRNA, which revealed
4.8, 2.5 and 1.5 kb transcripts, suggested that this upregula-
tion of surface glycoprotein associated with transformation
was a consequence of transcription. It is possible that
increased expression of CD44/gp90H`r` may facilitate mel-
anoma cell adherence and play a role in metastasis.
Changes in protein expression during melanoma differentiation
determined by computer analysis of 2-D gels
D. Easty', I.R. Hart', K. Patel2, C. Seymour2, M. Yacoub2,
A Domscheit3, S. Gunther3, W. Postel3, A. Gorg3
& M.J. Dunn2
'ICRF, Lincoln's Inn Fields, London, UK; 2Department of
Cardiothoracic Surgery, National Heart and Lung Institute,
London, UK; and 3Lehrstruhl fur Allgemeine Lebensmittel
Technologie, Technische Universitat, Munich, Germany.
Cytodifferentiation in many melanocytic cells is regulated
through the adenylate cyclase-cAMP pathway. To study
molecular changes associated with this process we have com-
pared the proteins produced by two closely related cell lines
which respond very differently to manipulation of this path-
way. The human melanoma DX3 shows little change in in
vitro characteristics following treatment with cAMP elevating
agents; in contrast the more malignant LT5.1 variant, derived
from the DX3 parental line, shows pronounced dendrifi-
cation, decreased proliferation and a reduction in metastatic
capacity after similar treatments. The two cell lines were
treated with phosphodiesterase inhibitors (I mM IBMX plus
I mM theophylline) for 5 days and then processed for 2-D gel
characterization using an immobilized pH gradient for
IEF. Proteins were detected by silver densitometer and PDQ-
scan software. 2-D gel patterns were matched and a mela-
noma protein data base of 637 spots constructed on an Orion
1/05 computer. Sixty-one proteins were downregulated in
both cell lines after treatment, whereas 30 new spots were
identified after treatment of DX3 cells and 52 new spots after
treatment of LT5.1 cells. The 22 novel proteins identified
may be associated with the observed changes in different-
iation patterns and metastasis. Our results illustrate the
resolving power of this technique and suggest potential ap-
plications to the study of cellular differentiation.
Isolation of a novel gene expressed differentially in human
melanoma lines of varying malignancy
D. Easty', C.J. Farr2, J. Rao' & I.R. Hart'
'Biology of Metastasis Laboratory and 2Human Molecular
Genetics Laboratory, ICRF, Lincoln's Inn Fields, London
WC2A 3PX, UK.
The rapid amplification of cDNA ends (RACE) procedure,
using as a primer an oligonucleotide sequence conserved in
genes encoding zinc-finger binding proteins, has been applied
to polyA+ mRNA derived from LT5.1, a human melanoma
cell line. Amplified cDNAs were ligated into a Bluescript
vector and 800 colonies were screened for differential hy-
bridization using as probes either cDNA prepared from un-
treated control cells or from cells which had been induced to
differentiate by treatment with phosphodiesterase inhibitors
(1 mM IBMX plus 1 mM theophylline). Northern blot
analysis was used to screen ten differentially hybridizing
clones and one ofthese BS35, was found to be upregulated in
the treated cell line (LT5.1) but not in the parental line
(DX-3) which was unaffected by treatment with phospho-
diesterase inhibitors. Southern blot revealed binding of BS35
to multiple bands, possibly suggesting it is one member of a
multigene family. Partial DNA sequence data have not estab-
lished significant homology with known genes. These results
suggest that BS35 represents a novel gene, differentially ex-
pressed in human melanoma cell lines whose expression is
regulated variably by cAMP in lines of distinct biological
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The development of ribozymes to control oncogene expression
P. Stephenson & I. Gibson
School of Biology, University of East Anglia, Norwich, UK.
The long term aim of antisense technology is the specific and
controlled regulation of gene expression. Ultimately the hope
would be that the control of oncogene expression could halt
or even reverse tumour progression. In this study we have
concentrated on the design and production of specific
'hammerhead' ribozymes directed against the N-ras onco-
gene. A full length CDNA clone of the MMTV/N-ras fusion
gene which had been used to transform mouse 3T3 cells was
transferred from A gtlO into a transcription vector so that
mRNA-like transcripts could be produced in quantity for in
vitro experiments. A subclone was also constructed which
contained approximately 300 bp spanning the translation
initiation site. To construct the ribozyme two complementary
oligodeoxynucleotides were synthesized. These encoded the
hammerhead consensus sequence (Haseloff & Gerlach (1988),
Nature, 334, 585; Forster & Symons (1987), Cell, 50, 9),
together with 10 bases on each side which would confer
homology to the N-ras gene. These oligos were annealed and
cloned into a vector such that transcription from the T7
promotor produced virtually pure ribozyme. In vitro this
ribozyme cleaved the N-ras mRNA-like molecules in a very
specific fashion to produce the predicted fragments at an
optimun pH of 8.0 and with a requirement for magnesium
ions. Pre-annealing the ribozyme and substrate molecules, or
the inclusion of urea in the reaction mixture, caused a
favourable reduction in the reaction temperature. The re-
action is not inhibited by the inclusion of excess non-
substrate RNA or high protein concentrations.
Expression of the myc, fos and ras oncogenes during
DMSO-induced detransformation of HT29 human colon cells
S. Smart & 1. Gibson
School of Biology, University of East Anglia, Norwich, UK.
The human colorectal cancer cell line, HT29, exhibits striking
morphological changes upon exposure to 1.5% DMSO: The
cells alter to a more flattened, elongated shape. The growth
rate decreases several-fold and further investigation demon-
strates a loss of clonogenicity of the cells and alterations
in the arrangement of the actin stress fibres. Such a system
is suitable for studies of detransformation. However, no
changes indicative of differentiation were observed, such
as brush-border formation or increase expression of the
brush-border related enzymes, alkaline phosphatase and
sucrose-isomaltase. A dramatic decrease in the level of
carcinoembryonic antigen (CEA) occurred concurrently with
a detransformation of the cells. Southern blotting experi-
ments indicated low level (3-5 fold) amplification of the
c-myc oncogene in the HT29 cells and in several clonal lines
derived from the parent population RNA dotblots demon-
strated reductions in C-myc expression within one hour of
addition of DMSO and using a sensitive ELISA assay system
the c-myc protein was found to be downregulated within two
hours. Low levels of thefos oncoprotein (p55) were observed
in all HT29 cells both before and after exposure to DMSO.
Expression of the H-, K- and N-ras oncogenes at the levels
of RNA and protein remained the same after exposure of the
cells to DMSO. It was concluded that c-myc may be impor-
tant in the detransformation of HT29 cells and preliminary
experiments suggest that it may be possible to inhibit the
expression of this oncogene using antisense oligodeoxy-
nucleotides in order to study this role further.
Most cervical cancers progress to metastasis without the
involvement of ras point mutations
G. Willis', B. Jennings', R. Ball2 & I. Gibson'
'University of East Anglia, Norwich NR4 7TJ; and 2Norfolk
and Norwich Hospital, Norwich, UK.
Ras point mutations are associated with many types of
cancer. However, the stage of progression at which they
occur has not been extensively studied. Comprehensive
surveys of the genetic differences between primary and
secondary tumours may lead to an understanding of genes
involved in the development of the metastatic phenotype. We
chose cervical cancer for our studies because tumour samples
from Wertheim's hysterectomy patients are available from
histopathology wax block archives and Riou et al. (1988,
Oncogene, 3, 329) claimed that mutation of c-Ha-ras cor-
related with late stage disease. Ten micro sections were cut
from the primary and metastatic tumours of 16 patients.
Areas of tumour were identified on haematoxylin and eosin
stained slides and tissue scraped from adjacent, unstained
sections. DNA from this tissue was amplified by PCR using
primers flanking codons 12 and 13 of Ha K and N ras genes
and codon 61 of K-ras. The amplified DNA was slot blotted
and analysed by hybridization to probes specific for all pos-
sible amino acid changes at these codons. The Ha-ras PCR
products were also analysed by digestion with restriction
enzyme MSP I. Ras point mutations were found in only one
of the sixteen patients. This patient had a point mutation in
codon 13 of K-ras which was present in two metastases, but
not in an area of invasive primary tumour or a third metas-
tasis. These data strongly argue that ras point mutations are
not a common phenomenon in patients with advanced cer-
vical cancer and even when present appear to confer no
strong selective advantage.
Measurement of c-myc protein in PHA stimulated lymphocytes
by SDS PAGE electrophoresis and immunoblotting: perchloric
acid pretreatment abrogates non-specific protein degradation
D.G. Spiller, A.F. Chapman, D.M. Tidd & H.M. Warenius
CRC Department of Radiation Oncology, University of
Liverpool, Clatterbridge Hospital, Wirral, L63 4JY, UK.
We have previously reported that myc protein was only
detectable in lymphocytes 72 hours after stimulation with
PHA (1989, Br. J. Cancer, 60, 480). We have since added
recombinant myc protein immediately before lysis with con-
ventional lysis buffer (10% SDS, 10% glycerol, 0.1 mM leu-
peptin, 0.1 mM phenylmethylsulphonyl fluoride in 0.04 M
Tris, pH 6.8), and discovered that the protein was degraded.
Examination of SDS PAGE gels stained for protein with
Coomassie Blue suggested that there was non-specific protein
degradation and the degradation was more severe in fresh
and also in unstimulated cultures. Boiling lysates immediately
after cell lysis increased the proportion of high molecular
weight proteins, but added myc protein was still degraded.
Pretreatment of cells with 4.2% w/v perchloric acid followed
by washing and dissolving the precipitated protein in normal
lysis buffer completely abrogated myc protein degradation
and again increased the proportion of high molecular weight
proteins. Using this method for preparing lymphocytes ex-
tracts myc protein was detectable in unstimulated lympho-
cytes and there was a rise in myc protein concentration
shortly after PHA addition. We conclude that lymphocytes
contain factors which rapidly degrade protein that are not
suppressed by the protease inhibitors in conventional lysis
buffers and perchloric acid pretreatment can be used to
eliminate non-specific protein degradation before SDS PAGE
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Secondary transfection of metastatic capability and
confinnation by PCR of concomitant transfer of donor
(human) DNA
M. Cairney, A. Taylor & D. Tarin
Nuffield Department ofPathology, University of Oxford, John
Radcliffe Hospital, Headington, Oxford OX3 9DU, UK.
Previous work at this laboratory provided evidence indicating
transfer of metastatic capability by transfection of mouse
tumour cells with total genomic DNA from human metasta-
tic melanoma (A375M) cells. The transfected cells heavily
colonized the lungs in 84% of inoculated animals. Human
DNA could be detected in the primary transfectants (desig-
nated AH8 test cells) by Southern blotting and by in situ
hybridization using human specific probes but the demon-
stration of such exogenous DNA was difficult and capricious
indicating that the amount of human DNA incorporated was
at the limit of resolution by standard techniques. In our
subsequent work the sensitivity of the polymerase chain re-
action (PCR) has been used therefore to verify the transfer of
donor (human) DNA by selective amplification of human
specific sequences. The results reproducibly show the pre-
sence of donor DNA in the primary transfectant line. In the
current work we report secondary transfection of heavy
metastatic capability with DNA from experimental lung
metastases formed by the primary transfectants. The DNA
designated AH8 LMC was transfected with the calcium phos-
phate precipitation technique into the same mouse fibrosar-
coma line (TR4 Nu) used as the recipient in the primary
transfection. The secondary transfectants were inoculated
into nude mice via the tail vein and heavily colonized the
lungs in 85% of animals. Using the PCR and primers specific
for human Alu repeat sequences we have also reproducibly
detected concomitant transfer of human DNA into the
secondary transfectants. The results provide further evidence
that metastatic capability can be conferred by transfer of
genomic DNA and provide a reliable data base for efforts to
clone the exogenous sequences and test whether they have a
specific causal role in the new behaviour induced.
Oestrogen-receptor (ERD5) in colorectal carcinoma
J.F.R. Robertson, D.L. Morris, I.O. Ellis & N.C. Armitage
Departments of Surgery and Pathology, University Hospital,
Nottingham, UK.
Oestrogen receptor status by the ERD5 method is an inde-
pendent prognostic factor in gastric cancer. We have studied
ERD5 immunocytochemical expression in 68 primary colo-
rectal cancers. Tumours were regarded as positive for ERD5
if any of the tumour cells showed immunostaining. ERD5
status was correlated with other tumour characteristics,
recurrence and survival. Fifty-six per cent of the tumours
stained positive for ERD5. ERD5 status did not correlate
with the sex of the patient (P = 1.000). ERD5 status did not
correlate with stage of disease (P = 0.16) histological grade
(P = 0.45), tumour cell proliferation (Ki67 antigen) expres-
sion (P = 0.29), DNA ploidy status (P = 0.37) or the site in
the colon of the primary tumour (P = 0.31). There was also
no correlation with the sex of the patient (ldf; P = 1.00).
ERD5 status showed no significant correlation with time to
recurrence for the whole group (P = 0.62), for men only
(P = 0.6) or for women only (P = 0.7). ERD5 status did not
correlate with overall survival (P = 0.51). In conclusion, oes-
trogen receptor was expressed in 56% of colorectal cancers in
this study compared to 55% of gastric cancers. However,
unlike gastric cancer, oestrogen expression in colorectal
primary tumours was of no prognostic significance.
A rapid and efficient method for separating infiltrating cells
and tumour cells from colorectal tumours
L.G. Durrant & R.W. Baldwin
Cancer Research Campaign Laboratories, University of
Nottingham, Nottingham NG7 2RD, UK.
As solid tumours are composed of a heterogeneous mixture
of cells, the role of any particular cell type is difficult to
analyze. A rapid method of sorting freshly disaggregated
highly viable single cell suspensions ofcolorectal tumours has
therefore been developed. Infiltrating cells were initially
sorted from tumour cell suspensions using magnetic beads
coated with a cocktail of monoclonal antibodies recognizing
leucocyte common antigen (lymphocytes), CDwl4 (macro-
phages and granulocytes) and thyl antigen (stromal cells).
Colorectal tumours are composed of a 1:1 mixture of infil-
trating cells:tumour cells. Between 4- 10 x 106 cells, 70- 87%
pure were rapidly sorted. The tumour c .lls were then sorted
from the remaining cell suspension using a cocktail of
monoclonal antibodies which recognize 100% of colorectal
tumours. Between 2-7 x 106 tumour cells, 70-87% pure
were rapidly sorted. Both populations of cells are 95% viable
and grow in vivo.
Pattern of ornithine decarboxylase (ODC) activity in
colorectal mucosa of normal subjects and of patients with
adenomatous polyps or cancer of both sexes
S. Bellentani, G. Saccoccio, C. Armocida, A. Grisendi,
A.M. Ferrari, F. Manenti & M. Ponz de Leon
Catt. Gastroent., Ist. Patol. Med. & Div. Med. Int., Modena,
Italy.
ODC activity is usually taken as a good index of cell pro-
liferation. The aims of our study were to define the normal
pattern of ODC activity in different tracts of the large bowel
in both sexes and to compare ODC activity in the apparently
normal mucosa of patients with polyp, or cancer. ODC
activity in the colorectal biopsies taken from 33 individuals
was measured by release of '4CO2 after incubation of the
colonic homogenate with '4C-L-ornithine for 30 minutes.
Results showed that: 1. no difference was present in ODC
colonic mucosa activity of controls neither between males
and females, nor between right and left colon; 2. ODC
activity in apparently normal mucosa was significantly higher
(P<0.05) in patients with polyps or tumours (1.3 ± 0.6 nM
CO2 mg' protein h-') than in controls (0.6 ± 0.4) in both
sexes, with a trend to be higher in females; 3. in patients with
adenoma, ODC activity was much lower in biopsy taken
directly from the polyp (0.3 ± 0.1) than those taken either in
the close vicinity (1.4 ± 0.7, P<0.01), or at distance from
the mass. We conclude that ODC activity may provide a
good biological marker to detect subjects at high risk for
large bowel cancer.
Immunological and biophysical studies on the peptide repeat of
polymorphic epithelial mucins
M.J. Scanlon"2, M.R. Price' & S.J.B. Tendler2
'Cancer Research Campaign Laboratories; and 2Department of
Pharmaceutical Sciences, University of Nottingham,
Nottingham NG7 2RD, UK.
The protein core of human polymorphic epithelial mucins
consists of a repeated sequence of 20 amino acids (Gendler et
al. (1988), J. Biol. Chem., 263, 12820) containing an immuno-
dominant region composed of seven amino acids (P DT R
P A P). Secondary structure predictions and hydropathicity
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should include a hydrophilic turn region of the protein which
would be accessible to recognition and binding by antibodies.
A series of synthetic peptides were prepared based upon the
repeat sequence and those containing the immunodominant
domain were shown to bind to several monoclonal antibodies
which are reactive with epithelial mucins (i.e., anti-breast
carcinoma antibodies, anti-human milk fat globule anti-
bodies). To probe the structural aspects of the immuno-
dominant domain, high field NMR studies were undertaken
on an antigenic eleven amino acid fragment (P D T R P A
P G S T A). A type I P-turn was identified between Asp2 and
Arg4 and this turn is further extended by the Arg4 to Pro'
bond being in the trans conformation. The NMR studies
confirm the secondary structure predictions and may indicate
that these elements of secondary structure are recognized in
breast carcinoma associated mucins by monoclonal anti-
bodies which react with a variety of human carcinomas
including breast tumours.
Familial adenomatous polyposis: clinical and epidemiological
features from 22 families
M. Ponz de Leon, R. Sassatelli, C. Sacchetti & G. Zanghieri
Istituto di Patologia Medica, Policlinico, Modena 41100, Italy.
Familial Adenomatous Polyposis (FAP) is a genetic disease
with an autosomal dominant transmission. FAP is character-
ized by the presence of more than 100 polyps in the large
bowel and by several extracolonic manifestations. Colorectal
cancer develops in almost all untreated patients. We describe
the main clinical and genetic features of 22 families with FAP
from Northern Italy; 269 unaffected and 84 affected family
members were studied. Gene frequency at birth was esti-
mated in the order of 1:7,000-1:20,000. In affected branches
the segregation ratio was 0.38, close to the 0.50 theoretically
expected for dominant transmission. The penetration of the
gene was 63% and the male:female ratio 44:40. All affected
individuals with symptoms already had a colorectal cancer at
diagnosis, whereas no malignancy was usually found in
patients in whom diagnosis was made before the appearance
of symptoms. Extracolonic changes were detected in all
families, the most frequent being cutaneous cysts and retinal
lesions. In conclusion, the gene frequency of FAP in Italy
seems similar to that reported in other countries. Early diag-
nosis, before the appearance of symptoms, is essential for
adequate surgical treatment. The frequency of extracolonic
manifestations suggests that clinical studies should not be
limited to the large bowel but should also include the skin,
the upper digestive tract, several bones and the retinal
epithelium.
Cell kinetics and DNA ploidy in colorectal cancer: relation to
grading, staging and site of tumours
M. Ponz de Leon, A. Costa, A. Scalmati, L. Roncucci,
G. Colella, S. Veneroni & R. Silvestrini
Istituto di Patologica Medica, Univ. Modena; and Istituto
Nazionale Tumori, Milan, Italy.
The prognostic value of cell kinetics has been well established
for many tumours whereas its importance in colorectal
cancer is still unknown. Therefore, we evaluated S-phase
fraction and DNA ploidy in 72 consecutive colorectal cancers
and related the observed findings to the most predictive
clinical parameters. Specimens of neoplastic tissue were
obtained at surgery and processed by a standard autoradio-
graphic technique; in 39 cases tumour cell suspensions were
stained with propidium iodide and analysed for DNA ploidy
in a FACS-STAR flow cytometer. Labelling Index (LI, % of
labelled cells, i.e., the proliferative fraction) was 20.0 ± 1.3
SEM. LI tended to increase in the more distal portions of the
large bowel (from 17.1 to 25.5%) though not significantly.
Grading was unrelated to LI, whereas staging was inversely
related to the S-phase fraction (Dukes' A + B 21.5 ± 1.5, C
22.7±3.1, D 15.2± 1.2, P<0.01, A+B or C versus D).
Ploidy was unrelated to tumour site, grading or LI. Aneu-
ploidy, however, was more frequent in metastatic (Dukes'
C-D) than in localized tumours (15 out of 17 versus 13 out
of 22, P<0.05). In conclusion, our findings suggest that in
advanced colorectal cancer cell proliferation tends to
decrease, while aneuploidy becomes more frequent. More-
over, cell proliferation seems more active in neoplasms of the
distal large bowel, which seem to be biologically and epid-
emiologically different from tumours of the right colon.
Genetics of large bowel cancer: evidence for an autosomal
recessive type of transmission
M. Ponz de Leon, C. Scapoli, R. Sassatelli, G. Zanghieri,
C. Sacchetti & I. Barrai
Istituto di Patological Medica, Univ. Modena and Istituto
Zoologia, Univ. Ferrara, Italy.
With the exception of a few well defined conditions (Adeno-
matosis Coli and Lynch syndrome) the contribution of heri-
table factors to the pathogenesis of the commonly observed
colorectal cancer is still poorly defined. We tested several
hypotheses of genetic transmission of this malignancy by
critically analysing the clinical data of a population-based
Cancer Registry. For each patient registered in 1984-86 for
colorectal cancer in the local Health District a careful
genealogical tree was traced. Information was obtained on
390 incident cases (the probands) and on a total of 2,851
first-degree relatives. Classical segregation analyses were car-
ried out on the whole series according to the maximum
likelihood method. After exclusion of a few families with
clinical evidence of Cancer Family Syndrome, segregation
analysis showed that the hypothesis of one recessive allele at
one locus with reduced penetration (both in intercrosses and
in backcrosses) did not deviate from the maximum likelihood
(X2 1.1-0.7 and 0.8 respectively for probability of ascertain-
ment of 1.0-0.8 and 0.6). All other tested hypotheses
deviated significantly from the maximum likelihood. In conc-
lusion, our data suggest that the susceptibility to colorectal
cancer in the majority of the affected population may be due
to a recessive gene with reduced penetration.
Human colorectal cancer, but not breast cancer, shows a high
frequency of chromosomal telomere shortening
A.M. Thompson",2, M.G. Dunlop",2, M. Dempster2,
C.A. Purdie3, R.C. Allshire2 & N.D. Hastie2
'University Department of Surgery, Royal Infirmary,
Edinburgh; 2MRC Human Genetics Unit, Western General
Hospital, Edinburgh; and 3University Department of
Pathology, Teviot Place, Edinburgh, UK.
Understanding the fundamental molecular mechanisms of
carcinogenesis may provide accurate prognostic indicators
and might lead to novel approaches to treatment. We report
the first demonstration of a high frequency of shortening of
chromosomal telomeres in colorectal cancer. The terminal
10-15 kilobases of normal human telomeric DNA comprise
repeat sequences which maintain the structural integrity of
each chromosome. We have examined telomere length in
blood/tumour DNA pairs from 52 colorectal and 50 breast
carcinomas. Twelve adenomas and 12 normal colonic mucosa
samples were also analysed. DNA was digested with restric-
tion endonuclease, gel fractionated, Southern blotted on
to nylon membranes, radiolabelled telomere DNA probe
hybridized to the DNA on the membranes and densitometric
analysis of autoradiographs performed. Eighty-eight per cent
(45/52) of colon cancers and 12% (6/50) of breast cancers546 BRITISH ASSOCIATION OF CANCER RESEARCH AND CANCER PHYSICIANS
demonstrated severe telomeric shortening compared to blood
DNA controls. Adenomas and normal mucosa did not show
such changes. In colon cancer, telomeric shortening showed
no correlation with tumour site, size or stage, ploidy level by
flow cytometry, or allele losses from chromosomes 17p, 18q
and Sq. Similarly, no correlation between telomere size and
clinicopathological parameters was apparent in breast
tumours. These data suggest structural chromosomal changes
are important in colorectal carcinogenesis but not in breast
carcinoma.
Site-directed integration of selectable gene in the adenomatous
polyposis coli (APC) locus on chromosome 5
H. Sasai & W.F. Bodmer
Director's Laboratory, Imperial Cancer Research Fund,
44 Lincoln's Inn Fields, London WC2A 3PX, UK.
As an alternative strategy for mapping and cloning the APC
gene, we are using techniques of gene targetting by homo-
logous recombination to integrate dominant selectable genes
near this locus. Targetting vectors have been made using the
close marker sequences D5S98 and D5S71 containing neo-
resistant gene and HSV-TK gene. Following transfection into
a human chromosome 5 containing CHO hybrid, selection
was then achieved using G418 and ganciclovir. Successful
targetting was checked using appropriate primers for PCR.
The integrated region can then be transfered using X ray
irradiation hybrids into further recipient cells for subsequent
isolation and characterization.
Abnormalities in the P53 gene in colorectal cancer
N. Rodrigues, A. Rowan, M. Smith, I.B. Kerr, D. Lane
& W. Bodmer
Imperial Cancer Research Fund, PO Box 123, Lincoln's Inn
Fields, London WC2A 3PX, UK.
The implication of the P53 gene as a possible suppressor
oncogene has come about since the reports of point muta-
tions in the coding region of the gene in many cancers,
including colon, breast and lung cancers, which show
chromosome 17p allele loss. We have used an antibody
PAb240 that recognizes an evolutionary conserved epitope on
p53, to study colorectal carcinomas. On immunocytochemical
staining, 13 out of 28 colorectal carcinomas showed increased
reactivity for presumably a mutant form ofp53, and of these,
3 were only focally reactive. None of the 10 adenomas from
both polyposis and sporadic cases showed any p53 staining.
Elisa assays on cell lines from colorectal carcinomas show
greater reactivity with PAb240 than with PAb421, an anti-
p53 antibody in 19 out of the 24 cell lines studied, while the
reverse was observed in lymphoblastoid cell lines with
putative normal p53 expression. We further analysed some of
the colorectal and lymphoblastoid cell lines in order to cor-
relate the antibody staining with the presence of a mutation.
We found that there was homozygous expression of mutant
p53 mRNA by using an asymmetric polymerase chain re-
action based mRNA sequencing strategy.
Detection of allele loss in ovarian cancer
B.J. Milner', N.E. Haites', K.F. Kelly', M. Hall2,
H. Kitchener2 & A.W. Johnston3
'Department of Genetics and Microbiology, University of
Aberdeen; 2Aberdeen Maternity Hospital; and 3Ward 3/4,
Aberdeen Royal Infirmary, Aberdeen AB9 2ZD, UK.
DNA has been analysed from eleven benign ovarian cysts, a
familial malignant ovarian carcinoma, and one metastatic
nodule from a previously removed ovarian carcinoma. Using
Jeffrey's minisatellite and chromosome 17p VNTR (variable
number of tandem repeat) probes, tumour and normal DNA
have been compared. DNA from the familial tumour demon-
strated a loss of heterozygosity at the 17p locus detected by
VNTR probe pYNZ22. Before this finding, a 6 kb fragment
loss had been seen in the tumour fingerprint of the same
individual, using Jeffreys' 33.15 probe. Steps are currently
being taken to identify the chromosomal location of this
sequence. The metastatic nodule also demonstrated 17p loss
of heterozygosity using the pYNZ22 probe. None of the
benign tumours were seen to lose 17p alleles at this locus.
This has led us to suggest that loss of function of an anti-
oncogene from 17p, such as P53, could be involved in the
transition from the benign to the more malignant stages of
ovarian cancer.
Cloning of mRNA sequences from human pancreatic
adenocarcinoma and identification of differentially
expressed cDNA
R. Flomen, D. Grant & A. Grant
Department ofSurgery, St. George's Hospital Medical School,
London SW17 ORE, UK.
A Agtll expression library prepared from a human pancre-
atic ductular adenocarcinoma cell line (GER) has been
screened with mRNA derived from normal and tumour cells
in order to identify sequences which are unique to either the
transformed, or normal pancreatic cell. Five clones have been
selected (GER 1-5) and amplified by the polymerase chain
reaction (PCR) using Taq polymerase and 24 mer primers
complementary to the P-galactosidase encoding regions which
flank the E coRl cloning site. Two of the inserts (AGER2,
1.8 kb and AGER4, 1.6 kb) were used to prepare cDNA
probes for Northern blot analysis of RNA isolated from a
variety of tumours and normal tissue. AGER2 identified a
major band of 1.7 kb in mRNA derived from both the GER
cell line and other pancreatic tumour biopsies, but absent
from normal pancreas. Although this transcript was assoc-
iated with the transformed state it was not pancreas specific
since it was also present in a number of other tumours.
Identical Northern blots probed a 1.1 kb restriction fragment
from AGER4 gave a different pattern of hybrization. This
probe hybridized to high molecular weight mRNA species in
both normal and neoplastic pancreatic tissues that were not
present in mRNA derived from other tumours. These inserts
are now being subcloned into M13 for sequencing by the
dideoxy method or primer directed PCR sequencing.
Isolation of a cDNA sequence homologous to HSP 86 and its
expression in human breast
A. Jameel, Y.A. Luqmani, R.A. Skilton, T. Campbell
& R.C. Coombes
St George's Hospital Medical School, London SW17 ORE,
UK.
To identify potential markers for breast cancer, a human
breast cDNA library constructed using mRNA from lymph
node metastases was screened with a rabbit polyclonal
antisera raised to deglycosylated breast metastases mem-
branes. From a primary screen of 3.3 x 105 pfu, 6 immuno-
positive clones have been isolated. One of these clones, AJ1,
was analysed in more detail; a partial sequence and a com-
puter aided homology search of the predicted amino acid
sequence in the Swiss protein data bank showed complete
identity with amino acids 226-311 of the human HSP86.
Using 32P labelled AJI, we studied its expression in various
human tissues by Northern and dot blot hybridization. A
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expressed in stomach and colon and to a much lesser degree
in thyroid, adrenal, ovary, lung and muscle and undetectable
in specimens of bladder, skin, placenta and spleen. In the
breast, we observed varying degrees of hybridization in all of
54 primary cancers examined; in contrast, 10 non-malignant
samples taken adjacent from tumours expressed this gene to
a much lesser extent. Similarly, high levels were found in
several breast cancer cell lines but low amounts in the
BHL100 line. Interestingly, however, mRNA from 4 separate
organoids made from normal reduction mammoplasties had
levels similar to the cancers and much higher than in unpro-
cessed normal tissues. Preliminary results using the MCF-7
cell line indicated that HSP86 message could be induced
several fold by incubation at 42°C, reaching a peak and
declining within 24 hours. We also found that oestradiol
could increase transcription in a time-dependent manner,
similar to that observed for mouse uterus (Shyamala et al.
(1989), Mol. Cell Biol., 9, 3567). The function of heat shock
proteins is somewhat obscure, but there is increasing evidence
to suggest an important role in steroid receptor regulation,
which will be studied in MCF-7 cells using this clone.
Cloning and characterization of the human topoisomerase II
promoter
D. Hochhauser, C. Stanway, A.L. Harris & I. Hickson
Molecular Oncology Laboratory, Imperial Cancer Research
Fund, Institute of Molecular Medicine, John Radcliffe
Hospital, Headington, Oxford OX3 9DU, UK.
Topoisomerase II is a key target for certain anticancer drugs,
such as adriamycin and more specifically etoposide (VP16). A
possible reason for tumour sensitivity to these drugs could be
over expression oftopoisomerase II. Therefore, we decided to
study the regulation of topoisomerase II expression. A cos-
mid library derived from placental tissue was screened, with a
radiolabelled 24-mer oligonucleotide homologous to the 5'
end of the published cDNA sequence. A genomic clone was
isolated encompassing the putative promoter and 5' region of
the gene. Sequence analysis revealed a series of potential
promoter elements including API and Spl sites. Mapping of
the 5' end of the topoisomerse 1I mRNA also suggests that
this region may function as a promoter. We have also
examined the transcriptional response of the promoter to
cellular transformation by SV40 and also to serum starva-
tion; both of which are known to alter topoisomerase II
expression.
Stress and cancer surveys: attitudes of participants in a
case-control study
P. Trowbridge, C. Taylor & C. Chilvers
Section ofEpidemiology, Institute ofCancer Research, Sutton,
Surrey SM2 5NG, UK.
It has been suggested that both cases and healthy controls
may be inadvertently subjected to stress when they are
included in a 'cancer survey'. Case-control studies requiring
personal interviews are common and both doctors and ethics
committees frequently express concern about the effect of
participation on their own patients and healthy controls. In
studies of cancer aetiology, controls from the general popula-
tion rather than hospitalized controls are often required. A
postal questionnaire was sent to women previously inter-
viewed in a case-control study of the aetiology of cervical
cancer. The questionnaire covered attitudes to taking part in
the study, stress engendered by participation, whether any
particular questions were distressing, factors relevant to the
decision to participate, and the role of their doctor with
respect to participation. Responses were received from 110
cases and 116 controls, a participation rate of 87%. Nearly
all respondents were glad that they had participated while
only 2/226 regretted taking part. Half the responders (115/
226) perceived some actual benefit from taking part. The
interview carried out in the case-control study was both long
and detailed and included topics such as numbers of sexual
partners and history of sexually transmitted diseases. As
expected, the questions causing most concern to interviewees
were those on number of sexual partners, but only 13% of
participants were bothered by these questions and only 4%
felt inclined to terminate the interview early. The lack of
evidence of stress caused by this potentially difficult inter-
view, suggests that, in the hands of experienced interviewers,
stress is unlikely to be caused by participation, and many
participants actually feel that they have benefited from taking
part. Doctors and ethics committees should find these results
reassuring.
Inheritance of gastric cancer: data from a population-based
registry
M. Ponz de Leon, G. Zanghieri, C. Sacchetti & R. Sassatelli
Istituto di Patologia Medica, Policlinico, 41100 Modena, Italy.
Gastric cancer still represents epidemiological and patho-
genetic enigma. This tumour has usually been related to
environmental factors, whereas less attention has been paid
to the possible relevance of genetic factors. In 1984 a
Tumour Registry was instituted in our Health Care District
and this gave us the possibility of investigating the impor-
tance of hereditary factors. The purpose of the present study
was, therefore, to describe the frequency of gastric cancer
among first-degree relatives of 154 patients with tumours of
the stomach registered in 1986 and 1987, and among relatives
of 154 controls matched for age and sex. Crude gastric
cancer incidence was 28.2/100,000/year. Among 907 first-
degree relatives of registered patients, 30 cases of cancer
of the stomach were observed versus 15 cases among 991
control relatives (Mantel-Haenszel x2 with Liang's correc-
tion = 5.93, P<0.01, odds ratio 3.14). This excess of cases
was particularly evident among siblings (17 vs. 7, M-H
X2= 4.23, P<0.02) whereas it was not significant among
parents (13 vs. 8). A family history of gastric cancer was
appreciably more frequent in diffuse than in intestinal carcin-
oma. No excess of other malignancies was observed among
relatives of incident cases. Our results therefore suggest that
gastric cancer is significantly more frequent among close
relatives of patients affected by cancer of the stomach. A
genetic susceptibility to gastric cancer might be supposed as
for other common malignancies.
A cytogenetic/histological study in non-Hodgkin's lymphoma
with particular reference to t (14,18)
J.A. Radford', S. Murray', C. Harrison3, P. Bishop2,
M. Harris2 & D. Crowther'
'CRC Department of Medical Oncology; 2Department of
Histopathology, Christie Hospital; and 3CRC Department
of Cytogenetics, Paterson Institute for Cancer Research,
Manchester, UK.
Concurrent histological and cytogenetic examination has
been performed on 64 lymph node biopsy specimens collected
between January 1981 and January 1989. The trypsin-Giemsa
banding technique was employed after short term cell culture
and cytogenetic abnormalities were recorded when found in
at least 20 cells. Review of paraffin embedded H and E
sections supplemented as necessary by special stains and
immunohistochemistry was also carried out and classification
made according to the Keil system. Twenty-five of 64 (39%)
cases had cb/cc follicular (F) or follicular and diffuse (FD)
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(45%) were other forms of NHL (immunoblastic 9, centro-
blastic 8, ML unclassified 5, centrocytic 4, lymphocytic 3).
Twenty-two of 64 (34%) cases had t(14,18) and of these, 15
had a concurrent cb/cc (F) histology and 2 were cb/cc (FD).
Of the remaining 5 cases, 3 had a cb/cc (F) or (FD) pattern
on a previous biopsy. Eight of 25 (31%) pts had (F) or (FD)
histology but no t(14,18) and a further 3 pts without the
translocation had a (F) or (FD) pattern on previous biopsy.
Overall, 20 of 22 (91%) cases with t(14,18) had a (F) or (FD)
histological pattern at some stage in their history. Details of
time to first recurrence, number of relapses and overall sur-
vival were available for 17 of 20 (F) or (FD) pts with t(14,18)
and 10 of 11 (F) or (FD) pts without the cytogenetic marker.
With a median follow up of 56 mths, 6 of 17 pts with
t(14,18) have died (3 from follicular NHL, 2 from diffuse
NHL and 1 from AML) against 5 of 10 pts where t (14,18)
was absent (2 from follicular NHL and 3 from diffuse NHL).
This is a significant difference between the 2 groups for
deaths from NHL (P = 0.02) but relapse free survival is the
same for both groups (P = 0.23). From this small study we
conclude that in (F) or (FD) non-Hodgkin's lymphoma, the
presence of t(14,18) is associated with a significantly better
prognosis than where t(14,18) is absent. Larger studies are
required to confirm these findings.
The role of flow cytometric nucleoid analysis in predicting a
response to radiotherapy in patients with bladder cancer
T.H. Lynch, P. Anderson, A.T.M. Vaughan, D.G. Gordon,
R.P. Beaney & D.M.A. Wallace
Department of Urology, Queen Elizabeth Medical Centre,
Birmingham, UK.
Flow Cytometric Nucleoid Analysis (FCNA) is a new techni-
que used by cell biologists to detect radiation damage to cells
in vitro. When cells are placed in a highly concentrated salt
solution, the nuclear envelope and histone proteins are
removed leaving the nucleoids. Nucleoids extracted from cells
which have been exposed to radiation are larger than those
extracted from non-irradiated cells. The amount of expansion
correlates with the known radiosensitivity ofcertain cell lines.
The purpose of this study is to determine if the technique of
FCNA can be applied to muscle invasive transitional cell
carcinoma of the bladder, to differentiate those tumours that
are radiosensitive from those that are radioresistant.
We analysed tumour specimens from 100 patients with
invasive bladder cancer before radiotherapy. Tumour samples
were received from either transurethral resection samples or
urine. All specimens were analysed fresh without any form of
fixative. Single cell suspensions were prepared and irradiated
with a cobalt 60 gamma source and analysed on the flow
cytometer. The degree of nuclear expansion is compared to
the subsequent local tumour response at 3 and 6 months
following radiotherapy. We have initial results on follow up
in 30 patients at 3 months after completion of radical radio-
therapy which show a correlation of radiosensitivity in vitro
as determined by nucleoid expansion with the response of the
patient to treatment. All tumours showing a nucleoid expan-
sion of greater than 10% responded to radiotherapy. This
technique can be applied using voided urine or TUR samples
of tumour and gives a result within hours. Therefore, it may
be of practical benefit in selecting patients for radical
radiotherapy as opposed to other treatment modalities.
x-Fucosidase (ALF) as a marker of genetic deletion in ovarian
carcinomas
J.E. Roulston', J.M. Richardson', J. Fisken'
& R.C.F. Leonard2
'Department of Clinical Chemistry, Royal Infirmary; and
2Department of Clinical Oncology, Western General Hospital,
Edinburgh, UK.
Wells et al. (Cancer Genetics, Cytogenetics, 25, 247) have
reported suppression of serum a-l-fucosidase in hereditary
EOC. The gene located on 6qter may thus be a target for
genetic deletion and in more recent studies using Southern
blotting techniques on tumour and blood DNA, other
workers and ourselves have found deletions at 6q, 17p and
1lp. We have therefore examined the activity of a-l-fuco-
sidase in the serum of 199 normal subjects (blood donors)
compared against 147 patients with EOC. ALF activity was
measured as the change in absorbance control of parani-
trophenyl-a-l-fucoside as a substrate. The range of activity in
both test and control populations measured as absorbance
units was between 0 and 2.6. No assumption was made about
the normality of distribution of data in either set and so the
results were compared non-parametrically. By this analysis
there was no difference between the two groups. We conclude
that there is no measurable reduction in activity of this gene
product in the serum of patients with common epithelial
ovarian carcinoma. Therefore, it is not a good screening
target for population studies. It does not, however, exclude
the possibility that a small subset of patients have lower
levels of ALF in association with hereditary predisposition.
Clinical trials - a game of chance?
M. Stewart, R. Rye & A. Young
ICRF Medical Oncology Unit, Western General Hospital,
Edinburgh, Scotland EH4 2XU, UK.
The management and monitoring of data in any clinical trial
can be fraught with difficulties. From its inception through to
the published paper there are many pitfalls to avoid. This
poster aims to illustrate both the problems in running a trial
and possible solutions through the analogy of the board
game 'snakes and ladders'. Progress through the squares on
the board is determined by landing on a square with a ladder
leading upwards or a snake leading downwards. Ladders
would thus represent events which would take the player
closer to the end point of the trial such as the protocol being
passed by the local ethics committee, or adequate patient
numbers being accrued to the trial. Snakes by contrast repre-
sent problematic events. These would include blood tests not
being done according to protocol, or X-rays missing for an
external audit. While on one hand more resources than ever
before are collectively facilitating progress towards improving
cancer treatments, on the other it is almost certain that a
clinical trial will never go completely according to plan.